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Generalised epilepsy and paroxysmal dyskinesia (GEPD) patients present with 
epilepsy (absence- and generalised tonic-clonic seizures), paroxysmal 
dyskinesia (non-kinesigenic), or a combination thereof. GEPD is linked to a 
missense mutation (D434G) in KCNMA1, which encodes the a-subunit of the BK 
channel, a Ca2+- and voltage-activated K+ channel. Previous studies have 
demonstrated that this mutation causes a gain of BK channel function by 
potentiating the allosteric coupling between Ca2+ binding and channel opening. 
Due to the role of BK channels in action potential repolarisation, it has been 
hypothesised that the D434G mutation narrows action potential width and 
increases neuronal firing frequencies, leading to seizures and dyskinetic attacks. 
 However, BK channels are expressed broadly throughout the human 
body, including various extra-neuronal tissues, and, on a subcellular level, 
localise not only to the plasma membrane but also to various intracellular 
organelles. Due to this pleiotropy, the organismal effects of the D434G mutation 
remain unclear. In this thesis, I present the generation, characterisation, and 
functional analysis of a novel knock-in fly model carrying the D434G-equivalent 
E366G mutation in slowpoke (slo), the Drosophila orthologue of KCNMA1 – this 
novel slo allele is termed sloE366G. 
 Evidence is provided that the E366G mutation increases the Ca2+-
sensitivity of Slo channels ex vivo. Moreover, sloE366G/+ animals exhibit a severe 
decrease in locomotion and altered action selection, phenotypes that correlate 
with aberrant motoneuron activity, as shown via electrophysiology and live optical 
imaging. Using a genetic approach, I demonstrate that cholinergic neurons 
mediate this locomotor defect. Further, via RNA-sequencing I provide evidence 
that sloE366G/+ flies exhibit altered metabolic-, redox-, and immune function, and 
that the stress-responsive transcription factor foxo genetically interacts with 
sloE366G. Together, these data suggest a pathogenic locus for GEPD and define 







The work presented in this thesis has direct academic impact within the fields of 
epilepsy and dyskinesia research, while also laying a foundation from which to 
potentially derive clinical benefit in the future. Importantly, the academic impact 
of this work reaches across scientific disciplines, as it provides a novel genetic 
tool with which to address a variety of questions within the biomedical sciences. 
Prior to the work presented in this thesis, GEPD – a combined epilepsy-
paroxysmal dyskinesia syndrome (Du et al., 2005) – had not been studied in a 
living organism due to the lack of an in vivo model. As a result, the pathogenesis 
of GEPD remained incompletely understood. This thesis presents the generation 
of the first in vivo model of GEPD, which I generated by introducing the mutation 
linked to GEPD – a D434G missense mutation in KCNMA1 (Du et al., 2005) – 
into the Drosophila orthologue slo, establishing the novel allele sloE366G.  
By studying this allele in vivo, two fundamental discoveries have been 
made: (1) the GEPD-linked mutation exerts its effects in cholinergic neurons – a 
finding of great academic and clinical interest because the neuroanatomical 
origins of dyskinesia are unclear (Kaji et al., 2018). Hence, localising GEPD 
pathology might inform translational dyskinesia research and facilitate the 
discovery of targeted therapeutics with minimal side effects. (2) GEPD 
pathogenesis is linked to perturbed metabolism. This unexpected finding is 
intriguing because it expands the scope of potential molecular mechanisms 
underlying both dyskinesia and epilepsy (Erro et al., 2017). Further research into 
these mechanisms might lead to novel therapeutic approaches for GEPD patients 
as well as for dyskinesia and epilepsy patients more generally.  
 Although slo was cloned in 1991 (Atkinson et al., 1991), the sloE366G allele 
presented in this thesis is the first gain-of-function allele of this gene in 
Drosophila. As such, it will greatly facilitate the study of the behavioural, cellular, 
and molecular functions of slo. The results of such investigations might have far-
reaching academic and clinical implications, because KCNMA1 is widely 
expressed throughout the human body and involved in a variety of physiological 




translate into an increased understanding of a wide range of human diseases and 
disorders. 
Altogether, the novel Drosophila knock-in model of GEPD presented in 
this thesis is predicted to contribute to both clinical and academic research into 
the pathophysiology underlying dyskinesia and epilepsy, while also impacting 
other areas within medicine and the biomedical sciences – with the ultimate aim 
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RNA-seq RNA-sequencing  
RNAi RNA interference 
ROI region of interest 
ROS reactive oxygen species 
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RT room temperature 
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TF transcription factor 
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UAS upstream activating sequence 
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1.1 Paroxysmal Dyskinesia 
Paroxysmal dyskinesia (PxD) describes a group of hyperkinetic movement 
disorders characterised by episodically occurring involuntary movements, the 
latter presenting mainly as dystonic, choreiform, ballistic, or a combination thereof 
(Bhatia, 2011; Blakeley and Jankovic, 2002). Dystonia is characterised by 
twisting movements that result in abnormal postures; chorea by brief, irregular 
movements of individual body parts; and ballismus by large-amplitude 
movements of the proximal parts of the limbs (Kandel et al., 2013). Three 
clinically distinct PxDs have been described, based on how dyskinetic attacks are 
triggered: paroxysmal kinesigenic dyskinesia (PKD), paroxysmal non-kinesigenic 
dyskinesia (PNKD), and paroxysmal exercise-induced dyskinesia (PED) (Bhatia, 
2011). Their distinct characteristics, including triggers, are listed in Table 1. 
Table 1 Paroxysmal Dyskinesias 
 PKD PNKD PED 
Trigger of attacks sudden movement1,5 mainly caffeine1,5 











Attack duration seconds1,2 minutes to 
hours1,2,5 
minutes1,2,5 
Attack frequency mostly daily1,2  mostly weekly1,2 mostly weekly1,2,5 
Age of onset mainly childhood1,2,5 mainly childhood1,2 mainly 
childhood1,2 
















1(Bhatia, 2011), 2(Erro et al., 2014), 3(Erro et al., 2017), 4(De Giorgis and Veggiotti, 2013), 





Of note, the information in Table 1 lists the most common characteristics, 
including the most common genetic causes, of the three PxDs and is not 
exhaustive. PxD is considered to be relatively rare, with one study describing its 
occurrence in 0.76% of 12063 movement disorder patients (Blakeley and 
Jankovic, 2002) – however, its exact prevalence in the general population is 
unknown (Bhatia, 2011). PxD can either be genetic (primary) or acquired 
(secondary), the latter of which can be elicited by stroke, trauma, infection, 
autoimmune disease, migraine, and hypo- as well as hyperglycaemia (Bhatia, 
2011; Blakeley and Jankovic, 2002). While common genetic mutations underlying 
each of the PxDs have been identified (Table 1), it should be noted that there is 
clinical overlap between these genotype-phenotype relationships. For example, 
patients with PRRT2 and PNKD mutations can also present with PED, while 
patients with mutations in SLC2A1 can also present with PKD and PNKD (Erro 
et al., 2014; Gardiner et al., 2015). Moreover, mutations in these genes can be 
associated with additional clinical phenotypes, either in isolation or in combination 
with PxD – most notably with seizures and migraine (Gardiner et al., 2015). The 
severity of paroxysmal attacks tends to decrease with age in PKD and PNKD, but 
not in PED (Erro et al., 2017). 
1.2 Pathophysiology of Paroxysmal Dyskinesia 
1.2.1 Genetic and Molecular Mechanisms 
Defining the physiological functions of the genes associated with PxD is an 
important pre-requisite for understanding their pathogenicity when mutated. An 
increased molecular understanding of PxD might allow for the development of 
targeted treatment approaches, aimed at improving the lives of patients with 
minimal side effects.  
1.2.1.1 PRRT2 
The PRRT2 protein is 340 amino acids long and carries two transmembrane (TM) 
domains (Erro et al., 2017). While three PRRT2 splice isoforms have been 
described, the majority of pathogenic mutations in PRRT2 occur in a conserved 




associated with PKD lead to loss-of-function alleles (Gardiner et al., 2015; Tan et 
al., 2018). PRRT2 is expressed in the mammalian spinal cord and brain, 
particularly in the cerebral cortex, basal ganglia, hippocampus, and cerebellum 
(Chen et al., 2011; Heron et al., 2012; Lee et al., 2012a). Importantly, PRRT2 
localises to pre-synaptic termini and physically interacts with components of the 
SNARE complex, as shown via co-immunoprecipitation (Coleman et al., 2018; 
Lee et al., 2012a; Tan et al., 2018; Valente et al., 2016). Since the SNARE protein 
complex is responsible for membrane fusion between pre-synaptic 
neurotransmitter-containing vesicles and the plasma membrane (Ungar and 
Hughson, 2003), these data suggest a role for PRRT2 in pre-synaptic 
neurotransmitter release. 
Indeed, knock-down of PRRT2 in primary rat hippocampal cultures caused 
a decrease in synaptic density and synaptic release probability, as identified via 
immuno-staining and autaptic electrophysiological recordings, respectively 
(Valente et al., 2016). While these data suggest that PRRT2 facilitates 
neurotransmitter release, more recent studies have provided strong evidence for 
PRRT2 to inhibit exocytosis. Using a mouse model recapitulating the c.649dupC 
loss-of-function PRRT2 mutation, which is linked to PKD, it could be shown that 
wild-type PRRT2 inhibits SNARE complex formation (Tan et al., 2018). 
Consequently, dis-inhibition of SNARE complex formation in response to a loss 
of PRRT2 function was demonstrated to facilitate synaptic transmission at 
the cerebellar parallel fibre-Purkinje cell synapse (Tan et al., 2018). Intriguingly, 
conditional Cre-mediated knock-out of PRRT2 in granule cells of the cerebellum 
recapitulated the electrophysiological and behavioural phenotypes exhibited by 
germline mutant mice, suggesting a pathogenic locus for PKD (Tan et al., 2018). 
Moreover, reconstituted in vitro fusion assays showed that PRRT2 negatively 
regulates SNARE-mediated vesicle fusion by affecting the vesicle 
docking/priming process (Coleman et al., 2018). Interestingly, the dis-inhibitory 
effect of two human PKD mutations on SNARE-mediated vesicle fusion 
correlated with the severity of their associated clinical symptoms, suggesting a 
molecular mechanism underlying PKD pathogenesis (Coleman et al., 2018).  
In addition to these pre-synaptic functions, PRRT2 has also been shown 




Nav1.6 at the axon initial segment via direct protein-protein interactions, as 
determined by co-immunoprecipitation (Fruscione et al., 2018). Indeed, iPSC-
derived neurons carrying the c.649dupC mutation in PRRT2 exhibited increases 
in Nav channel currents and intrinsic excitability, as determined via single-cell 
patch clamp recordings (Fruscione et al., 2018). Altogether, these studies 
suggest that PRRT2 negatively regulates both neurotransmitter release at pre-
synaptic termini and Nav channel currents at the axon initial segment. Hence, 
PKD-linked loss-of-function mutations of PRRT2 are predicted to potentiate both 
of these processes. 
1.2.1.2 PNKD 
PNKD expresses at least three splice isoforms, the largest one of which, PNKD-
L, is 385 amino acids long (Erro et al., 2017). Immunohistochemistry experiments 
in mice revealed a brain-specific expression pattern of PNKD-L, including the 
basal ganglia, cerebellum, and spinal cord (Lee et al., 2012b; Shen et al., 2011). 
Expression of GFP-tagged PNKD-L as well as immuno-staining against wild-type 
PNKD-L in vitro provided strong evidence for PNKD-L to be a membrane-
associated protein (Shen et al., 2011). While PNKD-linked mutations in PNKD 
have been suggested to lead to loss-of-function alleles via protein truncation or 
degradation (Gardiner et al., 2015; Shen et al., 2011), recent evidence indicates 
that they might, in fact, be neo- or hypermorphic (Shen et al., 2015). While PNKD 
knock-out mice exhibited lower levels of glutathione in the cerebral cortex, 
indicating a role for PNKD in regulating cellular redox state (Shen et al., 2011), 
more recent studies have linked PNKD function to the regulation of pre-synaptic 
neurotransmitter release. 
 Carbon fibre amperometry identified dysregulated dopamine signalling in 
striatal slices from a mouse model recapitulating human PNKD mutations, 
implicating PNKD in nigrostriatal neurotransmission, disturbance of which might 
be involved in PNKD pathogenesis (Lee et al., 2012b). Using c-Fos staining after 
dyskinetic attacks in this PNKD mouse model, increased activation of the basal 
ganglia was observed, providing additional evidence for it to contain the 
pathogenic locus for PNKD (Lee et al., 2012b). Importantly, a recent study 




(RIM1) and RIM2 at active zones (AZs) via co-immunoprecipitation and 
immunogold electron microscopy (Shen et al., 2015). RIMs are large scaffold 
proteins that associate with vesicle-, AZ-, and plasma membrane proteins, and 
are involved in regulating neurotransmitter release (Wang and Südhof, 2003), 
supporting a role for PNKD in neurotransmission. Indeed, using the pH-sensitive 
GFP indicator VGluT1-pHluorin in primary rat hippocampal cultures, it was 
demonstrated that PNKD inhibits exocytosis (Shen et al., 2015). Importantly, 
PNKD carrying human PNKD mutations failed to inhibit exocytosis, suggesting 
dis-inhibition of neurotransmitter release as a pathogenic mechanism underlying 
PNKD (Shen et al., 2015). Altogether, these data indicate an important role for 
PNKD in the regulation of pre-synaptic neurotransmitter release, which is 
suggested to be dysregulated in PNKD. 
1.2.1.3 SLC2A1 
SLC2A1 encodes the glucose transporter type 1 (GLUT1), an integral membrane 
protein with 12 TM domains and a length of 492 amino acids (Mueckler et al., 
1985; Wang et al., 2000). GLUT1 is expressed on the plasma membrane of most 
cells, and catalyses the facilitated diffusion of glucose across the lipid bilayer, 
acting as a uniporter (Brockmann, 2009; Deng et al., 2014). Importantly, GLUT1 
is the principal glucose transporter in erythrocytes, astrocytes, and endothelial 
cells of the brain microvasculature, where it facilitates the transport of glucose 
across the blood-brain barrier (BBB) (De Giorgis and Veggiotti, 2013). Impaired 
glucose transport into the brain leads to unmet neuronal energy demands and 
hypoglycorrhachia – low glucose concentrations in the cerebrospinal fluid (CSF) 
– eliciting the clinical symptoms of PED (Brockmann, 2009; De Giorgis and 
Veggiotti, 2013). Indeed, the effectiveness of the ketogenic diet in treating PED 
illustrates the malfunction of GLUT1: the ketogenic diet is a dietary intervention 
classically consisting of a fat:(carbohydrate + protein) ratio of 4:1, designed to 
mimic the metabolic state of fasting (De Giorgis and Veggiotti, 2013). In the 
absence of sufficient glucose transport into the brain, this fasting-like state 
induces the production of ketone bodies via fatty acid degradation in the liver (De 
Giorgis and Veggiotti, 2013). Since ketone bodies use a GLUT1-independent 




diffusion via the monocarboxylate transporter 1 (MCT1) – they provide an 
alternative energy source to glucose, restoring brain energy metabolism and 
relieving PED symptoms (De Giorgis and Veggiotti, 2013). Of note, the crystal 
structure of the human GLUT1 protein has recently been reported in an inward-
open conformation at 3.2 Å resolution – this resource may allow for the effects of 
PED-causing mutations on protein function to be appraised on a structural level 
(Deng et al., 2014). 
1.2.1.4 A Pathological Framework Based on Protein Function 
Since PRRT2 and PNKD regulate pre-synaptic neurotransmitter release, a 
dysregulation of this process is proposed to underlie PKD and PNKD, 
respectively. Due to this association of PKD and PNKD with synaptic defects, 
these disorders have been classified as “synaptopathies” (Erro et al., 2017). 
Similarly, due to the role of GLUT1 as a glucose transporter, SLC2A1-linked PED 
has been classified as a “transportopathy” (Erro et al., 2017). This pathological 
framework is completed by “channelopathies”, describing diseases caused by 
intrinsic changes to ion channel function (Erro et al., 2017; Shen et al., 2015). 
1.2.2 Neuroanatomy 
While movement disorders can theoretically originate in the cortex, the 
cerebellum, or the basal ganglia (Lee et al., 2012b), the cortico-basal ganglia-
thalamocortical (CBGT) circuit has been shown to be frequently affected (Kandel 
et al., 2013). Figure 1.1 illustrates a simplified version of the CBGT circuit based 
on the “three-pathway model” of the basal ganglia, comprising (1) the movement-
inducing direct striatopallidal pathway, (2) the movement-inhibiting indirect 
striatopallidal pathway, and (3) the modulatory activity of the striosomal 
striatonigral pathway (Graybiel et al., 2000). Notably, four similar circuits of this 
architecture exist, differentiated by their topographical cortico-striatal projections, 
which serve motor-, oculomotor-, executive/associative-, and emotion/motivation 
processing (Kandel et al., 2013; Poewe et al., 2017). However, only the motor 






Figure 1.1 The Cortico-Basal Ganglia-Thalamocortical Circuit 
This simplified diagram of the CBGT motor circuit illustrates the three-pathway 
model of the basal ganglia. The motor cortex forms excitatory connections (cyan 
arrows) with the striatal matrix component (M) and the striosomal component (S) 
of the striatum. The direct pathway sends inhibitory connections (red arrows) 
from M to the globus pallidus internus (GPi) and the substantia nigra pars 
reticulata (SNr), while the indirect pathway first sends inhibitory connections 
from M to the globus pallidus externus (GPe). The GPe inhibits the subthalamic 
nucleus (STN), which in turn excites the GPi and SNr. The GPi and SNr are the 
main output structures of the basal ganglia and inhibit the thalamus. Via their 
differences in connectivities, direct pathway activation causes increased-, and 
indirect pathway activation decreased thalamic activity. The thalamus sends 
excitatory connections back to the motor cortex, activating descending motor 
circuits and inducing motor output. Via the striosomal pathway from S to the 
substantia nigra pars compacta (SNc), the striatum can regulate dopaminergic 
modulatory input from the SNc (violet arrows), which acts on excitatory 
dopamine receptors (D1) of the direct-, and on inhibitory dopamine receptors 
(D2) of the indirect pathway. This figure was adapted from the following 
publications: (Goto et al., 2005; Graybiel et al., 2000; Kaji et al., 2018). 
 
A complex interaction between the direct-, indirect-, striosomal-, and other 
pathways within the basal ganglia, thalamus, and cortex implicate the CBGT 
circuit in motor behaviours such as action selection, movement preparation, and 
movement execution (Kandel et al., 2013). Disturbances in any of its components 
can cause aberrant network activity, manifesting as movement disorders that can 




CBGT circuit in PxD is derived from animal models as well as from functional and 
structural brain imaging in humans.  
Evidence for basal ganglia dysregulation in PNKD is provided by studies 
of a mouse model recapitulating human PNKD disease mutations, as introduced 
in Paragraph 1.2.1.2 (Lee et al., 2012b). These mice showed stress-, caffeine-, 
and alcohol-induced dyskinesia reminiscent of the human phenotype, which 
correlated with a specific increase in activity of the GP, STN, and SNr, as 
determined via immuno-staining for c-Fos (Lee et al., 2012b). Two lines of 
evidence strongly suggest dysregulated striatal dopamine signalling in this model 
of PNKD: (1) the PNKD mice showed altered striatal expression of proteins 
involved in dopamine signalling, and (2) exhibited decreased dopaminergic 
neurotransmitter release in the striatum (Lee et al., 2012b). Since injection of 
quinpirole, a specific D2 dopamine receptor agonist, was sufficient to induce 
dyskinesia in this PNKD mouse model, strong evidence points towards the 
indirect striatopallidal pathway as a pathogenic locus in PNKD (Figure 1.1) (Lee 
et al., 2012b). 
 Evidence for an involvement of the striatum in PED is provided by a study 
reporting a five-generation family with inherited PED and epilepsy linked to a 
heterozygous missense mutation in SLC2A1 (Suls et al., 2008). Using interictal 
fludeoxyglucose-positron emission tomography (FDG-PET), which measures the 
uptake of the glucose analogue fludeoxyglucose (FDG) into tissue, PED patients 
were shown to exhibit an increased metabolic demand in the putamen and 
midtemporal cortex bilaterally and in the right lingual cortex, while a decreased 
metabolic demand was detected in the thalamus, anterior cingulate cortex, and 
midfrontal and superior frontal cortex bilaterally (Suls et al., 2008). Interestingly, 
a positive correlation was found between the frequency of PED attacks and 
hypermetabolism in the left putamen as well as hypometabolism in the left 
superior frontal- and bilateral anterior cingulate cortex (Suls et al., 2008). 
Moreover, ictal single-photon emission computed tomography (SPECT) revealed 
hyperperfusion of the left putamen during a dyskinetic episode (Suls et al., 2008). 
These findings establish a link between altered glucose metabolism, activity in 




 Structural brain imaging has provided evidence for morphological 
abnormalities of the thalamus in PKD patients (Kim et al., 2015). Structural 
magnetic resonance imaging (MRI) volumetric analyses revealed a reduced 
bilateral thalamic volume in PKD patients compared to controls, while no 
difference could be detected in the caudate nucleus, putamen, GP, amygdala, 
and hippocampus (Kim et al., 2015). These data also showed significant 
alterations in thalamic morphology in PKD patients, and diffusion tensor imaging 
(DTI) demonstrated changes in thalamic fractional anisotropy (FA) in PKD 
patients, associating macro- as well as microstructural thalamic changes with this 
disorder (Kim et al., 2015).  
The CBGT circuit is involved in a variety of other disorders affecting 
movement, including Parkinson’s disease (PD), levodopa-induced dyskinesia 
(LID), and dystonia. Neuronal loss in areas of the SNc and intracellular 
accumulation of a-synuclein (“Lewy bodies”) are characteristic features of PD 
(Poewe et al., 2017). The resulting decrease in dopaminergic nigrostriatal 
signalling differentially affects the direct and indirect striatopallidal pathways, 
leading to increased GPi activity and a concomitant decreased activity of 
thalamocortical projections, manifesting as bradykinesia, rigidity and/or rest 
tremor (Figure 1.1) (Poewe et al., 2017). While L-DOPA is the standard treatment 
for PD, its long-term use can precipitate hyperkinetic motor problems classified 
as LID, which can manifest as choreic or dystonic (Poewe et al., 2017). The 
alterations in CBGT network activity in LID are incompletely understood, but 
might involve plasticity changes in CBGT connections due to discontinuous L-
DOPA delivery (Graybiel et al., 2000; Poewe et al., 2017). In order to treat both 
PD and LID, deep-brain stimulation (DBS) of the STN or GPi has the strongest 
evidence-base: DBS applies high-frequency stimulation (HFS; 100-200 Hz) to the 
target brain area, mimicking the effect of a lesion without the need to remove 
brain tissue (Poewe et al., 2017). How the same manipulation of the CBGT circuit 
can be an effective treatment for both hypo- (PD) and hyperkinesia (LID) is not 
understood, but might be linked to differential plasticity changes in the matrix- 




Dystonia causes sustained muscle contractions that can result in 
abnormal postures and twisting movements (Kaji et al., 2018). Autopsy studies 
on patients with X-linked dystonia-parkinsonism (XDP) identified striosomal-
specific lesions in the striatum during the dystonic phase of the disease, 
specifically implicating the degeneration of striosomal medium spiny neurons 
(MSNs) in dystonia (Figure 1.1) (Kaji et al., 2018). A loss of striosomal MSNs is 
predicted to disrupt striato-nigro-striatal signalling, reminiscent of the 
endophenotype suggested to underlie LID, and might lead to dystonia by dis-
inhibiting dopamine release from the SNc (Figure 1.1) (Kaji et al., 2018).  
Despite the evidence linking the basal ganglia to the pathogenesis of 
movement disorders, including PxD, it must be stressed that up- and downstream 
structures might also be involved – particularly the cerebellum, which sends 
projections to the basal ganglia via the intralaminar thalamic nuclei and has been 
associated with dystonia (Kaji et al., 2018; Kandel et al., 2013). Neuroimaging 
studies have linked cervical dystonia to cerebellar abnormalities (Batla et al., 
2015), while dystonic symptoms in a dystonia rat model were relieved by 
cerebellectomy (LeDoux et al., 1993). Moreover, acute in vivo knock-down of 
TOR1A, mutations in which are linked to DYT1 dystonia, in the cerebellum was 
sufficient to induce dystonia in mice (Fremont et al., 2017). The cerebellum has 
also been linked to PxD: as discussed in Paragraph 1.2.1.1, studies on a PKD 
mouse model recapitulating the human c.649dupC mutation in PRRT2 provided 
strong evidence for the cerebellum to be the pathogenic locus of PKD (Tan et al., 
2018). Hence, while the basal ganglia are clearly important for the pathogenesis 
of movement disorders, afferent cerebellar inputs might also be involved (Kaji et 
al., 2018). 
1.3 Association of Paroxysmal Dyskinesia with Epilepsy 
1.3.1 Epilepsy 
Epilepsy is a neurological disorder that chronically predisposes patients to the 
development of seizures and affects ~65 million people worldwide (Devinsky et 
al., 2018). A seizure is defined as a transient change in behaviour, internal or 




neural circuits in the brain (Devinsky et al., 2018). According to the International 
League Against Epilepsy (ILAE) classification scheme (Scheffer et al., 2017), 
seizures are grouped into three categories, based on the location of seizure 
onset: (1) focal seizures originate in isolated areas in one hemisphere, (2) 
generalised seizures have a more widespread origin in both hemispheres, while 
the origin of (3) unknown seizures is undetermined (Devinsky et al., 2018). Each 
of these three seizure categories can be sub-divided into motor- and non-motor 
seizures (Devinsky et al., 2018). Epilepsy can be caused by trauma, 
immunological challenges, metabolic disturbances, or genetic mutations 
(Devinsky et al., 2018).  
Research into the pathogenesis of epilepsy can be divided into the study 
of epileptogenesis and the study of ictogenesis – the former describing the 
pathological changes in neuronal structure and function that predispose a brain 
to epilepsy, the latter describing the mechanisms underlying the development of 
seizures (Devinsky et al., 2018). Several cellular and molecular changes have 
been associated with epileptogenesis, such as aberrantly high levels of mossy 
fibre sprouting in the hippocampus and altered adenosinergic signalling  (Boison, 
2016; Buckmaster, 2012; Devinsky et al., 2018). Studies on ictogenesis have 
demonstrated mechanistic differences between generalised and focal seizures. 
Absence seizures, a type of generalised seizure, often show bilaterally 
synchronous spike-wave discharges (SWDs) – symmetrical neuronal activity 
patterns that can be detected via electroencephalogram (EEG) – emanating from 
thalamo-cortical networks (Figure 1.1) (Devinsky et al., 2018; Snead III, 1995). 
Focal epilepsy is associated with two main interictal network events: (1) interictal 
epileptiform spikes (IESs), characterised by transiently synchronised activity of 
cortical principal neurons, and (2) fast high frequency oscillations (HFOs), 
generated by fast synchronised activity of pathologically interconnected cortical 
principal neurons (Devinsky et al., 2018; Staley et al., 2011; Zijlmans et al., 2012). 
Anti-epileptic drugs (AEDs) are the primary treatment for epilepsy (Devinsky et 
al., 2018). However, while they can reduce seizure frequency and severity, they 
do not treat the underlying cause (Devinsky et al., 2018). Drug-resistant epilepsy 




neurostimulatory device, or dietary intervention, such as the ketogenic diet 
(Devinsky et al., 2018). 
1.3.2 Combined Paroxysmal Dyskinesia-Epilepsy Syndromes 
The co-occurrence of PxD and epilepsy in the same family or individual has been 
increasingly recognised (Erro et al., 2017). Three PxD-epilepsy syndromes have 
been described, each combining different types of PxD and epilepsy: infantile 
convulsions and choreoathetosis (ICCA), GEPD, and GLUT1 deficiency 
syndrome (GLUT1-DS). An overview of these syndromes, including the types of 
PxD and seizures they combine, is presented in Table 2.  
Table 2 Combined Paroxysmal Dyskinesia-Epilepsy Syndromes 
 ICCA GEPD GLUT1-DS 

















Infancy1,5  early 
childhood4 
childhood3  infancy or early 
childhood2 


















1(Erro et al., 2017), 2(De Giorgis and Veggiotti, 2013), 3(Du et al., 2005), 4(Gardella et al., 2016), 
5(Szepetowski et al., 1997) 
 
Of note, the information in Table 2 lists the most common characteristics of the 
three combined PxD-epilepsy syndromes and is not exhaustive. Indeed, 




(Erro et al., 2017; De Giorgis and Veggiotti, 2013). Moreover, GLUT1-DS has a 
broad spectrum of clinical presentations, including epilepsy, intellectual disability, 
acquired microcephaly, as well as paroxysmal and non-paroxysmal movement 
disorders (De Giorgis and Veggiotti, 2013). Hence, GLUT1-DS is not necessarily 
a combined PxD-epilepsy syndrome, but can present as such. While GLUT1-DS 
and ICCA have been observed in multiple families (Erro et al., 2017), there is only 
one reported family presenting with GEPD (Du et al., 2005). 
It is interesting to note that PRRT2 and SLC2A1 are linked to both PxD 
and combined PxD-epilepsy syndromes (Table 1 and Table 2). This might be 
explained by varying effects of different genetic mutations on protein function. It 
has been suggested, for example, that a 25-35% decrease in GLUT1 function 
might result in milder-, a 40-75% decrease in more severe phenotypes, 
manifesting as PED and GLUT1-DS, respectively (Erro et al., 2017; De Giorgis 
and Veggiotti, 2013). On the other hand, the same PRRT2 mutation (c.649dupC) 
has been shown to result in varying clinical presentations inter- and intrafamilially 
– a pleitropic effect that is not yet understood, but likely attributable to 
environmental factors and the presence of modifier genes (Erro et al., 2017; 
Nobile and Striano, 2014). While mutations in PNKD, the main genetic cause for 
PNKD (Table 1), are not linked to epilepsy, GEPD patients present with a 
combined PNKD-epilepsy phenotype (Du et al., 2005). 
1.3.3 Generalised Epilepsy and Paroxysmal Dyskinesia 
GEPD has been reported in a single family of European descent, in which 4 
individuals presented with epilepsy, 7 with PxD, and 5 with a combination of both 
(Du et al., 2005). PxD was classified as PNKD, with an age of onset between 
infancy and childhood and clinical presentations of dystonic or choreiform 
movements affecting the mouth, tongue, and extremities (Du et al., 2005). These 
attacks were triggered by caffeine, alcohol, and stress, occurring weekly during 
the time of onset but gradually decreasing in frequency with age (Du et al., 2005). 
PNKD attacks lasted seconds to minutes, and were partially responsive to 
clonazepam in some family members (Du et al., 2005). Epileptic seizures were 
found to be generalised in all cases, mainly presenting as absence seizures – 




generalised tonic-clonic seizures in two individuals (Du et al., 2005). Epileptic 
seizures started between infancy and early childhood, occurring daily at first but 
decreasing in frequency to monthly in adolescence with valproate and lamotrigine 
treatment (Du et al., 2005). Pedigree analysis suggested an autosomal dominant 
inheritance pattern of GEPD, while microsatellite marker analysis restricted the 
mutational location to the chromosomal 10q22 region (Du et al., 2005). Sanger 
sequencing detected a heterozygous D434G missense mutation in exon 10 of 
KCNMA1, which was only present in affected individuals and not in unaffected 
family members and 500 independent healthy controls (Du et al., 2005). 
Moreover, the D434G missense mutation creates a Tsp45I restriction site, which 
was used to confirm the Sanger sequencing data via restriction fragment length 
polymorphism (RFLP) analysis (Du et al., 2005). Since KCNMA1 encodes the a-
subunit of the BK channel, which is discussed in detail in Paragraph 1.4, GEPD 
has been classified as a channelopathy (Erro et al., 2017), as part of a 
classification scheme introduced in Paragraph 1.2.1.4. 
1.3.4 KCNMA1 Beyond GEPD 
Four additional mutations in KCNMA1 have recently been linked to PxD and 
epilepsy. Two unrelated Chinese boys were reported to carry distinct 
heterozygous de novo missense mutations in KCNMA1, E884K or N1053S, as 
identified via Next Generation Sequencing of candidate genes, and confirmed by 
Sanger sequencing (Zhang et al., 2015). These patients presented with PNKD in 
infancy, which was successfully treated in one patient with clonazepam (Zhang 
et al., 2015). Developmental delay was present in both patients, but not epilepsy 
(Zhang et al., 2015). A second de novo case of the heterozygous N1053S 
mutation was independently reported in another Chinese boy using the same 
experimental pipeline as described above (Wang et al., 2017a). This patient 
presented with PNKD in infancy, the frequency of which could be reduced with 
clonazepam (Wang et al., 2017a). Developmental delay was present in this 
patient, but not epilepsy (Wang et al., 2017a) . 
In a third study, two sisters from a consanguineous Saudi family were 
reported as homozygous for an autosomal recessive frameshift duplication in 




sequencing, and confirmed by Sanger sequencing (Tabarki et al., 2016). Both 
patients presented with myoclonic seizures in infancy, which were well controlled 
with valproate in one patient, while evolving into tonic- and generalised tonic-
clonic seizures in the other (Tabarki et al., 2016). Both patients showed 
developmental delay, hypotonia, and severe non-progressive cerebellar atrophy, 
as revealed via MRI, but did not exhibit PxD (Tabarki et al., 2016).  
 A fourth study reported the discovery of a de novo heterozygous N995S 
missense mutation in KCNMA1 in two individuals from two independent families 
of European descent, as identified via whole-exome sequencing, and confirmed 
by Sanger sequencing (Li et al., 2018). One patient presented with generalised 
myoclonic absence seizures in early childhood, the other with absence seizures 
in infancy and additional myoclonic seizures in early childhood (Li et al., 2018). 
Both patients were effectively treated with levetiracetam and were not diagnosed 
with PxD (Li et al., 2018).  
Interestingly, only the D434G mutation is linked to a combined PxD-epilepsy 
syndrome (GEPD), while the other four KCNMA1 mutations correlate with 
isolated PxD or isolated epilepsy. Altogether, these mutations provide strong 
evidence for an important role of BK channels in PxD and epilepsy.  
1.4 BK Channels 
In order to understand how the GEPD-linked D434G mutation in KCNMA1 might 
elicit PNKD and epilepsy, the structure and function of BK channels under 
physiological conditions need to be defined. Hence, this paragraph describes (1) 
their protein structure and function, (2) their expression pattern, and (3) their 
physiological functions. Further, it discusses how these attributes might be 
affected by the D434G mutation. 
1.4.1 Protein Structure and Function 
1.4.1.1 Physiological Structure and Function 
BK channels are Ca2+- and voltage-sensitive K+ channels that assemble as 
homotetramers of a-subunits, encoded by KCNMA1 (Latorre et al., 2017). They 




contain a seventh TM segment (S0), which results in an extracellular N-terminus 
(Miller, 2000). BK channels comprise three structural domains: a voltage-sensing 
domain (VSD), a pore-gate domain (PGD), and an intracellular cytoplasmic tail 
domain (CTD), which can be thought of as functionally independent units that 
dynamically interact (Yang et al., 2015). The VSD is made up of 4 TM segments 
(S1-S4) and the PGD of 2 TM segments (S5-S6) separated by an intramembrane 
pore-loop, while the CTD is devoid of hydrophobic entry sites into the lipid bilayer 
but comprises two-thirds of the entire protein (Miller, 2000; Yuan et al., 2010). A 
schematic of one KCNMA1-encoded a-subunit is depicted in Figure 1.2. 
 
 
Figure 1.2 The a-subunit of the BK Channel 
This schematic illustrates the structure of one a-subunit of the BK channel, 
encoded by KCNMA1, as well as the locations of mutations linked to PxD, 
epilepsy, and combined PxD-epilepsy, shown in red (Paragraphs 1.3.3 and 
1.3.4). The a-subunit comprises three major domains: (1) the VSD (S1-S4), (2) 
the PGD (S5-S6 and a linker), and (3) the intracellular CTD. The CTD has two 
regulator of K+ conductance (RCK) domains, RCK1 and RCK2, which both 
contain a Ca2+ binding site (orange). The AC region, a 76-bp region including 
the secondary structures bA-aC (cyan), comprises the N-terminus of RCK1. 
Amino acid positions are shown as numbers next to the RCK domains. This 
figure was adapted from the following publications: (Wang et al., 2017a; Yang et 
al., 2010; Yuan et al., 2012) 
 
In order to form a BK channel, four a-subunits arrange symmetrically around an 




rejecting other ions (Miller, 2000). BK (Big Kalium) channels derive their name 
from their high unitary conductance for K+ (100-300 pS), which is, in fact, the 
highest amongst K+ channels (Yang et al., 2015). This high conductance is 
achieved by clusters of acidic residues at the intra- and extracellular sides of the 
pore, which attract local clusters of K+ ions, as well as a large inner vestibule and 
cytosolic entry site (Yang et al., 2015). However, BK channels are not 
constitutively open, but gated by physiological signals, transitioning between 
open- and closed conformations (Miller, 2000). The open-closed transition of the 
PGD is regulated by two processes: voltage-sensing by the VSD and ligand-
binding to the CTD  (Yang et al., 2015). Indeed, the VSD and the CTD are 
covalently attached to the N- and C-terminus of the PGD, respectively, and 
transduce physical- and chemical- into mechanical energy, respectively, leading 
to conformational changes of the PGD that open and close the pore (Yang et al., 
2015). Voltage alone is sufficient to open BK channels, but BK channels show 
lower voltage-sensitivity than Kv channels (Yang et al., 2015). Indeed, the 
voltage-sensing amino acid residues of BK channels are not concentrated in the 
S4 segment, as for Kv channels, but distributed over several TM segments 
between S1 and S4, leading to complex conformational rearrangements upon 
voltage-sensing that result in pore opening (Yang et al., 2015).  
The large CTD is a unique feature of BK channels, containing binding sites 
for Ca2+, Mg2+, H+, carbon monoxide, ethanol, and lipids (Yang et al., 2015). Ca2+ 
binds with high affinity to the CTD, and is sufficient to open BK channels 
independent of voltage (Yang et al., 2010). The main structural components of 
the CTD are two RCK domains, RCK1 and RCK2 (Figure 1.2) (Yang et al., 2015). 
In the tetrameric BK channel structure, 8 RCK domains from 4 CTDs assemble 
into a large gating ring that is covalently bound to the C-terminus of the PGD, 
with the RCK1 domains facing the lipid bilayer (Wu et al., 2010; Yang et al., 2015). 
X-ray crystallography of human CTDs has confirmed that each RCK domain can 
be further divided into three functional subdomains: (1) an N-terminal Rossmann-
folded subdomain forms the core of the gating ring, (2) an intermediate helix-
crossover domain connects the RCK1 and RCK2 domains within a-subunits, and 




the gating ring (Wu et al., 2010). The gating ring has a diameter of ~81 Å and a 
central hole of ~20 Å that facilitates K+ ion transfer even in the absence of Ca2+ 
(Wu et al., 2010; Yuan et al., 2012).  
Ca2+ binds to RCK domains within a concentration range of 100 nM – 300 
µM and induces a conformational change of the gating ring that pulls on the PGD 
and opens the channel, leading to the transfer of K+ ions (Yang et al., 2015). The 
major conformational change upon Ca2+ binding occurs at the N-terminal RCK1 
domain, which rotates relative to the RCK2 domain and increases in diameter 
from ~81Å to ~93 Å via a process that has been likened to the movement of 
“petals opening on a flower” (Yuan et al., 2012). There are two main Ca2+ binding 
sites in the CTD, one in RCK1 and another in RCK2 – the latter is known as the 
“Ca2+ bowl” (Latorre et al., 2017). X-ray crystallography of human CTDs has 
revealed that the Ca2+ bowl forms a helix-loop-helix motif similar to the EF-hand 
structure of calmodulin, and is located close to the “assembly interface” between 
RCK1 and RCK2, a strategic position to modulate protein structure upon Ca2+ 
binding (Wu et al., 2010; Yuan et al., 2010). Within the Ca2+ bowl, Ca2+ is 
coordinated via carboxylate groups at amino acid residues D895 and D897 as 
well as carbonyl groups at amino acid residues Q889 and D892 (Yuan et al., 
2010). X-ray crystallography data further suggest that the Ca2+ binding site within 
the RCK1 domain coordinates Ca2+ via carboxylate groups at amino acid residues 
D367 and E535 as well as a carbonyl group at amino acid residue R514 (Wu et 
al., 2010). These residue numbers are based on the human BK channel. The two 
Ca2+ binding sites are located ~25 Å apart, and have been shown to contribute 
roughly equally and independently to the Ca2+ sensitivity of the CTD (Yang et al., 
2015). Importantly, biochemical and electrophysiological analyses of the GEPD-
linked D434G mutation in KCNMA1 have revealed that the RCK1 and RCK2 
domains mediate BK channel opening via independent allosteric mechanisms, 
and that the D434G mutation affects a specific allosteric pathway that couples 
Ca2+ binding to channel opening (Yang et al., 2010). 
1.4.1.2 Structure and Function in GEPD 
The D434G mutation is located within the N-terminus of the RCK1 domain of the 




AC region contains the RCK1 Ca2+ binding site and is positioned close to the S6 
segment of the PGD (Yang et al., 2010). Although the D434G mutation does not 
lie within the Ca2+ binding site, but rather very close to it, electrophysiological 
analyses showed that it increases the Ca2+ sensitivity of BK channels (Yang et 
al., 2010). Expressing the D434G-equivalent murine D369G mutation in Xenopus 
laevis oocytes, inside-out patch clamp recordings at varying Ca2+ concentrations 
([Ca2+]) found a shift of the voltage at half-maximum conductance (V1/2) towards 
more negative voltages, as compared to wild-type BK channels (Yang et al., 
2010). To dissociate Ca2+- from voltage-sensitivity, the authors repeated these 
recordings at a holding voltage of -140 mV, showing that step-wise increases of 
[Ca2+] resulted in higher channel open probabilities in the presence of D369G 
(Yang et al., 2010). Together, these data provide strong evidence for the D369G 
mutation to increase the Ca2+ sensitivity of BK channels, resulting in a gain-of-
function.  
By selectively mutating the two Ca2+ binding sites within the CTD, it could 
be shown that D369G mediates its effects specifically via the RCK1 Ca2+ binding 
site, independent of the Ca2+ bowl (Yang et al., 2010). While an increased 
viscosity of the recording solution normally potentiates the Ca2+ sensitivity of BK 
channels, this effect was lost in the presence of the D369G mutation (Yang et al., 
2010). These data suggest that the D369G mutation enhances the allosteric 
coupling between Ca2+ binding to the RCK1 domain and channel opening by 
increasing the rigidity of the CTD (Yang et al., 2010). Indeed, molecular dynamics 
simulations strengthen this hypothesis, illustrating the importance of the AC 
region in transducing chemical energy released upon Ca2+ binding into 
mechanical energy that can pull on the PGD to open the BK channel pore (Yang 
et al., 2010). Altogether, these in vitro studies have provided great insight into the 
biophysical effects of the GEPD-linked mutation on BK channel function. 
However, in order to understand how these effects might contribute to GEPD 
pathology, further aspects of BK channels need to be understood, including their 




1.4.2 Expression Pattern 
BK channels are broadly expressed throughout the human body, including 
nervous-, digestive-, and endocrine tissue (Bailey et al., 2019). Within the CNS, 
the BK channel expression pattern is equally broad, including the basal ganglia, 
thalamus, and cerebellum (Bailey et al., 2019). On a cellular level, BK channel 
expression in the CNS covers various neuronal subtypes, including 
glutamatergic-, GABAergic-, and cholinergic neurons, as well as non-neuronal 
cells, such as astrocytes (Girouard et al., 2010; Griguoli et al., 2016). On the 
neuronal plasma membrane, BK channels have been detected at the pre- and 
post-synaptic termini, along the axon, and at the soma (Griguoli et al., 2016; 
Latorre et al., 2017). Furthermore, BK channels are expressed on a variety of 
intracellular organelles, including the nucleus, mitochondria, and lysosomes 
(Balderas et al., 2015; Li et al., 2014; Zhu, 2017). Altogether, this broad 
expression profile of BK channels makes it difficult to predict how the D434G 
gain-of-function KCNMA1 allele would affect an entire organism, since a vast 
array of physiological functions might be perturbed.  
1.4.3 Physiological Functions 
In addition to the broad nature of BK channel expression (Bailey et al., 2019) 
(Paragraph 1.4.2), functional diversity is amplified via three mechanisms: (1) BK 
channels associate with 8 different subunits, 4 b- (b1-b4) and 4 g-subunits (g1-g4), 
which modulate Ca2+-sensitivity, voltage dependence, gating properties, and the 
sensitivity to pharmacological agents to varying degrees (Griguoli et al., 2016). 
Indeed, the selective association between the BK channel a-, b- and g-subunits 
in different tissues, and in different subcellular compartments, fine-tunes BK 
channel function for specific environmental- and cellular requirements (Latorre et 
al., 2017). b-subunits consist of 2 TM segments, an extracellular loop, and 
intracellular N- and C-termini, and associate with the VSDs of a-subunits (Latorre 
et al., 2017). g-subunits consist of a single TM segment and a large extracellular 
N-terminal leucine-rich repeat domain (Latorre et al., 2017). (2) The mRNA of 
KCNMA1 and of genes encoding the b-subunits (KCNMB1-4) exhibit extensive 




(Griguoli et al., 2016; Latorre et al., 2017; Li and Gao, 2016). (3) Post-translational 
modifications of BK channels, including phosphorylation and lipidation, further 
modify BK channel function, especially via the CTD (Griguoli et al., 2016; Latorre 
et al., 2017). Altogether, these modulatory mechanisms result in functional 
adaptation of BK channels to different subcellular compartments. 
1.4.3.1 BK Channels on the Plasma Membrane 
BK channels have been detected on the plasma membrane of a variety of cell 
types. For example, they are prominently expressed on the plasma membrane of 
vascular smooth muscle cells, where they have been implicated in the negative 
regulation of vascular tone and blood pressure (Latorre et al., 2017). Interestingly, 
the b1-subunit is selectively expressed in smooth muscle cells, and has been 
shown to render BK channels Ca2+-insensitive at [Ca2+] below 300 nM, while 
increasing BK channel Ca2+ sensitivity at higher [Ca2+] (Latorre et al., 2017). BK 
channels are also expressed in urinary- and airway smooth muscle cells, 
negatively regulating urinary bladder contraction and airway inflammatory 
responses, respectively (Latorre et al., 2017).  
 In the kidney, BK channels are expressed on the apical side of principal- 
and intercalated cells in the cortical collecting duct (CCD), contributing to K+ 
homeostasis by K+ secretion into the CCD (Latorre et al., 2017). In these cells, 
BK channels might be directly coupled to TRPV4 Ca2+ channels, which are 
activated by luminal fluid flow-induced shear stress, facilitating BK channel 
activation via Ca2+ entry and binding to the intracellular CTD (Latorre et al., 2017). 
Interestingly, BK channels in principal- and intercalated cells associate with b1- 
and b4-subunits, respectively, implicating functional diversity in these 
neighbouring cells (Latorre et al., 2017). 
 BK channels are also expressed on the plasma membrane of inner- and 
outer cochlear hair cells, together with b1- and b4-subunits (Latorre et al., 2017). 
While the role of BK channels in the cochlea remains incompletely understood, 
their expression on murine inner hair cells has been implicated in affecting central 





In neurons, BK channels can be expressed at different locations along the 
plasma membrane, including the pre- and post-synaptic termini, the soma, and 
along axons (Griguoli et al., 2016; Latorre et al., 2017). At all these locations, BK 
channels are gated by a combination of membrane potential depolarisation and 
increases in [Ca2+] (Griguoli et al., 2016). K+ release by somatodendritic BK 
channels narrows the action potential (AP) width and mediates the fast after-
hyperpolarisation (fAHP) phase of the AP, thereby contributing to membrane 
potential repolarisation (Griguoli et al., 2016). In some neurons, this repolarising 
effect of BK channels is required for the initiation of APs, and therefore excitatory. 
For example,  KCNMA1-/- knockout mice exhibit ataxia that correlates with an 
inhibition of cerebellar Purkinje Cells due to depolarisation block and a 
concomitant dis-inhibition of deep cerebellar nuclei (Sausbier et al., 2004). 
Hence, in Purkinje Cells, BK channel-mediated repolarisation is required to de-
inactivate Nav channels, a necessary process for AP initiation. In other neurons, 
BK channels dampen neural activity and prevent hyperexcitability. For example, 
hippocampal dentate gyrus granule cells of b4-/- knockout mice exhibit faster 
gating kinetics that lead to AP narrowing, higher firing frequencies, and temporal 
lobe seizures (Brenner et al., 2005). The b4-subunit is most prominently 
expressed in the CNS, increasing BK channel Ca2+ sensitivity, while, importantly, 
slowing its gating kinetics, leading to a broadening of AP width (Latorre et al., 
2017). Hence, in the dentate gyrus of b4-/- knockout mice, slow-activating BK 
channels were effectively transformed into fast-activating BK channels, exhibiting 
a narrowed AP width and increased firing frequencies (Brenner et al., 2005). 
Consequently, in these neurons, BK channels inhibit neuronal activity. These 
opposing roles of BK channels are a prominent feature in the CNS, differentially 
affecting neuronal subpopulations.  
At the pre-synaptic terminus, BK channels associate with voltage-gated 
Ca2+ channels (Cav channels) within nanodomains and couple Ca2+ influx to K+ 
efflux (Griguoli et al., 2016). Indeed, a co-localisation between BK channels and 
L-, P/Q-, and N-type Cav channels has been demonstrated to be necessary for 
BK channel opening within a physiological range of membrane potentials 




limiting Ca2+ entry through Cav channels, thereby lowering the cytosolic [Ca2+] 
below the threshold for membrane fusion (Griguoli et al., 2016; Latorre et al., 
2017). However, in some neurons, such as hippocampal CA3 pyramidal cells, 
electrophysiological recordings have shown that pre-synaptic BK channels are 
not involved in neurotransmitter release under basal conditions (Griguoli et al., 
2016; Hu et al., 2001). In these neurons, it has been proposed, BK channels act 
as “emergency breaks”, becoming activated only in response to physiologically 
stressful states that cause substantial increases in intracellular [Ca2+], such as 
epilepsy (Griguoli et al., 2016). Of note, due to a suggested preferential 
expression in excitatory neurons, BK channels might also modulate the 
excitatory-inhibitory balance within neuronal circuits, which has been implicated 
in a variety of neuropsychiatric disorders (Griguoli et al., 2016).  
1.4.3.2 BK Channels on the Mitochondrial Membrane 
Mitochondria are double membrane-bound organelles responsible for cellular 
ATP production via oxidative phosphorylation (Nunnari and Suomalainen, 2012). 
They are composed of an outer mitochondrial membrane (OMM) and an inner 
mitochondrial membrane (IMM), creating an intermembrane space between 
these two lipid barriers as well as an inner matrix that is enclosed by the IMM (Li 
and Gao, 2016). The TCA cycle occurs within the mitochondrial matrix, 
generating the reducing agents NADH and FADH2, which donate electrons to the 
electron transport chain (ETC) located on the IMM, producing ATP via the 
establishment and release of a H+ gradient across the IMM (Nunnari and 
Suomalainen, 2012). Apart from ATP production, mitochondria are involved in a 
variety of cellular processes, including biosynthetic pathways, such as fatty acid 
b-oxidation, apoptosis, and Ca2+ homeostasis (Nunnari and Suomalainen, 2012).  
Mitochondria express a variety of ion channels on the OMM and IMM (Li 
and Gao, 2016). Amongst them, BK channels have been detected 
electrophysiologically and via immuno-staining on the IMM in excitable and non-
excitable cells of various species, including humans, being termed mtBK 
channels (Li and Gao, 2016). Patch clamp recordings from mitoplasts – 
mitochondria stripped off the OMM – determined that the mtBK channel N-




subunits have been identified to assemble with mtBK channels in a cell type-
specific manner, presumably fine-tuning mtBK channel function for different 
environments (Li and Gao, 2016). Interestingly, Western blots and immuno-
staining revealed that the b1- and b3-subunits were not-, and the b2-subunit only 
weakly expressed in the adult rat brain, while the b4-subunit was broadly 
expressed, with particularly high expression levels in thalamus and brainstem 
(Piwonska et al., 2008).  
Most studies on the physiological role of mtBK channels have been 
performed on cardiomyocytes, because these cells lack BK channels on the 
plasma membrane, while expressing high levels of mtBK channels (Li and Gao, 
2016). These studies revealed that mtBK channel activity mediates a 
cardioprotective effect upon myocardial ischaemia, as pre-ischaemic exposure of 
hearts to the BK channel agonist NS1619 significantly reduced myocardial infarct 
size (Singh et al., 2013; Xu et al., 2002). A recent study demonstrated that the 
levels of reactive oxygen species (ROS), by-products of oxidative 
phosphorylation, were elevated in murine KCNMA1-/- cardiomyocytes in post-
anoxic conditions when compared to controls, providing a possible explanation 
for the cardioprotective role of mtBK channels (Soltysinska et al., 2014). 
Moreover, oxidative phosphorylation capacities were reduced in KCNMA1-/- 
cardiomyocytes both during normoxia and upon re-oxygenation after anoxia 
(Soltysinska et al., 2014). These data suggest that mtBK channels are required 
for appropriate energy supply to the myocardium during normoxic conditions and 
upon re-oxygenation after anoxia, while also regulating the oxidative state of 
cardiomyocytes during post-anoxic conditions (Soltysinska et al., 2014).  
Moreover, mtBK channels have been shown to directly regulate the Ca2+ 
retention capacity of mitochondria by inhibiting mitochondrial protein transition 
pores (mPTPs) (Cheng et al., 2008, 2011). Since mPTPs are linked to the indirect 
activation of the intrinsic apoptotic pathway, it has been suggested that mtBK 
channel activity has an anti-apoptotic effect (Cheng et al., 2008, 2011). Indeed, 
a direct inhibition of mtBK channels by the pro-apoptotic protein Bax was 
demonstrated to activate mPTPs and induce the release of cytochrome c, a pro-




implicate mtBK channels with fundamental mitochondrial physiology, suggesting 
that changes in mtBK channel activity might affect a variety of cell types. 
1.4.3.3 BK Channels on the Nuclear Envelope 
The nucleus is a double membrane-bound organelle separating the genome from 
the cytoplasm and regulating gene expression (Li and Gao, 2016). The nuclear 
envelope (NE) surrounds the nucleus and is composed of an inner nuclear 
membrane (INM) and an outer nuclear membrane (ONM), generating the 
perinuclear space between these membranes and the nucleoplasm enclosed by 
the INM (Li and Gao, 2016). Molecular and ionic transport between the cyto- and 
nucleoplasm is mediated by nuclear pore complexes, large protein complexes 
spanning both the INM and ONM (Li and Gao, 2016).  
In addition to a variety of ion channels expressed on both the INM and the 
ONM, nuclear patch clamp recordings, immuno-staining, and immunoelectron 
microscopy have confirmed the presence of BK channels on the ONM, termed 
nBK channels (Li et al., 2014). Of note, the b4-subunit was found to co-assemble 
with nBK channels on the ONM (Li et al., 2014). Voltage imaging of murine 
hippocampal neurons revealed that nBK channels regulate the membrane 
potential across the ONM, as inhibition of nBK channels rendered the perinuclear 
lumen more negative (Li et al., 2014). Importantly, the perinuclear space is an 
independent Ca2+ store with the ability to raise the nuclear [Ca2+] by releasing 
Ca2+ into the nucleus, which regulates activity-dependent gene expression (Li 
and Gao, 2016). Indeed, Ca2+ imaging in murine hippocampal neurons 
demonstrated that specific inhibition of nBK channels increased nuclear [Ca2+] – 
a process mediated by perinuclear Ca2+ release through ryanodine receptors 
located on the INM (Li et al., 2014). Via Western blots and immuno-staining, the 
authors could demonstrate that the inhibition of nBK channels, and the 
concomitant increase in nuclear [Ca2+], induced the phosphorylation of the 
transcription factor (TF) CREB, which resulted in transcriptional changes leading 
to increased dendritic arborisation (Li et al., 2014). These data provide strong 
evidence for a direct regulatory role of nBK channels in gene expression, 
rendering conceivable the notion that aberrant nBK channel activity may be 




1.4.3.4 BK Channels on the Lysosomal Membrane 
Lysosomes are membrane-enclosed intracellular organelles important for the 
catabolism and recycling of intra- and extracellular macromolecules, including 
proteins, carbohydrates, lipids, and nucleic acids (Platt et al., 2018). Lysosomes 
are dynamic and undergo complex cellular trafficking, being involved in a variety 
of signalling processes, including nutrient sensing, ion homeostasis, and the 
exchange of metabolites and Ca2+ with other intracellular organelles (Platt et al., 
2018). In order to fulfil these tasks, lysosomes express a variety of proteins, 
including membrane-bound ion channels, which are important regulators of 
lysosomal pH (~4.5-5), lysosomal membrane potential (which is negative with 
respect to the cytosol), and lysosomal signalling processes (Zhu, 2017).  
Recent evidence confirmed the presence of BK channels on the lysosomal 
membrane via immuno-staining and whole-endolysosomal patch clamp 
recordings (Cao et al., 2015; Zhu, 2017). However, the function of BK channels 
on lysosomes remains unclear. One study reported that lysosomal BK channels 
generate a positive feedback loop between Ca2+ efflux from- and K+ influx into 
the lysosomal lumen, the latter being mediated by BK channel activation upon 
Ca2+ binding to the cytosol-facing CTD (Cao et al., 2015). K+ influx would increase 
the driving force of Ca2+ efflux, resulting in increased Ca2+ release from 
lysosomes (Cao et al., 2015). Interestingly, BK channels were found to co-
localise with lysosomal Ca2+ channels (MCOLN1) on the lysosomal membrane, 
efficiently coupling Ca2+ efflux to K+ influx – reminiscent of BK channel coupling 
to Cav channels on the neuronal plasma membrane (Cao et al., 2015).  
A more recent study confirmed that lysosomal BK channels are activated 
by cytosolic Ca2+ (Wang et al., 2017b). However, rather than being required for 
lysosomal Ca2+ release, this study identified BK channels to be important for the 
replenishment of lysosomal Ca2+ (Wang et al., 2017b). Despite these differences, 
both studies demonstrated that the loss of BK channels caused lysosomal 
trafficking- and storage defects (Zhu, 2017). These findings associate BK channel 
function with a spectrum of metabolic disorders classified as lysosomal storage 
diseases (LSDs) – such as Niemann-Pick disease type C1/2 (NPC1/2), which is 




present with a variety of symptoms, including ataxia, dystonia, and seizures (Platt 
et al., 2018). Importantly, NPC patients exhibit decreased lysosomal Ca2+ 
release, leading to impaired lysosomal trafficking and fusion, increased 
lysosomal lipid accumulation, mitochondrial dysfunction, and inflammation (Platt 
et al., 2018). Interestingly, it has been shown that overexpressing BK channels 
in human fibroblasts from NPC1 patients decreased lysosomal lipid accumulation 
by increasing lysosomal Ca2+ release, implicating BK channels with lysosomal 
trafficking and LSD pathology (Cao et al., 2015).  
1.4.4 Understanding GEPD 
The above sections collectively illustrate the complexity of BK channel expression 
and function. Hence, while in vitro studies on the D434G missense mutation have 
provided important insights into its biophysical effects on BK channel gating 
(Yang et al., 2010), it is impossible to bridge these data and the neurological 
phenotype exhibited by GEPD patients. In particular, two fundamental questions 
remain: (1) where does the D434G mutation exert its pathogenic effects? (2) 
What are the pathogenic effects of GEPD on a molecular level? 
In the original description of GEPD, the authors posited that an increased 
Ca2+ sensitivity and concomitant gain of BK channel function would likely result 
in a narrowing of APs and increased neuronal firing frequencies, hence causing 
PxD and epilepsy (Du et al., 2005). This hypothesis simultaneously suggests a 
pathogenic locus (the brain) and a molecular mechanism (increased neuronal 
firing frequencies) for GEPD. 
While it is possible that the D434G mutation increases neuronal firing 
frequencies, this effect might only apply to some neurons, while others could be 
affected differently, as described in Paragraph 1.4.3.1 (Griguoli et al., 2016). 
Moreover, how does the D434G mutation affect non-neuronal cells? Although 
GEPD patients present with predominantly neurological symptoms, it does not 
necessarily follow that the mutation exerts its pathogenic effects exclusively in 
the brain. Indeed, GLUT1-DS and most forms of PED are caused by mutations 
in SLC2A1, which encodes the glucose transporter GLUT1, as described in 
Paragraph 1.2.1.3 (De Giorgis and Veggiotti, 2013). In these disorders, PxD and 




CNS-intrinsic defects (De Giorgis and Veggiotti, 2013). A dysregulation in energy 
metabolism could also occur due to aberrant insulin release from pancreatic b-
cells, which have been shown to express BK channels (Düfer et al., 2011; 
Houamed et al., 2010) – might this contribute to GEPD? A variety of 
pathophysiological mechanisms in other cell types eliciting GEPD via different 
means are conceivable.  
In addition to identifying the pathogenic locus of GEPD, it would be of 
interest to reveal the molecular mechanisms via which the D434G mutation 
exerts its pathophysiological effects. BK channels regulate various processes 
apart from shaping the AP, as described in Paragraph 1.4.3 (Latorre et al., 2017). 
Hence, in addition to changing neuronal firing frequencies, altered BK channel 
function might affect the regulation of oxidative stress, transcription, and 
metabolism, all of which could contribute to GEPD (Cao et al., 2015; Li and Gao, 
2016). Consequently, in order to understand the pathogenesis of GEPD, the 
organismal effects of the D434G mutation need to be defined. This would require 
the study of an animal model replicating the GEPD genotype, which, to my 
knowledge, does not exist. 
1.5 Drosophila Models in Neurology 
Drosophila melanogaster has been used as a model organism for more than a 
century, and during this time elucidated a number of fundamental principles in 
biology, including the chromosomal theory of heredity, the physical mapping of 
genes, the mutational effects of ionising radiation, and embryological 
development (Rubin and Lewis, 2000). There are two main advantages to the 
use of Drosophila in disease research: (1) the vast array of genetic tools 
available, and (2) the conservation of genetic-, molecular-, and behavioural 
processes between flies and humans (Wangler et al., 2015, 2017; Wu and Lloyd, 
2015). Indeed, Drosophila has been used to study a variety of neurological 
pathologies (Wu and Lloyd, 2015), lending itself to the study of GEPD. 
1.5.1 Advantages of Drosophila  
Drosophila melanogaster exhibits various intrinsic features that render it a 




days), cheap and easy maintenance, high fecundity, a small and sequenced 
genome (4 sets of chromosomes), and a relatively low level of genetic 
redundancy (Cunliffe et al., 2015; St Johnston, 2002). Moreover, a variety of tools 
have been developed that aid genetic studies. For example, the coupling of 
balancer chromosomes, large chromosomal inversions that prevent meiotic 
recombination (St Johnston, 2002), to dominant markers allows for phenotype-
to-genotype inferences to be made, frequently eliminating the need for molecular 
genotyping. Furthermore, a large collection of Drosophila stocks carrying 
transposable element insertions throughout the Drosophila genome is 
commercially available (Bellen et al., 2011). In addition to disrupting most of the 
genes in the Drosophila genome, these insertions can introduce useful 
sequences into the endogenous genome that allow for protein tagging, the 
visualisation of gene expression, or site-specific recombination (Bellen et al., 
2011). Other mutagenic strategies, including EMS- and X-ray mutagenesis, have 
been employed to add to the list of available mutants (St Johnston, 2002). These 
mutant stocks can be used in forward- and reverse genetic screens aimed at 
identifying novel genes and genetic interactions (St Johnston, 2002; Venken et 
al., 2011). In order to manipulate gene expression in a spatially and temporally 
restricted manner, the Gal4/UAS system is available  (Brand and Perrimon, 1993; 
Venken et al., 2011). This binary expression system is based on the binding of 
the Gal4 yeast TF to the Upstream Activating Sequence (UAS), resulting in 
transcriptional initiation of responder elements downstream of UAS (Venken et 
al., 2011). Spatially controlled transcription of responder elements is achieved via 






Figure 1.3 The Gal4/UAS Binary Expression System 
Two separate transgenic Drosophila lines, carrying a Gal4 driver- and a UAS-
responder construct, are crossed together, resulting in the Gal4-mediated 
activation of UAS and the expression of a responder element (R) in the progeny. 
Spatial control of R expression is achieved by the conditional expression of Gal4 
(violet), which is under the control of tissue-specific promoters/enhancers (P/E).  
 
Depending on the responder element downstream of UAS, over-expression or 
knock-down of specific genes can be achieved as well as the labelling of cellular 
subpopulations (Venken et al., 2011). As for transposable element insertions, a 
vast array of transgenic Drosophila lines carrying Gal4- and UAS constructs is 
commercially available, facilitating the transcriptional manipulation of most of the 
genes in the Drosophila genome (Perrimon et al., 2010). Of note, the core 
structure of the Gal4/UAS system illustrated in Figure 1.3 has been expanded 
extensively. Gal4 activity can be repressed by Gal80, while the split-Gal4 system 
expresses two Gal4 heterodimers under separate regulatory control, only 
initiating transcription of the responder element when their expression patterns 
overlap (Venken et al., 2011). Moreover, two alternative binary expression 
systems exist, the LexA/LexOp- and the QF/QUAS system, which can be used 
alone or in combination with the Gal4/UAS system (Venken et al., 2011). To 
obtain temporal control over the expression of responder elements, heat- and 
drug-activatable versions of TFs and their repressors are available (Venken et 
al., 2011). 
 In Drosophila neurobiology research, the Gal4/UAS system is regularly 
used to selectively modulate neuronal activity via the conditional expression of 
pro-apoptotic genes (hid, reaper, grim), blockers of synaptic transmission (TNT, 
Shibirets1), inhibitory K+ channels (Kir2.1, EKO, dOrk), excitatory cation channels 




inhibit neurons (ChR2 and Arch, respectively) – an experimental strategy often 
employed to link neural activity to behaviour (Venken et al., 2011). In addition to 
manipulating neural activity, the latter can be passively recorded with 
conditionally expressed genetically-encoded Ca2+ indicators (GECIs), such as 
GCaMP, a fusion protein that undergoes a conformational change upon Ca2+ 
binding, resulting in increased fluorescence (Chen et al., 2013).  
 For the study of human disease-causing mutations, it might be desirable 
to precisely replicate disease-linked mutations in flies. While recessive diseases 
may be studied by using commercially available hypomorphic- or null alleles, 
some human disease-causing mutations are neo- or hypermorphic, as observed 
in GEPD (Du et al., 2005). Various gene editing technologies are available to 
generate fly models that precisely replicate such mutations, including ends-in- 
and ends-out homologous recombination (HR) and the CRISPR-Cas9 system 
(Bier et al., 2018; Wesolowska and Rong, 2010). Importantly, these methods 
modify genes at their endogenous loci, preserving endogenous regulation that 
might contribute to pathology (Venken et al., 2011).  
A further advantage of Drosophila as a model organism in neurological 
disease research is the conservation of genetic-, molecular-, and behavioural 
processes between flies and humans. It has been estimated that ~64% of human 
genes linked to neuropathologies are conserved in flies (Fortini et al., 2000), 
despite the evolutionary divergence of these two species an estimated 782.7 
million years ago (Hedges et al., 2006). The fly brain contains ~90000 neurons, 
about 1 million-fold fewer than the human brain, but it uses the same 
neurotransmitters (glutamate, ACh, GABA) and biogenic amines (dopamine, 
serotonin) to facilitate conserved mechanisms of neurotransmission (Venken et 
al., 2011). Moreover, ionic processes underlying the initiation and propagation of 
APs are conserved between flies and humans, including genes encoding various 
ion channels (Venken et al., 2011). However, there are important differences 
between the fly- and human brain: neuronal cell bodies in the Drosophila brain 
surround a brain neuropil, which is composed of axons, dendrites, and synapses, 
whereas the human brain contains both neurites and somata (Venken et al., 
2011). Notably, the roles for glutamate and ACh are reversed in fly- and human 




and glutamate at the neuromuscular junction (NMJ), and vice versa for the latter 
(Venken et al., 2011). Nevertheless, the study of human genes linked to 
neurological diseases and disorders can provide important functional insight into 
conserved pathophysiological processes of translational value, as has been 
demonstrated for a variety of neuropathologies. 
1.5.2 Drosophila Disease Models 
Studies in Drosophila have made important contributions to neurological disease 
research, particularly in the investigation of polyglutamine repeat diseases, 
frontotemporal dementia, Alzheimer’s disease, neurodegeneration, amyotrophic 
lateral sclerosis, sleep disorders, PD, and epilepsy (Cunliffe et al., 2015; Wu and 
Lloyd, 2015). While PxD has, to my knowledge, not yet been modelled in flies, 
studies on dystonia, a component of PxD, have led to an increased 
understanding of the molecular mechanisms underlying this movement disorder.  
 Autosomal dominant early-onset torsion dystonia (DYT1 dystonia) is 
linked to a 3-bp deletion in TOR1A (TOR1AD302/303), encoding the ATP-binding 
protein TorsinA, and considered the most common and severe form of hereditary 
dystonia (Ozelius et al., 1997). Early studies investigating the function of the fly 
TOR1A orthologue torsin applied conditional knock-down- and over-expression 
approaches to show that it prevents age-related retinal degeneration and might 
be involved in lysosomal function and the regulation of oxidative stress (Muraro 
and Moffat, 2006). The investigation of a torsin null allele – generated via ends-
out HR – identified decreased GTP cyclohydrolase I (GTPCH) protein levels in 
torsin null heterozygotes, implicating altered dopamine metabolism in DYT1 
dystonia (Wakabayashi-Ito et al., 2011). Indeed, a locomotor defect of torsin null 
L3 larvae could be rescued by dopamine supplementation (Wakabayashi-Ito et 
al., 2011). These results could be replicated via neuronal over-expression of 
human TOR1AD302/303, which acted in a dominant negative manner to reduce 
GTPCH protein levels in adult and larval brains, as shown via Western blots 
(Wakabayashi-Ito et al., 2015). Interestingly, transmission electron microscopy 
(TEM) revealed that loss of torsin results in the peri-nuclear retention of large 
ribonucleoproteins (megaRNPs) due to their abnormal attachment to the INM – 




from the nucleus (Jokhi et al., 2013). Consequently, megaRNP-associated 
mRNAs were shown via FISH to be mostly absent from post-synaptic termini at 
the torsin null larval NMJ, leading to an abnormal development of synaptic 
boutons (Jokhi et al., 2013). Since NE budding mediates part of the Wnt signalling 
pathway via Frizzled2, disruption of which was also found to result in aberrant 
synaptic bouton development at the larval NMJ, these data implicate a role for 
Torsin in synaptic development and plasticity (Speese et al., 2012). 
Autosomal dominant myoclonus-dystonia, a combined dystonia syndrome 
defined by non-epileptic myoclonic jerks and mild to moderate dystonia, has been 
linked to a missense mutation in KCTD17, encoding a Cullin-3 adaptor protein 
(Mencacci et al., 2015). Interestingly, two independent screens for Drosophila 
sleep mutants demonstrated that loss of insomniac (inc), the fly orthologue of 
KCTD17, causes severely reduced sleep duration and consolidation 
(Pfeiffenberger and Allada, 2012; Stavropoulos and Young, 2011). Weighted 
gene co-expression network analysis (WGCNA) based on human brain 
transcriptomic data identified HPCA, encoding a neuronal Ca2+ sensor protein, to 
be co-expressed with KCTD17 in the putamen, suggesting a functional 
connection between these genes (Mencacci et al., 2015). Intriguingly, not only 
have missense and null mutations in HPCA been linked to DYT2 dystonia (Atasu 
et al., 2018; Charlesworth et al., 2015), a recent study has shown that its fly 
orthologue Neurocalcin (Nca) regulates night-time sleep in Drosophila (Chen et 
al., 2019). Since conserved endophenotypes can elicit profoundly different 
organismal behaviours across species (Lehner, 2013), the investigation of 
Drosophila sleep might, therefore, lead to a better understanding of the molecular 
mechanisms underlying dystonia in humans, illustrating the versatility of this 
model organism in neurological disease research.  
 The study of epilepsy in Drosophila focusses, in part, on the “bang-
sensitive” class of Drosophila mutants, which exhibit seizure-like states both 
behaviourally and electrophysiologically, and are used as a model for human 
intractable epilepsy (Cunliffe et al., 2015; Parker et al., 2011). Larval 
motoneurons (MNs) of the bang-sensitive mutant slamdance (sda), for example, 
were shown to exhibit an increased persistent sodium current (INap), which has 




2015; Marley and Baines, 2011). Interestingly, this increase in INap was shown to 
be mediated by activity-dependent alternative splicing of the paralytic (para) 
transcript, which encodes the a-subunit of the only fly Nav channel (Cunliffe et 
al., 2015; Lin et al., 2009, 2012), illustrating how Drosophila can uncover novel 
molecular mechanisms underlying epileptogenesis, potentially contributing to 
improved AED design. 
 To directly study human epilepsy syndromes in flies, the point mutations 
in SCN1A linked to Dravet syndrome (DS) and genetic epilepsy with febrile 
seizures plus (GEFS+) were introduced into the fly orthologue para via ends-out 
HR (Schutte et al., 2014; Sun et al., 2012). Both knock-in flies exhibited 
temperature-induced seizures, and whole-cell recordings from local neurons 
(LNs) in the dorsolateral antenna lobe revealed that the GEFS+ mutation 
increased-, while the DS mutation decreased Nav channel function (Schutte et 
al., 2014; Sun et al., 2012). However, both mutations resulted in decreased 
evoked and spontaneous firing frequencies of LNs, suggesting shared cellular 
mechanisms underlying the seizure phenotypes (Schutte et al., 2014; Sun et al., 
2012). These studies illustrate how Drosophila knock-in models of known 
epilepsy mutations can lead to novel insights into the nature of human epilepsy 
syndromes. 
1.5.3 Drosophila slo 
1.5.3.1 Physiological Functions of slo 
As introduced in Paragraph 1.3.3, GEPD is linked to a D434G missense mutation 
in KCNMA1 (Du et al., 2005), whose Drosophila orthologue is called slo. Both 
genes encode the a-subunit of the voltage- and Ca2+-activated BK channel, also 
known as Slo (Latorre et al., 2017) (Paragraph 1.4). In fact, Drosophila slo was 
the first Slo channel a-subunit to be cloned and sequenced (Atkinson et al., 
1991). Subsequent inside-out patch clamp recordings form Xenopous laevis 
oocytes demonstrated that Drosophila Slo is functionally homologous to 
mammalian Slo, being both voltage- and Ca2+-sensitive (Adelman et al., 1992), 
as described in Paragraph 1.4.3.1 (Griguoli et al., 2016; Latorre et al., 2017). 




and C-terminal tail domains of Slo in Xenopus laevis oocytes resulted in the 
assembly of chimeric Slo channels functionally similar to full-length Slo of either 
species, as shown via inside-out patch clamp recordings (Wei et al., 1994). 
Importantly, as described for KCNMA1 (Latorre et al., 2017) (Paragraph 1.4.3), 
Drosophila slo exhibits extensive alternative splicing, giving rise to isoforms of 
varying biophysical properties, such as marked differences in Ca2+-sensitivity 
(Lagrutta et al., 1994). 
slo is broadly expressed in Drosophila larvae and adults, prominently in 
neurons and muscles, but also in the trachea and midgut (Becker et al., 1995). 
Within the adult brain, slo shows a broad expression pattern and strongly 
localises to the neuropil (Becker et al., 1995; Jepson et al., 2012). However, no 
regulatory b- and g-subunits have been described in Drosophila (Griguoli et al., 
2016). Instead, Slo function has been shown to be regulated by 4 direct- and 
indirect binding partners: (1) Slowpoke binding protein (Slob) was identified via a 
yeast two-hybrid screen to bind to the large CTD of Slo, a physical interaction 
that was confirmed via co-immunoprecipitation (Schopperle et al., 1998). The 
application of Slob to Slo-containing inside-out patches potentiated Slo currents, 
initially suggesting that Slob acts as a positive regulator of Slo activity 
(Schopperle et al., 1998). However, more recent studies have identified 6 Slob 
splice isoforms, four of which (Slob71, Slob65, Slob53, and Slob47) increase the 
voltage-sensitivity of Slo, while the other 2 (Slob57 and Slob51) decrease its 
voltage-sensitivity and increase its deactivation kinetics (Zeng et al., 2005). 
Hence, Slob can both activate and inhibit Slo function. (2) Using Slob as a bait in 
a follow-up yeast two-hybrid screen, the z isoform of 14-3-3 was identified as a 
physical interaction partner of Slob, as confirmed via co-immunoprecipitation 
(Zhou et al., 1999). While not directly binding to Slo, 14-3-3 negatively regulates 
Slo currents via Slob, significantly decreasing the voltage-sensitivity of Slo and 
Slo-mediated evoked current responses (Zhou et al., 1999). (3) dyschronic (dysc) 
was identified through a forward-genetic screen for arrhythmic locomotor 
behaviour in adult flies and its protein product Dysc shown to physically interact 
with Slo via co-immunoprecipitation (Jepson et al., 2012). Dysc was shown to be 




immunofluorescence was almost entirely lost in homozygous dysc null flies 
(Jepson et al., 2012). Whole-cell patch clamp recordings from dilp2-expressing 
neurons in the pars intercerebralis (PI) of the adult Drosophila brain 
demonstrated that Slo currents were significantly reduced in a dysc null 
background (Jepson et al., 2012). It was further shown that slo and dysc act in a 
common genetic pathway to regulate AZ structure and evoked synaptic 
transmission at the Drosophila larval NMJ (Jepson et al., 2014). (4) Perforated 
patch-clamp recordings from the posterior dorsal neuron 1 (DN1p) cluster have 
recently shown that wide awake (wake) positively regulates the fAHP, which is 
partly mediated by Slo (Tabuchi et al., 2018). Co-immunoprecipitation 
experiments demonstrated that Wake and Slob physically interact, suggesting 
that Wake affects Slo currents via Slob (Tabuchi et al., 2018). Indeed, immuno-
staining for Slob suggested a model in which Wake facilitates the binding of Slob 
to Slo, thereby modulating Slo currents in a circadian manner (Tabuchi et al., 
2018). 
1.5.3.2 Phenotypes Associated with Loss of slo 
While, to my knowledge, no Drosophila gain-of-function slo allele has been 
generated, the study of several loss-of-function alleles has greatly contributed to 
an increased understanding of slo function on a behavioural and cellular level. 
 The first slo null allele, slo1, was recovered during a screen for 
homozygous EMS-induced mutations that caused adult fly paralysis upon 
exposure to 38ºC (Elkins et al., 1986). slo1 homozygotes were not completely 
paralysed at 38ºC, but displayed uncoordinated movements and remained 
motionless for several minutes when transferred to 22ºC after a 4-min exposure 
to 38ºC (Elkins et al., 1986). Moreover, slo1 homozygotes exhibited a general 
locomotor defect, leg-shaking under anaesthesia, and diminished flight ability 
(Elkins et al., 1986). The temperature-induced semi-paralytic phenotype was later 
termed “sticky-feet” because the legs of slo null homozygotes would remain 
anchored to the ground even if flies were physically pushed sideways (Atkinson 
et al., 2000). In addition to heat shock, this phenotype could be induced with “cool 
but very bright light” (Atkinson et al., 2000). Interestingly, the ash218 allele, a 




complemented the slo flight defect but not the sticky-feet phenotype, suggesting 
the former to be due to a loss of slo in muscle tissue, while the latter is due to 
loss of neuronal slo (Atkinson et al., 2000). Moreover, slo1 homozygotes exhibited 
altered male courtship song patterns, most notably lower amplitude pulses and 
longer inter-pulse intervals (Peixoto and Hall, 1998). The expression of slo cycles 
in a circadian manner, and slo null homozygotes (slo1 and slo4, an X-ray-induced 
chromosomal inversion) showed arrhythmic locomotor activity under free-running 
conditions (constant darkness, DD), without a change in overall activity levels 
(Ceriani et al., 2002; Fernández et al., 2007). In particular, loss of slo expression 
resulted in a loss of morning anticipation, which, in slo4 homozygotes, was linked 
to disrupted dorsal projections of pdf-expressing neurons, possibly 
desynchronising the circadian network (Ceriani et al., 2002; Fernández et al., 
2007). Moreover, neuronal slo expression is necessary and sufficient for the 
development of rapid tolerance to the sedative effects of benzyl alcohol and 
ethanol, defined as a decrease in drug responsiveness as a result of prior drug 
exposure (Cowmeadow et al., 2005, 2006; Ghezzi et al., 2004). Interestingly, 
electrophysiological recordings from the dorsal longitudinal flight muscles (DLMs) 
showed that the increase in neuronal slo expression following benzyl alcohol 
exposure lowered the seizure threshold (Ghezzi et al., 2010). This result is 
congruent with earlier findings that slo null homozygotes exhibit increased 
seizure thresholds compared to controls (Kuebler et al., 2001). These data 
suggest that increased neuronal slo expression can have excitatory effects in the 
nervous system. Electrophysiological studies of slo null homozygotes have 
directly assessed this possibility in both muscles and neurons. 
 Intracellular recordings from the DLMs of slo1 homozygotes demonstrated 
that these mutants exhibited broadened DLM spikes (Elkins et al., 1986). Under 
voltage-clamp, it could be shown that slo1 homozygotes specifically lacked the 
Ca2+-gated fast K+ current (ICF), while retaining the other three K+ currents: ICS, 
IA, and IK (Elkins et al., 1986). Hence, this study established an important role for 
slo in mediating the fast repolarisation of the muscle AP. In response to a 
constant depolarising current, DLMs usually exhibit a delay before spike initiation, 
a process called “delayed excitation” (Elkins and Ganetzky, 1988). In slo1 




1988). Current clamp recordings from the DLMs further showed that slo1 
homozygotes exhibited abnormal AP train firing, initiating overshooting APs of 
longer duration for every AP except the first in a train, which can be mediated by 
IA (Elkins and Ganetzky, 1988). A role for slo in mediating ICF and contributing to 
AP repolarisation was confirmed via electrophysiological recordings from L3 
larval body wall muscles as well as from cultured neuroblasts, both exhibiting 
broadened APs in a slo1 background (Saito and Wu, 1991; Singh and Wu, 1990). 
Despite the excitatory effects associated with a loss of slo, early 
electrophysiological recordings from the larval NMJ of slo1 homozygotes 
identified a decreased amplitude of excitatory junctional currents (EJCs) 
(Warbington et al., 1996). More recent larval NMJ studies have shown that loss 
of slo had either no effect (Lee et al., 2008, 2014), or caused an increase in EJC 
amplitude (Jepson et al., 2014). Morphological abnormalities of the larval NMJ 
have also been identified in response to a loss of slo: the area of synaptic boutons 
and pre-synaptic AZs was found to be increased (Jepson et al., 2014), while 
another study identified an increased number of synaptic boutons and the 
emergence of satellite boutons, small boutons budding off from larger ones (Lee 
and Wu, 2010). Via voltage-imaging using Archaerhodopsin3, it could be shown 
that slo1 homozygotes exhibit an increased AP width at pre-synaptic termini of 
MNs at the larval NMJ, an effect that was particularly strong during trains of 
repetitive nerve stimulation (Ford and Davis, 2014). Moreover, the Ca2+-
dependent modulation of AP width was lost in slo1 homozygotes, suggesting that 
slo mediates ICF in MN pre-synaptic termini as well, where it would act as a break 
on neurotransmitter release (Ford and Davis, 2014). Whole-cell patch clamp 
recordings in situ confirmed that slo is required to mediate ICF and the fAHP in 
larval MNs (Kadas et al., 2015). Consequently, the endogenous intraburst firing 
frequencies of MNs decreased in slo null homozygotes (slo1 and slo4), while the 
synaptic drive potential amplitudes increased (Kadas et al., 2015). Thus, Slo 
channel activation can also lead to increased firing frequencies in neurons, 




1.6 Project Aim 
Three themes can be extracted from this chapter: (1) The pathogenic 
mechanisms underlying PxD and combined PxD-epilepsy syndromes are 
incompletely understood (Erro et al., 2017); (2) GEPD is linked to a D434G 
missense mutation in KCNMA1, but despite in vitro studies elucidating the 
biophysical effects of this mutation, it is unclear how it causes GEPD in vivo (Du 
et al., 2005; Yang et al., 2010); (3) KCNMA1 has a Drosophila orthologue, slo, 
and flies have been successfully used in the past to study a range of neurological 
pathologies (Wu and Lloyd, 2015). 
 Hence, the project aim of this thesis is to generate a Drosophila knock-in 
model of GEPD, in order to investigate the pathophysiological mechanisms 
underlying this PxD-epilepsy syndrome in a living organism. Using this model, 
three main questions will be addressed: (1) what are the organismal effects of 
the D434G-equivalent mutation in flies? (2) Where is the mutation required to 

















2 Generation of a GEPD Fly Model 
2.1 Introduction 
While the biophysical effects of the GEPD-linked D434G missense mutation on 
BK channels have been thoroughly described – demonstrating an increased 
efficiency of the allosteric coupling between Ca2+-binding and channel opening 
(Yang et al., 2010) (Paragraph 1.4.1.2) – GEPD pathogenesis on an organismal 
level is not yet understood. To address this problem, I used ends-out HR to 
introduce the GEPD-linked point mutation into the Drosophila gene slo, the fly 
orthologue of KCNMA1. This mutation results in a codon change from GAG to 
GGG via an A1097G transition, replacing glutamic acid with glycine at amino acid 
position 366 in Slo, thereby generating a novel allele called sloE366G. The E366G 
amino acid change is equivalent to human D434G (Du et al., 2005). Ends-out HR 
relies on in vivo HR between the endogenous slo locus and an artificially 
introduced DNA sequence, referred to as “donor template” (Figure 2.1). This 
donor template was designed to carry the A1097G point mutation, thus 
introducing the GEPD-linked missense mutation into the endogenous Drosophila 
genome.  
   
 
Figure 2.1 Ends-out Homologous Recombination 
Ends-out HR relies on an experimentally introduced donor template to 
recombine with its homologous locus within endogenous slo. The donor 
template carries the A1097G point mutation, introducing the GEPD-linked amino 
acid change (E366G, red) into slo. Exons, represented as rectangles, are drawn 





This chapter describes the generation and validation of sloE366G. To this 
end, I followed a protocol that has successfully been used previously to generate 
Drosophila knock-in models of epilepsy syndromes via ends-out HR (Schutte et 
al., 2014; Staber et al., 2011; Sun et al., 2012). It starts with the design and 
construction of a plasmid construct that carries homology arms to the locus of 
interest within slo. This plasmid construct is injected into fly embryos, where it 
randomly integrates into the endogenous genome via P-element transposition. 
Subsequently, the integrated plasmid is experimentally excised and linearised in 
vivo, in order to act as a donor template for HR at the endogenous slo locus 
(Staber et al., 2011). Successful germline recombination events were verified via 
PCR and Sanger sequencing. The resulting recombinants were then outcrossed 
into isogenic background and sequence-validated, confirming the successful 
























2.2 Statement of Contribution 
2.2.1 Direct Contributions 
This project was initially conceptualised by Dr. James Jepson, who designed the 
homology arms and PCR primers for their amplification. Dr. James Jepson’s 
contributions are acknowledged in the relevant figure legends (Figure 2.3, Figure 
2.4, Figure 2.5). Dr. Ko-Fan Chen optimised the PCR parameters for the 
amplification of the homology arms, which I used as an entry point to this project 
– this is also acknowledged in the relevant figure legend (Figure 2.5).   
2.2.2 Indirect Contributions 
Dr. James Jepson has been a fantastic fly genetics teacher and guided me with 
his experience through the ends-out HR protocol. Dr. Ko-Fan Chen was an 
equally fantastic teacher in molecular biology and an endless resource of 
experience and ideas, which were invaluable during the cloning stages of the 
















2.3 Materials and Methods 
2.3.1 Genetic Nomenclature 
The genotypes of flies used in this chapter are listed in Paragraph 2.3.2. In the 
main text, only transgenes, mutant constructs, and mutations deviating from iso31 
– an isogenised w1118 strain – are denoted. Semicolons in the main text are 
omitted, unless they are necessary to separate chromosomes. For example, 
;;sloE336G/TM6B,Tb is denoted as sloE366G/TM6B,Tb. The fourth chromosome is 
disregarded in both notations. Flies carrying the sloE366G and sloloxP alleles might 
be referred to collectively as “post-Cre” flies.  
2.3.2 Fly Stocks 
Table 3 Fly Stocks of Chapter 2 
Genotype Source 
iso31 Kind gift from Dr. Kyunghee Koh 
w1118 BestGene Inc. 
y,w;hs-FLP,hs-I-SceI/CyO; BDSC: 6934 
w;P[w25.2]-Arm2E366G-Arm1/CyO; This thesis 
y,w,ey-FLP;; BDSC: 5580 
w;Sco/CyO; Kind gift from Dr. Kyunghee Koh 
w;;TM2,Ubx130/TM6B,Tb Kind gift from Dr. Kyunghee Koh 
w;;sloE366G[w+]/TM6B,Tb This thesis 
w;;sloloxP[w+]/TM6B,Tb This thesis 
y,w,Cre;;D*/TM3,Sb BDSC: 851 
w;;sloE366G/TM6B,Tb This thesis 
w;;sloloxP/TM6B,Tb This thesis 
 
2.3.3 Fly Husbandry 
Unless otherwise indicated, fly stocks were maintained at room temperature (RT) 




Table 4 Fly Food Recipe 
Reagent Concentration 
Agar 10 g/L 
Sucrose 15 g/L 
Glucose 33 g/L 
Yeast 35 g/L 
Maize Meal 15 g/L 
Wheatgerm 10 g/L 
Treacle 30 g/L 
Soya Flour 7.22 g/L 
Nipagin 1g (in 10 mL ethanol)/L 
Propionic acid 5 mL/L 
 
2.3.4 Bioinformatics 
The Human Genome Assembly GRCh38.p12 and the Drosophila melanogaster 
Genome Assembly BDGP6 were used throughout this chapter, as well as 
Ensembl v. 95 (Zerbino et al., 2018). For analyses using the UCSC Genome 
Browser (http://genome.ucsc.edu), the genome assembly release from August 
2014 was used (Kent et al., 2002). 
2.3.4.1 Amino Acid Sequence Alignments 
For conservation analysis between human KCNMA1 and fly Slo, the amino acid 
sequences corresponding to their longest transcripts (human KCNMA1-210 and 
Drosophila Slo-RT, respectively) were retrieved from Ensembl and globally 
aligned to each other using the EMBOSS Needle pairwise sequence alignment 
tool (Needleman and Wunsch, 1970). For multiple sequence alignments of 
Sanger sequencing results, the Clustal Omega multiple sequence alignment tool 
was used (Sievers et al., 2011). 
2.3.4.2 BoxShade Plots 
The BOXSHADE software (v. 3.21), provided by ExPASy (Gasteiger et al., 2003), 





2.3.4.3 Design of Homology Arms 
To design homology arms around the E366 locus within slo, the UCSC genome 
browser was used. Sequence conservation between Drosophila melanogaster 
and related species was judged by manual inspection. 
2.3.4.4 Sequence Analysis of sloE366G and sloloxP 
To analyse the sequence variation present within endogenous sloE366G and sloloxP 
of post-Cre flies, I first downloaded genomic variation data for Drosophila 
melanogaster from the Ensembl File Transfer Protocol (FTP), provided in 
genome variation format (GVF) (Reese et al., 2010). Using the BLASTN tool on 
Ensembl, I extracted the absolute genomic positions for each of the variants 
identified in post-Cre flies, and, using basic Unix commands, queried the GVF file 
for any annotated variation at these genomic positions. 
2.3.5 DNA Extraction 
2.3.5.1 Standard Protocol 
This protocol was adapted from BDGP Resources and is available at 
https://www.fruitfly.org/about/methods/inverse.pcr.html. It was used to extract 
genomic DNA (gDNA) for the following downstream applications: (1) cloning the 
homology arms, (2) confirmation of positive recombinants via PCR, (3) allele 
identification of positive recombinants, and (4) sequence-validation of post-Cre 
flies. 10-30 anaesthetised flies were frozen at -80ºC for 30 min, before being 
homogenised in 400 µL Buffer A (100 mM Tris-HCl at pH = 7.5, 100 mM EDTA, 
100 mM NaCl, 0.5% SDS), using a tissue grinder (Kimble, 749540-0000) and 
disposable pestles (Kimble, 749521-0500). The homogenates were incubated at 
65ºC for 30 min, before adding 800 µL LiCl/KAc solution (1 part 5 M KAc stock:2.5 
parts 6 M LiCl stock) and incubating on ice for 10 min. The samples were then 
centrifuged at 14000 rpm for 15 min at RT, and 1 mL of the supernatant 
transferred into fresh 2 mL eppendorf tubes. 600 µL of isopropanol (Sigma-
Aldrich, I9516-500ML) were added and mixed well with the samples, before 
centrifuging at 14000 rpm for 15 min at RT. The supernatant was discarded and 
1 mL of 70% ethanol (Sigma-Aldrich, E7023-500ML) added to each sample, 




discarded and the samples dried at RT. 30 µL of warm nuclease-free water (50ºC) 
were added to the dry pellets to resuspend the DNA. The samples were either 
used immediately for downstream applications or stored at -20ºC.  
2.3.5.2 Quick Protocol 
This protocol was adapted from (Gloor et al., 1993). It was used to extract gDNA 
for the PCR-based outcrossing of post-Cre recombinants. Single flies were 
placed into individual 1.5 mL eppendorf tubes and frozen at -80ºC for 30 min. 
Flies were then squashed in 50 µL “squishing buffer” (10 mM Tris-HCl at pH = 8, 
1 mM EDTA, 25 mM NaCl, 200 g/mL Proteinase K), using a 200 µL pipette tip 
(Gloor et al., 1993). Proteinase K (NEB, P8107S) was added freshly to the 
squishing buffer stock solution prior to every gDNA extraction. The samples were 
incubated at 37ºC for 30 min, before heat-inactivating Proteinase K at 95ºC for 2 
min and centrifuging the samples at 14000 rpm for 7 min at RT. Lastly, the 
supernatant (containing the DNA) was transferred to fresh eppendorf tubes and 
either used immediately for downstream applications or stored at 4ºC. 
2.3.6 PCR  
2.3.6.1 PCR Primer Design 
To design PCR primers, the online tool Primer3Plus was used (Untergasser et 
al., 2012). The standard parameters were changed as follows: Max Tm 
Difference was set to 5°C, Min GC % to 40.0, and Max GC % to 60.0. Product 
Size Range was adjusted as required. Primers were ordered from Sigma-Aldrich. 
2.3.6.2 PCR Primers 
The primers used to amplify the homology arms from iso31 gDNA are shown in 
Table 5.  
Table 5 PCR Primers to Amplify the Homology Arms 












In order to validate recombination events, PCR was performed using the primers 
shown in Table 6. 
Table 6 PCR Primers to Validate Recombination Events 
Primer Name Primer Sequence 
pW-Acc3_F (forward primer) GCTCAGCTTGCTTCGCGATGTGTTCAC 
pW-Acc1_R (reverse primer) TTAGTTGAGTGCTTAAATTCAAAGGAT 
 
The primers used for PCR-based outcrossing of post-Cre recombinants are 
shown in Table 7. 
Table 7 PCR Primers for Post-Cre Outcrossing 
Primer Name Primer Sequence 
OCF (forward primer) AGACTAGTCTAGGGTACCGCA 
OCR (reverse primer) TAGTTCCTTGAATTGGCAGCG 
 
To validate the PCR strategy before commencing PCR-based outcrossing, an 
alternative forward primer was used, shown in Table 8. The same reverse primer 
as shown in Table 7 was used for this PCR. 
Table 8 PCR Validation Forward Primer 
Primer Name Primer Sequence 
a2_F1 (forward primer) GCAGCTCAATGGAATGTGATT 
 
The primers used to amplify Arm1 and Arm2 from the gDNA of post-Cre flies are 
shown in Table 9 and Table 10, respectively. 
Table 9 PCR Primers to Amplify Arm1 Post-Cre 
Primer Name Primer Sequence 
GEPD_arm1_F1 (forward primer) CGCCCATCGATTTGCGTTTT 
GEPD_arm1_R1 (reverse primer) CACATTCCATTGAGCTGCGG 
 
Table 10 PCR Primers to Amplify Arm2 Post-Cre 












To facilitate PCR using the primers shown in Table 5, Table 6, Table 9, and Table 
10, the gDNA was pre-digested with the restriction enzyme XhoI (NEB, R0146S) 
at 37ºC for 16 h. XhoI does not cut the loci of interest, but fragments the gDNA 
and increases primer accessibility. The reaction mixture used for pre-digestion is 
shown in Table 11. XhoI was heat-inactivated at 65ºC for 20 min. 
Table 11 XhoI Pre-digestion of gDNA 
Reagent Volume / µL 
Nuclease-free water 41 
gDNA 3 
NEB CutSmart Buffer 5 
XhoI enzyme 1 
Final volume 50 
 
2.3.6.4 PCR Reaction 
PCR using the primers shown in Table 5, Table 6, Table 9, and Table 10 was 
performed with the Q5 High-Fidelity 2X Master Mix (NEB, M0492S), using the 
reaction mixture shown in Table 12. 
Table 12 Q5 PCR Reaction 
Reagent Volume / µL 
Nuclease-free water 18  
Forward primer 2.5  
Reverse primer 2.5 
gDNA 2 




Final volume 50 
 
PCR using the primers shown in Table 7 and Table 8 was performed with the 
GoTaq G2 Green Master Mix (Promega, M7822), using the reaction mixture 
shown in Table 13. 
Table 13 GoTaq PCR Reaction 
Reagent Volume / µL 
Nuclease-free water 8 
Forward primer 1.25 
Reverse primer 1.25 
gDNA 2 
GoTaq G2 Green Master Mix (2X) 12.5 
Final volume 25 
 
2.3.6.5 PCR Cycling Parameters 
The underlined bases of the primer sequences in Table 5 denote restriction site 
overhangs added to genomic sequences and required for downstream 
applications: CGTACG = BsiWI (NEB, R0553S); GGCGCGCC = AscI (NEB, 
R0558S); GGTACC = Asc65I (NEB, R0599S); GCGGCCGC = NotI (NEB, 
R0189S). Due to their presence, a two-stage PCR was performed. The cycling 
parameters used to amplify Arm1 and Arm2 are shown in Table 14 and Table 15, 
respectively. 
Table 14 PCR Cycling Parameters to Amplify Arm1 
Repeats Temperature / ºC Duration / s 
1 98 30 
15 98 10 
 60.2 30 
 72 120 
25 98 10 




1 72 300 
 
Table 15 PCR Cycling Parameters to Amplify Arm2 
Repeats Temperature / ºC Duration / s 
1 98 30 
15 98 10 
 64.3 30 
 72 120 
25 98 10 
 72 150 
1 72 300 
 
The PCR cycling parameters for the primers shown in Table 6 are listed in Table 
16. 
Table 16 PCR Cycling Parameters to Validate Recombination Events 
Repeats Temperature / ºC Duration / s 
1 98 150 
35 98 10 
 61 30 
 72 120 
1 72 120 
 
The PCR cycling parameters used for the primers shown in Table 7 and Table 8 
are listed in Table 17. 
Table 17 PCR Cycling Parameters to Outcross Post-Cre Recombinants 
Repeats Temperature / ºC Duration / s 
1 95 300 
15 95 30 
 60 30 




1 72 300 
 
The PCR cycling parameters used for the primers shown in Table 9 and Table 
10 are listed in Table 18 and Table 19, respectively. 
Table 18 PCR Cycling Parameters for Sequence-validation of Arm1 
Repeats Temperature / ºC Duration / s 
1 98 150 
35 98 10 
 69.7 30 
 72 120 
1 72 120 
 
Table 19 PCR Cycling Parameters for Sequence-validation of Arm2 
Repeats Temperature / ºC Duration / s 
1 98 150 
35 98 10 
 61 30 
 72 120 
1 72 120 
 
2.3.7 Gel Electrophoresis 
Gel electrophoresis of PCR products was performed on 0.6-1% agarose gels 
(Sigma-Aldrich, A9539-25G), using GelRed as a nucleic acid dye (Biotium, 
41002) and the Quick-Load Purple 2-Log DNA Ladder as a size reference (NEB, 
N0550S). Images were acquired using the GelDoc-It Imaging System (UVP). The 





2.3.8 Molecular Cloning 
2.3.8.1 DNA Gel Purification 
PCR products were gel-purified using the Wizard SV Gel and PCR Clean-Up 
System (Promega, A9281), and DNA concentrations determined using a 
NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, ND-2000).  
2.3.8.2 TOPO Cloning 
The two homology arms amplified using the primers shown in Table 5 were 
separately cloned into pCR-Blunt II-TOPO (Zero Blunt TOPO PCR Cloning Kit, 
Thermo Fisher Scientific, 450245), referred to as TOPO, using the reaction 
mixture shown in Table 20. This reaction was incubated for 30 min at RT. 
Table 20 TOPO Cloning Reaction 
Reagent Volume / µL 
Homology arm PCR product (gel-
purified) 
4 (~100 ng) 
Salt solution 1 
TOPO 1 
Final volume 6 
 
The TOPO plasmids were then transformed into XL1-Blue competent cells 
(Stratagene, 200130). Once the competent cells were thawed on ice, the whole 
TOPO reaction mixture (6 µL) was added and incubated on ice for 30 min. The 
competent cells were then heat-shocked at 42ºC for 45 s, and immediately put 
back on ice for 2 min. 250 µL of pre-heated (42ºC) S.O.C. medium (Invitrogen, 
15544034) were then added to the competent cells, and the mixture shaken 
horizontally at 37ºC and 225 rpm for 1 h. 100 µL of the mixture were spread onto 
a pre-warmed (37ºC) kanamycin-containing agar plate (50 µg/mL kanamycin), 
which was prepared by adding a stock solution of kanamycin (50 mg/mL) to a 3.5 
% solution of LB Broth with agar (Sigma Aldrich, L2897-1KG). The agar plates 
coated with the transformed XL1-Blue competent cells were incubated at 37ºC 
for 16-18 h. Individual bacterial colonies were poked with a pipette tip and 




liquid medium (Sigma Aldrich, L3022-1KG) with 50 µg/mL kanamycin, followed 
by shaking at 225 rpm and 37ºC for 16-18 h. To recover the TOPO plasmid DNA 
from the transformed bacteria, a miniprep was performed using the PureYield 
Plasmid Miniprep System (Promega, A1223).  
2.3.8.3 P[w25.2] Cloning 
One TOPO-Arm1- and one TOPO-Arm2 sample, prepared as described in 
Paragraph 2.3.8.2, were amplified via transformation into XL1-Blue cells, as 
described in Paragraph 2.3.8.2. Plasmid midipreps were performed using the 
Plasmid Midi Kit (Qiagen, 12143). TOPO-Arm2 and P[w25.2] were double-
digested as described in Table 26, followed by Antarctic Phosphatase treatment 
of the P[w25.2] plasmid (NEB, M0289S), using the reaction mixture shown in 
Table 21. This reaction was performed at 37ºC for 1 h, before heat-inactivating 
both Antarctic Phosphatase and the restriction enzymes at 70ºC for 5 min. 
Table 21 Antarctic Phosphatase Treatment of P[w25.2] 
Reagent Volume / µL 
Nuclease-free water 15 
P[w25.2] 2 (~100 ng) 
Antarctic Phosphatase Reaction 
Buffer (10X) 
2 
Antarctic Phosphatase 1 
Final volume 20 
 
Arm2 and the cut P[w25.2] plasmid were then gel-purified, followed by the ligation 
of the former into the latter using T4 Ligase (NEB, M0202S) and the reaction 
mixture shown in Table 22. This reaction was performed at 16ºC for 16 h, before 
heat-inactivating T4 Ligase at 65ºC for 10 min. 
Table 22 T4 Ligation of Arm2 into P[w25.2] 
Reagent Volume / µL 
10X T4 DNA Ligase Buffer 2 




P[w25.2] 8 (~64 ng) 
T4 DNA Ligase 1 
Final volume 20 
 
The ligation products were amplified by transformation into XL1-Blue cells, as 
described in Paragraph 2.3.8.2. However, instead of 50 µg/µL kanamycin, as for 
TOPO cloning, P[w25.2] was grown in the presence of 100 µg/µL ampicillin. In 
order to insert Arm1 into P[w25.2]-Arm2, TOPO-Arm1 and P[w25.2]-Arm2 were 
restriction-digested as shown in Table 27, and column-purified using the Wizard 
SV Gel and PCR Clean-Up System (Promega, A9281). The purified digestion 
products were then subjected to another restriction digestion as shown in Table 
28. P[w25.2]-Arm2 was treated with Antarctic Phosphatase as described for 
P[w25.2] in Table 21, before heat-inactivating AscI and Antarctic Phosphatase at 
80ºC for 20 min. The BsiWI- and AscI-cut P[w25.2]-Arm2 backbone was column-
purified, as described above, while the BsiWI- and AscI-cut Arm1 of TOPO-Arm1 
was gel-purified. Arm1 was then ligated into P[w25.2]-Arm2 at 16ºC for 16 h using 
T4 Ligase and the reaction mixture shown in Table 23, before heat-inactivating 
T4 Ligase at 65ºC for 10 min. 
Table 23 T4 Ligation of Arm1 into P[w25.2]-Arm2 
Reagent Volume / µL 
Nuclease-free water 6 
10X T4 DNA Ligase Buffer 2 
Arm1 insert 5 (~117 ng) 
P[w25.2]-Arm2 6 (~75 ng) 
T4 DNA Ligase 1 
Final volume 20 
 
The ligation products were amplified by transformation into XL1-Blue cells as 




2.3.8.4 Restriction Digestion 
NEBcutter v. 2.0 was used for in silico digestion of all plasmids to predict the 
resulting amplicon sizes (Vincze et al., 2003). In order to confirm that the TOPO 
plasmids carried the correct inserts, restriction digestion with the restriction 
enzyme NotI-HF (NEB, R3189S) was performed, using the reaction mixture 
shown in Table 24. The reaction was run at 37ºC for 18 h, before NotI-HF was 
heat-inactivated at 65ºC for 20 min. 
Table 24 NotI Restriction Digestion  
Reagent Volume / µL 
Nuclease-free water 42 
TOPO (carrying either Arm1 or Arm2) 2 (~1 µg) 
NEB CutSmart Buffer 5 
NotI-HF enzyme 1 
Final volume 50 
 
An alternative restriction digestion of TOPO was performed with the restriction 
enzyme EcoRI-HF (NEB, R3101T), using the reaction mixture shown in Table 25. 
The reaction was run at 37ºC for 16 h, before EcoRI-HF was heat-inactivated at 
65ºC for 20 min. The same restriction digestion was performed with P[w25.2]-
Arm2 after ligation of Arm2 into P[w25.2]. 
Table 25 EcoRI Restriction Digestion  
Reagent Volume / µL 
Nuclease-free water 42 
TOPO (carrying either Arm1 or Arm2) 
or P[w25.2]-Arm2  
2 (~1 µg) 
NEB CutSmart Buffer 5 
EcoRI-HF enzyme 1 
Final volume 50 
 
Double-digestion of TOPO-Arm2 and P[w25.2] was performed with the restriction 




mixture shown in Table 26. Double digestion was performed at 37ºC for 3 h 
(TOPO-Arm2) and 2 h (P[w25.2]). 
Table 26 NotI/Acc65I Double-Digestion  
Reagent Volume / µL 
Nuclease-free water 39 
TOPO-Arm2 or P[w25.2]  4 (~2 µg) 
NEBuffer 3.1 5 
NotI enzyme 1 
Acc65I enzyme 1 
Final volume 50 
 
Restriction digestion of P[w25.2]-Arm2 and TOPO-Arm1 was performed with 
BsiWI (NEB, R0553S), using the reaction mixture shown in Table 27. This 
reaction was performed at 55ºC for 4 h, followed by heat-inactivation of BsiWI at 
65ºC for 20 min. 
Table 27 BsiWI Restriction Digestion 
Reagent Volume / µL 
Nuclease-free water 38 
P[w25.2]-Arm2 or TOPO-Arm1  5 (~3 µg) 
NEBuffer 3.1 5 
BsiWI enzyme 2 
Final volume 50 
  
The purified restriction products from Table 27 were used for restriction digestion 
with the restriction enzyme AscI (NEB, R0558S), using the reaction mixture 
shown in Table 28. Restriction digestion was performed at 37ºC for 3 h (TOPO-
Arm1) and 2h (P[w25.2]-Arm2). 
Table 28 AscI Restriction Digestion  
Reagent Volume / µL 




NEB CutSmart Buffer 5 
P[w25.2]-Arm2 or TOPO-Arm1 
(digested with BsiWI) 
10 (~1 µg) 
AscI enzyme 2 
Final volume 50 
 
To confirm the identities of P[w25.2]-Arm2-Arm1 and P[w25.2]-Arm2E366G-Arm1, 
restriction digestion with the meganuclease I-SceI (NEB, R0694S) was 
performed, using the reaction mixture shown in Table 29. This restriction 
digestion was run at 37ºC for 4 h, before heat-inactivating I-SceI at 65ºC for 20 
min. 
Table 29 I-SceI Restriction Digestion  
Reagent Volume / µL 
Nuclease-free water 40 
P[w25.2]-Arm2-Arm1 or P[w25.2]-
Arm2E366G-Arm1 
3 (~1 µg) 
NEB CutSmart Buffer 5 
I-SceI meganuclease 2 
Final volume 50 
 
In order to introduce the A1097G point mutation into P[w25.2]-Arm2, P[w25.2]-
Arm2 and pMA-T were double-digested with the restriction enzymes BglII (NEB, 
R0144S) and Acc65I (NEB, R0599S), using the reaction mixture shown in Table 
30. Restriction digestion was performed at 37ºC for 6 h (pMA-T) and 5 h 
(P[w25.2]-Arm2). 
Table 30 BglII/Acc65I Double-Digestion  
Reagent Volume / µL 
Nuclease-free water 38 
P[w25.2]-Arm2 or pMA-T 4 (~1 µg) 
NEBuffer 3.1 5 




Acc65I enzyme 1.5 
Final volume 50 
 
2.3.8.5 Introducing the A1097G point mutation into P[w25.2]-Arm2-Arm1 
In order to introduce the A1097G point mutation into Arm2 of P[w25.2]-Arm2-
Arm1, a customised DNA fragment was ordered from GeneArt Gene Synthesis 
(Thermo Fisher Scientific), which is provided inside the pMA-T plasmid. This DNA 
fragment is sequence-analogous to the 5' 722 bp of Arm2, apart from the A1097G 
point mutation located at nucleotide position 402. It also carries a 5’ Acc65I 
restriction site, resulting in a 728 bp fragment, and an endogenous 3' BglII 
restriction site, allowing for a cut-and-paste approach to exchange the 
endogenous 722 bp in Arm2 with this fragment. To do so, P[w25.2]-Arm2 and 
pMA-T were double-digested as shown in Table 30, before treating the cut 
P[w25.2]-Arm2 with Antarctic Phosphatase as described for P[w25.2] in Table 
21. Antarctic Phosphatase and Acc65I were then heat-inactivated for 5 min at 
70ºC (BglII cannot be heat-inactivated). The cut P[w25.2]-Arm2 and the released 
722 bp fragment (carrying the A1097G point mutation) were gel-purified, before 
ligating the latter into the former with T4 Ligase, using the reaction mixture shown 
in Table 31. The ligation was performed at 16ºC for 16 h, before heat-inactivating 
T4 Ligase at 65ºC for 10 min. 
Table 31 T4 Ligation of A1097G into P[w25.2]-Arm2-Arm1 
Reagent Volume / µL 
Nuclease-free water 13 
10X T4 DNA Ligase Buffer 2 
P[w25.2]-Arm2 1 (~75 ng) 
722 bp fragment (harbouring the 
A1097G point mutation) 
3 (~25 ng) 
T4 DNA Ligase 1 





The ligation products were amplified by transformation into XL1-Blue cells as 
described in Paragraph 2.3.8.3, resulting in the successful retrieval of a P[w25.2]-
Arm2 plasmid carrying the E336G-causing A1097G point mutation, termed 
P[w25.2]-Arm2E366G. In order to generate a P[w25.2] plasmid carrying both wild-
type Arm1 and mutant Arm2E366G, the latter was excised from P[w25.2]-Arm2E366G 
and cloned into P[w25.2]-Arm2-Arm1 in exchange for wild-type Arm2, following 
the same cloning procedure as described for the cloning of Arm2 from TOPO-
Arm2 into empty P[w25.2] (Paragraph 2.3.8.3) – resulting in a plasmid termed 
P[w25.2]-Arm2E366G-Arm1. 
2.3.9 Sanger Sequencing 
DNA samples were sent to Source BioScience for Sanger sequencing 
(https://www.sourcebioscience.com/). Sanger sequencing primers were 
generated and ordered as described for PCR primers in Paragraph 2.3.6.1. 
2.3.9.1 Sequence Validation of P[w25.2]-Arm2E366G-Arm1 
To confirm the absence of unwanted mutations in P[w25.2]-Arm2E366G-Arm1, 
Sanger sequencing was performed using sequencing primers shown in Table 32. 
Table 32 Sanger Sequencing Primers for P[w25.2]-Arm2E366G-Arm1 


















2.3.9.2 Allele Identification of Successful Recombinants 
In order to identify the sloE366G[w+] and sloloxP[w+] alleles in successful 
recombinants, Sanger sequencing was performed using the sequencing primers 
shown in Table 33. 
Table 33 Sanger Sequencing Primers for Allele Identification 
Primer Name Primer Sequence 
a2_alternative_R2-validation_F (R2F) TCCGCTTTAATCGCACACTA 
GEPD_seq_1 CCCCCACCTTCAACAACACA 
 
2.3.9.3 Sequence-validation of sloE366G and sloloxP 
In order to confirm the absence of additional mutations in endogenous sloE366G 
and sloloxP of post-Cre flies, the genomic Arm1 and Arm2 regions were Sanger-
sequenced using the sequencing primers shown in Table 34 and Table 35, 
respectively. 
Table 34 Sanger Sequencing Primers for Arm1 
















Table 35 Sanger Sequencing Primers for Arm2 













2.3.10 Embryonic injection 
Embryonic injections were performed by BestGene Inc., a Drosophila embryo 
injection service (http://www.thebestgene.com). I purchased “Plan C - P-element 
Premium Service”. P[w25.2]-Arm2E366G-Arm1 was injected into 200 individual 
w1118 embryos. Of these, 120 survived into the larval-, and 65 into the adult stage, 
which were then back-crossed into the w1118 genetic background. From these 











2.4.1 Homology Between Human KCNMA1 and Drosophila Slo 
In order to generate a Drosophila model of any mutation linked to a human 
disease, the protein affected by the mutation must be sufficiently conserved 
between the two species. An amino acid sequence comparison between the 
longest transcripts of KCNMA1 (Transcript ID: KCNMA1-210) and its fly 
orthologue Slo (Transcript ID: Slo-RT) revealed a sequence identity of 48.1% 
(Figure 2.2). Modelling GEPD in flies would be facilitated further if the pathogenic 
locus within the KCNMA1 protein was particularly well conserved, which would 
suggest functional significance. Indeed, the locus 10 amino acids up- and 
downstream of the D434G mutation is 81% conserved (Figure 2.2). However, it 
is important to note that the amino acid mutated in GEPD (D434) is only 
functionally conserved in the fly (E366): instead of aspartic acid, Drosophila 
melanogaster carries a glutamic acid residue at this position. However, there is 
strong electrophysiological evidence that aspartic- and glutamic acid at position 
434 of KCNMA1 result in functionally equivalent BK channels (Yang et al., 2010), 
as discussed in Paragraph 2.5.1. Hence, I hypothesise that a change of either 
aspartic- or glutamic acid to glycine at this position will result in similar changes 
in protein function, and therefore conclude that Drosophila melanogaster is a 





Figure 2.2 Sequence Conservation Between KCNMA1 and Slo 
Amino acid pairwise sequence alignment between the longest transcripts of 
KCNMA1 (KCNMA1-210) and Slo (Slo-RT) shows 48.1% overall amino acid 
sequence identity. Black shading indicates full-, grey shading functional-, and 
white shading no conservation. The protein sequence 10 amino acids up- and 
downstream of the D434 residue is shown enlarged at the bottom and exhibits 
81% amino acid sequence identity. The location of human D434 and fly E366 is 





2.4.2 Designing Homology Arms 
Throughout this chapter, the following protocol has been used as an experimental 
guide: (Staber et al., 2011) – any major deviations from it are specified in the 
main text. The donor template used to introduce the A1097G point mutation into 
the endogenous Drosophila genome is generated in vivo via the excision and 
linearisation of a DNA sequence that will be introduced into the gDNA via 
transposition of a P-element donor construct. This donor construct is prepared by 
cloning homology arms designed in silico into a dedicated plasmid called 
P[w25.2]. Each of the homology arms must be at least 2.5 kb in length, to allow 
for efficient HR, and both arms need to be positioned so as to span the E366 
residue within slo. Simultaneously, the homology arms must flank an intronic 
sequence that is poorly conserved across different Drosophila species and other 
insects, because this sequence will be replaced by a remnant vector sequence 
of 76 bp at the end of this protocol: the Cre-mediated removal of a floxed mini-
white gene from the recombined slo locus (Figure 2.13). A lack of sequence 
conservation across species is used as an indicator that the sequence is unlikely 
to be functionally significant. The endogenous- and the remnant vector sequence 
should also approximately match in length in order to preserve genomic spacing. 
Using the UCSC genome browser to compare gDNA sequences around the E366 
locus between Drosophila melanogaster and 27 other insect species, 23 of them 
other Drosophilae, an 18 bp region 5’ of E366 was identified that shows almost 





Figure 2.3 Positioning the Homology Arms 
The UCSC genome browser was used to identify a non-conserved intronic 
region close to the E366 locus, around which the homology arms could be 
centred. A sequence of 18 bp (chr3R:24,686,816-24,686,833) was identified to 
be non-conserved across the 27 species listed on the left and is highlighted by 
a violet box. Exon 10 of slo, containing the E366 locus, is highlighted by a red 
box. This analysis was originally performed by Dr. James Jepson, and the 
screenshot for this figure taken from the UCSC Genome Browser 
(http://genome.ucsc.edu). 
 
PCR primers were designed that could be used to amplify two homology arms 
within this region. The homology arm 5' of the flanked non-conserved sequence 
is referred to as Arm1, while the homology arm 3' of this sequence is referred to 
as Arm2. The identified primers amplify 2491 bp 5’ of position chr3R:24,686,818 
(Arm1) and 2731 bp 3’ of position chr3R:24,686,862 (Arm2). This creates a 45 
bp gap between the two homology arms that contains the 3’ 16 bp of the 18-bp 
non-conserved sequence shown in Figure 2.3 and an additional 29 bp 3’ of that 
sequence. As a result of this design, 45 bp of endogenous intronic sequence will 
be replaced by 76 bp of vector remnant sequence upon Cre-mediated excision 
of the floxed mini-white gene at the end of the ends-out HR protocol. This 
constitutes a compromise between leaving conserved endogenous sequences 
intact, preserving genomic spacing, and the availability of successful PCR 
primers to amplify the homology arms. To control for possible effects of this 
sequence replacement, a control allele will be generated that replicates this 
sequence replacement without carrying the A1097G point mutation. The final 





Figure 2.4 Anatomy of the Homology Arms 
This figure shows a zoomed-out version of Figure 2.3. The non-conserved region 
around which both homology arms are centred is enclosed by a violet box. The 
two homology arms are shown as black boxes and are drawn to scale. Arm2 
contains exon 10 (red rectangle), which carries the E366 amino acid residue that 
will be changed to glycine upon introduction of the A1097G point mutation, 
recapitulating the GEPD-linked D434G genotype. This analysis was originally 
performed by Dr. James Jepson, and the screenshot for this figure taken from 
the UCSC Genome Browser (http://genome.ucsc.edu). 
 
2.4.3 Cloning of Homology Arms into P[w25.2] 
With the homology arms designed in silico, I began the construction of a plasmid 
donor construct carrying these homology arms. This plasmid will later be injected 
into fly embryos, randomly integrating into the endogenous genome via P-
element transposition. Subsequent excision and linearisation of this construct in 
vivo generate the donor template for HR. To this end, I extracted the gDNA from 
20 isogenic flies (iso31), PCR-amplified and gel-purified the homology arms, and 
inserted them individually into TOPO plasmids, before sub-cloning them into a 
dedicated plasmid called P[w25.2], a P-element construct containing the floxed 






Figure 2.5 Cloning of Homology Arms into P[w25.2]  
This schematic shows the steps involved in generating a P[w25.2] plasmid 
carrying both homology arms and the E366G mutation in Arm2 – denoted as 
P[w25.2]-Arm2E366G-Arm1. On top, the absolute genomic location is shown, 
below which the genomic slo locus is indicated, with exons illustrated by 
rectangles and drawn to scale – exon 10 carries the E366 locus. The PCR 
strategy used to amplify the homology arms is shown by primers drawn as 
arrows and their tracing overhang restriction sites as rectangles. The homology 
arms are first separately cloned into TOPO plasmids, before being sub-cloned 
into P[w25.2]. A floxed mini-white gene separates the two homology arms. Short 
DNA sequences required for the random integration (P-element recognition 
sequences), excision (FRT inverted repeats), and linearisation (I-SceI 
recognition sites) of P[w25.2]-Arm2E366G-Arm1 are shown as coloured triangles. 
The primers used to amplify the homology arms were designed by Dr. James 
Jepson and the PCR parameters optimised by Dr. Ko-Fan Chen. 
 
Once both homology arms had been inserted separately into TOPO, I confirmed 
their identity via diagnostic restriction digestion with the restriction enzyme NotI. 
TOPO and Arm2 each carry one internal NotI restriction site, while Arm1 does 
not harbour this sequence. Hence, digesting TOPO-Arm1 with NotI causes a 
linearisation of the plasmid, with a length of 6024 bp. Depending on the 
orientation of Arm2 within TOPO, two possible combinations of fragments can be 
released from a restriction digestion with NotI: (1) 3487 bp + 2777 bp, or (2) 6224 
bp + 40 bp. I performed this restriction digestion with two independent TOPO-
Arm1- and two independent TOPO-Arm2 plasmid preparations, confirming by gel 





Figure 2.6 NotI Restriction Digestion of TOPO-Arm1/2 
Two independent TOPO-Arm1- and two independent TOPO-Arm2 plasmid 
preparations were digested with the restriction enzyme NotI. The expected 
fragment size for digested TOPO-Arm1 is 6024 bp, which was observed for both 
TOPO-Arm1 plasmids. The TOPO-Arm2 plasmids show two different band 
arrangements because of different insert orientations, resulting in two fragments 
of 3487 bp and 2777 bp (TOPO-Arm2 #1), and two fragments of 6224 bp and 
40 bp (TOPO-Arm2 #2). The 40 bp fragment lies outside the range of this gel. 
 
I then chose one TOPO-Arm1- and one TOPO-Arm2 plasmid for downstream 
applications. Upon amplification of these plasmids, I performed a second 
diagnostic restriction digestion to ensure that the correct plasmids had been 
amplified. This time, I digested TOPO-Arm1 and TOPO-Arm2 with the restriction 
enzyme EcoRI, because the resulting digestion pattern is more distinct than the 
one resulting from NotI digestion: EcoRI cuts TOPO-Arm1 twice, resulting in two 
bands of 3501 bp and 2523 bp in length. TOPO-Arm2 is cut four times by EcoRI, 
yielding the following fragments: 3501 bp, 1440 bp, 814 bp, and 509 bp. Indeed, 
digesting both plasmids with EcoRI, I observed this exact pattern via gel 







Figure 2.7 EcoRI Restriction Digestion of TOPO-Arm1/2 
TOPO-Arm1 and TOPO-Arm2 were digested with EcoRI. The expected 
restriction fragments for TOPO-Arm1 are 3501 bp and 2523 bp in length, the 
ones for TOPO-Arm2 3501 bp, 1440 bp, 814 bp, and 509 bp. All six fragments 
are present, confirming the identities of TOPO-Arm1 and TOPO-Arm2. 
 
With both homology arms successfully cloned into TOPO, I began the process of 
sub-cloning them sequentially into the P[w25.2] plasmid (Figure 2.5). Upon 
ligation of Arm2 into P[w25.2], I confirmed via diagnostic restriction digestion 
using EcoRI that P[w25.2]-Arm2 had successfully been generated. P[w25.2]-
Arm2 carries 4 EcoRI restriction sites, resulting in the following expected 
fragments upon EcoRI digestion: 6248 bp, 4641 bp, 509 bp, and 295 bp. Indeed, 
this is the band arrangement I observed upon digesting three independent 






Figure 2.8 EcoRI Restriction Digestion of P[w25.2]-Arm2 
Upon ligation of Arm2 into P[w25.2], the P[w[25.2]-Arm2 construct was digested 
with the restriction enzyme EcoRI. This gel shows the presence of the 4 
expected restriction fragments: 6248 bp, 4641 bp, 509 bp, and 295 bp. Note that 
the ladder ran slightly faster than the samples. Nevertheless, the correct relative 
fragment sizes were observed, confirming the plasmid identities. 
 
Following the successful generation of P[w25.2]-Arm2, the other homology arm 
(Arm1, carried within TOPO-Arm1, Figure 2.7) was ligated into one of the 
P[w25.2]-Arm2 preparations. To confirm that I had successfully generated a 
P[w25.2] plasmid carrying both homology arms, denoted as P[w25.2]-Arm2-
Arm1, I performed a diagnostic restriction digestion with the meganuclease I-
SceI. This enzyme will cut the I-SceI recognition sequences that flank the two 
homology arms and the mini-white gene (Figure 2.5). If both arms are present 
within P[w25.2], the expected products of this restriction digestion are 10027 bp 
(Arm1 + mini-white + Arm2) and 4121 bp (P[w25.2] plasmid backbone). Indeed, 
digesting 6 independent P[w25.2]-Arm2-Arm1 plasmid preparations, I was able 






Figure 2.9 I-SceI Restriction Digestion of P[w25.2]-Arm2-Arm1 
Six independent P[w25.2]-Arm2-Arm1 plasmids were restriction-digested with I-
SceI, in order to confirm the presence of the correctly sized homology arms. I-
SceI cuts 5’ of Arm1 and 3’ of Arm2, releasing a 10027 bp fragment that consists 
of these two homology arms and the mini-white gene located in between. 
Indeed, this band is present for each of the 6 P[w25.2]-Arm2-Arm1 plasmids. 
The second band corresponds to the P[w25.2] plasmid backbone, which is 4121 
bp in size. 
 
With the P[w25.2]-Arm2-Arm1 plasmid successfully generated (Figure 2.9), I 
introduced the E366G-causing A1097G point mutation into Arm2 (Figure 2.5). 
This point mutation will result in a codon change from GAG (glutamic acid) to 
GGG (glycine), recapitulating the GEPD genotype (Du et al., 2005). To this end, 
I replaced the 5' 722 bp of Arm2 with a 722 bp fragment that is identical in 
sequence with the exception of carrying the A1097G point mutation, via a cut-
and-paste approach using restriction digestion and DNA ligation. This sequence 
replacement was performed in the P[w25.2]-Arm2 plasmid, thereby generating a 
novel plasmid carrying the E366G-containing Arm2 – this plasmid is denoted as 
P[w25.2]-Arm2E366G. Upon successful generation of P[w25.2]-Arm2E366G, I 
replaced wild-type Arm2 within P[w25.2]-Arm2-Arm1 with mutant Arm2E366G, 
generating a P[w25.2] construct that carries wild-type Arm1 and mutant 
Arm2E366G, denoted as P[w25.2]-Arm2E366G-Arm1. To confirm the plasmid identity 
of P[w25.2]-Arm2E366G-Arm1, I performed the same diagnostic restriction 
digestion with I-SceI as for P[w25.2]-Arm2-Arm1, demonstrating the successful 






Figure 2.10 I-SceI Restriction Digestion of P[w25.2]-Arm2E366G-Arm1 
12 independent P[w25.2]-Arm2E366G-Arm1 plasmid preparations were restriction-
digested with I-SceI, in order to confirm the presence of the correctly sized 
homology arms, as described in Figure 2.9. 11 of the 12 plasmids showed the 
expected band arrangement.  
 
Finally, I confirmed the absence of any unwanted mutations in the homology arms 
by Sanger sequencing of one P[w25.2]-Arm2E366G-Arm1 plasmid preparation. 
Upon alignment of the Sanger sequencing results to the BDGP6 reference 
genome, no mutations could be detected apart from the GEPD-linked A1097G 
missense mutation, rendering P[w25.2]-Arm2E366G-Arm1 suitable for embryonic 





Figure 2.11 Sanger Sequencing of P[w25.2]-Arm2E366G-Arm1 
The two homology arms within P[w25.2]-Arm2E366G-Arm1 (top schematic) were 
Sanger-sequenced in order to confirm the absence of any unwanted mutations. 
The approximate positions of the sequencing primers for both arms are shown 
in the middle as grey arrows. No unwanted mutations were detected in either 
arm. The presence of the E366G-causing A1097G point mutation in Arm2 was 





At this stage, my protocol deviates from the one described in (Staber et al., 
2011): usually, both plasmids, P[w25.2]-Arm2-Arm1 and P[w25.2]-Arm2E366G-
Arm1, would be injected separately into fly embryos, in order to generate the 
novel alleles sloloxP and sloE366G, respectively: sloloxP only carries the 45-to-76-
bp sequence replacement, including a loxP sequence, while sloE366G carries 
this sequence replacement and the E366G mutation. The sloloxP allele is 
required to account for any potential effects the sequence replacement alone 
might have. I reasoned that both alleles could be generated by injecting only 
the P[w25.2]-Arm2E366G-Arm1 plasmid, because, depending on where along 
Arm2 HR occurs, the A1097G point mutation may or may not be integrated into 
the endogenous slo locus. Any HR event occurring 5’ of the mutation will not 
introduce it into the endogenous genome, while any HR event 3’ of the mutation 
will (Figure 2.13). Given a sufficiently large number of HR events, both alleles 
can, therefore, be generated from P[w25.2]-Arm2E366G-Arm1. Hence, I decided 
to proceed with the protocol by injecting only P[w25.2]-Arm2E366G-Arm1, 
disregarding P[w25.2]-Arm2-Arm1. 
2.4.4 Generation of sloE366G[w+] and sloloxP[w+] 
Once P[w25.2]-Arm2E366G-Arm1 had been sequence-verified (Figure 2.11), this 
plasmid was injected into fly embryos. Balanced stocks of positive transformants 
are referred to as “donor flies”: these flies carry a stably integrated P[w25.2]-
Arm2E366G-Arm1 transgene on chromosome 2, balanced over CyO. The presence 
of the integrated P[w25.2]-Arm2E366G-Arm1 can be confirmed by orange eye 
colour, encoded by the mini-white gene present between the two homology arms 
(Figure 2.5). In order to generate sloE366G[w+] and sloloxP[w+] from the donor flies, 
the crossing scheme shown Figure 2.12 was performed. sloE366G[w+] and sloloxP[w+] 
flies still carry the floxed mini-white gene within the endogenous slo locus, as 
indicated by the [w+] superscript. The genetic mechanisms underlying this 
crossing scheme are illustrated in Figure 2.13. First, donor fly males were crossed 
to y,w;hs-FLP,hs-I-SceI/CyO virgin females. These flies carry heat shock-
inducible FLP recombinase and heat shock-inducible I-SceI endonuclease on 
chromosome 2. The resulting offspring were heat-shocked as embryos and 




increased temperature activates FLP recombinase and I-SceI endonuclease, 
which act to excise the P[w25.2]-Arm2E366G-Arm1 transgene and linearise it, 
respectively. The resulting donor template can localise to- and recombine with its 
complementary sequence at the endogenous slo locus (Figure 2.13).  
 
 
Figure 2.12 Crossing Scheme to Generate sloE366G[w+] and sloloxP[w+] 
This diagram illustrates the genetic crosses involved in the generation of 
sloE366G[w+]/TM6B,Tb and sloloxP[w+]/TM6B,Tb stocks from donor flies, which carry 
the P[w25.2]-Arm2E366G-Arm1 transgene on chromosome 2. Only the relevant 
genotypes are shown for simplicity. Fly collection criteria are marked in green, 
additional actions taken in blue. F0-F4 denote generation numbers. This figure 







Figure 2.13 Genetics Underlying Ends-out Homologous Recombination 
This schematic shows the genetic processes underlying ends-out HR. Donor 
flies carrying P[w25.2]-Arm2E366G-Arm1 randomly integrated on chromosome 2 
are shown on top. Flanking the homology arms of P[w25.2]-Arm2E366G-Arm1 are 
P-element inverted repeats (maroon), FRT sites (green), and I-SceI recognition 
sequences (blue). Crossing the donor flies to flies expressing heat shock-
inducible FLP and I-SceI (hs-FLP, hs-I-SceI) causes the excision of P[w25.2]-
Arm2E366G-Arm1 (via hs-FLP) and its linearisation (via hs-I-SceI), producing a 
donor template. The donor template can recombine with the endogenous slo 
locus, and, depending on where along Arm2 HR occurs, introduce the GEPD-
linked A1097G missense mutation into the endogenous genome (GGG, red), or 
not (GAG, cyan). Positive recombinants still carry the floxed mini-white marker 
gene inside slo, which can be removed by crossing these flies to Cre-expressing 
stocks. This process leaves behind a 76 bp remnant vector sequence, consisting 
of AscI- and Acc65I restriction sites, two six-frame stop codons, and one residual 
loxP sequence (black).  
 
The aim of the F0 cross in Figure 2.12 is for HR to occur in the germline of the 
developing F1 larvae and embryos, which will allow for the subsequent 
generation of stable stocks carrying the sloE366G[w+] and sloloxP[w+] alleles. Since 
germline events cannot directly be observed in the F1 progeny, their likelihood 
was assayed by somatic activity of FLP recombinase: efficient somatic excision 




colour, due to the removal of the mini-white gene from a w1118 background (Figure 
2.13). To this end, 150 F1 virgin females with white eye colour were collected and 
potential germline events assayed by setting up single-virgin crosses to y,w,ey-
FLP/Y males (Figure 2.12). This cross distinguishes between non-excision 
events of the P[w25.2]-Arm2E366G-Arm1 transgene and successful HR events: 
FLP driven by the eyless (ey) promoter excises the P[w25.2]-Arm2E366G-Arm1 
transgene in the eye by acting on the flanking FRT sites (Figure 2.13), resulting 
in white-eyed F2 progeny. Importantly, true recombinants will have lost their FRT 
sites upon HR into the endogenous genome, resulting in orange-eyed F2 progeny 
(Figure 2.13). Hence, orange-eyed F2 progeny are promising candidates for true 
HR events. Out of ~10,000 F2 adults screened, I retrieved 15 mini-white+ virgin 
females (~0.15% efficiency). These flies were individually crossed to 
TM2,Ubx130/TM6B,Tb males, in order to create stable lines balancing the 
potentially successful recombination event on chromosome 3 over TM6B,Tb 
(Figure 2.12).  
2.4.5 Validation of Successful Homologous Recombination Events 
To confirm that ends-out HR occurred at the correct genomic position in the 15 
recombinants identified, I employed a PCR strategy that only yields an amplicon 
if the donor template has recombined with its complementary sequence within 
the endogenous slo locus: the forward primer is located within the mini-white 
gene, while the reverse primer is positioned 3' of Arm2. Using this strategy, I 
confirmed that all of the 15 orange-eyed F2 flies are true recombinants (Figure 
2.14). The naming scheme for the recombinants consists of three numbers 
separated by dots: the first number is the number of the vial in which crosses 
between white-eyed y,w;hs-FLP,hs-I-SceI/P[w25.2]-Arm2E366G-Arm1 virgin 
females and y,w,ey-FLP/Y males were set up; since these crosses were flipped 
four times, the second number indicates the flip number; the third number 
indicates the number of the positive recombinant identified from that particular 





Figure 2.14 Confirmation of Positive Recombinants via PCR 
To test for true HR events, a PCR strategy was employed that only yields an 
amplicon upon successful HR of the donor template with slo (Figure 2.13). The 
schematic at the top illustrates the design of the primer pair: the forward primer, 
pW-Acc3_F, is located within the mini-white gene (orange), while the reverse 
primer, pW-Acc1_R, is positioned 3' of Arm2 within slo (green dotted line). The 
gel images show that all 15 orange-eyed F2 flies were confirmed as true 
recombinants due to the presence of a 3259 bp amplicon. The negative control 
added to this experiment (-ve ctrl) was gDNA from donor flies, which did not yield 
an amplicon. The 55.1.1 stock later died and is hence struck through. 25.1.1 
(red) and 132.1.1 (cyan) are the sloE366G[w+] and sloloxP[w+] stocks used for most 
downstream analyses, respectively. 
 
I next sought to identify which recombination events integrated the A1097G point 
mutation into the endogenous slo locus and which ones did not (Figure 2.13). To 
this end, I performed the PCR strategy as shown in Figure 2.14 and gel extracted- 
and purified the 3259 bp amplicons, followed by Sanger sequencing. Altogether, 
I prepared 14 of the 15 recombinant stocks for sequencing because the 55.1.1 
stock died (Figure 2.14). Of these 14 recombinant stocks, Sanger sequencing 
identified 4 to carry the sloloxP[w+] allele (~29%) and 10 to carry the sloE366G[w+] 





Figure 2.15 Sequence Validation of Successful Recombinants 
The 14 surviving recombinant stocks were queried for the presence of the 
GEPD-linked A1097G mutation by Sanger sequencing. Depending on where 
along Arm2 HR occurs, this mutation may or may not be integrated into the 
endogenous genome (Figure 2.13). 4 of the 14 recombinants did not integrate 
the point mutation (top row, green), whereas 10 did (black). The respective 
codons are indicated as GAG for non-integration of the point mutation (glutamic 





Finally, four independent sloloxP[w+] recombinants (132.1.1, 111.1.1, 7.1.1, 
132.1.2) and four independent sloE366G[w+] recombinants (25.1.1, 137.1.3, 
135.1.1, 72.1.1) were outcrossed for 5 generations into isogenic background, as 
shown in Figure 2.16. 
 
 
Figure 2.16 Crossing Scheme to Outcross sloE366G[w+] and sloloxP[w+] 
The sloE366G[w+] and sloloxP[w+] stocks generated as illustrated in Figure 2.12 might 
still carry chromosomes encoding transgenes or harbouring deletions. In 4 
independent sloE366G[w+]- and sloloxP[w+] stocks, these chromosomes were first 
exchanged with their isogenic homologues, before outcrossing these stocks into 
iso31 background for 5 generations. Green notes indicate fly collection criteria, 






2.4.6 Establishing sloE366G and sloloxP 
To remove the mini-white gene from the 14 sloE366G[w+]/TM6B,Tb and 
sloloxP[w+]/TM6B,Tb stocks (Figure 2.12), males from these stocks were separately 
crossed to y,w,Cre;;D*/TM3,Sb virgin females, before establishing TM6B,Tb-
balanced stocks of sloE366G and sloloxP (Figure 2.17). 
 
 
Figure 2.17 Crossing Scheme to Generate sloloxP and sloE366G 
This crossing scheme was employed to remove the floxed mini-white gene via 
Cre recombinase activity, swap unwanted chromosomes, and outcross and 
balance the resulting sloloxP and sloE366G alleles. Green indicates fly collection 






In order to account for possible genetic background effects that may influence 
future analyses of sloE366G and sloloxP, I outcrossed four independent sloE366G 
recombinants (25.1.1, 137.1.3, 135.1.1, 72.1.1) and four independent sloloxP 
recombinants (132.1.1, 111.1.1, 7.1.1, 132.1.2) into isogenic background (iso31) 
for five generations (Figure 2.17). Since these post-Cre stocks have lost the eye-
colour marker, I employed a PCR strategy to perform these outcrosses. For this 
strategy, the forward primer anneals to the 76 bp remnant sequence that is only 
present in recombinants, not in isogenic controls into which outcrossing was 
performed (Figure 2.18). I successfully validated this strategy on three 
independent recombinants (Figure 2.18). 
 
 
Figure 2.18 PCR-based Outcrossing of post-Cre Recombinants 
The PCR strategy illustrated at the top was employed to outcross sloE366G and 
sloloxP flies into isogenic background: primers “a” and “c” (black arrows) will only 
yield an amplicon if the sloE366G or sloloxP allele is present because primer “a” 
anneals to the 76 bp remnant sequence that is not present in the isogenic (iso31) 
background, into which outcrossing occurred. The gel at the bottom validates 
these primers: on the left, three separate recombinant lines and three 
independent iso31 negative controls were run after performing PCR using 
primers “a” and “c”. No bands are present for iso31, while all recombinants show 
a clear single band of expected size (301 bp). A separate forward primer (b, grey 
arrow in top schematic) confirmed that the gDNA used for this validation 
experiment was not degraded, as it successfully amplified a 283 bp amplicon 
together with primer “c” for all samples. Primers “a” and “c” were used to outcross 
post-Cre recombinants for five generations (Figure 2.17). In the schematic on 
top, the 76 bp remnant vector sequence is shown in black, while exon 10, 





2.4.7  Sequence Validation of sloE366G and sloloxP 
Before performing experiments on the sloE366G and sloloxP alleles, it is necessary 
to confirm that the entire sequence of the slo locus spanned by the homology 
arms does not contain any unwanted mutations. Although the P[w25.2]-
Arm2E366G-Arm1 plasmid does not contain any such mutations (Figure 2.11), 
sequencing the endogenous slo locus of post-Cre recombinants is important to 
confirm that no unintended mutagenesis happened in vivo. To this end, I 
extracted gDNA from one sloE366G/TM6B,Tb stock (25.1.1/TM6B,Tb, Figure 2.15) 
and one sloloxP/TM6B,Tb stock (132.1.1/TM6B,Tb, Figure 2.15), PCR-amplified 
Arm1 and Arm2 separately, and gel-extracted and -purified the PCR products, 
followed by Sanger sequencing. Upon aligning the Sanger sequencing results to 
the BDGP6 Drosophila melanogaster reference genome, I identified 11 single-
nucleotide polymorphisms (SNPs) and 1 insertion in Arm1, and 8 SNPs and 2 
deletions in Arm2, in addition to the A1097G mutation in Arm2. In order to 
determine whether these variations are known to occur naturally, I queried 
published genome variation data on Ensembl for each of the sequence variants 
manually. Of note, Ensembl does not, to my knowledge, provide structural 
variation data for Drosophila melanogaster, preventing me from analysing the 
insertions and deletions directly. Instead, I analysed their respective genomic 
positions for the presence of SNPs, which would indicate that these loci show 
sequence variation. The results of this analysis are shown in Table 36 for Arm1 
and in Table 37 for Arm2. 
Table 36 Sequence Variation in Arm1 
Class Variation Consequence Genomic 
Location 





SNP C>A intron variant 3R:24684415 ENSVDME
05071548 
yes yes DPGP 




yes yes DPGP 




yes yes DPGP 
INS A intronic 
insertion 
3R:24685501 - yes yes - 
SNP A>C intron variant 3R:24685666 ENSVDME
05071625 








yes yes DPGP 
SNP A>T intron variant 3R:24685813 ENSVDME
05071635 
yes yes DPGP 
SNP T>C intron variant 3R:24685845 ENSVDME
05071638 
yes yes DPGP 
SNP C>T intron variant 3R:24685848 ENSVDME
05071639 
yes yes DPGP 




yes yes DPGP 




yes yes DPGP 
SNP T>A intron variant 3R:24685875 ENSVDME
05071643 
yes yes DPGP 
 
Table 37 Sequence Variation in Arm2 
Class Variation Consequence Genomic 
Location 












no yes DPGP 
- A>G exonic E366G 
missense 
mutation 
3R:24687264 - yes no - 
SNP C>A intron variant 3R:24688025 ENSVDME
05071753 
yes yes DPGP 
SNP G>C intron variant 3R:24688138 ENSVDME
05071755 
yes yes DPGP 
SNP A>T intron variant 3R:24688292 ENSVDME
05071763 
yes yes DPGP 
SNP T>G intron variant 3R:24688426 ENSVDME
05071766 
yes yes DPGP 




yes yes DPGP 
SNP G>A intron variant 3R:24688625 ENSVDME
05071783 
yes yes DPGP 







yes yes DPGP 




yes yes DPGP 
SNP C>A intron variant 3R:24688900 ENSVDME
05071805 





All of the 11 SNPs present in Arm1 have been reported by the Drosophila 
Population Genomics Project (DPGP) and are annotated on Ensembl (Langley 
et al., 2012; Pool et al., 2012). All of these SNPs are intronic and present in both 
sloE366G and sloloxP. I identified one single-nucleotide insertion (adenine, A) at a 
position that shows no annotated sequence variation (Table 36). This insertion is 
located in an intronic stretch of 9 adenine residues and present in both alleles. 
Within the Arm2 sequence, I confirmed that the GEPD-linked A>G missense 
mutation is only present in sloE366G. Moreover, all of the 8 SNPs in Arm2 have 
been reported by the DPGP, are intronic, and are present in both sloE366G and 
sloloxP (Table 37). I further identified a three-nucleotide deletion (3 x thymine, TTT) 
that is present in both alleles and is located within an intronic stretch of 8 
consecutive thymine residues that shows considerable sequence variation: 4 of 
the 8 thymine residues exhibit annotated SNPs. Lastly, I identified a two-
nucleotide deletion (2 x cytosine, CC) located within an intronic stretch of 6 
consecutive cytosine residues that shows considerable sequence variation: 4 of 
these 6 cytosine residues exhibit annotated SNPs. This deletion is only present 


















This chapter describes the generation of a novel Drosophila knock-in model of 
GEPD. Using ends-out HR, an A1097G point mutation was introduced into slo – 
the fly orthologue of KCNMA1 – resulting in an E366G amino acid change that is 
equivalent to the GEPD-linked D434G missense mutation in humans (Du et al., 
2005). The sloE366G allele is the first in vivo model of GEPD, facilitating the study 
of this PxD-epilepsy syndrome on a molecular, cellular, and behavioural level 
within a living organism.  
2.5.1 Experimental Notes and Caveats 
2.5.1.1 Functional Conservation of D434 in Drosophila 
The human D434 amino acid residue (aspartic acid) is only functionally 
conserved in flies, which carry a glutamic acid residue (E) at the equivalent 
position (Figure 2.2). This could reflect a functional difference between 
mammalian and Drosophila BK channels, which would raise the question whether 
a missense mutation to glycine (G) would equally affect both channels. 
Importantly, electrophysiological data provide strong evidence for BK channels to 
be functionally similar in the presence of either aspartic- or glutamic acid at amino 
acid position 434 – as shown via expressing the D434G-equivalent murine 
D369G mutation in Xenopous laevis oocytes and recording macroscopic currents 
in the inside-out patch clamp mode (Yang et al., 2010). These experiments 
generated conductance-voltage (G-V) curves for a range of [Ca2+], demonstrating 
that V1/2 was shifted to more negative voltage ranges only for D369G BK 
channels, while D369E showed equivalent properties to D369D (Yang et al., 
2010). Indeed, glycine was the only out of 7 amino acid residues tested that 
caused an increase in Ca2+ sensitivity, and molecular dynamics simulations 
suggested that this is due to a conformational change of the BK channel CTD 
that only occurs in the presence of glycine (Yang et al., 2010). Hence, I 
hypothesise that mammalian and Drosophila BK channels will be equally affected 





2.5.1.2 Endogenous Sequence Replacement in sloE366G 
In addition to carrying the E366G missense mutation, the sloE366G allele 
exchanges a 76 bp remnant vector sequence with 45 bp of endogenous gDNA. 
While the HR design ensures that these 45 bp are intronic and exhibit poor 
evolutionary conservation (Figure 2.3), this sequence can still be functionally 
important. For example, it has recently been shown that an intronic retroelement 
within slo affects the male Drosophila courtship song (Ding et al., 2016). In order 
to account for any potential effects of this sequence replacement, the sloloxP allele 
was generated in parallel, which carries the 76 bp remnant vector sequence but 
not the E366G missense mutation (Figure 2.13). This allele serves as the control 
against which sloE366G can be compared. 
2.5.1.3 Sequence Variation in sloE366G and sloloxP 
Extensive sequence variation within the slo locus of the sloE366G and sloloxP alleles 
was identified, as compared to the BDGP6 Drosophila melanogaster reference 
genome. However, via manual SNP analysis, I was able to show that all of the 
19 point mutations present within the Arm1 and Arm2 regions of sloE366G and 
sloloxP – excluding A1097G – represent naturally occurring SNPs (Table 36 and 
Table 37). These SNPs are annotated on Ensembl and derive from the DPGP 
database, a large-scale genome sequencing effort covering >200 naturally 
occurring, mainly African, Drosophila melanogaster populations (Lack et al., 
2016; Langley et al., 2012; Pool et al., 2012). Since P[w25.2]-Arm2E366G-Arm1 
was cloned from an iso31 genetic background, while embryonic injections were 
performed into a w1118 genetic background, it is likely that these SNPs represent 
sequence variation naturally present in the w1118 stock used by BestGene for 
embryonic injections. This would also explain the presence of all 19 SNPs in both 
alleles, sloE366G and sloloxP, as it is considered unlikely that independent 
mutagenic events occurring after embryonic injection result in precisely the same 
sequence variation. Further evidence for this hypothesis is provided by the 
presence of a two-nucleotide deletion (2 x cytosine, CC) only in the sloloxP allele: 
for all sloloxP alleles, the HR event on Arm2 must have happened 5' of the A1097G 
point mutation, in order not to introduce it into the endogenous slo locus (Figure 




3' of A1097G, in order to successfully integrate it. Hence, any sequence variation 
naturally present within the w1118 genetic background that is located 5' of A1097G 
on Arm2 can, by definition, only be present in the sloloxP allele. Indeed, the 
deletion of two cytosine residues is the only sequence variant that is 
simultaneously 5’ of A1097G on Arm2 and only present in sloloxP – all other 
sequence- and structural variation, excluding A1097G, is present in both alleles 
(Table 36 and Table 37).  
2.5.1.4 A Potential 5' Bias of Homologous Recombination 
An interesting note with respect to ends-out HR is worth mentioning: assuming 
an equal probability of HR occurring along Arm2 and given that 14 HR events 
happened, one recombination event would be expected to occur every ~195 bp 
– this result is obtained by dividing the length of Arm2, 2731 bp, by the number 
of HR events, 14. Since the GEPD-linked A1097G mutation is located at position 
402 (Figure 2.3), one would, therefore, expect 2 HR events amongst the 14 not 
to integrate the point mutation into the endogenous slo locus (Figure 2.13) – 
instead, I recovered 4. Hence, it might be the case that, within the scope of this 
experiment, HR has a 5' bias within Arm2. 
2.5.2 Clinical Relevance 
2.5.2.1 The First in vivo Model of GEPD 
As discussed in Paragraph 1.4, BK channels show a complex pattern of 
expression and function (Bailey et al., 2019; Griguoli et al., 2016; Latorre et al., 
2017). While in vitro studies of the D434G mutation have provided important 
biophysical insight (Yang et al., 2010), the organismal effects of this mutation are 
unknown. The novel sloE366G allele presented in this chapter is the first in vivo 
model of GEPD and will facilitate the study of this disorder in a living organism. 
In particular, despite having evolutionarily diverged >700 million years ago 
(Hedges et al., 2006), the aim of this thesis is to discover pathological 
endophenotypes that are conserved between flies and humans (Lehner, 2013). 
Such cellular and molecular mechanisms would not only increase our 
understanding of GEPD, but might also reveal pathological principles that are 





The first in vivo model of GEPD has been generated via the introduction of the 
E366G missense mutation into Drosophila slo, replicating the human GEPD-
linked D434G missense mutation (Du et al., 2005). The first step towards a 
mechanistic understanding of GEPD is a thorough phenotypic characterisation of 





























3 Phenotypic Characterisation of sloE366G  
3.1 Introduction 
While electrophysiological studies have thoroughly described the biophysical 
effects of the GEPD-linked D434G missense mutation in vitro (Yang et al., 2010), 
its effects in vivo are unknown. As described in Paragraph 1.4.4, understanding 
how this mutation affects an entire organism might yield important and 
unexpected insights into the pathogenesis of GEPD. The newly established 
sloE366G allele allows, for the first time, to study GEPD in a living organism. In this 
chapter, this task is approached on a cellular and behavioural level, including the 
video-tracking of Drosophila larvae and adults, electrophysiological recordings 
from the larval NMJ, and imaging of fixed- and live tissue.  
To this end, it is first established that the sloE366G allele is homozygous 
lethal for post-pupal stages. Working with heterozygotes, it is shown that 
sloE366G/+ larvae and adults exhibit severe locomotor defects, confirming the 
dominant nature of the sloE366G allele. Pupal-, larval-, and adult morphology as 
well as adult life span are also markedly affected in sloE366G/+ animals. Moreover, 
electrophysiological evidence is provided that sloE366G is a gain-of-function allele 
ex vivo, exhibiting increased Ca2+ sensitivity in a manner similar to its murine 
D369G and human D434G equivalents (Du et al., 2005; Lee and Cui, 2009; Yang 
et al., 2010). Further cellular analyses of the larval nervous system, both 
electrophysiologically and via confocal imaging, revealed that the larval NMJ is 
structurally and functionally intact under physiological conditions, but that MNs in 
the ventral nerve cord (VNC) fire abnormally. Altogether, this chapter provides an 
in-depth characterisation of the sloE366G allele and represents a first step towards 








3.2 Statement of Contribution 
3.2.1 Direct Contributions 
The video-tracking software AnimApp (Paragraph 3.4.2) was developed by Dr. 
Srinivasa Rao (code), Dr. Sam Olechnowicz (artwork, beta testing), Narayana 
Rao (code), and myself (beta testing), and is available on GitHub: 
https://github.com/sraorao/ (Rao et al., 2019). Dr. Srinivasa Rao and I wrote an 
R-based analysis script for the AnimApp tracking data, which is also available on 
GitHub: https://github.com/PatrickKratsch/. Confocal imaging of the larval NMJ, 
ensuing data analysis, and visualisation were performed by Dr. James Jepson 
(Paragraph 3.4.3). Electrophysiological recordings from the larval NMJ and 
corresponding data analyses were performed by Dr. Simon Lowe, while Dr. 
James Jepson visualised the data (Paragraphs 3.4.3, 3.4.4, and 3.4.5). Live-
imaging of larval MNs was performed by both Dr. James Jepson and myself, each 
of us preparing and imaging 6 samples per genotype (Paragraph 3.4.5). Dr. 
James Jepson and I analysed the live-imaging data independently, but only the 
results from my own analyses are presented in this chapter (Paragraph 3.4.5). 
Table 38 lists these contributions and the corresponding figures in this chapter. 
Table 38 Experimental Contributions to Chapter 3 
Contributing Researcher Corresponding Figure 
Dr. Simon Lowe and Dr. James 
Jepson 
Figure 3.10, Figure 3.11, Figure 3.12 
Dr. James Jepson Figure 3.9 
Dr. James Jepson and Patrick 
Kratschmer 
Figure 3.13, Figure 3.14, Figure 3.15 
 
3.2.2 Indirect Contributions 
Throughout the work described in this chapter, Dr. James Jepson and Dr. Ko-
Fan Chen have provided invaluable intellectual input, without which the 




3.3 Materials and Methods 
3.3.1 Genetic Nomenclature 
The genotypes of flies used in this chapter are listed in Paragraph 3.3.2. 
Nomenclature guidelines are described in Paragraph 2.3.1. 
3.3.2 Fly Stocks 
Table 39 Fly Stocks of Chapter 3 
Genotype Source 
iso31 Kind gift from Dr. Kyunghee Koh 
w;;sloE366G/TM6B,Tb This thesis 
w;;sloloxP/TM6B,Tb This thesis 
w;OK371-Gal4,UAS-GCaMP6M; Kind gift from Dr. Stefan Pulver 
 
3.3.3 Fly Husbandry 
Unless otherwise indicated, all fly stocks were maintained on standard fly food at 
RT. The recipe of the standard fly food is shown in Table 4. All flies and larvae 
used for behavioural experiments were maintained at 25ºC on a 12 h light:12 h 
dark cycle.  
3.3.4 Experimental Genotypes 
Unless otherwise indicated, recombinant 25.1.1/TM6B,Tb was used as a 
representative for sloE366G/TM6B,Tb, and recombinant 132.1.1/TM6B,Tb as a 
representative for sloloxP/TM6B,Tb. 
3.3.4.1 sloE366G/+ and sloloxP/+ 
sloE366G/+ and sloloxP/+ larvae and adults were generated by crossing 
sloE366G/TM6B,Tb and sloloxP/TM6B,Tb to isogenic controls (iso31), respectively.  
3.3.4.2 Live-imaging 
To generate OK371-Gal4,UAS-GCaMP6M/+;sloE366G/+ and OK371-Gal4,UAS-
GCaMP6M/+;sloloxP/+, OK371-Gal4,UAS-GCaMP6M was crossed to 




3.3.5 Pupal Morphology Analysis 
Pupae were collected from vials kept at 25ºC, aligned above a ruler, and pictures 
taken with an iPhone 8 (Apple Inc.) through a stereomicroscope. Images were 
loaded into FIJI for analysis (Schindelin et al., 2012): width and length were 
measured in pixels and the results converted to mm in Microsoft Excel (Microsoft 
Excel for Mac, v 16.22). The data were loaded into RStudio (RStudio Inc., v. 
1.2.1335), using R (v. 3.6.0) to perform statistical tests and data visualisation. 
The same versions of R and RStudio were used throughout this chapter. 
3.3.6 Larval Video-recordings 
Larvae were age-matched by restricting parental egg laying to a period of 24 h. 
4 days after egg-laying, wandering L3 larvae were collected: the walls of food 
vials containing the larvae were cleared so as to avoid collecting pupariating 
larvae, before filling the vials with 20% sucrose solution (EMD Millipore, 5737-
1KG), causing larvae to float to the surface due to buoyancy. After 10 min, larvae 
were poured into separate containers, gently collected with a paint brush, and 
cleaned with Milli-Q water. Following this, larvae were gently dried using 
Precision Wipes (KIMTECH SCIENCE, 7552) and placed onto a large surface 
coated with 2% agar (Sigma-Aldrich, A1296-1KG), located in an incubator (LSM) 
at 25ºC and a relative humidity between 50% and 55%. Videos of individual 
larvae were taken with the open-source Android Open Camera app (available at 
https://opencamera.sourceforge.io/) on a Samsung S5 mobile phone at 15 fps 
and 640x480 resolution. Videos were taken between 2:15 pm and 8:15 pm. The 
order in which genotypes were recorded was inverted between experimental 
repeats, to avoid circadian confounds. 
3.3.7 Pre-processing of Larval Videos 
Larval videos were cropped from 10 s to 70 s (duration = 1 min), allowing for 10 
s of acclimatisation. The audio information was removed from videos in order to 
reduce file size. Cropping and removal of the audio information were performed 
on the Unix command line using the open-source software FFmpeg (v. 4.1.1, 




Table 40 Pre-processing of Larval Videos 
#!/bin/bash 
# for each video, remove sound 
for i in $(echo *.mp4); do 
  ffmpeg -i $i -an $j\_nosound.mp4 
done 
# for each silent video, crop from 10 s to 70 s 
for i in $(echo *_nosound.mp4); do 
  ffmpeg -i $i -ss 00:00:10.0 -t 00:01:00.0 \ 




For downstream analyses, it is important for each video to have the same number 
of frames. This was confirmed by using the bash script shown in Table 41, 
determining each video to consist of 900 frames.  
Table 41 Retrieval of Video Frame Numbers 
#!/bin/bash 
# display frame number for each cropped video file 
for i in $(echo *.mp4); do 
  ffprobe -v error -select_streams v:0 -show_entries 3 \ 
  stream=nb_frames \  




3.3.8 Tacking Larval Locomotion 
Pre-processed larval videos were used for video-tracking with the desktop 
version of the AnimApp video tracker, available at https://github.com/sraorao/ 
(Rao et al., 2019). To execute Python scripts from the Unix command line, Python 
v. 2.7.15 was used (http://www.python.org). First, the optical threshold values for 




set_thresholds_v5.py adjusts the hue, saturation, and value (HSV) for each of 
the videos, in order to establish the maximum contrast between the larvae and 
the background, facilitating accurate tracking. The HSV values used are shown 
in Table 42. 
Table 42 HSV Values for Larval Tracking 
Parameter Value 
Hue Lower 0 
Saturation Lower 0 
Value Lower 176 
Hue Upper 179 
Saturation Upper 255 
Value Upper 255 
 
These values were used as input parameters for the tracking function 
opencv_colour_tracking_v12.py, whose output, including x- and y-positions over 
time, was used for the analysis of larval locomotion (Paragraph 3.3.9). 
3.3.9 Analysis of Larval Locomotion 
A customised R script was used to analyse the video-tracking data generated by 
AnimApp (Paragraph 3.3.8). This script is available on GitHub: 
https://github.com/PatrickKratsch/. It loads the AnimApp output files (CSV files) 
for each genotype into R, binds the x- and y-positions into a single data object, 
and confirms via exploratory plotting of the x- and y-values that each larva was 
accurately tracked. It then calculates the Euclidean distance travelled between 
consecutive frames via the Pythagorean Theorem as shown in Table 43. 
Table 43 Calculation of Larval Locomotion 
𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒	𝑡𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑 = 	.(𝑥1 − 𝑥3)1 + (𝑦1 − 𝑦3)1 
(𝑥3, 𝑦3) = 𝑖𝑛𝑖𝑡𝑖𝑎𝑙	𝑝𝑜𝑠𝑖𝑡𝑖𝑜𝑛	𝑜𝑓	𝑙𝑎𝑟𝑣𝑎 





Total larval displacement is then calculated as the sum of consecutive frame 
displacements. This value was converted from pixels (default) to mm by 
interactively measuring a reference scale of 3 cm using the function 
set_thresholds_v5.py. For the videos analysed in this chapter, 3 cm correspond 
to 109 pixels. Hence, dividing the total distance in pixels by 3.63 pixels/mm yields 
the total distance in mm. In order to plot normalised paths for each larva, larval 
starting positions were subtracted from individual (x, y) positions for each frame. 
For the analysis of larval lengths and widths, the frame-wise length and width 
values of the tracked object were extracted from the AnimApp output data. The 
mean lengths and widths were calculated by taking the average of the larval 
lengths and widths over the course of the whole 1-min video recordings. Larval 
peristalsis was visualised by extracting the larval length via the same means and 
plotting it over time. Turning behaviour was calculated by dividing larval width by 
larval length, generating a novel parameter that increases prior to larval turning. 
By manually inspecting 30 videos, I identified a threshold value of 0.4 for the 
width:length ratio as a reliable indicator for larval turning. The width:length ratio 
was then plotted over time, and I manually counted how often the 0.4 threshold 
was crossed for each larva. This analysis was performed blinded to genotype.   
3.3.10 Larval Morphology Analysis 
To analyse larval length and width manually, wandering L3 larvae were collected 
and snap-frozen at -80ºC for 30 min. Using fine forceps (#5, Dumont, 0103-5-
PO), larvae were gently stretched to their maximum length from anterior (mouth 
hooks) to posterior (spiracles). All larvae were dead at this stage. Data analysis 
was performed as described in Paragraph 3.3.5 for pupal morphology. 
3.3.11 Live-imaging of Larval Motoneurons 
Wandering L3 larvae of genotypes OK371-Gal4,UAS-GCaMP6M/+;sloE366G/+ 
and OK371-Gal4,UAS-GCaMP6M/+;sloloxP/+ were collected from within the food 
and dissected in the recording solution shown in Table 44 (pH = 7.15), as adapted 




Table 44 Recording Solution for Live-imaging 








Larvae were submerged in the recording solution during the dissection. Using 
fine forceps, the entire larval CNS (consisting of two brain lobes, the 
subesophageal zone, and the VNC) was gently removed and attached to a glass-
bottom dish (CELLview, GBO, 627860) coated with poly-L-lysine (Sigma Aldrich, 
P4832-50mL). The glass-bottom dish contained the same recording solution as 
described in Table 44. Because an inverted confocal microscope was used for 
image acquisition, the dorsal side of the larval VNC was oriented to face the poly-
L-lysine-covered bottom of the glass-bottom dish – this is necessary due to the 
dorsal location of MNs within the VNC. Larval dissections were performed 
immediately prior to image acquisition, and samples were imaged within 5 min 
after dissection. Image acquisition was performed on a Zeiss LSM 710 confocal 
microscope, using the Zen software (Zeiss). 5-min time series were recorded at 
20x magnification, using the EC “Plan-Neofluar” 20x/0.50 M27 air objective 
(Zeiss, 420350-9900-000). The frame size was 256x256 pixels and the bit depth 
8 bit. The scan time was 390.98 ms per frame, with 200 ms intervals between 
scans. The pinhole was maximally opened, so as to capture fluorescence from 
multiple focal planes. An Argon laser at 488 nm (A488) was used to excite 
GCaMP6M, which has an excitation wavelength of 450-490 nm (Chen et al., 
2013).  
3.3.12 Analysis of Live-imaging Data 
Live-imaging data analysis was performed blinded to genotype and adapted from 
(Pulver et al., 2015) and (Streit et al., 2016). To analyse MN activity, using FIJI 




bundles innervating segments 7 and 4 on each side of the VNC (left and right), 
and fluorescence activity measured over time. The ROI area was kept constant 
at 115.809 µm2. The background fluorescence was measured via an additional 
ROI placed at the upper left-hand corner of the image. The resulting fluorescence 
values were exported from FIJI into Microsoft Excel for further analysis (Microsoft 
Office 365, v. 16.24). First, the background fluorescence was subtracted from all 
other fluorescence values. Next, the frame number was converted into time (in 
ms) by multiplying it by 590.98 ms, the duration of each frame (Paragraph 3.3.11), 
resulting in fluorescence time series for ROIs from 4 segments: ROI 4 left (4L), 
ROI 4 right (4R), ROI 7 left (7L), and ROI 7 right (7R). To visualize the data and 
prepare them for analysis, the following five ROI fluorescence values were plotted 
over time: (1) 4L, (2) 4R, (3) 4L and 4R, (4) 4L and 7L, and (5) 4R and 7R – 
generating 5 individual plots. Using a manual counting approach, 4 parameters 
were analysed: (1) the fluorescence amplitude of Ca2+ spikes in segment 4 that 
occurred during forward peristaltic movements – forward peristaltic movements 
were identified as synchronous Ca2+ spikes on both sides of segment 4 that were 
preceded by synchronous Ca2+ spikes on both sides of segment 7 (posterior-to-
anterior Ca2+ activity); (2) the frequency of Ca2+ spikes identified in (1); (3) the 
time interval between Ca2+ spikes in segments 7 and 4 during forward peristaltic 
movements; (4) the number of turn initiations, as identified by anti-correlated Ca2+ 
fluorescence between each side of segment 4. Parameters (1) and (3) were 
quantified for each side of the VNC (left and right) separately. For these analyses, 
only the first 508 video frames were used, which corresponds to 300217.84 ms. 
For simplicity, this duration is referred to as 5 min, ignoring the additional 217.84 
ms.  
3.3.13 Scoring Wing Inflation 
Pictures of adult flies were taken with an iPhone 8 (Apple Inc.) through a 
stereomicroscope. Three separate wing phenotypes were scored and quantified 





3.3.14 Adult Video Recordings 
Flies were video-recorded inside 65-mm long, food-containing glass tubes 
(TriKinetics), which were attached to an even surface using Blu Tack (Bostik). To 
prepare the glass tubes with food, a solution of 2% agar (w/v, Sigma Aldrich, 
L2897-1KG) and 4% sucrose (w/v, EMD Millipore, 5737-1KG) was homogenised 
by heating in a microwave, followed by pouring it into a plastic tray, into which 
clean glass tubes were placed vertically. Once the food had cooled and solidified, 
the food-containing glass tubes were cleaned and the food-containing sides 
sealed with liquified paraffin wax (Sigma Aldrich, 327204-1KG). Flies were 
anaesthetised on CO2 pads (Flystuff, Genesee Scientific) and loaded into the 
prepared glass tubes, which were then sealed with cotton. Loaded glass tubes 
were positioned in an incubator (LMS) and videos recorded using a USB-webcam 
(Logitech c920 HD pro) at a 12 h light:12 h dark regime at 25ºC and an average 
humidity of 65% to 70%. The infrared filter of this webcam was manually removed 
to allow for recordings in darkness. Flies were acclimatised to the new 
environment for at least 24 h. Flies were between 3 and 6 days old at the time of 
recording.   
3.3.15 Tracking Adult Locomotion 
Adult video-tracking was performed with the Drosophila ARousal Tracker (DART) 
system, a MATLAB-based offline video-tracker (Faville et al., 2015), using videos 
recorded as described in Paragraph 3.3.14 as input files. The tracking algorithm 
outputs CSV files containing the x- and y-positions for each fly over time. 
3.3.16 Analysis of Adult Locomotion  
A customised R script was used to analyse the DART video-tracking data, which 
is available on GitHub: https://github.com/PatrickKratsch/. This script first creates 
an “offset table” from the DART tracking data, obtained by subtracting successive 
x- and y-values. Hence, the offset table defines the displacement for each fly 
between consecutive frames. The total distance travelled between consecutive 
frames was calculated for each fly as described for the analysis of larval 
locomotion, using the Pythagorean Theorem (Table 43). Summing all frame-to-




period. Flies that did not move during the second half of the experiment (hours 7 
to 12) were identified as dead and excluded from further analysis. Of note, the 
precise duration analysed was 716 min (11 h and 56 min) due to the removal of 
2 min post-lights-on and 2 min pre-lights-off, during which the lighting conditions 
prevented appropriate video-tracking. For simplicity, I refer to 716 min as 12 h. 
The analyses of movement parameters other than total distance travelled are 
based on a period of 1 h after the dark-light transition (9:02 am – 10:02 am). To 
analyse the distribution of locomotor speed, empirical cumulative distribution 
plots were generated based on 1-s movement bins (3600 bins for a 1-h period). 
To analyse movement initiation, a sliding window of length 2 quantified how often 
a 1-s bin of non-movement was followed by a 1-s bin of movement. To analyse 
the mean bout length, the fly movement data were transformed into a binary 
matrix, with 1’s indicating movement and 0’s non-movement. Subsequently, the 
lengths of movement streaks (streaks of 1’s) were extracted and averaged. 
3.3.17 Adult Life Span Analysis 
110 sloE366G/+ and 100 sloloxP/+ males were age-matched by emptying parental 
vials < 12 h prior to the start of the experiment. These males were then housed 
with an excess number of females for 48 h before the start of the experiment, 
increasing the probability of mating. sloE366G/+ and sloloxP/+ males were then 
separately placed into standard food vials in groups of 10. These vials were 
flipped onto fresh food every 2 days, counting dead flies in the process.  
3.3.18 Statistics 
Statistical tests were performed in R using RStudio. For comparisons between 
two groups, Mann-Whitney-Wilcoxon tests were performed using the function 
wilcox.test. For multiple comparisons, Kruskal-Wallis tests were performed to 
confirm a difference between groups, using the kruskal.test function. A Dunn’s 
post-hoc test was performed to identify which comparisons were significant, using 
the dunnTest function from the FSA package (Ogle, D.H. 2018. FSA: Fisheries 
Stock Analysis. R package, v. 0.8.20). To adjust p-values for multiple 
comparisons, the Holm method was used (default). To test for differences 




performed, using the ks.test function. For data not analysed by me, the figure 
caption indicates the analyses performed.  
3.3.19 Data Visualisation 
Figures were generated in R and RStudio, using the ggplot2 package (Wickham, 
ggplot2: Elegant Graphics for Data Analysis, 2016). Figures were arranged in 
Microsoft PowerPoint (Mac, v. 16.24, Office 365), and exported as JPG files at 
300 dpi. Boxplots are drawn according to Tukey: the lower hinge corresponds to 
the first-, the upper hinge to the third quartile. The upper whisker reaches to the 
largest value less than or equal to 1.5-times the inter-quartile range (IQR) above 
the third quartile hinge. The lower whisker reaches to the smallest value larger 
than or equal to 1.5-times the IQR below the first quartile hinge. The median is 
marked within the box by an additional line. Figures generated by Dr. James 






















3.4.1 sloE366G/sloE366G Alters Pupal Morphology 
In order to study the effects of the sloE366G allele at the organismal level, I first 
undertook a morphological examination of homozygotes for the mutant allele. 
Homozygous sloE366G/sloE366G larvae were very rare. Under good stock 
conditions, occasional sloE366G/sloE366G larvae developed to the L3 stage and 
successfully pupated. However, these pupae looked misshapen compared to 
sloloxP/sloloxP. Moreover, sloE366G/sloE366G pupae were significantly longer and 
thinner than their sloloxP/sloloxP counterparts (Figure 3.1). Importantly, none of the 
sloE366G/sloE366G pupae eclosed, rendering the sloE366G allele homozygous lethal 
by the adult stage. A conventional parameter used to describe pupal dimensions 
is the axial ratio – pupal length divided by pupal width – and it has been reported 
that the popular wild-type strains w1118 and Oregon R have a mean axial ratio of 
3.0 ± 0.1 (Guan et al., 2006). The axial ratio of sloE366G/sloE366G pupae was 
significantly greater than the axial ratio of sloloxP/sloloxP pupae, with a median axial 
ratio of 4.4 (sloE366G/sloE366G) compared to 3.2 (sloloxP/sloloxP) – the latter being 
close to the reported wild-type average (Figure 3.1) (Guan et al., 2006). 
 
 
Figure 3.1 sloE366G/sloE366G Alters Pupal Morphology 
Homozygous sloE366G/sloE366G pupae exhibit severe morphological abnormalities, 
as shown in A. The ruler at the bottom in A indicates steps in mm. (B) 
sloE366G/sloE366G pupae showed a significantly increased axial ratio, defined as 
pupal length divided by pupal width. Looking at these parameters in isolation 
showed that sloE366G/sloE366G pupae were significantly thinner (C) and longer (D) 
than sloloxP/sloloxP (B). (n = 10; Mann-Whitney-Wilcoxon test; **** = p < 0.0001, 





3.4.2 sloE366G/+ Affects Larval Locomotion 
GEPD patients exhibit PxD and/or epilepsy in the presence of a heterozygous 
KCNMA1D434G allele (Du et al., 2005). Hence, a key question is whether motor 
control is also affected in the GEPD fly model. To investigate this possibility, I 
performed video-tracking of individual age-matched sloE366G/+ and sloloxP/+ L3 
larvae and compared the total distances travelled during 1 min. Three 
independent recombinants per genotype were used for these experiments, in 
order to account for potential genetic background effects. The following sloE366G/+ 
recombinants were used: 25.1.1/+, 137.1.3/+, and 72.1.1/+. For sloloxP/+, the 
following three recombinants were used: 132.1.1/+, 111.1.1/+, and 7.1.1/+ 
(Figure 2.15). To analyse the video-recordings, a novel video-tracking software 
called AnimApp was used (Rao et al., 2019), as illustrated in Figure 3.2.  
 
 
Figure 3.2 Pipeline for Larval Video-tracking 
This figure illustrates how larval videos were taken (using a mobile phone), pre-
processed (on the Unix command line using FFmpeg), how larvae were tracked 
(with the AnimApp software), and the resulting tracking data analysed (using 
customised R scripts in RStudio). At the bottom, the movement of a single larva 
is shown. The green numbers represent the larval diameter in pixels. White 
arrows indicate the larval trajectory. The larval genotype shown is sloloxP/+ 
(recombinant 132.1.1/+). The AnimApp video-tracking algorithm is available at 





L3 larvae were individually recorded for 1 min, and the resulting video files pre-
processed on the Unix command line, before tracking larval movement using 
AnimApp (Figure 3.2) (Rao et al., 2019). The output CSV files contain the larval 
x-y positions for each video frame – amongst other information, such as the 
length and width of the tracked object. In order to confirm that the larvae had 
been properly tracked, I plotted their x-y trajectories manually and appraised 
whether they were physically possible (Figure 3.3). Only 1 out of 164 larvae was 
not tracked properly, and this larva, of genotype 72.1.1/+, was excluded from 






Figure 3.3 Exploratory Analysis of Larval Locomotion 
Larval trajectories for each of the 164 recorded larvae were plotted in order to 
confirm proper tracking. This figure illustrates the procedure for 25 larvae of 
genotype sloloxP/+ (recombinant 132.1.1/+). Each graph plots larval x-y positions 
in pixels. The duration of each path is 1 min. 1 out of 164 larvae was identified 
as poorly tracked and excluded from further analyses (Figure 9.1). 
 
The remaining 163 larvae were used for the quantification of total distance 
travelled during 1 min, demonstrating that sloE366G/+ larvae moved significantly 
shorter distances than sloloxP/+ larvae, while no within-genotype differences were 
observed (Figure 3.4). The reduction in mean travelling distance exhibited by 
sloE366G/+ larvae was ~2-fold after pooling the recombinants by genotype (32.9 
mm for sloE366G/+ vs 66.3 mm for sloloxP/+). Plotting the normalised trajectories of 




132.1.1/+ for sloloxP/+, illustrates the locomotor defect of sloE366G/+ larvae (Figure 
3.4). Of note, the directionality of larval movement for each genotype appears to 




Figure 3.4 sloE366G/+ Reduces Larval Travelling Distance 
Normalised larval trajectories of two representative recombinants per genotype 
are illustrated: (A) sloloxP/+ (recombinant 132.1.1/+, 28 larvae) and (B) sloE366G/+ 
(recombinant 25.1.1/+, 26 larvae), illustrating that sloloxP/+ larvae travel farther 
than sloE366G/+ larvae (C). (D) Total distance travelled during 1 min was 
quantified for three separate sloloxP/+ and three separate sloE366G/+ 
recombinants. sloE366G/+ larvae moved significantly shorter distances than 
sloloxP/+ larvae. No within-genotype differences were observed. Data from two 
independent experimental repeats were pooled. (n= 25-31; Kruskal-Wallis 
multiple comparison with Dunn’s post-hoc test; **** = p < 0.0001) 
 
I proceeded to investigate whether the sloE366G allele affects larval peristalsis. To 




inspected the resulting graphs for qualitative differences. The change of larval 
length over time was used as an indicator for larval peristalsis because larval 
contractions and expansions occur along the direction of this axis. A similar 
parameter, larval area over time, was recently used for the same purpose (Otto 
et al., 2018). Figure 3.5 shows representative examples for one sloE366G/+ larva 
(25.1.1/+) and one sloloxP/+ larva (132.1.1/+), suggesting that the peristaltic 
frequency of the sloE366G/+ larva is reduced, which would provide a possible 
explanation for the reduction in travelling distance (Figure 3.4). However, these 
traces also suggest that the peristaltic amplitude of the sloE366G/+ larva is 
increased, which would have the opposite effect. Hence, quantitative analyses 
need to be performed, in order to draw definitive conclusions about changes in 
peristaltic behaviour.  
 
 
Figure 3.5 sloE366G/+ Might Affect Larval Peristalsis 
Larval length is plotted over time for one representative sloloxP/+ larva (A, 
recombinant 132.1.1/+) and one representative sloE366G/+ larva (B, recombinant 
25.1.1/+). These traces suggest that sloE366G/+ larvae exhibit a reduced 
peristaltic frequency and an increased peristaltic amplitude. The dip at the end 
of trace A represents the initiation of a larval turn, which is preceded by a 





Careful inspection of Figure 3.5 suggests that sloE366G/+ larvae have an increased 
baseline length compared to sloloxP/+. A difference in larval size could indicate 
that the sloE366G allele affects larval metabolism. GLUT1-DS and PED are both 
linked to mutations in SLC2A1, associating glucose metabolism with PxD and 
epilepsy (De Giorgis and Veggiotti, 2013) (Paragraph 1.2.1.3). Hence, I 
wondered whether there could be a link between altered metabolism and GEPD 
that affects larval size. To investigate this possibility, I extracted the median larval 
lengths and widths from the AnimApp tracking data for each larva, before pooling 
these values by genotype for statistical comparison. Indeed, sloE366G/+ larvae 
exhibited a significantly greater median length than sloloxP/+ larvae (Figure 3.6). 
There is also a non-significant trend towards an increased median width of 
sloE366G/+ larvae (Figure 3.6). 
 
 
Figure 3.6 sloE366G/+ Alters Larval Dimensions 
The median larval lengths and widths for three separate sloloxP/+ recombinants 
(132.1.1/+, 111.1.1/+, 7.1.1/+) and three separate sloE366G/+ recombinants 
(25.1.1/+, 137.1.3/+, 72.1.1/+) were calculated from the AnimApp video-tracking 
data, and pooled by genotype. sloE366G/+ larvae exhibit a significantly greater 
median length than sloloxP/+ larvae (A), in addition to a non-significant trend 
towards increased width (B). (n = 76-87; Mann-Whitney-Wilcoxon test, **** = p 
< 0.0001) 
 
Figure 3.6 raises the question whether sloE366G/+ larvae are actually larger than 
sloloxP/+, or whether the difference observed via video-tracking is due to an effect 




larval MNs to properly contract body wall muscles might result in more 
outstretched larvae. To address this question, I measured the lengths and widths 
of wandering sloE366G/+ and sloloxP/+ larvae manually. As shown in Figure 3.7, the 
quantified results are congruent with Figure 3.6, suggesting that the increase in 




Figure 3.7 sloE366G/+ Alters Larval Dimensions: Additional Evidence 
(A) Wandering L3 larvae of genotypes sloloxP/+ and sloE366G/+ were snap-frozen 
at -80ºC and manually stretched to their maximal length. A ruler at the bottom 
marks steps in mm. (B) sloE366G/+ larvae were significantly longer than sloloxP/+ 
larvae, with a non-significant trend towards increased width of sloE366G/+ larvae 
as well (C). (n = 10; Mann-Whitney-Wilcoxon test; * = p < 0.05) 
 
Careful inspection of the larval traces in Figure 3.4 further suggests that sloE366G/+ 
larvae might turn less frequently than sloloxP/+. Since turning is a form of action 
selection, investigating this behaviour has clinical relevance due to its impairment 
in dyskinesia and other movement disorders (Kandel et al., 2013; Ryan et al., 
2018). As it proved difficult to manually count turns from larval traces shown in 
Figure 3.4, I resorted to take another approach: larvae decrease in length before 
turning, because they retract before advancing into a different direction. Dividing 
the larval width by larval length yields a parameter that increases prior to turning 
events – due to a decreasing denominator. To identify a larval width:length ratio 
that can serve as a reliable indicator for larval turning, I manually counted larval 




well with larval retraction prior to turning. Hence, I quantified the number of times 
the larval width:length ratio crossed a threshold of 0.4 during 1 min. As shown in 
Figure 3.8, sloloxP/+ larvae exhibit significantly more turns than sloE366G/+ larvae, 
while there are no within-genotype effects. These data suggest that action 
selection is impaired in sloE366G/+ larvae. 
 
 
Figure 3.8 sloE366G/+ Decreases the Number of Larval Turns 
The larval width:length ratio was used to score turning behaviour. 
Representative traces for this parameter are shown for one sloloxP/+ larva 
(132.1.1/+) in A and one sloE366G/+ larva (25.1.1/+) in B. Peaks crossing a 
width:length ratio of 0.4 (dashed line) were defined as turning events and 
manually counted. The sloloxP/+ larva shown exhibited 12 turns (A), the sloE366G/+ 
larva exhibited 2 (B). (C) sloE366G/+ larvae turned significantly less frequently than 
sloloxP/+ larvae – with the exception of the comparison between 137.1.3/+ and 
111.1.1/+ (p = 0.055). (n = 25-31; Kruskal-Wallis multiple comparison with 
Dunn’s post-hoc test; **** = p < 0.0001). (D) Pooled sloE366G/+ larvae turned 
significantly less frequently than pooled sloloxP/+ larvae. Analyses were 
performed blinded to genotype. (n = 76-87; Mann-Whitney-Wilcoxon test, **** = 





3.4.3 sloE366G/+ Does not Change NMJ Structure and Function 
The decreased larval locomotion exhibited by sloE366G/+ (Figure 3.4) could imply 
larval NMJ abnormalities. Since loss of slo has previously been shown to affect 
NMJ morphology (Jepson et al., 2014; Lee and Wu, 2010) (Paragraph 1.5.3.2), 
the sloE366G/+ NMJ was investigated via confocal microscopy. Wandering 
sloE366G/+ and sloloxP/+ L3 larval NMJs were immuno-labelled for horseradish 
peroxidase (HRP), staining neuronal membrane, and Discs-large (DLG), staining 
post-synaptic termini. Three parameters were quantified: (1) total synapse size, 
(2) synaptic bouton number, and (3) synaptic bouton area – none of which 
showed a significant difference between genotypes (Figure 3.9). 
 
 
Figure 3.9 sloE366G/+ Does not Affect NMJ Morphology 
(A) NMJs of wandering sloloxP/+ and sloE366G/+ L3 larvae were immuno-labelled 
with antibodies against HRP (green) and DLG (magenta). (B) Total synapse 
size, (C) synaptic bouton number, and (D) synaptic bouton area showed no 
significant differences between genotypes. The white scale bar indicates 20 µm. 
Data acquisition, analysis, and visualisation were performed by Dr. James 






Despite an unchanged morphology for the parameters tested (Figure 3.9), 
sloE366G/+ NMJs might function abnormally. As described in Paragraph 1.5.3.2, 
loss of slo has been linked to electrophysiological abnormalities at the NMJ (Ford 
and Davis, 2014; Jepson et al., 2014; Lee et al., 2008, 2014; Warbington et al., 
1996). To investigate sloE366G/+ NMJ function, sharp-electrode intracellular 
recordings from larval body wall muscles 6/7 were performed in modified HL3.1 
saline at an extracellular [Ca2+] of 1 mM, quantifying two events: (1) excitatory 
junction potentials (EJPs), evoked by electrically stimulating the severed motor 
nerve, and (2) spontaneously occurring miniature excitatory junction potentials 
(mEJPs) – neither of which differed between genotypes (Figure 3.10). These data 




Figure 3.10 sloE366G/+ Does not Affect NMJ Function 
(A) Representative EJP traces from the L3 larval NMJ of sloloxP/+ and sloE366G/+ 
are shown. Neither EJP amplitude (B) nor EJP decay rate (C) differed 
significantly between genotypes. (D) Representative traces of mEJPs for both 
genotypes are shown. Neither mEJP amplitude (E) nor interval (F) showed 
significant differences between genotypes. Recordings were performed at an 
extracellular [Ca2+] of 1 mM. Data acquisition and analysis were performed by 
Dr. Simon Lowe. Dr. James Jepson visualised the data. (B: n = 15-16; C: n = 12-





3.4.4 sloE366G is a Gain-of-function Allele ex vivo 
It was surprising to find that the sloE366G allele does not affect NMJ function 
(Figure 3.10), because the equivalent murine D369G mutation in KCNMA1 has 
been shown to cause a gain-of-function by increasing the sensitivity of BK 
channels to Ca2+ (Yang et al., 2010). In neurons, BK channels link Ca2+ influx 
through Cav channels to K+ efflux, contributing to the repolarisation of the AP 
(Bean, 2007). Hence, the initial hypothesis had been that this coupling of Ca2+ 
influx to K+ efflux would be potentiated in sloE366G/+ MNs. This would lead to a 
decrease in AP width, resulting in an overall reduction of pre-synaptic Ca2+ influx 
and decreased neurotransmitter release, a Ca2+-dependent process (Südhof, 
2012). A decrease in neurotransmitter release from MNs was predicted to 
decrease the EJP amplitude in the muscle. This was not observed (Figure 3.10). 
However, it is possible that a gain-of-function effect of the E366G mutation is 
masked under an extracellular [Ca2+] of 1mM, used for the recordings in Figure 
3.10, because both mutant and wild-type Slo might be maximally potentiated at 
this [Ca2+]. Indeed, macroscopic current recordings in inside-out patch clamp 
mode have shown that the murine D369G mutation does not affect BK channel 
function at nominal zero- or saturating (100 µM) intracellular [Ca2+] (Yang et al., 
2010). Instead, an increased Ca2+ sensitivity was only observed at intermediate 
intracellular [Ca2+] (Yang et al., 2010). To investigate a Ca2+-dependent effect in 
sloE366G/+, larval NMJ recordings were performed as described in Paragraph 
3.4.3, but at varying extracellular [Ca2+]: 0.15 mM, 0.25 mM, and 1 mM. Indeed, 
at 0.25 mM, a significant decrease in EJP amplitude was detected in sloE366G/+ 
when compared to sloloxP/+, while no significant difference was observed at 1 mM 
(Figure 3.11). A non-significant trend towards a decreased EJP amplitude was 






Figure 3.11 sloE366G is a Gain-of-function Allele ex vivo 
Example EJP traces from the L3 larval NMJ of sloloxP/+ and sloE366G/+ at (A) 0.25 
mM- and (B) 1 mM extracellular [Ca2+] are shown. (C) A significant decrease in 
EJP amplitude was detected at 0.25 mM extracellular [Ca2+] for sloE366G/+. Data 
acquisition and analysis were performed by Dr. Simon Lowe. Dr. James Jepson 
visualised the data. (n = 7-16; ns = p > 0.05, * = p < 0.05; Mann-Whitney-
Wilcoxon test with Bonferroni correction) 
 
A significant decrease in EJP amplitude would be the expected effect of a pre-
synaptically expressed gain-of-function slo allele, as described above. Hence, 
these data strongly suggest that sloE366G is a gain-of-function allele ex vivo, 
consistent with its murine and human orthologues in vitro (Du et al., 2005; Lee 
and Cui, 2009; Yang et al., 2010).  
3.4.5 sloE366G/+ Affects Endogenous NMJ- and Motoneuron Activity 
Having demonstrated normal NMJ morphology and function under physiological 
conditions (Paragraph 3.4.3), it is conceivable that the larval locomotor 
phenotype is caused by abnormal activity of MNs innervating the NMJ. For 
electrophysiological analyses in Figure 3.10, the MNs innervating muscles 6/7 
were severed. This is common practice in NMJ electrophysiology in order to allow 
for controlled current injections into the innervating nerve (Zhang and Stewart, 
2010). While the NMJ itself is intact in this setup, any pre-synaptic input from 
endogenous MN activity is lost. In order to investigate whether endogenous MN 




performed from the NMJ with intact CNS efferents to the muscle at an 
extracellular [Ca2+] of 1 mM. Interestingly, while all of the sloloxP/+ NMJs showed 
normal burst firing (n = 11), more than half of the sloE366G/+ NMJs were completely 
silent (14/26 = 54 %) – another 27% of sloE366G/+ NMJs exhibited uncoordinated 
firing (7/26), while only 19% showed burst firing (5/26) (Figure 3.12). These data 
suggest that, while the sloE366G/+ larval NMJ can function normally (Paragraph 
3.4.3), it receives aberrant endogenous input. This strongly supports the 
hypothesis that pre-synaptic MN activity at the larval NMJ is affected in sloE366G/+.  
 
 
Figure 3.12 sloE366G/+ Affects Endogenous NMJ Activity 
Electrophysiological recordings of endogenous L3 larval NMJ activity with intact 
MN efferents were performed. (A) All intact recordings from sloloxP/+ NMJs (n = 
11) showed normal burst firing – three examples are shown to illustrate the 
variability in cycle period. (B) NMJs of sloE366G/+ larvae (n = 26) showed three 
different endogenous activity patterns: burst firing (5), uncoordinated firing (7), 
and no firing (14). Recordings were performed at an extracellular [Ca2+] of 1 mM. 
Data acquisition and analysis were performed by Dr. Simon Lowe. Dr. James 
Jepson visualised the data.  
 
In order to directly investigate MN activity, live-imaging of larval MNs was 
performed using the GECI GCaMP6M (Chen et al., 2013), as described in (Pulver 
et al., 2015). GCaMP6M was expressed in sloE366G/+ and sloloxP/+ using the 
OK371-Gal4 driver, an enhancer trap line that expresses Gal4 under the control 
of an enhancer of the Drosophila vesicular glutamate transporter (CG9887), 
resulting in an expression pattern that limits Gal4 transcription mainly to MNs 





GCaMP6M/+;sloloxP/+. Specifically, the fluorescence activity of MN axon bundles 
innervating abdominal segments 4 and 7 of the larval VNC was measured, as 
described in (Pulver et al., 2015) and illustrated for segment 4 in Figure 3.13. 12 
CNS preparations per genotype were imaged on a confocal microscope on two 
separate days, in batches containing 6 preparations per genotype. Each 
recording lasted 5 min, which represents a trade-off between maximising 
information retrieval and minimising photobleaching. 
 
 
Figure 3.13 Live-imaging of Larval Motoneurons 
MN activity in sloloxP/+ and sloE366G/+ VNCs was measured using GCaMP6M, as 
shown in A: L and R indicate the left and right side of the VNC, respectively, 
while 4 and 7 denote abdominal VNC segments. ROIs were drawn around MN 
axon bundles innervating segment 4 for illustrative purposes, but segment 7 was 
also included in downstream analyses. (B) The corresponding fluorescence 
traces for these preparations during 5 min-recordings are shown for segments 
4L and 4R in both genotypes. The black arrowheads in the upper panel indicate 
anti-correlated MN activity on either side of segment 4, which was interpreted as 
larval turning. 
 
4 parameters from the live-imaging data were quantified: (1) the frequency of 
forward peristaltic waves, (2) the amplitude of Ca2+ spikes during forward 
peristaltic waves, (3) the forward wave propagation time from segment 7 to 




were interpreted as turning events – these parameters are illustrated in Figure 
3.14. Parameters 2 and 3 were quantified for each side of the VNC separately. 
 
Figure 3.14 Live-imaging Parameter Illustration 
Live-imaging of larval MNs was performed using GCaMP6M, and the resulting 
data analysed according to 4 parameters: (A) the frequency and amplitude of 
Ca2+ spikes in segment 4 during forward peristaltic waves, (B) the propagation 
time of forward peristaltic waves between segment 7 and segment 4, and (C) 
the frequency of turning events, defined as anti-correlated Ca2+ activity between 
the left and right sides of segment 4. The amplitude of Ca2+ spikes and the 
propagation time of forward peristaltic waves were quantified for each side of the 
VNC separately. All traces shown are derived from sloloxP/+. 
 
Analyses of the live-imaging data revealed altered sloE366G/+ MN activity 
according to each of the four parameters investigated: OK371-Gal4,UAS-
GCaMP6M/+;sloE366G/+ MNs showed (1) a decreased frequency of forward 
peristaltic waves, (2) a decreased amplitude of Ca2+ spikes during forward 
peristaltic waves, (3) a decreased wave propagation time from segment 7 to 






Figure 3.15 sloE366G/+ Alters Endogenous Motoneuron Activity  
Live-imaging of sloloxP/+ and sloE366G/+ MN activity was performed using 
GCaMP6M. sloE366G/+ MNs showed (A) a decreased number of forward 
peristaltic waves as well as (B) a decreased amplitude of Ca2+ fluorescence 
peaks. (C) Peristaltic forward waves of Ca2+ activity travelled faster in sloE366G/+. 
(D) sloE366G/+ MNs exhibited a decreased number of turning events. The 
recording time was 5 min. Data from two independent experimental repeats were 
pooled and analyses performed blinded to genotype. The data were acquired by 
both Dr. James Jepson and myself. (Mann-Whitney-Wilcoxon test, * = p < 0.05, 
**** = p < 0.0001) 
 
The data shown in Figure 3.15 strongly support the hypothesis that endogenous 
MN activity is affected in sloE366G/+ larvae. I next sought to characterise the effect 
of sloE366G/+ in adults. 
3.4.6 sloE366G /+ Partially Suppresses Wing Inflation 
Similar in chronology to phenotyping sloE366G/+ larvae, I began the phenotypic 
characterisation of adult sloE366G/+ flies by investigating morphological 
abnormalities. It was evident that some sloE366G/+ flies exhibited a non-inflated 




wings had properly inflated, they often appeared brittle and slightly curled. To 
quantify this phenotype, I collected 92 sloE366G/+ males and 96 sloE366G/+ females, 
scoring wing inflation as follows: (1) fully inflated wings, (2) semi-inflated wings, 
and (3) non-inflated wings. ~15% of male- and ~11% of female sloE366G/+ flies 
had non-inflated wings, while ~4% of male- and ~15% of female sloE366G/+ flies 
had semi-inflated wings (Figure 3.16). In contrast, I collected 219 sloloxP/+ males 
and 185 sloloxP/+ females, none of which showed a non-inflated wing phenotype, 
whereas 1 male (~0.5%) and 3 females (~2%) showed semi-inflated wings.  
 
 
Figure 3.16 sloE366G/+ Partially Suppresses Wing Inflation 
Wing inflation of 92 sloE366G/+ males (A) and 96 sloE366G/+ females (B) was 
scored according to three categories: non-inflation of wings, semi-inflation of 
wings, and fully inflated wings. Of note, even fully inflated wings of sloE366G/+ flies 
appeared brittle and slightly curled. 
 
3.4.7 sloE366G/+ Affects Adult Locomotion 
Having observed a significant decrease in travelling distance of sloE366G/+ larvae 
(Figure 3.4), I wondered whether this behaviour was conserved in adults. To this 
end, I used the DART system to video-track adult fly locomotion (Faville et al., 
2015). This system tracks adult flies within glass tubes that mainly allow for 
movement along one axis. For these experiments, I used sloE366G/+ and sloloxP/+ 




analogous to the larval locomotor analysis (Figure 3.4): 25.1.1/+, 137.1.3/+, and 
72.1.1/+ for sloE366G/+, and 132.1.1/+, 111.1.1/+, and 7.1.1/+ for sloloxP/+. 
Importantly, I only used flies with fully inflated wings (Figure 3.16). In a 12 h 
light:12 h dark cycle, I recorded fly movement for a whole day period of 12 h. 
Figure 3.17 shows that both male and female sloE366G/+ flies moved significantly 
shorter distances than their sloloxP/+ counterparts. In fact, the effect size of this 
decrease was greater than observed for larvae: sloE366G/+ males and females 
showed an ~3-fold decrease in mean locomotion compared to sloloxP/+ flies (5 m 
vs 16.9 m for males, respectively; 5.7 m vs 18.2 m for females).  
 
 
Figure 3.17 sloE366G/+ Decreases Adult Locomotion 
(A) sloE366G/+ males (25.1.1/+, 137.1.3/+, and 72.1.1/+) showed a significant 
decrease in locomotion compared to sloloxP/+ males (132.1.1/+, 111.1.1/+, and 
7.1.1/+). (B) A similar reduction in total distance travelled was observed for 
sloE366G/+ females. No within-genotype differences were observed for either sex. 
Total distance is measured in metres during 12 h lights-on. Data from three 
independent experimental repeats were pooled. (n = 27-37; Kruskal-Wallis 
multiple comparison with Dunn’s post-hoc test; **** = p < 0.0001) 
 
Due to a lack of within-genotype differences in locomotion (Figure 3.17), I pooled 
the DART data by genotype and sex for the analysis of more specific locomotor 
parameters. One possible explanation for a decrease in locomotion could be a 
decrease in locomotor speed, which I proceeded to quantify. Due to its 
crepuscular nature, Drosophila is most active during dusk and dawn (Peschel 
and Helfrich-Förster, 2011). Hence, in order to obtain a representation of their 




flies during a period of 1 h after the dark-light transition. Indeed, Figure 3.18 
shows a significant decrease in speed exhibited by sloE366G/+ males and females 
compared to sloloxP/+, illustrating that sloloxP/+ flies achieved speeds within a 
range that is not reached by sloE366G/+ (Figure 3.18). 
 
 
Figure 3.18 sloE366G/+ Decreases Locomotor Speed 
Adult sloE366G/+ and sloloxP/+ males (A) and females (B) were analysed for their 
cumulative distribution of locomotor speeds, measured as the distance in mm 
travelled during 1-s bouts for a period of 1 h after the dark-light transition. For 
both sexes, sloE366G/+ flies exhibited significantly lower locomotor speeds than 
sloloxP/+ flies. (n = 94-105; Kolmogorov-Smirnov test, **** = p < 0.0001) 
 
Moving at lower speeds could potentially explain the decrease in travelling 
distance observed in sloE366G/+ flies (Figure 3.17). It might also indicate that 
sloE366G/+ flies exhibit impaired movement execution, a phenotype linked to basal 
ganglia dysfunction in a variety of movement disorders (Kandel et al., 2013) 
(Paragraph 1.2.2). Another important role of the basal ganglia is action selection 
(Kandel et al., 2013; Ryan et al., 2018), which was found to be impaired in 
sloE366G/+ larvae (Figure 3.8). The larval readout for action selection was turning 
initiation, which could not be measured in adults due to the one-dimensional 
recording environment of the DART system. Instead, I quantified the number of 
movement initiations during a period of 1 h after the dark-light transition. As 
shown in Figure 3.19, sloE366G/+ flies initiated movement significantly more often 






Figure 3.19 sloE366G/+ Increases the Number of Movement Initiations 
sloE366G/+ and sloloxP/+ flies were analysed for the total number of movement 
initiations during a period of 1 h after the dark-light transition. sloE366G/+ males 
(A) and females (B) initiated movement significantly more often than sloloxP/+. (n 
= 94-105; Mann-Whitney-Wilcoxon test; **** = p < 0.0001) 
 
To confirm the data provided in Figure 3.19, I quantified the mean durations of 
sustained movement bouts – termed “mean bout length” – exhibited by sloE366G/+ 
and sloloxP/+ flies. A staccato movement pattern would predict that sloE366G/+ flies 
fail to sustain movement for as long as sloloxP/+. As for Figure 3.18 and Figure 
3.19, this analysis was performed for a period of 1 h after the dark-light transition. 
Indeed, sloE366G/+ flies exhibited a significant decrease in mean bout lengths 
(Figure 3.20). These data indicate that sloE366G/+ flies do not sustain movement 
for as long as sloloxP/+ flies, which is congruent with an increased number of 
movement initiations (Figure 3.19). Together, these data provide strong evidence 






Figure 3.20 sloE366G/+ Decreases the Length of Movement Bouts 
The mean lengths of movement bouts were analysed for sloE366G/+ and sloloxP/+ 
flies during a period of 1 h after the dark-light transition. sloE366G/+ males (A) and 
females (B) exhibited significantly decreased periods of sustained movement 
compared to sloloxP/+. (n = 94-105; Mann-Whitney-Wilcoxon test; **** = p < 
0.0001) 
 
3.4.8 sloE366G/+ Flies Are Not Bang- But Temperature-sensitive 
While this chapter has focussed on movement abnormalities of sloE366G/+ larvae 
and adults, some GEPD patients also present with epilepsy, either in isolation or 
in combination with PxD (Du et al., 2005). As described in Paragraph 1.5.2, the 
bang-sensitive Drosophila mutants exhibit paralysis and seizures upon being 
subjected to a mechanical stimulus (Cunliffe et al., 2015; Parker et al., 2011). 
Hence, I investigated whether sloE366G/+ flies exhibit bang-sensitivity. This was 
not the case with a variety of mechanical stimuli employed, such as vibration or 
tapping. 
As described in Paragraph 1.5.2, Drosophila knock-in models of DS and 
GEFS+ exhibit temperature-induced seizures: exposing these flies to 40ºC for 2 
min induced leg twitching, wing flapping, and abdominal curling (Schutte et al., 
2014; Sun et al., 2012). I replicated this experimental protocol but did not observe 
temperature-induced seizures in sloE366G/+ flies. However, once vials containing 
sloE366G/+ flies had been removed from 40ºC, sloE366G/+ flies remained motionless 
for an extended period of time, lasting from 30 min to more than 1 h. An extended 




for the GEFS+ knock-in flies (Sun et al., 2012) and is reminiscent of the sticky-
feet phenotype observed in slo null homozygotes (Atkinson et al., 2000; Elkins et 
al., 1986). As this phenotype might indicate an extended state of aberrant neural 
activity (Atkinson et al., 2000), it warrants future investigation. 
3.4.9 sloE366G/+ Reduces Adult Life Span 
While GEPD is not explicitly linked to a decrease in patient life span (Du et al., 
2005), the locomotor defect of sloE366G/+ flies is chronic, not paroxysmal. Hence, 
I wondered whether this continuous effect of the sloE366G allele on Drosophila 
health might affect longevity. Indeed, analysing 110 sloE366G/+ males and 100 
sloloxP/+ males uncovered a significant difference in life span (Figure 3.21). While 
sloloxP/+ males showed a sudden onset of mortality around day 40, sloE366G/+ 
males started dying during the first week of the experiment (Figure 3.21).  
 
 
Figure 3.21 sloE366G/+ Reduces Adult Life Span 
sloE366G/+ males show a marked decrease in life span compared to sloloxP/+ 
males. The last sloE366G/+ male died between days 60 and 62, the last sloloxP/+ 
male between days 80 and 82. While sloE366G/+ males are steadily dying, 
sloloxP/+ males exhibit a sudden drop in survival at day 40. (n = 100-110; 







3.5  Discussion 
This chapter addresses the first question set out in the project aim: what are the 
organismal effects of the D434G-equivalent mutation in flies? The sloE366G allele 
was found to be homozygous lethal by the adult stage, and sloE366G/+ larvae and 
adults showed severe locomotor abnormalities, most notably a decrease in 
travelling distance and impaired action selection. Electrophysiological recordings 
from the larval NMJ provided evidence that the sloE366G allele increases the Ca2+ 
sensitivity of Slo. While sloE366G/+ NMJ function under physiological conditions 
was found to be unaffected, electrophysiological recordings from the intact NMJ 
and live-imaging of larval MNs provide strong evidence for altered endogenous 
MN activity in sloE366G/+. Altogether, this chapter provides an in-depth phenotypic 
characterisation of the sloE366G allele at the cellular and behavioural level. 
3.5.1 Experimental Notes and Caveats 
3.5.1.1 SloE366G Might Alter the Function of CCAP-positive Neurons 
It has recently been shown that the over-expression of wake in CCAP-positive 
neurons causes a wing-inflation defect similar to the one observed in sloE366G/+ 
(Figure 3.16) (Tabuchi et al., 2018). This Wake-induced phenotype could be 
rescued by the simultaneous knock-down of slo in CCAP-positive neurons 
(Tabuchi et al., 2018). Since Wake is a positive regulator of Slo, the over-
expression of wake is functionally similar to the expression of a gain-of-function 
slo allele (Tabuchi et al., 2018). Hence, these data suggest that SloE366G might 
act as a gain-of-function allele in CCAP-positive neurons, which would be 
consistent with its function at the larval NMJ (Figure 3.11). This increased Slo 
function in CCAP-positive neurons might cause the wing-inflation defect 
observed in sloE366G/+ (Figure 3.16). 
3.5.2 Clinical Relevance 
3.5.2.1 sloE366G is a Gain-of-function Allele ex vivo 
Macroscopic current recordings in vitro have previously shown that the D434G-
equivalent murine D369G mutation in KCNMA1 causes an increased BK channel 




an intracellular [Ca2+] of 1 µM, but absent at nominal zero- and saturating (100 
µM) intracellular [Ca2+] (Yang et al., 2010). Similarly, electrophysiological 
recordings at the sloE366G/+ larval NMJ showed that the EJP amplitude decreases 
at an extracellular [Ca2+] of 0.25 mM, but not at a physiological concentration of 
1 mM (Figure 3.11). This decrease in EJP amplitude in sloE366G/+ larvae is likely 
caused by a gain of Slo function at the pre-synaptic terminus, which would 
decrease Ca2+ influx and glutamate release. Hence, these data provide strong 
evidence that sloE366G acts as a gain-of-function allele ex vivo. To definitively test 
this hypothesis, in vivo patch clamp recordings could be performed from neurons 
known to express Slo, such as the DN1p clock neurons (Tabuchi et al., 2018). A 
Slo gain-of-function would be expected to increase ICF in these neurons. 
Importantly, the Ca2+-dependence of this effect suggests variable 
consequences of this mutation for different neuronal subpopulations, as pre-
synaptic termini exhibiting low intracellular [Ca2+] or weak coupling between BK- 
and Cav channels are expected to be most affected (Griguoli et al., 2016). At 
these synapses, an increased Ca2+ sensitivity of BK channels might decrease the 
probability of neurotransmitter release, potentially affecting neuronal circuit 
function and plasticity. On the other hand, synapses exhibiting high intracellular 
[Ca2+] or strong coupling between BK- and Cav channels would be less affected 
in GEPD, because the abundance of Ca2+ might maximally potentiate both 
mutant and wild-type BK channels. Such differential effects of the D434G 
mutation in different brain areas might explain the specific phenotypes of GEPD, 
despite the broad expression pattern of BK channels (Bailey et al., 2019; Griguoli 
et al., 2016; Latorre et al., 2017) (Paragraph 1.4.2).  
3.5.2.2 sloE366G/+ Induces Aberrant Motoneuron Activity 
Electrophysiological recordings at an extracellular [Ca2+] of 1 mM showed that 
synaptic transmission at the sloE366G/+ larval NMJ was normal upon severing the 
innervating nerve but exhibited severe abnormalities when MN efferents were 
preserved (Figure 3.10, Figure 3.12). These data suggest that the sloE366G/+ 
larval NMJ can function normally but receives aberrant endogenous input from 
MNs. Indeed, this hypothesis was confirmed via live-imaging of larval MNs, which 




change in MN firing might either indicate dendritic defects of MNs, or a 
dysregulation of neural activity upstream of MNs. Two previous studies support 
the latter hypothesis: (1) ex vivo patch clamp recordings from homozygous slo 
null larval MNs detected an increased peristaltic frequency-like activity (Kadas et 
al., 2015) – the opposite to what was observed in sloE366G/+ larvae (Figure 3.5, 
Figure 3.12). However, RNAi-mediated knock-down of slo specifically in MNs did 
not mimic this effect, suggesting that peristaltic frequency is regulated by slo 
upstream of MNs (Kadas et al., 2015) – potentially by neural populations also 
involved in mediating the sloE366G/+ locomotor defect. (2) By surgically removing 
specific regions of the larval CNS prior to GCaMP3-mediated live-imaging of VNC 
MNs, it could be shown that descending inputs from the brain lobes to the VNC 
are required for modulating both the cycle period of peristaltic Ca2+ waves and 
fictive turning behaviour (Pulver et al., 2015). Since both of these parameters are 
affected in sloE366G/+ (Figure 3.15), these data suggest neuronal populations in 
the larval brain to mediate the sloE366G/+ locomotor defect – such as the central 
pattern generator (CPG), a neuronal network innervating MNs and providing 
rhythmic synaptic drive that allows for coordinated muscle contractions and 
movement (Kadas et al., 2015; Marder and Bucher, 2001; Pulver et al., 2015). 
3.5.2.3 sloE366G/+ Induces a Potential Cellular Seizure Phenotype 
While no behavioural seizure phenotype could be observed in sloE366G/+ flies, 
live-imaging of larval MNs revealed a decreased inter-segmental time delay of 
Ca2+ activity, analogous to more synchronous MN firing (Figure 3.15). Using a 
similar experimental approach, an increased synchronicity of MN activity has 
recently been observed in the bang-sensitive bss1 larvae as well as in paraK1270T 
larvae, a model of the human epilepsy syndrome GEFS+ (Streit et al., 2016; Sun 
et al., 2012). This increased synchronicity of MN activity could be rescued by 
feeding AEDs to bss1 larvae, suggesting this phenotype to be a cellular readout 
for epileptic seizures (Streit et al., 2016). Hence, future experiments might test 
whether AEDs can also rescue the increased synchronicity of MN firing in 
sloE366G/+ larvae, which would suggest the presence of a cellular seizure 




3.5.2.4 In Search of a Behavioural Seizure Phenotype in sloE366G/+ 
GEPD patients present with PxD, epilepsy, or combined PxD-epilepsy (Du et al., 
2005), illustrating variable expressivity of the D434G mutation that might depend 
on environmental and genetic background effects. sloE366G/+ flies exhibit severe 
locomotor abnormalities but no seizure-like behaviour, rendering this GEPD 
model more dyskinesia- than epilepsy-like. However, it is possible that triggers 
other than mechanical stimulation and temperature are required to induce 
seizures in sloE366G/+ flies, and this will be tested in future experiments. Moreover, 
outcrossing the sloE366G allele into different genetic backgrounds might unmask 
seizure-like behaviour.  
3.5.2.5 sloE366G/+ Induces a Chronic Locomotor Defect 
Both sloE366G/+ adults and larvae exhibit severe locomotor defects, which 
manifest as a decrease in travelling distance and aberrant action selection 
(Figure 3.4, Figure 3.17, Figure 3.8, Figure 3.19). This locomotor defect is 
chronic, not paroxysmal, differentiating it from its human counterpart (Du et al., 
2005). This difference might be explained by the absence of regulatory b- and g-
subunits in flies (Griguoli et al., 2016) (Paragraph 1.4.3). Not only do these 
subunits affect wild-type BK channel function, a previous study also 
demonstrated that b-subunits differentially modulate the effect of the D434G 
mutation, as shown via inside-out patch clamp recordings in vitro (Lee and Cui, 
2009). Indeed, the presence of the b3b-subunit almost entirely abolished the 
increase in BK channel Ca2+ sensitivity associated with the D434G mutation (Lee 
and Cui, 2009). Since b-subunits are expressed in a tissue- and neuronal 
subtype-specific manner (Griguoli et al., 2016; Latorre et al., 2017) (Paragraph 
1.4.3), these data suggest that some human tissues and brain regions would be 
more affected by the D434G mutation than others. The lack of this additional layer 
of functional modulation in flies might explain the more severe locomotor 
phenotype observed compared to humans. 
3.5.2.6 sloE366G/+ Alters Action Selection 
A specific movement phenotype investigated in this chapter is action selection. 




exhibit a decrease in turning behaviour, a form of action selection (Figure 3.8, 
Figure 3.15). The adult readout for action selection was also affected, with 
sloE366G/+ adults exhibiting a significant increase in the number of movement 
initiations, leading to more staccato locomotor patterns (Figure 3.19, Figure 3.20). 
Impaired action selection might indicate an involvement of pre-motor circuits in 
sloE366G/+, which is consistent with the electrophysiological- and live-imaging 
data, suggesting that the pathogenic locus of sloE366G/+ lies within the CNS 
(Paragraph 3.5.2.2). In dyskinesia patients, action selection is thought to be 
affected by a pathological imbalance between direct- and indirect striatopallidal 
pathway activity in the basal ganglia (Figure 1.1) (Kandel et al., 2013; Ryan et al., 
2018). Striatopallidal connections are formed by GABAergic MSNs in the striatum 
(Kandel et al., 2013; Ryan et al., 2018). Interestingly, a recent study on a mouse 
model of LID identified a subpopulation of MSNs of the direct pathway whose 
firing rates positively correlated with dyskinesia severity, as measured via single-
unit recordings in awake behaving mice (Ryan et al., 2018). Moreover, 
optogenetic activation of direct pathway MSNs was sufficient to evoke dyskinetic 
attacks in control mice (Ryan et al., 2018). Hence, it would be intriguing to 
investigate whether functionally analogous brain structures and neuronal 
subtypes mediate the sloE366G/+ locomotor defect in flies. 
3.5.2.7 A Potential Metabolic Component in sloE366G/+ 
Identifying a significant increase sloE366G/+ larval body size might indicate 
metabolic disturbances in this mutant (Figure 3.6, Figure 3.7). GLUT1-DS and 
PED patients experience seizures and PxD due to abnormal glucose metabolism 
(De Giorgis and Veggiotti, 2013), making conceivable the notion that GEPD, too, 
might have a metabolic component. Indeed, an increased larval body size might 
implicate dysregulated insulin signalling in GEPD, as broad over-expression of 
dilp2, one of eight insulin-like peptides (dilps) in Drosophila, has been shown to 
increase adult Drosophila body size (Brogiolo et al., 2001).  
3.5.3 Conclusion 
A phenotypic characterisation of sloE366G/+ larvae and adults identified severe 




circuits upstream of MNs. To test this hypothesis, the expression of the sloE366G 






























4 Spatial Dissection of sloE366G/+ Pathogenesis 
4.1 Introduction 
As described in Paragraph 1.4.2, KCNMA1 is broadly expressed throughout the 
human body, and, within the CNS, in a variety of brain areas, including the basal 
ganglia, thalamus, and cerebellum, all of which have been implicated in 
movement disorders (Bailey et al., 2019). On a cellular level, KCNMA1 is 
expressed by a variety of neuronal subtypes, including glutamatergic-, 
GABAergic-, and cholinergic neurons (Griguoli et al., 2016) (Paragraph 1.4.2). 
Moreover, due to alternative splicing, post-translational modifications, and the co-
expression of regulatory subunits, BK channel function varies between cells and 
tissues (Griguoli et al., 2016; Latorre et al., 2017) (Paragraph 1.4.3). As a result, 
it is difficult to predict where the D434G mutation in KCNMA1 exerts its 
pathogenic effects that lead to GEPD. Importantly, Chapter 3 provided strong 
evidence for pre-motor circuits in the larval brain to induce the sloE366G/+ 
locomotor defect. The aim of this chapter is to test this hypothesis by spatially 
restricting Slo expression. 
 Via the selective re-expression of dysc in dysc null homozygotes – Dysc 
is a positive post-transcriptional regulator of Slo (Jepson et al., 2012) (Paragraph 
1.5.3) – Slo expression was restricted to various cellular subpopulations. Using 
this strategy, it is demonstrated that the brain-specific activity of SloE366G is 
sufficient to induce the sloE366G/+ locomotor defect, while its selective activity in 
muscle tissue does not affect locomotion. By further restricting Slo expression, it 
is shown that the activity of SloE366G in cholinergic neurons is sufficient to 
decrease locomotion, an effect not observed in glutamatergic MNs and other 
neuronal subpopulations. These data support the hypothesis, proposed in 
Chapter 3, that neuronal circuits in the central brain define the pathogenic locus 
of GEPD, and suggest that cholinergic neurons are important mediators of the 





4.2 Statement of Contribution 
4.2.1 Direct Contributions 
Dr. James Jepson and I conceived of the genetic strategy for the spatial 
dissection of the sloE366G/+ locomotor defect together, and Dr. James Jepson’s 
intellectual input was invaluable. As acknowledged in Paragraph 3.2.1, Dr. 
Srinivasa Rao and Dr. Sam Olechnowicz are the main developers of the AnimApp 
video-tracking software (Rao et al., 2019). 
4.2.2 Indirect Contributions 
Dr. James Jepson and Dr. Ko-Fan Chen provided invaluable intellectual input for 






















4.3 Materials and Methods 
4.3.1 Genetic Nomenclature 
The genotypes of flies used in this chapter are listed in Paragraph 4.3.2. 
Nomenclature guidelines are described in Paragraph 2.3.1. 
4.3.2 Fly Stocks 
Table 45 Fly Stocks of Chapter 4 
Genotype Source 
iso31 Kind gift from Dr. Kyunghee Koh 
w;;TM2,Ubx130/TM6B,Tb Kind gift from Dr. Kyunghee Koh 
w;Sco/CyO; Kind gift from Dr. Kyunghee Koh 
w;;sloE366G/TM6B,Tb   This thesis 
w;;sloloxP/TM6B,Tb This thesis 
w;UAS-sloRNAi/CyO; VDRC: 104421 
w;;nSyb-Gal4/TM2,Ubx130 Kind gift from Dr. Kyunghee Koh 
w;UAS-sloRNAi/CyO;sloE366G/TM6B,Tb This thesis 
w;UAS-sloRNAi/CyO;sloloxP/TM6B,Tb This thesis 
w;;dyscs168/TM6B,Tb Kind gift from Dr. Kyunghee Koh 
w;;sloE366G,dyscs168/TM6B,Tb This thesis 
w;;sloloxP,dyscs168/TM6B,Tb This thesis 
w;;da-Gal4/TM6B,Tb BDSC: 55850 
w;UAS-dysc; Kind gift from Dr. Kyunghee Koh 
w;UAS-dysc/CyO;sloE366G,dyscs168/TM6C,Sb This thesis 
w;UAS-dysc/CyO;sloloxP,dyscs168/TM6C,Sb This thesis 
w;;da-Gal4,dyscs168/TM6B,Tb This thesis 
w;;nSyb-Gal4,dyscs168TM6B,Tb This thesis 
w;;Mef2-Gal4/TM6B,Tb BDSC: 27390 
w;;Mef2-Gal4,dyscs168/TM6B,Tb This thesis 
w;UAS-CD8::GFP; Kind gift from Dr. Kyunghee Koh 
w;OK371-Gal4/CyO; Kind gift from Dr. Kyunghee Koh 
w;OK371-Gal4/CyO;dyscs168/TM6B,Tb This thesis 
w;c929-Gal4/CyO; Kind gift from Dr. Kyunghee Koh 




w;GAD-Gal4/CyO; Kind gift from Dr. Kyunghee Koh 
w;GAD-Gal4/CyO;dyscs168/TM6B,Tb This thesis 
w;ChAT-Gal4/CyO; Kind gift from Dr. Kyunghee Koh 
w;ChAT-Gal4/CyO;dyscs168/TM6B,Tb This thesis 
 
4.3.3 Fly Husbandry 
Unless otherwise indicated, all fly stocks were maintained on standard fly food at 
RT. The fly food recipe is shown in Table 4. All flies and larvae used for 
behavioural experiments were raised in an incubator (LMS) at 25ºC and a 12 h 
light:12 h dark cycle. 
4.3.4 Experimental Genotypes 
Unless otherwise indicated, recombinant 25.1.1/TM6B,Tb was used as a 
representative for sloE366G/TM6B,Tb, and recombinant 132.1.1/TM6B,Tb as a 
representative for sloloxP/TM6B,Tb. 
4.3.4.1 sloE366G/+ and sloloxP/+ 
sloE366G/+ and sloloxP/+ flies were generated by crossing sloE366G/TM6B,Tb and 
sloloxP/TM6B,Tb to isogenic controls (iso31), respectively.  
4.3.4.2 RNAi-mediated Knock-down of slo 
The experimental genotypes UAS-sloRNAi/+;nSyb-Gal4/sloE366G and UAS-
sloRNAi/+;nSyb-Gal4/sloloxP were generated by crossing UAS-
sloRNAi/CyO;sloE366G/TM6B,Tb and UAS-sloRNAi/CyO;sloloxP/TM6B,Tb to nSyb-
Gal4/TM6B,Tb, respectively. nSyb-Gal4/+ and UAS-sloRNAi/+ were generated 
by crossing nSyb-Gal4/TM6B,Tb and UAS-sloRNAi/CyO to iso31, respectively.  
4.3.4.3 sloE366G,dyscs168/dyscs168 and sloloxP,dyscs168/dyscs168 
sloE366G,dyscs168/dyscs168 and sloloxP,dyscs168/dyscs168 flies were generated by 






UAS-CD8::GFP/+;Mef2-Gal4/+ and UAS-CD8::GFP/+;nSyb-Gal4/+ flies were 
generated by crossing UAS-CD8::GFP to Mef2-Gal4/TM6B,Tb and nSyb-
Gal4/TM2,Ubx130, respectively. 
4.3.4.5 Dysc-mediated Spatial Dissection 
All experimental genotypes used for Dysc-mediated spatial dissection 
experiments were generated by crossing UAS-
dysc/CyO;sloE366G,dyscs168/TM6C,Sb and UAS-
dysc/CyO;sloloxP,dyscs168/TM6C,Sb to the Gal4 driver lines shown in Table 46.  
Table 46 Experimental Genotypes for Spatial Dissection 









Crossing the Gal4 drivers to sloE366G,dyscs168/TM6B,Tb and 
sloloxP,dyscs168/TM6B,Tb generated the driver controls shown in Table 47. 
Table 47 Driver Controls for Spatial Dissection 









Crossing UAS-dysc/CyO;sloE366G,dyscs168/TM6C,Sb and UAS-




transgene controls UAS-dysc/+;sloE366G,dyscs168/dyscs168 and UAS-
dysc/+;sloloxP,dyscs168/dyscs168, respectively. 
4.3.5 Adult Fly Behavioural Tracking 
To track adult locomotion, the Drosophila Activity Monitor (DAM) system was 
used (DAM2, TriKinetics). This system consists of individual monitors containing 
32 channels, into which the same glass tubes were inserted as described for the 
DART system in Paragraph 3.3.14. The glass tubes were prepared, and flies 
loaded, as described in Paragraph 3.3.14. Flies used for this experiment were 
between 2 and 6 days old at the time of recording. Fly-containing glass tubes 
were placed into DAM monitors and the monitors positioned in an incubator 
(LMS) at 25ºC, 65%-70% relative humidity, and a 12 h light:12 h dark regime. 
Flies were acclimatised to the new environment for at least 24 h, followed by 
recording of a whole 12 h light:12 h dark period (24 h) from 9 am to 9 am the 
following day.  
4.3.6 Behavioural Tracking Analysis 
DAM data were analysed using a customised R script (R v. 3.6.0), which is 
available on GitHub: https://github.com/PatrickKratsch/. This script reads the 
DAM output (TXT files) for each monitor into separate data objects and extracts 
the relevant experimental time. It then extracts the beam break data for each fly 
and sums the corresponding values over 24 h, yielding the total number of beam 
breaks per fly. Flies that did not move at all (0 beam breaks) during the second 
12 h of the experiment were identified as dead and removed from further 
analyses. 
4.3.7 Scoring Wing Inflation 
Adult wing inflation was scored as described in Paragraph 3.3.13. 
4.3.8 Antibody Staining of Adult Brains 
Adult flies were anaesthetised on CO2 pads (Flystuff, Genesee Scientific) and 
dissected using fine forceps (#5, Dumont, 0103-5-PO) in 0.3% PBT (0.3% Triton 




eppendorf tubes containing 450 µL of 4% PFA solution in 0.3% PBT on ice (Alfa 
Aesar, 43368). Fixation in 4% PFA was performed while shaking the samples at 
4ºC for 1.5 h. The 4% PFA was washed off with three quick washes (pipetting off 
the solution contained within the 0.5 mL eppendorf tubes, followed by adding 450 
µL of 0.3% PBT) and three long washes (same procedure as quick washes but 
with an additional 15 min of shaking at RT upon addition of 450 µL of 0.3% PBT). 
Following the third long wash, the 450 µL of 0.3% PBT were pipetted off and 
replaced with 450 µL of 5% goat serum in 0.3% PBT (Thermo Fisher Scientific, 
16210064). The fixed brains were blocked with 5% goat serum while shaking at 
RT for 1 h. The 5% goat serum was then pipetted off and replaced with 450 µL 
of a 5% goat serum solution containing a 1:200 dilution of a primary mouse anti-
Bruchpilot antibody (DSHB, AB_2314866) and a 1:1000 dilution of a primary 
chicken anti-GFP antibody (Thermo Fisher Scientific, AB_2534023). Primary 
antibody staining was then performed by shaking these samples at 4ºC for 16 h. 
The primary antibody-containing 5% goat serum solution was then washed off 
with three quick and three long washes, as described above, before adding 450 
µL of a 5% goat serum solution containing a 1:1000 dilution of a secondary goat 
anti-mouse Alexa Fluor 555 antibody (Thermo Fisher Scientific, AB_2536164) 
and a 1:1000 dilution of a secondary goat anti-chicken Alexa Fluor 488 antibody 
(Thermo Fisher Scientific, AB_2534096). Samples were covered in aluminium foil 
to prevent photobleaching and left shaking at 4ºC for 16 h. The secondary 
antibody-containing 5% goat serum solution was then washed off with three quick 
and three long washes, as described above, before adding 50 µL of Slowfade to 
each sample (Thermo Fisher Scientific, S36936). The brains suspended in 
Slowfade were stored in -20ºC until the day of imaging. 
4.3.9 Confocal Imaging of Adult Brains 
For bridge mounting, two coverslips (VWR, 631-0121) were glued onto each side 
of a microscopy slide (Thermo Fisher Scientific, 49514), creating a gap in 
between. Into this gap, the brain-containing Slowfade solution (containing 3-6 
brains per sample) was pipetted, before the gap was covered with a third 




were imaged on a Zeiss LSM 710 confocal microscope, using Zen software 
(Zeiss) and the EC “Plan-Neofluar” 20x/0.50 M27 air objective (Zeiss, 420350-
9900-000) at a resolution of 1024x1024 and a 16-bit bit depth. An argon laser at 
488 nm was used to excite the goat anti-chicken Alexa Fluor 488 fluorophore, 
while a wavelength of 568 nm was used to excite the goat anti-mouse Alexa Fluor 
555 fluorophore. For all images, z-stacks from the most anterior to the most 
posterior brain signals were acquired.  
4.3.10 Analysis of Confocal Imaging Data 
Confocal imaging data were loaded into FIJI (Schindelin et al., 2012), where the 
two channel colours (488 nm and 568 nm) were merged and maximum z-
projections, including scale bars, generated. 
4.3.11 Larval Video-recordings 
Larval video recordings were performed as described in Paragraph 3.3.6. An 
iPhone 8 (Apple Inc.) was used to take the videos for this chapter, at a resolution 
of 1080x1920 and a frame rate of 30 fps.  
4.3.12 Pre-processing of Larval Videos 
Larval videos were pre-processed as described in Paragraph 3.3.7, with the 
following differences: (1) videos were cropped from 13 s to 73 s, and (2) due to a 
higher frame rate, each 1-min video was composed of 1800 frames. 
4.3.13 Tacking Larval Locomotion 
Larval video-tracking was performed using the desktop version of AnimApp (Rao 
et al., 2019), as described in Paragraph 3.3.8. The HSV values used for the 
videos analysed in this chapter are shown in Table 48. 
Table 48 HSV Values for Larval Tracking 
Parameter Value 
Hue Lower 0 
Saturation Lower 0 




Hue Upper 180 
Saturation Upper 255 
Value Upper 255 
 
4.3.14 Analysis of Larval Locomotion 
The larval video-tracking output was analysed as described in Paragraph 3.3.9. 
The pixel-to-mm conversion was performed by dividing the distance travelled in 
pixels by 10.3 pixels / mm, because 3 cm correspond to 309 pixels with the video 
resolution used in this chapter. 
4.3.15 Data Visualisation 
The data were visualised as described in Paragraph 3.3.19, with boxplots drawn 
according to Tukey. 
4.3.16 Statistics 
Statistical analyses were performed using R (v. 3.6.0) and RStudio (RStudio Inc., 















4.4.1 The DAM System Detects the sloE366G/+ Locomotor Defect 
The aim of this chapter is to identify subpopulations of cells sufficient to induce 
the sloE366G/+ locomotor defect – a process referred to as “spatial dissection”. 
Although the cellular characterisation of the sloE366G allele was performed in 
larvae (Paragraphs 3.4.3, 3.4.4, and 3.4.5), adults were used for the spatial 
dissection experiments because larval video-tracking does not lend itself to high-
throughput analyses. To measure adult locomotion, I used the DAM system, 
which infers activity from the number of times flies break an infrared beam 
(Pfeiffenberger et al., 2010). This system does not require the pre-processing of 
large video files and offline video-tracking, making it suitable for large-scale 
experiments. However, it first needed to be confirmed that the DAM system is 
sensitive enough to detect the reduction in travelling distance of sloE366G/+ adults, 
as observed using the DART system (Figure 3.17). To this end, two independent 
recombinants of sloE366G/+ and sloloxP/+ were tested: 25.1.1/+ and 137.1.3/+ for 
sloE366G/+ and 132.1.1/+ and 111.1.1/+ for sloloxP/+. Indeed, the DAM system 
detected the sloE366G/+ locomotor defect in 24-h recordings at a 12 h light:12 h 
dark cycle (Figure 4.1) – these are the recording conditions used for all DAM 





Figure 4.1 Validation of the DAM System for Locomotor Tracking 
The DAM system detected a significant decrease in locomotion of sloE366G/+ 
(25.1.1/+ and 137.1.3/+) males (A) and females (B), compared to sloloxP/+ 
(132.1.1/+ and 111.1.1/+). No within-genotype differences were detected. (n = 
15-16; Kruskal-Wallis multiple comparison with Dunn’s post-hoc test, * = p < 
0.05, *** = p < 0.001) 
 
Figure 4.1 confirms that the DAM system can be used for the spatial dissection 
of the sloE366G/+ locomotor phenotype. As a reduction in locomotion was detected 
for both sexes, I proceeded by focussing exclusively on males. First, a strategy 
needed to be designed that allows for the spatially restricted modification of Slo 
activity.  
4.4.2 slo Knock-down does not Affect Locomotion 
A common approach to downregulate the expression of target genes is RNA 
interference (RNAi)-mediated knock-down, which induces the degradation or 
translational inhibition of specific target mRNAs (Heigwer et al., 2018). Due to the 
gain-of-function nature of the sloE366G allele (Figure 3.11), I hypothesised that 
RNAi-mediated knock-down of slo should rescue the sloE366G/+ locomotor defect 
by scaling Slo function back to more physiological levels. In order to test this 
hypothesis, I expressed slo-RNAi pan-neuronally under the control of the nSyb-
Gal4 driver, using the Gal4/UAS system (Figure 1.3) (Brand and Perrimon, 1993). 




vesicle-associated membrane protein (VAMP) that is required for the secretion of 
synaptic vesicles and expressed specifically by neurons (Bhattacharya et al., 
2002). To perform pan-neuronal knock-down of slo in the background of 
sloE366G/+ and sloloxP/+, I generated the novel fly lines UAS-
sloRNAi/CyO;sloE366G/TM6B,Tb and UAS-sloRNAi/CyO;sloloxP/TM6B,Tb 
according to Figure 4.2. This crossing scheme was used throughout this chapter 
to combine two constructs on the second and third chromosomes in a single 
Drosophila line.  
 
 
Figure 4.2 Combining Constructs on Chromosomes 2 and 3 
This generic crossing scheme illustrates how novel fly stocks were generated by 
bringing together constructs located on the second (A, red) and third (B, cyan) 
chromosomes into a single fly stock. 
 
The novel stocks UAS-sloRNAi/CyO;sloE366G/TM6B,Tb and UAS-
sloRNAi/CyO;sloloxP/TM6B,Tb were used to generate the experimental 
genotypes UAS-sloRNAi/+;nSyb-Gal4/sloE366G and UAS-sloRNAi/+;nSyb-
Gal4/sloloxP, which induce the pan-neuronal knock-down of slo in the background 
of sloE366G/+ and sloloxP/+, respectively. Pan-neuronal knock-down of slo did not 
rescue the sloE366G/+ locomotor defect (Figure 4.3). In a sloE366G/+ background, 
the control genotype nSyb-Gal4/sloE366G alone increased the number of beam 






Figure 4.3 Pan-neuronal Knock-down of slo does not Affect Locomotion 
Pan-neuronal knock-down of slo did not rescue the sloE366G/+ locomotor defect. 
Similarly, locomotion in a sloloxP/+ background was unaffected. Data from three 
independent experimental repeats were pooled. (n = 18-45; Kruskal-Wallis 
multiple comparison with Dunn’s post-hoc test, ns = p > 0.05) 
 
4.4.3 Selective Expression of Slo via Dysc 
Why did the pan-neuronal RNAi-mediated knock-down of slo fail to rescue the 
sloE366G/+ locomotor defect (Figure 4.3)? It is possible that the slo-RNAi construct 
used for these experiments exhibits inefficient knock-down of slo, which could be 
tested via qPCR and the use of alternative slo-RNAi constructs. However, a 
general drawback of the RNAi strategy is that it induces an indiscriminate knock-
down of both the wild-type and the mutant slo allele in a sloE366G/+ background. 
Maybe the preservation of relative expression levels prevents a behavioural 
rescue. Rather than optimising this experimental design, I opted to take another 
approach. Recently, it was shown that dysc encodes a PDZ domain-containing 
scaffolding protein (Dysc) that is required for the post-transcriptional expression 




expression in the adult brain was almost entirely lost, and dysc null neurons 
exhibited a reduction in Slo-dependent K+ currents (Jepson et al., 2012). 
Furthermore, Dysc and Slo were shown to regulate each other’s expression via 
direct protein-protein interactions (Jepson et al., 2012). This dependence of Slo 
function upon Dysc could potentially be harnessed for the selective expression of 
Slo in specific subpopulations of cells if the following two hypotheses could be 
confirmed: 
1. A homozygous dysc null background should rescue the sloE366G/+ 
locomotor defect, since the expression of SloE366G should be greatly 
reduced. 
2. The selective re-introduction of dysc in dysc null homozygotes should 
allow for Slo to be expressed wherever dysc is expressed, while the rest 
of the fly body should mostly lack Slo expression. If dysc is re-introduced 
in a sloE366G/+ background, both Slo and SloE366G should be expressed, 
which should re-instate the sloE366G/+ locomotor defect. 
To test the first hypothesis, I compared the locomotor behaviour of sloE366G/+ to 
sloE366G/+ in a homozygous dysc null background. dysc is located on the third 
chromosome and expresses two major isoforms, a short and a long one, and it 
has been shown that the long isoform, which contains 3 C-terminal PDZ domains, 
is necessary and sufficient for normal locomotor behaviour in adult flies (Jepson 
et al., 2012). I hence performed this experiment using the dyscs168 allele, a 
hypomorphic P-element insertion within the dysc locus that results in the selective 
loss of the long isoform, while leaving the short isoform intact (Jepson et al., 
2012). The novel lines sloE366G,dyscs168/TM6B,Tb and sloloxP,dyscs168/TM6B,Tb 
were generated according to Figure 4.4, which illustrates in general terms how 






Figure 4.4 Generating Third Chromosome Recombinants 
This crossing scheme illustrates how constructs A (red) and B (cyan) were 
recombined on the third chromosome. 
  
The sloE366G,dyscs168/TM6B,Tb and sloloxP,dyscs168/TM6B,Tb recombinants were 
used to generate the experimental genotypes sloE366G,dyscs168/dyscs168 and 
sloloxP,dyscs168/dyscs168, whose locomotion was compared to sloE366G/+ and 
sloloxP/+, respectively. Strikingly, homozygous dyscs168 completely rescued the 
sloE366G/+ locomotor defect, while also significantly increasing locomotion in a 
sloloxP/+ background (Figure 4.5). The latter effect is consistent with previous 
reports that dyscs168 homozygotes exhibit increased day- and night-time activity 
(Jepson et al., 2012). Interestingly, locomotion is also increased in 
sloE366G,dyscs168/dyscs168 when compared to sloloxP,dyscs168/dyscs168 (Figure 4.5). 
These data confirm the first hypothesis, as outlined above: loss of dysc 
completely rescues the sloE366G/+ locomotor defect, rendering the dyscs168 allele 






Figure 4.5 dyscs168/dyscs168 Rescues the sloE366G/+ Locomotor Defect 
The sloE366G/+ locomotor defect was completely rescued in dyscs168 
homozygotes, while locomotion was significantly increased in a sloloxP/+ 
background as well. A significant difference in locomotion could also be 
observed between dyscs168 homozygotes of either genetic background. Data 
from six independent experimental repeats were pooled. (n = 60-96; Kruskal-
Wallis multiple comparison with Dunn’s post-hoc test, * = p < 0.05, **** = p < 
0.0001) 
  
I proceeded to test whether the re-introduction of dysc in 
sloE366G,dyscs168/dyscs168 could re-instate the sloE366G/+ locomotor defect. To this 
end, I used da-Gal4 to drive dysc expression (Wodarz et al., 1995): Daughterless 
(Da) is a TF involved in processes ranging from nervous system development to 
sex determination, showing a broad expression pattern that becomes detectable 
during embryonic stages (http://flybase.org/reports/FBgn0267821). Hence, this 
driver will induce dysc expression widely throughout the Drosophila body, starting 
early in development. In order to perform this experiment, the stocks UAS-
dysc/CyO;sloE366G,dyscs168/TM6C,Sb and UAS-
dysc/CyO;sloloxP,dyscs168/TM6C,Sb were generated according to Figure 4.2. Of 
note, the UAS-dysc construct drives the expression of the wild-type long isoform 
of dysc, which is lost in dyscs168/dyscs168. In order to establish homozygosity for 




Figure 4.4. Figure 4.6 illustrates the experimental design for the Dysc-mediated 
spatial dissection strategy – these crossing schemes were used throughout this 
chapter to generate experimental genotypes with different Gal4 drivers.  
 
 
Figure 4.6 Dysc-mediated Spatial Dissection Strategy 
This figure illustrates the genotypes required for the conditional re-introduction 
of dysc (cyan) in an otherwise dysc null background (grey) that also harbours 
the heterozygous sloE366G allele (red). For simplicity, this strategy is only shown 
for the sloE366G allele, but it equally applies to sloloxP. A illustrates this strategy for 
Gal4 drivers located on chromosome 3, while B shows the genotypes involved 
for Gal4 drivers located on chromosome 2. The conditional re-introduction of 
dysc induces Slo expression in specific subpopulations of cells, while every cell 
not expressing dysc will mostly lack Slo expression. The UAS-dysc construct 
drives the expression of the wild-type long isoform of dysc, which is lost in 
dyscs168 homozygotes. 
 
As shown in Figure 4.7, the broad re-introduction of dysc using the da-Gal4 driver 
significantly decreased the number of beam breaks in a sloE366G/+ background, 
while not affecting locomotion in a sloloxP/+ background (Figure 4.7). These data 
confirm the second hypothesis, as stated above: the re-introduction of dysc in 
dyscs168 homozygotes re-instates the sloE366G/+ locomotor defect. Hence, this 






Figure 4.7 Broad Expression of SloE366G Decreases Locomotion 
The broad re-introduction of dysc in dyscs168 homozygotes via da-Gal4 
significantly decreased locomotion in a sloE366G/+ background – an effect not 
observed in a sloloxP/+ background. Data from three independent experimental 
repeats were pooled. (n = 24-50; Kruskal-Wallis multiple comparison with Dunn’s 
post-hoc test, ns = p > 0.05, ** = p < 0.01) 
 
4.4.4 Neuronal SloE366G Induces the sloE366G/+ Locomotor Defect 
The selective re-introduction of dysc in dyscs168 homozygotes mediates the 
selective expression of Slo. In a sloE366G/+ background, this leads to the 
expression of both SloE366G and Slo, while in a sloloxP/+ background, only Slo is 
expressed. Using the broad driver da-Gal4, the sloE366G/+ locomotor defect could 
be re-instated in a sloE366G/+ genetic background (Figure 4.7). I next investigated 
the selective expression of Slo in the nervous system and muscle tissue. To 
express dysc pan-neuronally, the nSyb-Gal4 driver was used, as described in 
Paragraph 4.4.2 (Bhattacharya et al., 2002). To selectively target muscle tissue, 
I used Mef2-Gal4. Mef2 is a TF involved in muscle differentiation, and the Mef2-




that allow for Gal4 expression in somatic-, visceral-, and cardiac muscle 
(Ranganayakulu et al., 1998). For these experiments, the novel genotypes nSyb-
Gal4,dyscs168/TM6B,Tb and Mef2-Gal4,dyscs168/TM6B,Tb were generated 
according to Figure 4.4, the experimental genotypes according to Figure 4.6. 
Strikingly, pan-neuronal re-introduction of dysc in a sloE366G/+ background 
recapitulated the da-Gal4-mediated locomotor defect, while locomotion in a 
sloloxP/+ background was unaffected (Figure 4.8).  
 
 
Figure 4.8 Pan-neuronal Expression of SloE366G Decreases Locomotion 
The pan-neuronal re-introduction of dysc in dyscs168 homozygotes via nSyb-Gal4 
induced a significant decrease in locomotion in a sloE366G/+ background – an 
effect not observed in a sloloxP/+ background. Data from four independent 
experimental repeats were pooled. (n = 18-44; Kruskal-Wallis multiple 
comparison with Dunn’s post-hoc test, ns = p > 0.05, **** = p < 0.0001) 
 
The similar effects of pan-neuronal- (Figure 4.8) and broad (Figure 4.7) 
expression of SloE366G on locomotion suggested muscle tissue not to be involved 
in sloE366G/+ pathogenesis. Indeed, Mef2-Gal4-mediated re-introduction of dysc 




data provide strong evidence that the pathogenic locus of the sloE366G/+ 
locomotor defect lies within the nervous system. 
 
 
Figure 4.9 SloE366G in Muscle Tissue does not Affect Locomotion 
Mef2-Gal4-mediated muscle-specific re-introduction of dysc in dyscs168 
homozygotes did not affect locomotion in a sloE366G/+ background, while an 
increase could be observed in a sloloxP/+ background. Data from four 
independent experimental repeats were pooled. (n = 41-63; Kruskal-Wallis 
multiple comparison with Dunn’s post-hoc test, ns = p > 0.05, ** = p < 0.01) 
 
Why did the muscle-specific re-introduction of dysc cause an increase in 
locomotion in a sloloxP/+ background, but not in a sloE366G/+ background (Figure 
4.9)? One possibility is that Slo and SloE366G have a pro-locomotive effect when 
selectively expressed in muscle tissue, but the Mef2-Gal4 driver might show 
some expression in the brain as well. As a result, the locomotion-decreasing 
activity of SloE366G in the brain might offset its pro-locomotive activity in the 
muscle, specifically affecting the sloE366G/+ background. I tested this hypothesis 
by visualising the expression pattern of Mef2-Gal4 in UAS-CD8::GFP/+;Mef2-




tethered protein CD8 to GFP, facilitating the visualisation of the plasma 
membrane (Lee and Luo, 1999). The Mef2-Gal4 expression pattern was 
compared to UAS-CD8::GFP/+;nSyb-Gal4/+, which is expected to label the brain 
pan-neuronally. The brain neuropil was visualised by co-staining against 
Bruchpilot (BRP), a pre-synaptic cytoskeletal protein (Rein et al., 2002). 
Interestingly, while nSyb-Gal4 showed broad GFP expression throughout the 
brain, Mef2-Gal4-mediated GFP expression could also be detected, particularly 
in the PI and the ellipsoid body (EB, Figure 4.10). Hence, it is possible that the 
activity of SloE366G in these neurons suppresses its pro-locomotive effect in the 
muscle (Figure 4.9). 
 
 
Figure 4.10 Mef2-Gal4 Expression in the Adult Drosophila Brain 
UAS-CD8::GFP/+;nSyb-Gal4/+ and UAS-CD8::GFP/+;Mef2-Gal4/+ adult male 
brains were stained for GFP and the pre-synaptic marker BRP. (A) nSyb-Gal4 
is widely expressed throughout the brain. (B) Mef2-Gal4 shows a more restricted 
expression pattern, with strong staining in the PI and the EB (white arrowheads). 
Scale bars indicate 50 µm. 
 
4.4.5 Expression of SloE366G in Neuronal Subpopulations 
Having shown that pan-neuronal re-introduction of dysc in a sloE366G/+ 




investigated more restricted neuronal subpopulations. While cellular analyses 
demonstrated abnormal MN activity in sloE366G/+ larvae (Figure 3.15), it remained 
unclear whether SloE366G induces this effect by altering dendritic excitability of 
MNs or by acting in neuronal populations upstream of MNs (Paragraph 3.5.2.2). 
I addressed this question in sloE366G/+ adults by re-introducing dysc specifically 
in MNs using the glutamatergic OK371-Gal4 driver described in Paragraph 3.4.5 
(Mahr and Aberle, 2006). The novel line OK371-Gal4/CyO;dyscs168/TM6B,Tb was 
generated according Figure 4.2, the experimental genotypes according to Figure 
4.6. Interestingly, the re-introduction of dysc in MNs had no effect on locomotion, 
suggesting that SloE366G does not act autonomously in MNs to induce the 
sloE366G/+ locomotor defect (Figure 4.11).  
 
 
Figure 4.11 SloE366G in Motoneurons does not Affect Locomotion 
The MN-specific re-introduction of dysc in dyscs168 homozygotes via OK371-
Gal4 did not affect locomotion in either a sloE366G/+ or a sloloxP/+ background. 
Data from two independent experimental repeats were pooled. (n = 30-48; 





I proceeded to investigate alternative subpopulations of neurons. Since the non-
inflated wing phenotype observed in sloE366G/+ adults might be caused by altered 
peptidergic signalling involving CCAP-positive neurons (Tabuchi et al., 2018) 
(Paragraph 3.5.1.1), I hypothesised that altered peptidergic signalling might also 
be involved in eliciting the sloE366G/+ locomotor defect. Hence, I re-introduced 
dysc in peptidergic neurons using the c929-Gal4 driver. c929-Gal4 is an 
enhancer trap line located within the locus of the pro-secretory TF dimmed, 
labelling most peptidergic neurons in the CNS (Hewes et al., 2003). The novel 
line c929-Gal4/CyO;dyscs168/TM6B,Tb was generated according to Figure 4.2, 
the experimental genotypes according to Figure 4.6. No locomotor defect was 
observed upon re-introduction of dysc in peptidergic neurons (Figure 4.12).  
 
 
Figure 4.12 SloE366G in Peptidergic Neurons does not Affect Locomotion 
The re-introduction of dysc in peptidergic neurons of dyscs168 homozygotes via 
c929-Gal4 did not affect locomotion in either a sloE366G/+ or a sloloxP/+ 
background. Data from two independent experimental repeats were pooled. (n 






Although not affecting locomotion, the re-introduction of dysc in peptidergic 
neurons of dyscs168 homozygotes induced the non-inflated wing phenotype 
observed in sloE366G/+ (Figure 3.16): ~26% (6/23) of males exhibited non-inflated 
wings in a sloE366G/+ background, a phenotype that was not observed in a sloloxP/+ 
background (0/20) (Figure 4.13). Of note, only flies with fully inflated wings were 
used for the behavioural experiments shown in Figure 4.12. 
 
 
Figure 4.13 Peptidergic SloE366G Partially Suppresses Wing Inflation 
23 UAS-dysc/c929-Gal4;sloE366G,dyscs168/dyscs168 males were scored according 
to wing inflation: non-inflation of wings, semi-inflation of wings, and fully inflated 
wings. While the peptidergic re-introduction of dysc induced a non-inflated wing 
phenotype in ~26% of these flies (6/23), none of 20 males exhibited this 
phenotype in a sloloxP/+ background. 
 
These data dissociate the wing- from the locomotor phenotype, suggesting that 
the activity of SloE366G in peptidergic neurons specifically induces the former. In 
order to identify a neuronal subpopulation capable of recapitulating the sloE366G/+ 
locomotor defect, I next re-introduced dysc in GABAergic neurons with the GAD-
Gal4 driver. GAD-Gal4 drives Gal4 expression under the control of upstream 
regulatory sequences of GAD1, a gene encoding the enzyme Glutamic acid 




expressed in all GABAergic neurons (Ng et al., 2002). The novel line GAD-
Gal4/CyO;dyscs168/TM6B,Tb was generated according to Figure 4.2, 
experimental genotypes according to Figure 4.6. As shown in Figure 4.14, the re-
introduction of dysc in GABAergic neurons did not affect locomotion in a 
sloE366G/+ background, while causing a significant increase in a sloloxP/+ 
background. However, in contrast to the muscle-specific re-introduction of dysc 
(Figure 4.9), a trend towards increased locomotion in a sloE366G/+ background 
could be observed (Figure 4.14), suggesting that GABAergic neurons do not play 
a major role in eliciting the sloE366G/+ locomotor defect.  
 
 
Figure 4.14 SloE366G in GABAergic Neurons does not Affect Locomotion 
The re-introduction of dysc in GABAergic neurons of dyscs168 homozygotes via 
GAD-Gal4 did not affect locomotion in a sloE366G/+ background, while 
significantly increasing it in a sloloxP/+ background. Data from two independent 
experimental repeats were pooled. (n = 30-40; Kruskal-Wallis multiple 





4.4.6 Cholinergic SloE366G Induces the sloE366G/+ Locomotor Defect 
Cholinergic neurons release the neurotransmitter ACh and are prominently 
expressed throughout the Drosophila brain (Yasuyama and Salvaterra, 1999). 
Hence, I tested whether cholinergic re-introduction of dysc might affect 
locomotion, using the ChAT-Gal4 driver. ChAT-Gal4 drives Gal4 expression 
under the control of a 7.4 kb DNA region 5’ of the Drosophila cholinergic locus, 
and has been shown to label the vast majority of cholinergic neurons (Salvaterra 
and Kitamoto, 2001). The novel line ChAT-Gal4/CyO;dyscs168/TM6B,Tb was 
generated according to Figure 4.2, the experimental genotypes according to 
Figure 4.6. Indeed, cholinergic re-introduction of dysc significantly decreased the 
number of beam breaks only in a sloE366G/+ background (Figure 4.15).  
 
 
Figure 4.15 SloE366G in Cholinergic Neurons Decreases Locomotion 
The re-introduction of dysc in cholinergic neurons of dyscs168 homozygotes via 
ChAT-Gal4 significantly reduced locomotion in a sloE366G/+ background, while 
not affecting locomotion in a sloloxP/+ background. Data from three independent 
experimental repeats were pooled. (n = 46-93; Kruskal-Wallis multiple 





These data strongly suggest a role for cholinergic neurons in eliciting the 
sloE366G/+ locomotor defect in adults. To test whether such an effect could also 
be observed in larvae, I repeated this experiment using the AnimApp video-
tracking pipeline, which is illustrated in Figure 3.2 (Rao et al., 2019). As shown in 
Figure 4.16, the cholinergic re-introduction of dysc in larvae failed to induce the 
sloE366G/+ locomotor defect.  
 
 
Figure 4.16 Cholinergic SloE366G does not Affect Larval Locomotion 
The re-introduction of dysc in cholinergic neurons of dyscs168 homozygotes via 
ChAT-Gal4 did not affect larval locomotion in either a sloE366G/+ or a sloloxP/+ 
background. Larval video-recordings were performed for 1 min per larva. Data 
from two independent experimental repeats were pooled. (n = 19-35; Kruskal-










This chapter addresses the second question set out in the project aim: where is 
the sloE366G allele required to exert its pathogenic effects? Using a targeted dysc 
re-introduction strategy into dysc null homozygotes, in vivo evidence is provided 
that the specific expression of SloE366G in the nervous system is sufficient to 
induce the sloE366G/+ locomotor defect. Furthermore, the data presented in this 
chapter support the hypothesis, as outlined in Chapter 3, that this phenotype is 
caused by altered neural activity upstream of MNs. Specifically, cholinergic 
neurons are shown to contain the pathogenic locus of sloE366G/+. Altogether, 
these data suggest a neuroanatomical basis for GEPD pathogenesis. 
4.5.1 Experimental Notes and Caveats 
4.5.1.1 Experimental Design of the Spatial Dissection Strategy 
In order to restrict Slo expression to subpopulations of cells, dysc was 
conditionally expressed in a dysc null homozygous background. Due to the 
dependence of Slo expression upon Dysc (Jepson et al., 2012), this strategy 
allows for the expression of Slo specifically in cells into which dysc has been re-
introduced. Indeed, the sloE366G/+ locomotor defect was completely suppressed 
in dyscs168 homozygotes but could be re-instated by broadly re-introducing dysc 
(Figure 4.7). However, these data also show that homozygous dyscs168 increases 
locomotion in a sloloxP/+ background (Figure 4.5). This result demonstrates that 
the genetic background used for this spatial dissection strategy independently 
affects locomotion. Since slo null homozygotes (slo1 and slo4) have been shown 
to exhibit normal overall activity levels (Ceriani et al., 2002), the increased 
locomotion of dyscs168 homozygotes illustrates the pleitropic nature of dysc, being 
involved in cellular processes other than the regulation of Slo expression. Indeed, 
immuno-staining detected Dysc in areas with little or no Slo expression, including 
parts of the antennal lobes, mushroom body, and ellipsoid body, suggesting that 
in these brain areas, Dysc performs cellular functions independent of Slo (Jepson 
et al., 2012). To control for these effects, it is important that the spatial dissection 
results presented in this chapter are independently confirmed. For example, 




performed, targeting genes that Slo function depends on, such as dysc, or genes 
encoding Cav channels (Griguoli et al., 2016) (Paragraph 1.4.3.1). Alternatively, 
the RNAi-mediated knock-down of slo could be optimised by testing alternative 
RNAi lines, doubling the dose of slo-RNAi, or co-expressing Dicer2, which 
encodes a dsRNA-specific endonuclease involved in the RNAi pathway that 
increases RNAi efficacy (Perrimon et al., 2010). Using ChAT-Gal4 to drive these 
RNAi constructs, a rescue of the sloE366G/+ locomotor defect would confirm the 
results obtained via the Dysc-mediated expression of Slo.  
4.5.1.2 Discrepant Results in Larvae and Adults 
It is unclear why the expression of SloE366G in cholinergic neurons did not induce 
the sloE366G/+ locomotor defect in larvae (Figure 4.16). Electrophysiological and 
optical live-imaging evidence suggest that larval peristaltic frequency is affected 
by neurons upstream of MNs (Kadas et al., 2015; Pulver et al., 2015), including 
the CPG, which, as described in Paragraph 3.5.2.1, implicates pre-motor circuits 
in the sloE366G/+ larval locomotor defect. Moreover, it has recently been shown, 
via serial section TEM, that the majority of pre-MNs in L1 larvae are cholinergic 
(Zarin et al., 2019). These data support the hypothesis that in larvae, too, 
cholinergic neurons might be involved in mediating the sloE366G/+ locomotor 
defect. Importantly, Dysc has been shown to interact with Slo at the larval NMJ 
to regulate synapse- and AZ morphology as well as neurotransmission (Jepson 
et al., 2014). Moreover, it has been shown via immuno-staining that homozygous 
dysc null larvae lack Slo expression in the VNC (Jepson et al., 2014). These data 
strongly suggest that the dependence of Slo expression upon Dysc is conserved 
between L3 larvae and adults. Nonetheless, re-introducing dysc more broadly in 
larvae via da-Gal4, as performed in adults, will be necessary to validate this 
experimental strategy in larvae. 
4.5.1.3 SloE366G in CCAP-positive Neurons Might Cause Wing-inflation Defect 
The peptidergic re-introduction of dysc in a sloE366G/+ background induced the 
non-inflated wing phenotype observed in sloE366G/+ adults (Figure 4.13, Figure 
3.16), while leaving locomotion unaffected (Figure 4.12), thereby dissociating the 
two phenotypes. These data strengthen the hypothesis outlined in Paragraph 




the activity of SloE366G in CCAP-positive neurons. Indeed, the c929-Gal4 driver, 
used for the peptidergic re-introduction of dysc, labels a subset of 14 CCAP-
expressing neurons that directly release bursicon into the haemolymph – a 
hormone critical for wing expansion and cuticle tanning (Luan et al., 2006). 
Hence, I hypothesise that bursicon release from these 14 neurons is 
dysregulated in sloE366G/+, resulting in the non-inflated wing phenotype – a 
hypothesis that could be tested by re-introducing dysc specifically in CCAP-
expressing neurons using the CCAP-Gal4 driver (Park et al., 2003).  
4.5.2 Clinical Relevance 
4.5.2.1 Cholinergic Neurons as a Pathogenic Locus for GEPD 
As described in Paragraph 1.4.2, KCNMA1 is expressed broadly throughout the 
human body, suggesting that the D434G mutation is likely to affect BK channel 
function in a variety of organs and tissues (Bailey et al., 2019). The results 
presented in this chapter provide the first in vivo evidence that the expression of 
this mutation in the nervous system is sufficient to induce GEPD pathogenesis 
(Figure 4.8). Moreover, by further restricting SloE366G expression, evidence is 
provided that cholinergic neurons contain the pathogenic locus of GEPD (Figure 
4.15). How do these results fit into the PxD and movement disorder literature? As 
shown in Figure 1.1, the striatum is the main input structure of the human basal 
ganglia, receiving afferent connections from cortical areas. The most common 
cell type in the striatum is the GABAergic MSN (Kandel et al., 2013), as 
introduced in Paragraph 3.5.2.6. This neuronal subtype sends inhibitory 
projections via the direct and indirect pathways to the GPi-SNr and GPe, 
respectively, as well as reciprocal connections to the dopaminergic SNc (Figure 
1.1) (Kandel et al., 2013). Hence, MSNs are integral components of motor 
behaviours such as action selection and the preparation and execution of 
movement (Kandel et al., 2013). As such, the activity of MSNs is under intricate 
control from a variety of brain areas: cortical and thalamic afferents form 
glutamatergic connections-, afferents from the SNc dopaminergic connections 
with MSN dendrites (Kandel et al., 2013). Importantly, while small local 




interneurons within the striatum form cholinergic connections with MSNs (Kandel 
et al., 2013).  
4.5.2.2 Focus on Striatal Cholinergic Interneurons 
Considering the role of the basal ganglia in PxD and other movement disorders 
(Kandel et al., 2013) (Paragraph 1.2.2), the data provided in this chapter suggest 
that altered activity of striatal cholinergic interneurons might be involved in GEPD 
pathogenesis via dysregulating the activity of striatal MSNs. This hypothesis is 
strengthened by the finding that action selection – a behaviour under striatal MSN 
control (Kandel et al., 2013) – was found to be perturbed in sloE366G/+ (Paragraph 
3.5.2.6). As described in Paragraph 3.5.2.6, a recent study on a mouse model of 
LID identified a correlation between the firing rate of direct pathway striatal MSNs 
and dyskinesia severity, while also showing that the optogenetic activation of 
these neurons is sufficient to induce dyskinetic attacks in control mice (Ryan et 
al., 2018). These data illustrate the importance of striatal MSN activity in 
dyskinesia. Further evidence for their importance in regulating movement is 
provided by studies of DYT1 dystonia, a severe form of inherited dystonia linked 
to a deletion in TOR1A (Ozelius et al., 1997), which was introduced in Paragraph 
1.5.2. Ex vivo sharp microelectrode recordings from MSNs in a DYT1 knock-in 
mouse model showed a bidirectional impairment of synaptic plasticity at 
corticostriatal synapses: DYT1 mice exhibited a loss of long-term depression 
(LTD) and an increased long-term potentiation (LTP) amplitude (Maltese et al., 
2014; Martella et al., 2014). In particular, it could be shown that synaptic 
depotentiation (SD), the process of reversing LTP with a train of low-frequency 
stimulation (LFS), was severely impaired at DYT1 corticostriatal synapses 
(Maltese et al., 2014; Martella et al., 2014). Intriguingly, SD was completely 
restored upon application of specific M1 muscarinic ACh receptor (mAChR) 
antagonists, demonstrating the importance of cholinergic modulation of MSNs in 
dystonia (Maltese et al., 2014; Martella et al., 2014). Indeed, anticholinergic drugs 
can be used to treat generalised and segmental dystonia as well as Parkinsonian 
tremor clinically (Jankovic, 2006; Poewe et al., 2017).  
Since cholinergic modulation of striatal MSNs is performed by striatal 




channels, as this might suggest their function to be altered in GEPD. Indeed, 
whole-cell recordings in rat striatal slices have demonstrated that neostriatal 
cholinergic interneurons express BK channels (Bennett et al., 2000; Goldberg 
and Wilson, 2005). By pharmacologically blocking specific types of Cav channels, 
strong evidence was provided that BK channels in striatal cholinergic 
interneurons are coupled to P/Q-type Cav channels and negatively regulate AP 
width (Bennett et al., 2000; Goldberg and Wilson, 2005). Striatal cholinergic 
interneurons are tonically active and exhibit three distinct rhythmic firing patterns 
that are sustained in vitro: regular single-spiking, irregular single-spiking, and 
rhythmic bursting (Goldberg and Wilson, 2005; Goldberg et al., 2009). 
Interestingly, selective inhibition of specific types of Cav channels can cause a 
transition between these intrinsic firing patterns (Goldberg and Wilson, 2005). 
Moreover, electrophysiological recordings from cholinergic interneurons in the 
primate putamen demonstrated that parkinsonian symptoms are linked to a 
transition from tonic- to oscillatory activity exhibited by these neurons (Raz et al., 
1996). Hence, it is possible that the D434G mutation modulates the firing 
behaviour of striatal cholinergic interneurons via altered BK channel function, 
leading to a perturbed modulation of striatal MSN activity, which in turn might 
contribute to GEPD pathogenesis. 
4.5.3 Conclusion 
This chapter presented a genetic approach to specifically express SloE366G in 
subpopulations of cells and identified cholinergic neurons as a potential 
pathogenic locus of GEPD. It is still unclear, however, how the D434G mutation 











5 Molecular Analysis of sloE366G/+ 
5.1 Introduction 
Chapter 4 provided strong evidence suggesting that the pathogenic locus of 
sloE366G/+ encompasses cholinergic neurons. An outstanding question, however, 
is how the sloE366G allele affects molecular and cellular function. In the presence 
of this mutant allele, it is conceivable that two scenarios take place: (1) 
physiological cellular function is perturbed, and (2) compensatory responses are 
aimed at counteracting this perturbation in a homeostatic manner, in order to re-
establish physiological function. Both processes could affect behaviour and 
contribute to the sloE366G/+ locomotor defect. This chapter aims at establishing a 
link between molecular function and behaviour by identifying cellular pathways 
perturbed in sloE366G/+. While contributing to an increased molecular 
understanding of GEPD, this approach might also uncover pathological principles 
that apply to PxD and epilepsy more generally.  
 To experimentally link molecular mechanisms and behaviour, I performed 
RNA-sequencing (RNA-seq) of sloE366G/+ and sloloxP/+ adult fly heads – a strategy 
aimed at detecting transcriptomic changes between these genotypes that might 
uncover pathophysiological disturbances of cellular function. Bioinformatic 
analyses of 1036 differentially expressed genes (DEGs) demonstrate that 
sloE366G/+ flies exhibit perturbed metabolic-, redox-, and immune function, while 
the TF Foxo is predicted to regulate almost half of the genes over-expressed in 
sloE366G/+. Functionally testing these results via a dominant modifier screen 
based on locomotor behaviour identified a genetic interaction between foxo and 
sloE366G, while also implicating dysregulated insulin signalling with the sloE366G/+ 
locomotor defect. These results establish a first in vivo link between molecular 





5.2 Statement of Contribution 
5.2.1 Direct Contributions 
Deborah Hughes operated the HiSeq 3000 sequencing system, while also 
performing the final Bioanalyzer run of pooled cDNA libraries. Together with 
Deborah Hughes, I generated a sample sheet used by Dr. Alan Pittman for de-
multiplexing and file conversion of the sequencing data. Table 49 lists these 
contributions and indicates the figures generated based on the data. 
Table 49 Experimental Contributions to Chapter 5 
Contributing Researcher Corresponding Figure 
Deborah Hughes and Patrick 
Kratschmer 
Figure 9.2 
Dr. Alan Pittman Table 55 




5.2.2 Indirect Contributions 
Dr. Ko-Fan Chen has been of great help during the initial stages of RNA 
extraction, sharing his expertise in molecular biology. Deborah Hughes has been 
of great help in setting up an experimental pipeline for the generation of cDNA 
libraries. Dr. Ko-Fan Chen and Tony Brooks have been of incredible help during 
the optimisation of the cDNA library preparation protocol. Dr. Alan Pittman has 
been a fantastic bioinformatics teacher and greatly contributed to my progress in 
programming. Dr. James Jepson provided invaluable intellectual input during the 







5.3 Materials and Methods 
5.3.1 Genetic Nomenclature 
The genotypes of flies used in this chapter are listed in Paragraph 5.3.2.  
The nomenclature guidelines described in Paragraph 2.3.1 were adjusted for the 
insulin-themed modifier screen: only mutations of interest are denoted in the main 
text, not every mutation deviating from iso31. For example, 
cn,chico1/+;ry/sloE366G/loxP is denoted as chico1/+;+/sloE366G/loxP.  
5.3.2 Fly Stocks 
Table 50 Fly Stocks of Chapter 5 
Genotype Source 
iso31 Kind gift from Dr. Kyunghee Koh 
w;;sloE366G/TM6B,Tb   This thesis 
w;;sloloxP/TM6B,Tb This thesis 
w;;sloE366G[w+]/TM6B,Tb   This thesis 
w;;sloloxP[w+]/TM6B,Tb This thesis 
w;;dilp11 BDSC: 78055 
w;;dilp21 BDSC: 30881 
w;;dilp31 BDSC: 30882 
w;;dilp41 BDSC: 30883 
w;;dilp51 BDSC: 30884 
y,w,dilp668;; BDSC: 30886 
w,dilp71;; BDSC: 30887 
y,w;;dilp8M727  BDSC: 33079 
w;;dilp2-3 BDSC: 30888 
w;;dilp2-3,53/TM3,Sb BDSC: 30889 
y,w,dilp668;;dilp2-3,53/TM3,Sb BDSC: 30891 
w,dilp71;;dilp2-3,53/TM3,Sb BDSC: 30893 
w;;dilp1-4,54/TM3,Sb BDSC: 30890 
w,dilp71;;dilp1-4,54/TM3,Sb BDSC: 30894 




;;InRE19/TM2,Ubx130 BDSC: 9646 
;cn,chico1/CyO;ry BDSC: 10738 
;;ry,AktP4226/TM3,ry,Sb,Ser BDSC: 11627 
w;;foxoD94/TM6b,Tb BDSC: 42220 
w;;toP632 BDSC: 10202 
w;;ImpL2M4721 BDSC: 24219 
5.3.3 Fly Husbandry 
Unless otherwise indicated, all fly stocks were kept on standard fly food at RT. 
The recipe of the standard fly food is shown in Table 4. All flies used for 
behavioural experiments were maintained at 25ºC on a 12 h light:12 h dark cycle.  
5.3.4 Experimental Genotypes 
Unless otherwise indicated, recombinant 25.1.1/TM6B,Tb was used as a 
representative for sloE366G/TM6B,Tb, and recombinant 132.1.1/TM6B,Tb as a 
representative for sloloxP/TM6B,Tb. 
5.3.4.1 sloE366G/+ and sloloxP/+ 
sloE366G/+ and sloloxP/+ flies were generated by crossing sloE366G/TM6B,Tb and 
sloloxP/TM6B,Tb to isogenic controls (iso31), respectively.  
5.3.4.2 Insulin-themed Modifier Screen 
Experimental genotypes for the insulin-themed modifier screen were generated 
by crossing the BDSC-acquired stocks shown in Table 50 to sloE366G/TM6B,Tb 
and sloloxP/TM6B,Tb. Table 51 lists the experimental genotypes as well as the 
nature of the mutant alleles. 
Table 51 Experimental Genotypes for Insulin-themed Modifier Screen 
Experimental Genotype Allele Type 
dilp11/sloE366G/loxP Null allele1 
dilp21/sloE366G/loxP Null allele1  
dilp31/sloE366G/loxP Null allele1 
dilp41/sloE366G/loxP Null allele1 




dilp668/Y;;+/sloE366G/loxP Null allele1 
dilp71/Y;;+/sloE366G/loxP Null allele1 
dilp8M727/sloE366G/loxP Hypomorphic allele2 
dilp2-3/sloE366G/loxP Null alleles1 
dilp2-3,53/sloE366G/loxP Null alleles1 
dilp668/Y;;dilp2-3,53/sloE366G/loxP Null alleles1 
dilp71/Y;;dilp2-3,53/sloE366G/loxP Null alleles1 
dilp1-4,54/sloE366G/loxP Null alleles1 
dilp71/Y;;dilp1-4,54/sloE366G/loxP Null alleles1 
InRP45/sloE366G/loxP Hypomorphic allele3 
InRE19/sloE366G/loxP Unknown 
chico1/+;+/sloE366G/loxP Null allele4  
AktP4226/sloE366G/loxP Unknown 
foxoD94/sloE366G/loxP Null allele5 
toP632/sloE366G/loxP Unknown 
ImpL2M4721/sloE366G/loxP Unknown 
1(Grönke et al., 2010), 2(Garelli et al., 2012), 3(Fernandez et al., 1995), 4(Naganos et al., 2012),  
5(Slack et al., 2011) 
5.3.5 Adult Head Isolation 
sloE366G/+ and sloloxP/+ males were combined with an excess number of orange-
eyed sloE366G[w+]/+ and sloloxP[w+]/+ females, respectively, for 48 h, in order to 
increase the probability of mating. Flies between the ages of 3 and 6 days were 
flash-frozen in 15 mL Falcon tubes pre-cooled in liquid nitrogen. Importantly, no 
anaesthetisation of flies with CO2 was performed for at least 48 h prior to flash-
freezing. The Falcon tubes containing the flash-frozen flies were vortexed at 
maximum speed with intermittend shaking, in order to mechanically dislocate fly 
heads from bodies. Fly heads were poured onto Petri dishes on dry ice and 16-
20 heads per sample collected into 1.5 mL eppendorf tubes under a 
stereomicroscope. Male heads were identified by white eye colour, as all females 
had orange eyes. Once all samples had been collected, RNA extraction was 




between 4 pm and 6 pm, in order to account for circadian effects on gene 
expression.  
5.3.6 RNA Extraction and DNase Treatment 
Adult male Drosophila heads were isolated as described in Paragraph 5.3.5 and 
transferred onto wet ice, before adding 200 µL of TRIzol (Thermo Fisher 
Scientific, 15596026) to each sample. Head tissue was homogenised in TRIzol 
using a cordless motorised tissue grinder and pestles (Sigma Aldrich, Z359971-
1EA and Z359947-100EA), before adding another 300 µL of TRIzol and 
transferring the samples to RT. The samples were shaken vigorously for 10 s and 
incubated at RT for 5 min, before adding 50 µL of BCP (Sigma Aldrich, B9673-
200ML) to each sample, followed by another 10 s of vigorous shaking and 
incubation at RT for 10 min. Samples were then centrifuged at 15000 x g and 4ºC 
for 15 min. Upon phase separation, 180 µL of the RNA-containing aqueous phase 
were carefully transferred into fresh 1.5 mL eppendorf tubes, and 450 µL of 
isopropanol (Sigma Aldrich, I9516-25ML) added to each sample, followed by 
gentle mixing by inversion and incubation at RT for 10 min. Samples were then 
centrifuged at 15000 x g and 4ºC for 8 min, the supernatant discarded, and 1 mL 
of freshly prepared, cold 75% ethanol added to the samples (Sigma-Aldrich, 
E7023-500ML). The RNA pallet was ethanol-washed by gentle inverse-mixing, 
followed by centrifugation at 7500 x g and 4ºC for 5 min. The ethanol supernatant 
was discarded, and the wash with 75% ethanol repeated. After the second wash, 
the ethanol supernatant was discarded, and the samples left uncapped at RT to 
facilitate ethanol evaporation (3-5 min). 89 µL of nuclease-free water were added 
to the dried RNA pallets and the samples dissolved at 65ºC for 5 min. In order to 
eliminate DNA contamination, DNase treatment with the TURBO DNA-free Kit 
(Thermo Fisher Scientific, AM1907) was performed, using the reaction mixture 
shown in Table 52. 
Table 52 TURBO DNase Treatment 
Reagent Volume / µL 
RNA in nuclease-free water 89 




TURBO DNase  1 (2 U) 
Final volume 100 
 
DNase treatment was performed at 37ºC for 30 min, before adding 10 µL of the 
DNase Inactivation Reagent (Thermo Fisher Scientific, AM1907) to the reaction 
mixture and letting the samples incubate at RT for 5 min under constant pipette-
mixing. The samples were then centrifuged at 10000 x g and 22ºC for 1.5 min, 
and 80 µL of the supernatant containing the DNase-treated RNA carefully 
transferred to new 1.5 mL eppendorf tubes on wet ice. RNA concentrations were 
quantified (Paragraph 5.3.7), and samples stored at -80ºC.  
5.3.7 RNA and DNA Quantification 
Throughout this chapter, the concentrations of RNA and DNA were quantified 
using a Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Q32866). For RNA, the 
Qubit RNA HS Assay Kit (Thermo Fisher Scientific, Q32852) was used, while for 
DNA, the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, Q32851) was 
used. 
5.3.8 On-chip Gel Electrophoresis 
On-chip gel electrophoresis was performed with an Agilent 2100 Bioanalyzer 
(Agilent Technologies). To test for RNA integrity, total RNA samples were run on 
an Agilent RNA 6000 Nano Chip (Agilent Technologies, 5067-1511), after heat-
denaturing the samples for 2 min at 70ºC, which minimises secondary structure 
formation. To analyse cDNA library quality, cDNA samples were run on a High 
Sensitivity DNA Chip (Agilent Technologies, 5067-4626). Screenshots of the 
Bioanalyzer results were taken to generate figures in this chapter. 
5.3.9 cDNA Library Preparation 
cDNA libraries were generated with the KAPA mRNA HyperPrep Kit (KAPA 
Biosystems Inc., KK8580), using protocol v. 4.17. Some parameters in this 
protocol are variable, and Table 53 lists the parameters I used as well as the 




Table 53 cDNA Library Preparation Parameters 
Parameter Value Protocol Paragraph 
Total RNA input 200 ng 2.8 
mRNA fragmentation temperature 94ºC 3.3 
mRNA fragmentation time 8 min 3.3 
Adapter concentration 68.2 nM 6.2 
Number of PCR amplification cycles 13 9.3 
 
For adapter ligation, the KAPA Single-Indexed Adapter Sets A and B (KAPA 
Biosystems Inc., KK8710) were used. Table 54 lists the sample-index 
combinations as well as KAPA index IDs for the 18 cDNA libraries successfully 
generated and sequenced.  
Table 54 Sample-Index Combinations of cDNA Libraries 
cDNA Library Sample Index Sequence KAPA ID 
17_GEPD1 ATCACG 1 
17_GEPD2 TTAGGC 3 
17_GEPD5 TAGCTT 10 
17_loxP1 GTGGCCTT 20 
17_loxP3 CGTACGTA 22 
17_loxP6 ATTCCTTT 27 
18_GEPD1 CGATGT 2 
18_GEPD2 TGACCA 4 
18_GEPD3 ACAGTG 5 
18_GEPD4 GCCAAT 6 
18_GEPD5 CAGATC 7 
18_GEPD6 CTTGTA 12 
18_loxP1 AGTCAACA 13 
18_loxP2 AGTTCCGT 14 
18_loxP3 ATGTCAGA 15 
18_loxP4 CCGTCCCG 16 




18_loxP6 GTGAAACG 19 
 
Successfully prepared cDNA libraries were suspended in 20 µL of 10 mM Tris-
HCl (pH = 8.0 – 8.5, Sigma Aldrich, T3038-1L) and stored at -20ºC. For this 
experiment, all instruments used, such as pipettes, tube racks, and ice buckets, 
were treated with RNAseZAP RNase Decontamination Solution (Thermo Fisher 
Scientific, AM9780). 
5.3.10 Bioinformatics 
5.3.10.1 Operating Systems and Programming Languages 
Computational operations up until and including the generation of BAM and BAI 
files (Paragraph 5.3.10.5) were performed on a cluster computer running Red Hat 
Enterprise Linux 6.6 (Santiago). BAM and BAI files were then transferred onto a 
local computer running macOS Mojave (v. 10.14.5) for further analysis. All 
analyses were performed on the Unix command line and in R (v. 3.6.0), using 
RStudio (v. 1.2.1335). Throughout this chapter, the following protocol was used 
as a guide for the RNA-seq analysis: (Love et al., 2016) – a more detailed 
description of this analysis pipeline is available at 
https://www.bioconductor.org/packages/devel/workflows/vignettes/rnaseqGene/i
nst/doc/rnaseqGene.html.  
5.3.10.2 RNA-seq Data Retrieval 
FASTQ files were generated from BCL files by Dr. Alan Pittman using the 
bcl2fastq conversion software provided by Illumina (v. 1.8.4) via the Unix 
command line arguments shown in Table 55.  
Table 55 De-multiplexing RNA-seq Data 
## BCL-to-FASTQ file format conversion for 8-bp indices 
> ./bcltofastq --sample-sheet <sampleSheetName>.csv  \ 
--use-bases-mask Y75n,I8,I8,Y75n 
## BCL-to-FASTQ file format conversion for 6-bp indices 






The sample sheets needed to specify sample-index information 
(<sampleSheetName>.csv in Table 55) were generated by Deborah Hughes and 
myself, and are shown in Figure 9.2. Sample-index information is used for de-
multiplexing the sequencing reads. The use-bases-mask argument in Table 55 
specifies to use the first 75 base calls for each read and to ignore the 76th base 
call (Y75n). I8 and I6 specify 8- and 6-bp index sequences, respectively, based 
on which de-multiplexing occurred. 
5.3.10.3 Quality Control of FASTQ Data 
The open-source software FASTQC was used to generate quality reports on 
FASTQ data (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
FASTQC was run on the Unix command line, using the command shown in Table 
56.  
Table 56 FASTQC Analysis 
## Run FASTQC on each of the FASTQ files 
> fastqc <FASTQ_file_name>.fastq 
 
FASTQC outputs quality reports as HTML files, which were analysed by manual 
inspection. Screenshots of these HTML files were taken to generate the figures 
based on FASTQC data. 
5.3.10.4 Alignment of RNA-seq Reads 
RNA-seq reads in FASTQ file format were aligned to the BDGP6 Drosophila 
melanogaster reference genome using the STAR alignment software (v. 2.5.3a) 
(Dobin et al., 2013). Alignment with STAR occurs in two steps: first, genome index 
files are built, which are used during the mapping step (step two) as a reference 
for the splice-aware alignment of RNA-seq reads (Dobin, 2017). Genome index 
files were built based on the BDGP6 Drosophila melanogaster reference 
genome, using chromosomal, mitochondrial, and non-chromosomal DNA (dos 
Santos et al., 2014). As the bash script in Table 57 shows, the relevant genomic 
FASTA files of the BDGP6 reference genome were downloaded directly from the 
Ensemble FTP (Ensembl release 91), facilitating reproducibility (Zerbino et al., 




structure information, was downloaded from the Ensemble FTP (Table 57). 
Allowing the alignment algorithm to access and extract splice-junction information 
from GTF files has been described to greatly increase mapping accuracy (Dobin, 
2017). 
Table 57 Retrieval of FASTA and GTF Files 
## Download genomic FASTA files of BDGP6 
> wget ftp://ftp.ensembl.org/pub/release- 
91/fasta/drosophila_melanogaster/dna/*.dna.chromosome* 
> wget ftp://ftp.ensembl.org/pub/release- 
91/fasta/drosophila_melanogaster/dna/*.dna.nonchromosomal* 
## Download GTF file for BDGP6 
> wget ftp://ftp.ensembl.org/pub/release91/gtf/drosophila_ 
melanogaster/Drosophila_melanogaster.BDGP6.91.gtf.gz 
## Unzip 
> gunzip *.gz 
 
STAR genome index files were built as shown in Table 58.  
Table 58 Building STAR Genome Index Files 
#!/usr/bin/bash 
## Build STAR genome index files 
$STAR --runThreadN $CPUS --runMode genomeGenerate \ 
--genomeDir $GENOMEDIR/STAR_index \ 
--genomeFastaFiles $GENOMEDIR/*.fa --sjdbGTFfile $GTF \  
--sjdbOverhang 74 --genomeSAindexNbases 13 
## Variable definitions 
# $STAR       = full path to the STAR executable 
# $CPUS       = number of CPU cores (24) 
# $GENOMEDIR  = path to the directory containing the BDGP6  
#               genome in FASTA format 






Of note, the argument genomeSAindexNbases was set to 13 (default = 14), due 
to the Drosophila melanogaster genome size of 142573017 bp, as described in 
(Dobin, 2017). The argument sjdbOverhang was set to 74, as it is defined by the 
read length (75 bp) minus 1 (Dobin, 2017). Both of these arguments affect the 
structure of the resulting genome index files, which contain information about the 
genome sequence and corresponding splice junction coordinates as well as 
further information regarding chromosomes, genes, and transcripts (Dobin, 
2017). Using these genome index files, RNA-seq reads in FASTQ format were 
aligned to the BDGP6 Drosophila melanogaster reference genome, as shown in 
Table 59. Of note, due to the paired-end nature of the RNA-seq experiment, read 
alignment was performed for paired-end reads.  
Table 59 RNA-seq Read Alignment 
#!/usr/bin/bash 
## Run STAR alignment for every set of read pairs 
$STAR --runThreadN $CPUS --alignIntronMax $MAXINTRON \ 
--alignIntronMin $MININTRON --genomeDir $GENOME \ 
--readFilesIn $FASTQ/<Read_1>.fastq $FASTQ/<Read_2>.fastq 
## Variable definitions 
# $STAR       = full path to the STAR executable 
# $CPUS       = number of CPU cores (24) 
# $MAXINTRON  = maximum intron size for alignments (26745) 
# $MININTRON  = minimum intron size for alignments (51) 
# $GENOME     = full path to genome index files 
# $FASTQ      = full path to FASTQ files  
exit 
 
In order to determine the maximum and minimum intron sizes of Drosophila 
melanogaster (Table 59), I downloaded a FASTA file containing information on 
all annotated Drosophila melanogaster introns from the FlyBase FTP, as shown 
in Table 60. 
Table 60 Retrieval of Intron Information 




> wget ftp://ftp.flybase.net/genomes/Drosophila_melanogaster/ 
dmel_r6.21_FB2018_02/fasta/dmel-all-intron-r6.21.fasta.gz 
## Unzip file 
> gunzip *.gz 
 
Using this file, intron lengths were extracted with the command line arguments 
shown in Table 61, generating a new file (introns in Table 61) that was loaded 
into R for further analysis. 
Table 61 Retrieval of Drosophila melanogaster Intron Lengths 
## Retrieve intron lengths and write to new file 
> grep "^>" introns | cut -f7 -d ";" | cut -f2 -d "=" > 
introns 
 
Using R, the intron lengths at the 1st and 99th centiles were calculated, which 
correspond to 51 bp and 26745 bp, respectively. These values were then used 
as input to the STAR alignment software, as shown in Table 59. The output of 
the mapping process is provided in SAM file format, with read pairs from two 
FASTQ files generating a single SAM file due to the paired-end alignment mode. 
5.3.10.5 Generation of Sorted BAM and BAI Files 
The open-source software SAMtools (v. 1.9) was used to convert SAM files into 
sorted BAM files (Li et al., 2009). Indexing of BAM files, which generates BAI 
files, was performed simultaneously, as shown in Table 62. 
Table 62 Generation of Sorted BAM and BAI Files 
#!/usr/bin/bash 
## Generate sorted BAM files from SAM files 
$SAMTOOLS sort -@ $CPUS -o <BAM_file_name>.bam \ 
<SAM_file_name>.sam 
## Generate BAI files by indexing sorted BAM files 
$SAMTOOLS index -@ $CPUS <BAM_file_name>.bam 
## Variable definitions 




# $CPUS     = number of CPU cores (24) 
exit 
 
5.3.10.6 Investigating Alignment Statistics 
Alignment statistics were retrieved from STAR LOG files, which are automatically 
generated by the STAR alignment software upon completion of the alignment 
process (Dobin and Gingeras, 2015).  
5.3.10.7 Visualising Genomic Alignments 
The Integrative Genomics Viewer (IGV) was used to visualise RNA-seq 
alignments (Robinson et al., 2011). BAM and BAI files were used as input files 
for this visualisation (Paragraph 5.3.10.5). Screenshots of IGV alignments were 
taken to generate figures in this chapter. 
5.3.10.8 Gene Expression Quantification 
BAM files containing RNA-seq alignment information for each sample (Paragraph 
5.3.10.5) were loaded into R, alongside gene structure information in GTF file 
format (Paragraph 5.3.10.4). The GTF file was then used to generate a 
GRangesList object, which is a data class that stores every gene listed in the 
GTF file as a separate GRanges object, containing gene-specific exon information 
(Lawrence et al., 2013). Hence, the GRangesList object can be thought of as a 
“list of exons grouped by gene” (Love et al., 2016). To quantify gene expression, 
the summarizeOverlaps function was used, as shown in Table 63 (Lawrence et 
al., 2013). 
Table 63 Quantification of Gene Expression 
## Quantify gene expression 
## Explanation for the preprocess.reads argument can be found 
## on https://support.bioconductor.org/p/65844/ 
se <- summarizeOverlaps(features = ebg, reads = bamfiles, 
                        mode = "Union", 
                        singleEnd = FALSE, 




                        fragments = TRUE, 
                        preprocess.reads = invertStrand) 
## Variable definitions 
# ebg      = “exons-by-gene” GRangesList object containing  
             a list of all exons grouped by genes – generated 
             based on the BDGP6 GTF file 
# bamfiles = a list containing all BAM files generated from                             
#            RNA-seq alignment                
 
The arguments used in the call to summarizeOverlaps (Table 63) specify that 
the RNA-seq alignment data derive from paired-end sequencing (singleEnd = 
FALSE), that the data are strand-specific (ignore.strand = FALSE and 
preprocess.reads = invertStrand), and that single reads without a mapped 
mate should be counted rather than discarded (fragments = TRUE). 
Algorithmically, this function identifies and counts overlaps between the RNA-seq 
alignments (stored in BAM files) and exons in the Drosophila melanogaster 
reference genome (stored in the GTF file), resulting in a matrix of sample-specific 
fragment counts per gene (se in Table 63) (Obenchain, 2016). Importantly, the 
measure of “fragment counts per gene” indicates that paired reads are quantified 
as single units for this analysis, rather than being counted separately. Moreover, 
each fragment is only counted once, even if it overlaps multiple exons of the same 
gene, and any fragment overlapping exons from multiple genes is discarded 
(Obenchain, 2016). 
5.3.10.9 Computing Euclidean Distances Between cDNA Libraries 
Gene counts stored within the DESeqDataSet R object class were transformed 
using the regularised logarithm (rlog) (Love et al., 2014), and the Euclidean 
distances between cDNA libraries calculated based on entire gene expression 
profiles using the dist function. The Euclidean distance calculation is shown for 




Table 64 Euclidean Distance Calculation 




𝑑 = 𝐸𝑢𝑐𝑙𝑖𝑑𝑒𝑎𝑛	𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 
𝑆3 = 𝑠𝑎𝑚𝑝𝑙𝑒	1 
𝑆1 = 𝑠𝑎𝑚𝑝𝑙𝑒	2 
𝑆3B = 𝑐𝑜𝑢𝑛𝑡𝑠	𝑜𝑓	𝑔𝑒𝑛𝑒	𝑖	𝑖𝑛	𝑠𝑎𝑚𝑝𝑙𝑒	1 
𝑆1B = 𝑐𝑜𝑢𝑛𝑡𝑠	𝑜𝑓	𝑔𝑒𝑛𝑒	𝑖	𝑖𝑛	𝑠𝑎𝑚𝑝𝑙𝑒	2 
𝑛 = 𝑡𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑔𝑒𝑛𝑒𝑠 
 
5.3.10.10 Generating Heatmaps 
All heatmaps in this chapter were generated using the pheatmap R package 
(https://cran.r-project.org/web/packages/pheatmap/index.html). The function call 
to generate heatmaps automatically performs agglomerative hierarchical sample 
clustering and visualises clustering results as dendrograms.  
5.3.10.11 Principal Component Analysis 
Principle component analysis (PCA) was performed using the plotPCA function 
in R, which performs standard PCA analysis and outputs the first and second 
principal components, including their percentage-variation.  
5.3.10.12 Differential Gene Expression Analysis 
The DESeq2 R package was used to analyse differential gene expression (DGE), 
performed via the DESeq function as shown in Table 65 (Love et al., 2014). 
Table 65 Differential Gene Expression Analysis 
## Perform DGE analysis based on gene expression data 
DE <- DESeq(dds) 
## Variable definitions 
# dds = data object containing gene count information 
 
The DESeq2 package is described in (Love et al., 2014). Briefly, DESeq first 




of sample-specific gene counts to average gene counts across samples. This is 
done for all genes. Next, the median of this ratio is taken for each sample, and 
the results converted into a normal number, generating sample-specific scaling 
factors – a process known as “median-of-ratios” (Love et al., 2014). All gene 
counts are then divided by these sample-specific scaling factors, resulting in 
normalised counts. DESeq then estimates the dispersion of gene counts and 
builds a generalised linear model (GLM) for the expression of each gene. Log2-
fold-changes (LFCs) between genotypes are then estimated and a Wald test 
performed on these estimates. The resulting Wald test p-values are corrected for 
multiple comparisons by performing the Benjamini-Hochberg-adjustment (BH-
adjustment), using independent filtering of genes to increase sensitivity (Love et 
al., 2014).  
5.3.10.13 MA- and Volcano Plots 
MA plots were generated in R using the plotMA function (Love et al., 2014). 
Volcano plots were generated in R using the EnhancedVolcano package 
(https://github.com/kevinblighe/EnhancedVolcano). 
5.3.10.14 Gene Ontology Analysis 
Gene ontology (GO) analysis was performed using DAVID (Huang et al., 2009). 
The complete list of 1036 DEGs was used as input to DAVID (v. 6.8), which 
applies a modified Fisher’s Exact test in order to identify functional enrichment of 
GO terms compared to the Drosophila melanogaster reference genome. GO 
enrichments were retrieved at a cut-off p-value of 0.1. All p-values were then 
subjected to the BH correction to yield false discovery rates (FDRs).  
5.3.10.15 KEGG Pathway Analysis 
KEGG pathway analysis was performed with DAVID as described in Paragraph 
5.3.10.14, using the KEGG PATHWAY database to identify functional enrichment 
(Kanehisa et al., 2017). 
5.3.10.16 Visualisation of Gene Ontology and Pathway Analyses 
GO and KEGG Pathway analyses were visualised in R using the GOPlot package 
(https://wencke.github.io/), following a protocol that I briefly describe below, and 




package is the circ function, which links DGE data (Paragraph 5.3.10.12) and 
GO or KEGG pathway data (Paragraphs 5.3.10.14 and 5.3.10.15) into a single 
data object containing information on gene identity, DGE, and functional 
annotation. The object also contains a z-score, which is calculated as shown in 
Table 66. Importantly, z-scores are annotation-specific, so each functional 
annotation term is attributed its own z-score. This data object was fed into 
GOBubble, a customised function for the generation of bubble plots. 





𝑢𝑝 = 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑔𝑒𝑛𝑒𝑠	𝑢𝑝𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑒𝑑	𝑖𝑛	𝐺𝐸𝑃𝐷 
𝑑𝑜𝑤𝑛 = 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑔𝑒𝑛𝑒𝑠	𝑑𝑜𝑤𝑛𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑒𝑑	𝑖𝑛	𝐺𝐸𝑃𝐷 
𝑐𝑜𝑢𝑛𝑡 = 𝑡𝑜𝑡𝑎𝑙	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑔𝑒𝑛𝑒𝑠 
 
Multi-dimensional string plots were also generated with the GOPlot package. 
First, all DEGs associated with a subset of enriched functional annotations were 
retrieved. Using the chord_data function, a novel data object was generated that 
combines gene- and associated LFC information in a binary matrix, indicating 
whether a gene is (“1”) or is not (“0”) associated with a given functional 
annotation. This data object was used as input to GOChord, a customised function 
for the generation string plots. 
5.3.10.17 iRegulon Analysis 
iRegulon is a Cytoscape plugin (https://cytoscape.org/, v. 2.8.3) available at 
http://iregulon.aertslab.org/index.html (Janky et al., 2014). To identify gene 
regulatory networks (GRNs) and associated TFs, a list of DEGs was loaded into 
Cytoscape, before the iRegulon plugin was used to apply motif enrichment 
analysis to the data. To predict regulators and targets, the default parameters for 
Drosophila melanogaster were used: a motif collection of 9713 position-weight 
matrices (PWMs) and a normalised enrichment score (NES) threshold of 2.5. 




5.3.11 Adult Fly Behavioural Tracking 
To track adult locomotion, the DAM system was used, as described in Paragraph 
4.3.5. 
5.3.12 Behavioural Tracking Analysis 
Adult fly behavioural tracking analysis was performed as described in Paragraph 
4.3.6. Total beam breaks were normalised to the median number of beam breaks 
exhibited by the relevant genetic background, sloE366G/+ or sloloxP/+. Hence, the 
resulting values indicate fold-changes of beam breaks compared to the relevant 
genetic background.  
5.3.13 Data Visualisation 
Data generated as part of the RNA-seq analysis pipeline were visualised as 
described in Paragraph 5.3.10. Figures for behavioural data were generated as 
described in Paragraph 3.3.19, with boxplots drawn according to Tukey. 
5.3.14 Statistics 
Statistical methods underlying RNA-seq data analysis are described in 
Paragraph 5.3.10. DAM behavioural data were analysed by performing Mann-
Whitney-Wilcoxon tests between two groups. To account for multiple 
















5.4.1 RNA Preparation from Adult Drosophila Head Tissue 
In order to obtain a global overview of how the sloE366G allele impacts a variety of 
molecular pathways, I compared the transcriptomes of sloE366G/+ and sloloxP/+ 
flies via RNA-seq. The analysis of DGE might implicate specific cellular pathways 
involved in the pathogenesis of GEPD, providing an entry point into the 
understanding of GEPD pathophysiology. The first step of any RNA-seq protocol 
is the extraction of high-quality RNA from the tissue of interest (Wang et al., 
2009). I extracted total RNA from Drosophila head tissue, because the spatial 
dissection data in Chapter 4 provided strong evidence suggesting that the brain 
is the pathogenic locus of the sloE366G/+ locomotor defect. However, due to the 
broad expression pattern of BK channels (Bailey et al., 2019) (Paragraph 1.4.2), 
it is possible that extra-cerebral tissues are involved in GEPD pathogenesis as 
well. In addition to the brain, the head capsule contains tissues such as the 
pericerebral fat body. Hence, isolating whole heads represents a trade-off 
between enriching for neuronal changes in gene expression and maintaining 
sensitivity for gene expression changes outside the brain. 
Total RNA from sloE366G/+ and sloloxP/+ adult fly heads was extracted from 
12 samples per genotype, each sample consisting of 16-20 individual heads. 
RNA extractions were performed in two independent batches on two separate 
days, each batch consisting of 6 sloE366G/+ and 6 sloloxP/+ samples, and all 
samples were treated with DNase, in order to prevent DNA contamination. A 
major determinant of RNA-seq data quality is RNA integrity, as degraded RNA 
leads to various biases, such as a 3’ bias for the sequencing of mRNA (Kukurba 
and Montgomery, 2015). I measured RNA integrity using a Bioanalyzer, which 
employs on-chip gel electrophoresis to separate total RNA fragments based on 
size (Kukurba and Montgomery, 2015). The quality of total RNA is inferred from 
the quality of the 28S and 18S rRNAs, which present as sharp and distinct 
electrophoretic peaks at ~5 kb and ~2 kb in mammals, respectively. Based on 
these two peaks as well as other electrophoretic features, a trained artificial 
neural network has been developed to classify RNA integrity into 10 separate 




RNA Integrity Number (RIN) (Imbeaud et al., 2005). However, the 28S rRNA of 
insects has been shown to be thermolabile due to a “hidden break” in the 
molecule, which connects two similarly sized rRNA subunits via hydrogen bonds 
that readily break in response to increased temperature (Winnebeck et al., 2010). 
As a result, the rRNA profile in Drosophila is markedly different from the one 
observed in mammals: the individual 28S rRNA fragments (28Sa and 28Sb) 
migrate closely with the 18S rRNA fragment, resulting in electrophoretic peaks at 
~2 kb (18S and 28Sb superimposed) and at ~1.7 kb (28Sa) (Long and Dawid, 
1980; Winnebeck et al., 2010). This difference in rRNA composition renders 
Drosophila total RNA incompatible with the RIN algorithm described above. 
Instead, Drosophilists have to manually appraise total RNA integrity based on the 
sharpness of three peaks: the two peaks at ~2 kb and ~1.7 kb described above 
and an additional peak at ~120 bp, which corresponds to the 5.8S rRNA (Pavlakis 
et al., 1979). Indeed, Figure 5.1 shows that the 24 total RNA samples I extracted 
from sloE366G/+ and sloloxP/+ adult head tissue were of high quality, indicating the 
presence of all three peaks. Of note, whilst a shift towards increased fragment 
sizes can be observed for all samples, the consistency of this shift across the 
three rRNA peaks suggests an experimental artifact of either slowly running 
samples or a fast-running ladder. Hence, these 24 total RNA samples were 
considered to be of high enough quality to proceed to the next stage of the RNA-






Figure 5.1 Quality Control of Total RNA 
24 total RNA samples extracted from sloE366G/+ and sloloxP/+ adult fly heads were 
run on a Bioanalyzer. The first batch of total RNA samples is shown in A and B, 
the second batch in C and D. A and C show the resulting data as gel-like images, 
B and D as electropherograms. Three sharp peaks can be observed for all 
samples at 200-300 bp (5.8S rRNA), ~3.5 kb (28Sa rRNA), and ~4 kb (18S rRNA 
and 28Sb rRNA superimposed). These peaks are normally expected at ~120 bp, 
~1.7 kb, and ~2 kb, respectively, but the consistency of the size shift suggests 
either slowly running samples or a fast-running ladder. A 25-bp peak indicates 
the marker. This figure was generated from screenshots of the Bioanalyzer 
results. 
 
5.4.2 cDNA Library Preparation  
RNA-seq is usually performed by sequencing cDNA, and multiple steps have to 
be taken in order to prepare cDNA libraries from total RNA samples for 
sequencing (Kukurba and Montgomery, 2015). I generated cDNA libraries from 




two independent batches on two separate days, with each batch consisting of 6 
sloE366G/+ and 6 sloloxP/+ samples. cDNA library preparation was performed using 
the KAPA mRNA HyperPrep Kit (KAPA Biosystems Inc., KK8580), which is 
optimised for the generation of cDNA libraries from mRNA. An mRNA-specific 
RNA-seq protocol was chosen because investigating DGE of protein-coding 
genes increases the probability of identifying molecular pathways perturbed in 
sloE366G/+. It should be noted, however, that this experimental design precludes 
the analysis of other potential mediators of GEPD pathology, such as ncRNAs 
and miRNAs.  
The main steps of the cDNA library preparation protocol are illustrated in 
Figure 5.2. First, mRNA was captured from total RNA via oligo-dT beads, which 
bind to the 3’ poly-A tail of mRNA. Captured mRNA was fragmented in the 
presence of heat and Mg2+, in order to render the cDNA libraries size-compatible 
with short-read sequencing platforms (Kukurba and Montgomery, 2015). 
Fragmented mRNA was reverse-transcribed to yield a cDNA:RNA hybrid, which 
was converted into dscDNA via second-strand synthesis, incorporating dUTP into 
the newly synthesised cDNA strand. A-tailing of the dscDNA 3’ ends was 
performed in order to facilitate the subsequent ligation to the 3’ poly-T tails of 
adapters. Adapters are DNA oligomers that (1) are required for the adhesion of 
the cDNA library fragments to the flow cell lane of the sequencing platform, and 
(2) carry DNA sequences (known as “indices”) that allow for multiplexed 
sequencing (Kukurba and Montgomery, 2015) – unique adapters were ligated to 
each of the 24 samples. Finally, the cDNA fragments were PCR-amplified in a 
strand-specific manner because the dUTP-containing cDNA strand serves as an 
inefficient template for the DNA polymerase used in this protocol (Hrdlickova et 
al., 2017). As shown in Figure 5.2, the resulting cDNA libraries are strand-







Figure 5.2 cDNA Library Preparation 
Total RNA from Drosophila head tissue, having passed quality control (QC), was 
used as input material for the KAPA mRNA HyperPrep Kit, in order to generate 
mRNA-specific stranded cDNA libraries. First, oligo-dT beads capture mRNA 
poly-A tails, excluding other RNA species. mRNA is then fragmented and 
reverse-transcribed (RT), yielding a cDNA:RNA hybrid. Second-strand synthesis 
(SSS) is performed on the cDNA strand (cDNA1) to yield dscDNA. This step 
incorporates dUTP (U) into the newly formed cDNA strand (cDNA2), which 
prevents it from being PCR-amplified at the next step. This specific amplification 
of only one cDNA strand (cDNA1) generates strand-specific cDNA libraries, with 
all cDNA fragments being antisense (-) to the original mRNA fragments – 
illustrated by cyan and red colours, respectively. The dotted cyan line indicates 
the complementary cDNA strand to cDNA1 (cDNA1’). A-tailing during SSS and 
adapter ligation before PCR amplification are not shown for simplicity 
(Paragraph 5.4.2). QC of cDNA libraries is performed prior to RNA-seq.  
 
From a total of 24 cDNA libraries, 20 were subjected to quality control using a 
Bioanalyzer, as described in Paragraph 5.4.1. 4 cDNA libraries were excluded 
prior to quality control, due to low concentrations upon library generation. Figure 
5.3 shows that 18 cDNA libraries exhibit an even cDNA fragment size distribution 
around a mean of ~300 bp. These 18 cDNA libraries were used for RNA-seq. The 
other 2 cDNA libraries (hollow circles in the electropherograms of Figure 5.3) 




distributions were skewed towards larger values, suggesting problems during the 
mRNA fragmentation step (Figure 5.2). 
 
 
Figure 5.3 Quality Control of cDNA Libraries 
20 cDNA libraries prepared from total RNA extracted from sloE366G/+ and sloloxP/+ 
adult fly heads were run a Bioanalyzer. The first batch of cDNA libraries is shown 
in A and B (samples 1-8), the second batch in A and B (samples 9-11) and in C 
and D. A and C show the resulting data as gel-like images, B and D as 
electropherograms. 18 cDNA libraries (filled circles in B and D) show an even 
cDNA fragment size distribution around a mean of ~300 bp. These samples 
passed the quality control. Samples 4 and 6 in B (hollow circles) were not used 
for RNA-seq, due to different size distributions of cDNA fragments. A 35-bp peak 
indicates the lower marker, a 10380 bp peak the upper marker. This figure was 
generated from screenshots of the Bioanalyzer results. 
 
To allow for an even sequencing depth across samples, equal amounts of the 18 




subsequently run on a Bioanalyzer, confirming high sample quality (Figure 5.4). 
The primer-dimers detected in this sample (Figure 5.4) will not affect sequencing 
quality, as these molecules lack the adapter sequences required to attach to the 
flow cell. Altogether, the pooled cDNA libraries passed the final quality control 
step and were used for the next step of the RNA-seq protocol: RNA-sequencing.  
 
 
Figure 5.4 Quality Control of Pooled cDNA Libraries 
The 18 cDNA libraries that passed quality control (Figure 5.3) were pooled and run 
on a Bioanalyzer as two replicates. A shows gel-like images of the samples, while 
B and C show their electropherograms, illustrating an even size distribution around 
a mean of ~300 bp. A 35-bp peak indicates the lower marker, a 10380 bp peak the 
upper marker. The two additional peaks close to the lower marker (40-50 bp) are 
likely primer-dimers. I prepared and pooled the cDNA libraries shown in this figure, 
while Deborah Hughes performed the Bioanalyzer run. This figure was generated 
from screenshots of the Bioanalyzer results. 
 
5.4.3 RNA-seq of cDNA Libraries 
The 18 pooled cDNA libraries, having passed quality control (Figure 5.4), were 




“sequencing-by-synthesis” approach – the cyclic reversible termination (CRT) 
method – to sequence cluster-amplified clones of individual cDNA fragments 
(Kukurba and Montgomery, 2015; Metzker, 2010). The 18 cDNA libraries were 
multiplexed for sequencing on a single flow cell lane. Paired-end sequencing was 
performed, producing two reads of 75 bp each for every cDNA fragment 
sequenced (Read1 and Read2). As shown in Figure 5.2, Read1 will generate the 
antisense (-) sequence of the original mRNA molecule, while Read2 will generate 
the sense (+) sequence. During the sequencing process, sequencing- and quality 
information for each base call is stored in BCL file format. For downstream 
analyses, these data need to be converted into FASTQ file format, which stores 
similar information about base call identity and quality, but organises it on a per-
read- rather than per-cycle basis. Moreover, the sequencing data need to be de-
multiplexed based on adapter-contained index sequences that are unique for 
each sample (Paragraph 5.4.2), in order to obtain sample-specific gene 
expression data. File conversion and de-multiplexing produced two FASTQ files 
per sample: one for Read1 and one for Read2. Hence, 36 FASTQ files were 
generated for the 18 cDNA libraries. 
5.4.4 Quality Control of RNA-seq Data 
Prior to DGE analysis, I performed quality control of the FASTQ data via the open-
source software FASTQC (Conesa et al., 2016), focussing on two questions: (1) 
what is the overall sequence quality? (2) Are there any over-represented 
sequences in the data that cannot be explained by the experimental design 
(Kukurba and Montgomery, 2015)? Question (1) addresses problems that might 
occur during the sequencing run itself. In particular, for paired-end sequencing 
on Illumina short-read sequencing platforms, three important observations have 
been made: (a) the read-quality drops towards the 3’ end of a read, (b) the quality 
of Read2 is significantly lower compared to Read1, and (c) Read2 sequence 
quality shows great variability between samples of the same sequencing run (Tan 
et al., 2019). Phasing errors have been suggested to underly (a) and (b), while 
(c) describes a phenomenon that has been attributed to the fragment size 
distribution of cDNA libraries (Tan et al., 2019). Hence, it is crucial to confirm that 




entire reads, both for Read1 and Read2, before analysing these data – low-
quality sequencing reads might need to be trimmed prior to analysis (Kukurba 
and Montgomery, 2015). The FASTQC results for one representative cDNA 
library (18_GEPD1) illustrate that the overall read quality for all 18 cDNA libraries 
was high (Figure 5.5). The lowest mean base quality score, present at the 5’ and 
3’ ends of Read2, is still around 30, which translates into a probability of ~0.1% 
that the base call at this position is incorrect.  
 
 
Figure 5.5 Sequence Quality of cDNA Libraries 
FASTQ data quality control was performed using FASTQC for each of the 18 
cDNA libraries, illustrated in this figure by one representative example 
(18_GEPD1). A shows the base qualities for Read1, B for Read2. The per-base 
quality scores (y-axis) for the 75-bp reads (x-axis) are shown on the left. The 
boxplots represent the median quality scores as red lines, the first-to-third 
quartile ranges as yellow boxes, and the ranges from 10% to 90% as whiskers. 
The mean quality scores are indicated by a blue line. Per-base quality scores 
are high, with ~30 being the lowest mean quality score. The formula underlying 
the base quality score is shown as an inset in A. The graphs on the right show 
the per-sequence quality scores for entire 75-bp reads. The mean quality score 
for most Read1 reads is 40 (A), while for Read2 reads it is 39 (B). This figure 





Observations (a) and (b) described above are confirmed in Figure 5.5: the base 
quality scores decrease towards the 3’ end of both reads, and Read2 is of lower 
quality than Read1. However, the overall per-base sequence quality is 
considered to be high enough for downstream analyses without pre-processing.  
Importantly, FASTQC did not identify over-represented sequences in the data, 
defined as individual sequences that make up more than 0.1% of all sequences 
present in a sample. This finding illustrates the absence of rRNA and other 
contaminating sequences (Delhomme et al., 2014), confirming that poly-A 
selection during cDNA library preparation was successful (Figure 5.2). Of note, 
FASTQC did report that the base content along the sequencing reads is biased, 
both for Read1 and Read2. As Figure 5.6 illustrates, Read1 shows a consistent 
bias towards thymine, Read2 towards adenine. However, this is consistent with 
the nature of the cDNA libraries, which are prepared from poly-A-selected mRNA. 
Indeed, the specific bias towards thymine in Read1 and adenine in Read2 
illustrates that the cDNA libraries consist of cDNA that is antisense (-) to the 
original mRNA molecules. 
 
 
Figure 5.6 Per-base Sequence Bias in cDNA Libraries 
FASTQC reported a per-base sequence bias for Read1 (A) and Read2 (B), as 
illustrated in this figure based on one representative cDNA library (18_GEPD1). 
The graphs in A and B plot the percentage base content (y-axis) over read length 
(x-axis) for Read1 and Read2, respectively. The bias towards thymine in Read1 
(A) and adenine in Read2 (B) is consistent with the nature of the cDNA libraries, 
which were prepared from poly-A-selected mRNA. This figure was generated 
from screenshots of the FASTQC results. 
 
Of note, the erratic nature of the graphs in Figure 5.6 for the first 12 bases is 
characteristic of Illumina RNA-seq data, and has been proposed to be due to 




Altogether, quality control of the FASTQ files did not indicate any problems with 
the data that would require pre-processing. 
5.4.5 Genomic Alignment of RNA-seq Reads 
Throughout this chapter, I followed a workflow available on Bioconductor to 
perform DGE analysis on the RNA-seq data, which is available at 
https://www.bioconductor.org/packages/devel/workflows/vignettes/rnaseqGene/i
nst/doc/rnaseqGene.html. The corresponding publication is (Love et al., 2016). 
Bioconductor is an open-source, R-based software environment that provides 
extensive computing resources to analyse high-throughput biological data 
(Gentleman et al., 2004; Huber et al., 2015). Figure 5.7 shows a schematic of the 
RNA-seq data analysis pipeline I employed, illustrating that the step following 
FASTQ quality control is the alignment of RNA-seq reads to the Drosophila 






Figure 5.7 RNA-seq Data Analysis Pipeline 
This schematic illustrates the RNA-seq data analysis pipeline, with methods 
employed shown in grey, and the resulting data shown in black. First, cDNA 
libraries were sequenced on an Illumina HiSeq 3000 short-read sequencing 
platform in paired-end mode, and quality control of the resulting FASTQ data 
performed via FASTQC. Sequencing reads were then aligned to the BDGP6 
Drosophila melanogaster reference genome using the STAR aligner, producing 
SAM files. SAM files were converted to sorted BAM files, whose index 
information is stored in BAI files, allowing alignment data to be visualised using 
IGV. Alignment quality information was retrieved via STAR LOG files. DGE 
analysis was performed using DESeq2. The resulting list of DEGs was used for 
GO analysis with DAVID and GRN analysis with iRegulon. Results of these 
analyses were combined with manual inspection to yield a list of candidate 
modifier genes of the sloE366G/+ locomotor defect. References for the methods 
used are provided in the main text. 
 
Read alignment was performed using the STAR alignment tool (Dobin et al., 
2013). The mapping algorithm underlying STAR aligns non-contiguous reads to 
the reference genome via a Maximal Mappable Prefix (MMP) approach, which 




pre-empt confusion, some terminology needs to be clarified at this stage: while 
STAR aligns individual RNA-seq reads to the reference genome, it treats both 
reads of the same read pair (Read1 and Read2) as a single “fragment”, since 
both reads derive from the same cDNA library molecule (Dobin and Gingeras, 
2015). Hence, the term “fragment” is used to refer to paired-end reads, while the 
term “read” is used to refer to individual reads (Dobin and Gingeras, 2015). 
Aligning the FASTQ data of the 18 cDNA libraries to the BDGP6 Drosophila 
melanogaster reference genome yielded 18 files in SAM format, which were 
converted to sorted BAM files and indexed using the open-source software 
SAMtools (Li et al., 2009). BAM and SAM files contain equivalent information, but 
the former stores it in a compressed binary formant, which requires less computer 
memory. Upon alignment, it is of interest to retrieve information about the 
alignment process as a means of quality control. The STAR alignment software 
automatically generates LOG files, which contain various alignment statistics, two 
of which are listed in Table 67: (1) the percentage of fragments that uniquely 
mapped to the reference genome and (2) the total number of uniquely mapped 
fragments per sample. The former informs about alignment quality, while the 
latter serves as a measure of future experimental sensitivity (Conesa et al., 2016). 
The prefixes “17_” and “18_” in Table 67 identify the two different batches of 
cDNA libraries, generated on the 17th and 18th of December 2017, respectively. 
Table 67 RNA-seq Alignment Statistics 
Sample Uniquely Mapped Fragments / % # Mapped Fragments 
17_GEPD1 92.47 14380590 
17_GEPD2 91.58 14874699 
17_GEPD5 93.20 17705943 
17_loxP1 93.09 18386802 
17_loxP3 92.74 15438189 
17_loxP6 93.45 17989924 
18_GEPD1 92.70 19985141 
18_GEPD2 92.62 17149622 




18_GEPD4 92.90 18966126 
18_GEPD5 93.22 17622781 
18_GEPD6 92.73 18389412 
18_loxP1 93.16 18192140 
18_loxP2 93.62 19201277 
18_loxP3 93.03 16966936 
18_loxP4 93.03 16711160 
18_loxP5 92.99 18776976 
18_loxP6 92.72 16252085 
 
The percentages of uniquely mapped fragments shown in Table 67 are 
consistently above 90%, suggesting that both cDNA library quality and RNA-seq 
read alignment quality are high (Dobin and Gingeras, 2015). To visualise the 
RNA-seq alignments, the open-source software IGV was used (Robinson et al., 
2011). Investigating read alignments at the slo locus showed that reads clustered 
within exons, as expected for mRNA-specific RNA-seq data (Figure 5.8). The 
exonic sequencing depth at exon 10 of slo, which harbours the E366 locus 
mutated in sloE366G, was ~200 reads per base. Importantly, Figure 5.8 illustrates 
that both slo alleles are transcribed to similar degrees in sloE366G/+, with 54% 
(112/206) of reads carrying the wild-type GAG codon (glutamic acid) and 46% 
(94/206) carrying the mutant GGG codon (glycine). Hence, there does not seem 







Figure 5.8 Visualising RNA-seq Alignments at the slo Locus 
IGV was used to visualise RNA-seq read alignment at the slo locus, represented 
by one sloE366G/+ (18_GEPD1) and one sloloxP/+ (18_loxP1) sample. The top 
panel shows read alignments around exon 10, which harbours the E366 locus. 
Red and blue colours indicate forward (Read2) and reverse (Read1) reads, 
respectively. Reads are clustered within exons, as expected from mRNA-specific 
sequencing. Exon 10 is magnified in the bottom panel. While grey bars above 
the read alignments indicate wild-type bases, the brown/green-coloured bar in 
sloE366G/+ represents the GEPD-linked A>G transition. A further level of 
magnification focusses on the amino acid E366, shown vertically on the right. 
The height of the vertical bars above the read alignments indicates sequencing 
depth, illustrating that transcription of the mutant (guanine, brown) and wild-type 
(adenine, green) alleles seems indiscriminate: 112 reads carry adenine (54%), 






5.4.6 Differential Gene Expression Analysis 
As shown in Figure 5.7, the step following alignment visualisation is the 
quantification of gene expression and a concomitant analysis of DGE between 
sloE366G/+ and sloloxP/+. This task was performed as a continuation of the 
Bioconductor workflow introduced in Paragraph 5.4.5 (Love et al., 2016). The 
BAM files generated as described in Paragraph 5.4.5 were loaded into R, along 
with a GTF file that stores annotated gene structure information about the BDGP6 
Drosophila melanogaster reference genome. The R package 
GenomicAlignments was used to count the number aligned RNA-seq fragments 
(stored in BAM files) that overlap exons of the BDGP6 Drosophila melanogaster 
reference genome (stored in the GTF file), resulting in a matrix containing the 
number of fragment counts per gene for each sample, referred to as a “count 
matrix” (Love et al., 2016; Obenchain, 2016). To provide an illustration of the 
count matrix, a screenshot from within R is provided in Figure 5.9. Of note, 
throughout this chapter, abbreviations for the genotypes sloE366G/+ and sloloxP/+ 
will be used: sloE366G/+ is often referred to as “GEPD”, while sloloxP/+ is often 
referred to as “loxP”. Another note on terminology: when describing DEGs 
throughout this chapter, up- and down-regulation always refer to the gene 
expression in sloE366G/+ relative to sloloxP/+, so that up-regulated genes are more 
strongly expressed in sloE366G/+ when compared to sloloxP/+, and down-regulated 
genes are more weakly expressed in sloE366G/+ when compared to sloloxP/+. 







Figure 5.9 Count Matrix for Differential Gene Expression Analysis 
This screenshot from within R illustrates the structure of the count matrix, which 
was obtained upon counting the number of aligned RNA-seq fragments that 
overlap exons of the BDGP6 Drosophila melanogaster reference genome. 
Genes are organised in rows, samples in columns. The numbers in the body of 
the matrix represent the fragment counts per gene (row) for each sample 
(column). Only the first 10 out of 17737 genes are shown for simplicity, and only 
the first 6 of the 18 samples. 
 
Having generated the count matrix as shown in Figure 5.9, the total number of 
fragments counted per sample across all genes was calculated. This parameter 
is of interest because it provides a comparison to Table 67, which lists the number 
of fragments aligned to the reference genome for each sample. Hence, 
comparing these numbers reveals how many aligned fragments were excluded 
from the DGE analysis. Such exclusion occurs due to a violation of the counting 
algorithm. For example, fragments aligning to overlapping exons from different 
genes are discarded (Obenchain, 2016). Table 68 indicates that a substantial 
number of fragments (> 1 million) was removed from each sample, as calculated 
by subtracting the total number of fragments counted (Table 68) from the total 
number of fragments aligned (Table 67). 
Table 68 Total Fragments Counted for RNA-seq Analysis 
Sample Total Fragment Counts Discarded Fragments 
17_GEPD1 13263469 1117121 
17_GEPD2 13786109 1088590 
17_GEPD5 16362239 1343704 
17_loxP1 16953133 1433669 
17_loxP3 14186909 1251280 
17_loxP6 16686004 1303920 




18_GEPD2 15915560 1234062 
18_GEPD3 15174939 1102475 
18_GEPD4 17619092 1347034 
18_GEPD5 16363097 1259684 
18_GEPD6 17051747 1337665 
18_loxP1 16918410 1273730 
18_loxP2 17983492 1217785 
18_loxP3 15732874 1234062 
18_loxP4 15586179 1124981 
18_loxP5 17642913 1134063 
18_loxP6 15181822 1070263 
 
While the count matrix contains one row per gene for all genes of the Drosophila 
melanogaster genome (Figure 5.9), some rows will contain zero counts across 
samples because some genes are not expressed in head tissue, or expressed at 
such low levels so as to escape experimental sensitivity. In fact, the gene 
FBgn0000022 (seventh row in Figure 5.9) is one such example. In order to reduce 
the object size of the count matrix and increase programming speed, the count 
matrix was filtered by removing all genes exhibiting less than 1 count across all 
18 samples (Love et al., 2016). Following this minimal filtering, which removed 
~13% of genes (2381/17737), I performed exploratory analysis of the count 
matrix data, in order to obtain general information about the cDNA libraries (Love 
et al., 2016).  
Some exploratory data analysis approaches, such as sample clustering, 
have been shown to work best on homoskedastic data – data with uniform 
variance across data points – because using heteroskedastic data results in 
highly variable data points dominating the results, while less variable data points 
contribute disproportionately little (Love et al., 2016). The variance of RNA-seq 
counts is greatest for highly expressed genes, enabling them to contribute more 
strongly to exploratory data analysis results than lowly expressed genes (Love et 
al., 2016). A simple logarithmic transformation of gene counts inverts this 




2016). As a possible solution to this problem, a log2-like transformation termed 
rlog has been developed (Love et al., 2014, 2016). This transformation yields 
similar results to the log2-transformation for high gene counts, while shrinking low 
gene counts towards a reference value, therefore stabilising the overall variance, 
rendering the count data homoskedastic, and allowing all genes to contribute 
equally to the results of exploratory data analyses (Love et al., 2014, 2016). 
Importantly, rlog-transformed data are only used for exploratory data analysis, 
not for statistical testing of DGE, for which raw counts are required, as described 
later in this chapter. In order to investigate the differences between cDNA 
libraries, I calculated the Euclidean distances between their rlog-transformed 
gene counts and visualised the resulting distance matrix as a heatmap (Figure 
5.10). Moreover, hierarchical clustering of the cDNA libraries was performed, and 
the resulting cluster agglomerations visualised with dendrograms connected to 
the heatmap – proximity within the dendrograms represents similarity between 
cDNA libraries (Figure 5.10). Splitting the heatmap into the two main horizontal 
and vertical clusters reveals that the cDNA libraries cluster based on genotype, 
an important confirmation of systematic differences in gene expression (Figure 
5.10). Interestingly, one of the sloE366G/+ samples, 18_GEPD2, appears to exhibit 
substantial differences to the other GEPD samples, rendering it a potential outlier 





Figure 5.10 Euclidean Distance Between cDNA Libraries 
The Euclidean distances between cDNA libraries were calculated and visualised 
as a heatmap. The legend on the right indicates that no difference between 
samples is represented by the darkest shade of blue, with increasingly lighter 
shades illustrating increasing differences. The results of hierarchical clustering 
are represented as dendrograms on the left and top – proximity within the 
dendrograms represents similarity between cDNA libraries. The heatmap was 
split into two horizontal and two vertical clusters, based on the hierarchical 
clustering results, illustrating that the samples cluster by genotype. Sample 
18_GEPD2 appears to be an outlier. 
 
Another approach to illustrate the relationships between samples is PCA, a 
method used to visualise the differences between multi-dimensional data objects 
in 2-dimensional space. Performing PCA on the cDNA libraries confirmed the 
results of Figure 5.10: cDNA libraries cluster by genotype into one sloE366G/+ 
cluster and one sloloxP/+ cluster (Figure 5.11). Notably, PCA also confirmed that 
sample 18_GEPD2 is an outlier, as it strongly segregated from both clusters – 
hence, it was removed from the ensuing DGE analysis. No batch effect could be 






Figure 5.11 Principle Component Analysis of cDNA Libraries  
PCA was performed on the 18 cDNA library samples and the results visualised 
with the first principal component on the x- (PC1) and the second principal 
component on the y-axis (PC2). The amount of variance each principal 
component accounts for is provided in the axis labels. Genotypes are colour-
coded, while the two batches (17 and 18) can be identified by shape. Two main 
clusters separate by genotype. Sample 18_GEPD2 appears to be an outlier and 
was removed from further analyses. No batch effect could be observed. 
 
After discarding sample 18_GEPD2, I performed DGE analysis between 
sloE366G/+ (8 cDNA libraries) and sloloxP/+ (9 cDNA libraries), using the R package 
DESeq2 (Love et al., 2014). This analysis was performed for each of the 15356 
genes that survived the low-count filtering described above. DESeq2 is 
mathematically complex, but conceptually, it operates in five steps, as described 
in more detail in (Love et al., 2014): (1) the count data are normalised based on 
library size – this is a different procedure from rlog-transformation, and it is 
important to stress that raw counts are used for DGE analysis, not rlog-
transformed counts. Normalisation of raw counts based on library size is 




counts, which could result in between-sample differences that are biologically 
meaningless. (2) DESeq2 estimates the dispersion for the expression of each 
gene, which is a measure of the variability of gene counts across samples. (3) 
GLMs are built to describe the gene expression data. (4) LFCs of gene 
expression between genotypes are estimated and a Wald test for significance 
performed on these LFCs. (5) Due to the high number of comparisons, multiple-
testing correction is performed by calculating BH-adjusted p-values, also known 
as FDRs, from the Wald test p-values (Love et al., 2014). The final result of this 
analysis is a matrix-like data object containing gene identifiers, mean levels of 
gene expression, LFCs between genotypes, and FDRs, amongst other 
parameters. A screenshot of this data object is shown in Figure 5.12. 
 
 
Figure 5.12 Differential Gene Expression Results Data Structure 
DESeq2 was used to perform DGE analysis between sloE366G/+ (8 cDNA 
libraries) and sloloxP/+ (9 cDNA libraries). A screenshot from within R showing 
the resulting matrix-like data object is shown in this figure. Row names denote 
FlyBase gene IDs, while columns contain mean gene expressions across 
samples (baseMean), LFCs between genotypes (log2FoldChange), standard 
errors associated with LFC estimates (lfcSE), Wald test statistics (stat), Wald 
test p-values (pvalue), and BH-adjusted p-values known as FDRs (padj). This 
data object has been sorted by decreasing LFC, showing the 10 most strongly 
DEGs at a significance level of FDR < 0.05. 
 
Using an FDR threshold of FDR < 0.05, 514 (3.3%) of the analysed genes were 
found to be significantly up-, and 522 (3.4%) genes to be significantly down-
regulated in sloE366G/+ compared to sloloxP/+. The whole list of 1036 DEGs is 
provided in Table 69. To visualise global patterns of DGE, MA plots are often 
used, which represent the LFC on the y-, and the mean gene expression on the 
x-axis (Dudoit et al., 2002). A complementary visualisation is the volcano plot, 
which plots the logarithmically transformed FDR on the y-, and the LFC on the x-





Figure 5.13 Global Gene Expression Patterns 
DGE results for 15356 genes are visualised as an MA plot (A) and a volcano 
plot (B), with each gene represented by a dot. (A) The MA plot indicates the LFC 
on the y-, and the mean gene expression on the x-axis. DEGs at FDR < 0.05 are 
coloured red. Triangles at the top and bottom indicate genes that lie outside the 
y-axis boundaries of the plot. (B) The volcano plot indicates the negative 
logarithm of the FDR on the y-, and the LFC on the x-axis. The colouring scheme 
illustrates genes that are not significantly (FDR >= 0.05) differentially expressed 
(grey, “NS”), genes that are significantly (FDR < 0.05) differentially expressed 
(blue, “FDR”), and genes that are significantly differentially expressed with an 
up- or downregulation of at least 2-fold (red, “LFC & FDR”). Green dots would 
indicate genes that show a non-significant up- or downregulation of at least 2-
fold, but none were present. Dashed lines in B represent FDR = 0.05 (horizontal) 
and LFC = +/- 1 (vertical). LFCs in both graphs represents the gene expression 
of sloE366G/+ relative to sloloxP/+.  
 
An observation that can be made from both plots in Figure 5.13 is that, within the 
set of significantly DEGs, high fold-changes are rare. Moreover, both plots 
illustrate that significantly DEGs are evenly split between up- and downregulation. 
In order to visualise the expression pattern of the 40 most significantly DEGs, I 
retrieved their rlog-transformed count data from the original count matrix (Figure 






Figure 5.14 Most Significant Gene Expression Pattern 
The expression pattern of the 40 most significantly DEGs is visualised as a 
heatmap. Each tile represents the expression level of one gene (row) per sample 
(column). Gene expression levels are indicated as the difference between 
sample-specific gene expression and mean gene expression across samples, 
as quantified by rlog-transformed counts. This measure gives an indication of 
how strongly sample-specific gene expression deviates from mean gene 
expression across samples. Positive numbers, represented by shades of red, 
indicate above-average gene expression, negative numbers, represented by 
shades of blue, below-average gene expression. Both genes and samples were 
hierarchically clustered, resulting in two main horizontal and three main vertical 
clusters, which are illustrated by cuts through the heatmap. Dendrograms 
visualise the clustering results. Samples naturally cluster by genotype, whereas 
no batch effect could be observed. 
 
The heatmap in Figure 5.14 illustrates that hierarchical clustering separates the 
17 cDNA libraries based on genotype without indicating the presence of a batch 
effect, which is congruent with Figure 5.10 and Figure 5.11. Three main clusters 
were established based on gene expression profiles, two of which contain genes 
down-regulated- (top and bottom clusters), a third one contains genes up-




volcano plots, and heatmaps provide a good overview over large data sets, with 
a total of 1036 DEGs, it is important to obtain a better functional understanding 
of the transcriptomic differences between sloE366G/+ and sloloxP/+.  
5.4.7 Functional Analysis of RNA-seq Data 
High-throughput data sets, such as the DGE data generated in Paragraph 5.4.6, 
harbour a wealth of latent information, and it is a major challenge to extract 
biological meaning from them (Huang et al., 2009). A common entry point is to 
perform GO analysis. The Gene Ontology project aims to classify genes 
systematically into three groups: (1) cellular component (CC), describing cellular 
location, (2) molecular function (MF), describing gene function on a molecular 
level, and (3) biological process (BP), describing higher-order functions a gene is 
involved in (The Gene Ontology Consortium, 2007). By performing GO analysis 
on the set of DEGs between sloE366G/+ and sloloxP/+, my aim was to identify 
biological themes that might be involved in GEPD pathogenesis, which could 
allow for the generation of testable hypotheses. In order to perform GO analysis, 
I used the open-source software DAVID (Huang et al., 2009), addressing the 
following question: does the set of 1036 DEGs contain any GO terms that are 
significantly enriched compared to the Drosophila melanogaster reference 
genome? Conceptually, DAVID operates by first annotating each of the 1036 
DEGs with GO terms (CC, MF, and BP), before statistically testing for functional 
enrichment against the Drosophila melanogaster reference genome via a 
modified Fisher’s Exact test (Huang et al., 2009). Upon completion of the GO 
analysis, I extracted the results from DAVID and loaded them into R, in order to 






Figure 5.15 Gene Ontology Analysis 
GO analysis was performed on the set of 1036 DEGs between sloE366G/+ and 
sloloxP/+. The enriched GO terms are visualised as a bubble plot, with each 
bubble representing a different colour-coded GO term (MF = molecular function; 
BP = biological process; CC = cellular component). The bubble size is 
proportional to the gene number contained within bubbles. The y-axis plots the 
negative logarithm of the FDR, with greater numbers indicating smaller FDRs 
and, hence, greater significance. The x-axis plots the z-score, which is a 
measure of whether the genes within a particular GO term are up- (positive 
values) or down-regulated (negative values) in sloE366G/+ compared to sloloxP/+. 
An orange line demarcates the FDR threshold of 0.05, above which GO terms 
are labelled. The major themes emerging are metabolism, oxidation-reduction, 
and immunity. 
 
The bubble plot in Figure 5.15 is multidimensional, providing simultaneous insight 
into GO term identity, significance of GO term enrichment, the number of genes 
contained within individual GO terms, and whether these genes are up- or down-
regulated in sloE366G/+ compared to sloloxP/+. Three biological themes stand out: 
metabolism, oxidation-reduction, and immunity, suggesting that these 
physiological processes could be involved in GEPD pathogenesis. In addition to 




KEGG PATHWAY database, which is of particular interest because it contains 
manually curated pathway information based on biochemical evidence (Kanehisa 
et al., 2017). Complementing the GO analysis, I used DAVID to test for enriched 
KEGG pathways within the set of 1036 DEGs. Figure 5.16 illustrates the results 
of this analysis as described for Figure 5.15. Interestingly, enriched KEGG 
pathways are almost exclusively metabolic in nature, supporting the hypothesis 
that metabolism is a biological theme affected in GEPD. However, caution must 
be applied, because the KEGG PATHWAY database is more thoroughly curated 
for, and therefore more sensitive towards the detection of, metabolic- over other 
biological pathways (Kanehisa et al., 2017). 
 
 
Figure 5.16 KEGG PATHWAY Analysis 
The KEGG PATHWAY database was used to analyse the 1036 DEGs between 
sloE366G/+ and sloloxP/+ for enriched KEGG pathway annotations, and the results 
are visualised as outlined for Figure 5.15. Most identified pathways are down-





Apart from strengthening the hypothesis that metabolism is a potential biological 
theme involved in GEPD pathogenesis, Figure 5.16 lists specific metabolic 
pathways affected in sloE366G/+, such as fatty acid- and amino acid metabolism. 
However, bubble plots lack resolution about the nature of individual genes 
affected in sloE366G/+. To gain such insight, I extracted the gene information from 
a set of metabolic KEGG PATHWAY annotations at FDR < 0.05 for visualisation 
in a multi-dimensional string plot that combines information about functional 





Figure 5.17 Metabolic Gene Relationships 
This string plot illustrates KEGG PATHWAY-gene expression relationships. The 
genes associated with five significantly enriched KEGG PATHWAY annotations 
(shown in the bottom legend) were extracted from the set of 1036 DEGs. These 
28 genes were sorted according to LFC, with genes up-regulated in sloE366G/+ 
represented by shades of red and genes down-regulated in sloE366G/+ 
represented by shades of blue, before being linked to KEGG pathways via 
coloured strings. 
 
Figure 5.17 provides novel insight into the differential regulation of metabolic 
pathways in sloE366G/+ and sloloxP/+. While Figure 5.16 suggested that most 
metabolic pathways are down-regulated in sloE366G/+, Figure 5.17 provides a 
more nuanced picture, in which every metabolic KEGG PATHWAY annotation 
contains both up- and down-regulated genes, suggesting a dys-, rather than 




interest to identify regulatory genes that have the potential to affect the 
transcriptional landscape to elicit such a dysregulation – a task I approached by 
using the open-source software iRegulon (Janky et al., 2014). iRegulon aims to 
identify GRNs, defined as sets of genes regulated by single TFs, within a list of 
DEGs (Janky et al., 2014). Conceptually, iRegulon operates in three steps, as 
described in more detail in (Janky et al., 2014): (1) using large databases of TF 
binding motifs, it first builds an associative database between cis-regulatory 
elements (CREs) and all genes in the Drosophila melanogaster reference 
genome, thereby establishing genomic co-localisations between genes and 
CREs. (2) The algorithm then analyses which CREs can recover the greatest 
proportion of genes from an input list of DEGs, thereby identifying CRE 
enrichment within the DGE data. (3) Finally, iRegulon identifies TFs that are 
predicted to bind to enriched CREs, thereby generating a list of “master 
regulators” that are capable of inducing large-scale transcriptional changes 
(Janky et al., 2014). 
For this analysis, I split the list of 1036 DEGs into one list of 514 up-, and 
a second list of 522 down-regulated genes. Both lists were analysed separately 
for TF binding site enrichment. Upon analysing the list of 514 up-regulated genes, 
the TF Foxo was predicted to bind to two separate groups of enriched TF binding 
motifs. Foxo is an interesting candidate because it is functionally implicated in 
metabolism, oxidation-reduction, and immunity (Becker et al., 2010; 
Eijkelenboom and Burgering, 2013), three major biological themes identified to 
be dysregulated in sloE366G/+ (Figure 5.15, Figure 5.16). Based on the iRegulon 
analysis, Foxo is predicted to bind to TF binding sites associated with ~47% of 






Figure 5.18 Foxo Gene Regulatory Network 
iRegulon was used to analyse all 514 differentially up-regulated genes in 
sloE366G/+ for enriched TF binding motifs. Enriched binding motifs were then 
linked to TFs that are predicted to bind to them. Foxo was identified as a TF that 
is predicted to bind to ~47% of differentially up-regulated genes (234/514), 
shown as a network diagram in this figure, with Foxo as a pink octagon at the 
centre. Grey dotted edges connect Foxo to the genes it regulates, illustrated as 
blue circles. The 514 up-regulated genes were enriched for two independent 
groups of Foxo TF binding motifs, and this network diagram represents both. 
Hence, some genes are innervated by two edges, indicating that these genes 
are associated with both motifs, while other genes are innervated by a single 
edge, indicating that these genes are associated with one of the two motifs. 
 
Further analysis showed that Foxo is not predicted to bind to the 522 down-
regulated genes, supporting the hypothesis that its activity might be increased in 
sloE366G/+. An interesting TF specifically linked to the down-regulated genes is 
CrebB. As for Foxo and the set of up-regulated genes, two separate groups of 




genes. CrebB was found to bind to ~46% of down-regulated genes (239/522), a 
value strinkingly similar to the one ascribed to Foxo and the up-regulated genes. 
The GRN associated with CrebB is shown in Figure 5.19.  
 
 
Figure 5.19 CrebB Gene Regulatory Network 
iRegulon analysis was performed as described in Figure 5.18, using all 522 
differentially down-regulated genes in sloE366G/+. CrebB was identified as a TF 
that is predicted to bind to ~46% of differentially down-regulated genes (239/522). 
The 522 down-regulated genes were enriched for two independent groups of TF 
binding motifs CrebB is predicted to bind, and this network diagram represents 
these interactions as described in Figure 5.18. 
 
Due to the identification of Foxo as a TF predicted to bind specifically to a subset 
of up-regulated genes, and CrebB as a TF predicted to bind specifically to a 
subset of down-regulated genes, one might expect their respective GRNs to 




particular, one would expect the Foxo-specific GRN to recover up-regulated GO 
terms and the CrebB-specific GRN to recover down-regulated GO terms. Indeed, 
this is exactly what I found: GO analysis with the Foxo- and CrebB-specific GRNs 
identified the GO terms “immune response” (GO:0006955) and “innate immune 
response” (GO:0045087) as significantly enriched in the Foxo-specific GRN 
(FDR = 0.0053 and FDR = 0.0069, respectively), and the GO terms “oxidation-
reduction process” (GO:0055114) and “neuropeptide signaling pathway” 
(GO:0007218) as significantly enriched in the CrebB-specific GRN (FDR = 0.014 
and FDR = 0.025, respectively). These data suggest that differential regulation of 
Foxo and CrebB in sloE366G/+ might elicit the metabolic-, redox-, and immune 
dysregulation observed in this fly model of GEPD. Hence, one might predict a 
modulation of Foxo and CrebB activity in sloE366G/+ to affect locomotor behaviour, 
the main phenotype associated with sloE366G/+ animals (Figure 3.4, Figure 3.17).  
5.4.8 RNA-seq-informed Behavioural Modifier Screen  
Foxo is activated by oxidative stress, inhibited by insulin signalling, and has been 
shown to induce the innate immune response via the expression of anti-microbial 
peptides (AMPs) (Becker et al., 2010; Eijkelenboom and Burgering, 2013). These 
functional implications are well aligned with the main GO annotations associated 
with the gene expression changes between sloE366G/+ and sloloxP/+: oxidation-
reduction, metabolism, and immunity (Figure 5.15). Intriguingly, manual curation 
of the DGE data revealed that four components of the insulin signalling pathway 
are differentially regulated between sloE366G/+ and sloloxP/+: the insulin-like 
peptides dilp6 and dilp2 are up- and down-regulated in sloE366G/+, respectively, 
while insulin receptor (InR) and its adapter chico are up-regulated in sloE366G/+. 
The differential expression of these genes and the prediction of their downstream 
target Foxo to bind to almost half of the up-regulated genes in sloE366G/+ suggest 
a role for insulin signalling in GEPD pathogenesis. I tested this hypothesis by 
performing an insulin-themed dominant modifier screen. Using locomotor activity 
as a readout, dominant suppressors of the sloE366G/+ locomotor defect are 
predicted to cause an increase in locomotion, while dominant enhancers should 




performed in a sloloxP/+ background. A schematic of insulin- and Foxo signalling 
in Drosophila is shown in Figure 5.20.  
 
 
Figure 5.20 Insulin- and Foxo Signalling in Drosophila 
The Drosophila genome encodes 8 Dilps via the genes dilp1-8, which bind to 
InR, inducing a signalling cascade involving Chico, PI3K, Akt, and the inhibition 
of the TF Foxo. Foxo activity is regulated by multiple upstream processes apart 
from insulin signalling, such as oxidative stress, which activates Foxo (ROS = 
reactive oxygen species). This figure was adapted from the following 
publications: (Eijkelenboom and Burgering, 2013; Garofalo, 2002; Nässel et al., 
2015). 
 
For this modifier screen, I tested alleles of the 8 dilps the Drosophila genome 
encodes (dilp1-8), different combinations of dilps simultaneously, two InR alleles, 
and alleles of chico, Akt, foxo, to, and ImpL2. Most of these alleles are reportedly 
hypo- or amorphic, as listed in Table 51. to and ImpL2 were included in this 
screen because both genes are down-regulated in sloE366G/+, while also being 
implicated in insulin signaling: ImpL2 has been shown to bind to secreted Dilps 
antagonistically (Figueroa-Clarevega and Bilder, 2015; Kwon et al., 2015), while 
To mediates downstream metabolic and behavioural effects of insulin signalling 
(Sheldon et al., 2011). The mutant alleles were crossed into sloE366G/+ and 
sloloxP/+ genetic backgrounds and locomotion measured over 24 h at a 12 h 
light:12 h dark cycle. For locomotor analysis, total beam breaks over 24 h were 







Figure 5.21 Insulin-themed Dominant Modifier Screen 
This figure illustrates the results of an insulin-themed dominant modifier screen. 
The mutant alleles tested are shown on the x-, and their locomotion on the y-
axis. Locomotion was normalised to genetic background, which is indicated in 
red for sloE366G/+ and in grey for sloloxP/+. A dashed line demarcates a fold-
change of 1 with respect to the genetic backgrounds. Between 1 and 3 
independent experimental repeats per genotype were performed, and the 
resulting data pooled. (n = 9-99; Mann-Whitney-Wilcoxon tests with Bonferroni 
correction; **** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, * = p < 0.05, ns = p 
> 0.05) 
  
The behavioural data in Figure 5.21 indicate that some mutant alleles increase 
locomotion in sloloxP/+, but do not affect it in sloE366G/+ (dilp11, dilp21, and dilp2,3), 
while others do not affect locomotion in sloloxP/+, but decrease it in sloE366G/+ 
(dilp2,3,53, dilp668;;dilp2,3,53, and foxoD94). Intriguingly, the foxo null allele foxoD94 
enhances the sloE366G/+ locomotor defect, consistent with its potential role as a 
master regulator in GEPD pathogenesis (Figure 5.18). In order to confirm this 
result, I performed an experimental repeat with foxoD94, using the independent 
sloE366G/+ and sloloxP/+ recombinants 137.1.3/+ and 111.1.1/+, respectively. 
Indeed, the data confirm that partial loss of foxo enhances the sloE366G/+ 






Figure 5.22 Partial Loss of foxo Enhances the sloE366G/+ Locomotor Defect 
Partial loss of foxo significantly decreased locomotion in sloE366G/+, while not 
affecting sloloxP/+ locomotor activity, indicative of a genetic interaction. Data from 
two independent experimental repeats were pooled. (n = 28-47; Mann-Whitney-




















This chapter addresses the third question set out in the project aim: what are the 
molecular mechanisms underlying GEPD? In order to investigate GEPD 
pathophysiology on a molecular level, I performed RNA-seq of sloE366G/+ and 
sloloxP/+ adult male head tissue. The transcriptomic differences between these 
genotypes point towards potential roles for dysregulated metabolic-, redox-, and 
immune function in sloE366G/+. Furthermore, behavioural evidence is provided that 
partial loss of foxo enhances the sloE366G/+ locomotor defect, while also 
suggesting a potential role for insulin signalling in modulating this phenotype. 
Altogether, the results presented in this chapter serve as an entry point towards 
an increased molecular understanding of GEPD, while simultaneously focussing 
attention on specific pathophysiological mechanisms. 
5.5.1 Experimental Notes and Caveats 
5.5.1.1 Interpreting RNA-seq Data 
It is important to scrutinise from first principles how the RNA-seq data were 
generated, and how the process of sample preparation might affect their 
interpretability. Could it be, for example, that sloE366G/+ flies are more prone to 
infection, which might explain the up-regulation in immune-related genes (Figure 
5.15)? Similarly, being a weak genotype, might poor stock conditions of sloE366G/+ 
flies prevent proper feeding, resulting in a differential expression of genes 
involved in metabolism (Figure 5.15, Figure 5.16)? These questions illustrate the 
fundamental importance of the quality of starting material in RNA-seq 
experiments (Conesa et al., 2016). Indeed, I took multiple measures to reduce 
the number of confounding variables affecting gene expression: (1) all males 
used for RNA-seq were age-matched with a resolution of 2 days (4-6 days old). 
(2) All males were housed with an excess number of females for 48 h prior to 
head isolation, in order to increase the probability of mating. (3) Head isolation 
was always performed during the same time of day – between 4 pm and 6 pm – 
due to the circadian cycling of slo expression (Ceriani et al., 2002). (4) None of 
the flies were anaesthetised with CO2 for 48 h prior to head isolation. (5) All flies 




prevent a build-up of mould and bacteria, which could affect nutritional- and 
infectious status. Despite this rigorous effort to minimise the number of 
confounding variables, some could not be controlled for, such as potential effects 
of the sloE366G allele on the biophysical properties of the male Drosophila 
courtship song (Ding et al., 2016; Peixoto and Hall, 1998), which could in turn 
affect mating success, or the chronically reduced locomotion of sloE366G/+ flies, 
which might result in transcriptomic changes as well. Hence, the RNA-seq data 
likely represent a chimera of primary transcriptional changes induced by the 
presence of the sloE366G allele and secondary changes that occur in response to 
altered molecular-, cellular-, and organismal function of sloE366G/+ animals. To 
identify primary, disease-relevant changes, functional studies, such as the 
behavioural screen presented in this chapter, are required (Figure 5.21, Figure 
5.22). 
5.5.1.2 Validation of Behavioural Data 
Before discussing the behavioural data presented in this chapter, it has to be 
stressed that these data are preliminary and require independent experimental 
validation (Figure 5.21, Figure 5.22). None of the alleles, including foxoD94, were 
outcrossed, making it impossible to exclude genetic background effects from 
affecting behaviour. Hence, it will be important to repeat these experiments with 
outcrossed modifier alleles. To confirm the genetic interaction between foxo and 
sloE366G, conditional over-expression and knock-down of foxo in a sloE366G/+ 
background might be employed as well. 
5.5.2 Clinical Relevance 
5.5.2.1 Foxo as a Potential Master Regulator in GEPD 
It is possible that multiple parallel processes induce the transcriptional changes 
between sloE366G/+ and sloloxP/+. Alternatively, a small number of TFs might 
orchestrate them. This hypothesis was tested via CRE enrichment analysis 
(Janky et al., 2014), identifying Foxo as a TF predicted to bind to ~47% of genes 
up-regulated in sloE366G/+ (Figure 5.18). While this analysis also identified CrebB 
as a TF predicted to bind to ~46% of down-regulated genes, I focussed on Foxo 




(Eijkelenboom and Burgering, 2013), processes captured by the enriched GO- 
and KEGG PATHWAY annotations (Figure 5.15, Figure 5.16). Indeed, a 
dominant modifier screen identified the foxo null allele foxoD94 as a genetic 
enhancer of the sloE366G/+ locomotor defect (Figure 5.22), suggesting that 
increased Foxo activity might be a homeostatic response to the presence of the 
sloE366G allele.  
 Further evidence for an involvement of Foxo in GEPD pathogenesis is 
provided by its downstream transcriptional signature. Foxo has previously been 
shown to induce the expression of AMPs, which are integral components of the 
innate immune response in Drosophila (Becker et al., 2010). Strikingly, the 
authors identified a Foxo-mediated increase in the expression of 8 AMPs, 6 of 
which are also up-regulated in sloE366G/+: Atta, Drs, Dpt, Dro, Cec, and Def 
(Becker et al., 2010). These data provide further evidence for Foxo to be involved 
in mediating the transcriptional changes observed in sloE366G/+, implicating its 
activity with each of the main GO annotations enriched in the DGE data: 
metabolism, oxidation-reduction, and immunity (Figure 5.15). 
 While the Drosophila genome encodes a single Foxo isoform, the 
mammalian genome encodes four: FoxO1, FoxO3, FoxO4, and FoxO6 (Salih and 
Brunet, 2008). The regulation of both Drosophila and mammalian Foxo is 
complex and involves a variety of upstream signalling pathways as well as post-
translational modifications of Foxo, including phosphorylation, methylation, 
ubiquitylation, and acetylation (Eijkelenboom and Burgering, 2013). 
Fundamentally, Foxo acts as a convergence point of insulin signalling and 
oxidative stress, which act antagonistically to inhibit and activate Foxo, 
respectively (Figure 5.20) (Salih and Brunet, 2008). Insulin signalling induces the 
phosphorylation of Foxo, inhibiting it via cytoplasmic retention, while oxidative 
stress induces activation of Foxo by mediating its translocation into the nucleus 
and facilitating the transcription of Foxo target genes (Eijkelenboom and 
Burgering, 2013). Hence, Foxo functions as a “homeostatic regulator”, inducing 
transcriptional responses to counteract oxidative- and metabolic stress as well as 
growth factor deprivation (Eijkelenboom and Burgering, 2013). These 




by, affecting metabolism, protein homeostasis, cell fate decisions, damage repair, 
and stress resistance (Eijkelenboom and Burgering, 2013; Salih and Brunet, 
2008). Hence, identifying foxoD94 as a genetic modifier of the sloE366G/+ locomotor 
defect strongly suggests that sloE366G/+ flies experience a state of stress and 
depend on the homeostatic activity of Foxo. On the other hand, sloloxP/+ flies 
might tolerate a partial loss of foxo because they do not experience this stressful 
state (Figure 5.22). Investigating potential stressors that induce Foxo activity in 
sloE366G/+ might, therefore, represent a strategy to identify upstream molecular 
pathways that are perturbed in this genotype, facilitating the discovery of the 
prima causa of GEPD. Following this approach, I focussed on a potential role for 
insulin signalling GEPD. 
5.5.2.2 Altered Insulin Signalling in GEPD 
GLUT1-DS is linked to mutations in SLC2A1 (De Giorgis and Veggiotti, 2013). As 
described in Paragraph 1.2.1.3, SLC2A1 encodes GLUT1, a glucose transporter 
facilitating the transport of glucose across the BBB (De Giorgis and Veggiotti, 
2013). The clinical symptoms of GLUT1-DS – including dyskinesia, seizures, and 
a variety of comorbidities – are due to unmet neuronal energy demands as a 
result of hypoglycorrhachia (Brockmann, 2009; De Giorgis and Veggiotti, 2013). 
Both GO- and KEGG PATHWAY analyses identified altered metabolism in 
sloE366G/+ (Figure 5.15, Figure 5.16), indicating a metabolic component to GEPD 
as well – an unexpected but intriguing finding.  
 Four lines of evidence suggest that insulin signalling might be involved in 
mediating the sloE366G/+ locomotor defect: (1) perturbed insulin signalling could 
lead to the metabolic disturbances identified via GO- and KEGG PATHWAY 
analyses (Figure 5.15, Figure 5.16); (2) perturbed insulin signalling could be the 
upstream mechanism affecting Foxo activity (Eijkelenboom and Burgering, 2013) 
(Paragraph 5.5.2.1); (3) manual curation of the RNA-seq data identified 4 genes 
of the insulin signalling pathway to be differentially expressed between sloE366G/+ 
and sloloxP/+: dilp6, InR, and chico are up-, while dilp2 is down-regulated in 
sloE366G/+; (4) dysregulated insulin signalling would be congruent with the 
increased larval body size and decreased adult life span observed in sloE366G/+ 




been shown to increase adult Drosophila body size (Brogiolo et al., 2001), while 
loss of dilp2 extended Drosophila life span (Grönke et al., 2010). Indeed, via an 
insulin-themed dominant modifier screen, I identified differential effects of altered 
insulin signalling on sloE366G/+ and sloloxP/+ locomotion – suggesting a potential 
role for insulin signalling in GEPD (Figure 5.21).  
While dilp11/+, dilp21/+, and dilp2-3/+ specifically increased sloloxP/+ 
locomotion, dilp2,3,53/+ and dilp668/Y;;dilp2,3,53/+ specifically reduced sloE366G/+ 
locomotion (Figure 5.21). Dilp2, Dilp3, and Dilp5 are released from 14 median 
neurosecretory cells (MNCs) in the PI, termed insulin-producing cells (IPCs), 
implicating a role for dysregulated cerebral insulin signalling in sloE366G/+ 
locomotion (Nässel et al., 2015). However, since insulin signalling negatively 
regulates Foxo activity (Figure 5.20), reducing dilp levels should increase Foxo 
activity and would, therefore, be expected to result in a behavioural rescue – 
instead, simultaneously reducing dilp2-, dilp3-, and dilp5 levels enhanced the 
sloE366G/+ locomotor defect (Figure 5.21).  
These contradictory results might be explained by a complex 
transcriptional network regulating dilp expression, which could lead to 
unexpected transcriptional changes in response to dilp2,3,53/+ and 
dilp668/Y;;dilp2,3,53/+. For example, homozygosity for dilp21 leads to increased 
dilp3 and dilp5 expression, while loss of dilp3 increases dilp2 and dilp5 
expression (Grönke et al., 2010). Moreover, ablation of dilp5 is linked to an 
increase in dilp3-, and ablation of dilp6 to a decrease in dilp3 expression (Grönke 
et al., 2010). Hence, without molecular analysis, it is difficult to predict actual 
changes of dilp expression in the presence of dilp2,3,53/+ and 
dilp668/Y;;dilp2,3,53/+. Moreover, dilp expression has been shown not to directly 
correlate with Dilp release (Nässel et al., 2015; Park et al., 2014), further 
complicating the results. Hence, additional experiments are required to confirm a 
role for insulin signalling in GEPD pathogenesis. 
5.5.3 Conclusion 
This chapter provided a preliminary link between dysregulated insulin signalling, 




findings might lead towards a better understanding of the molecular mechanisms 
































6 Concluding Remarks 
This thesis described the generation, characterisation, and functional analysis of 
a novel Drosophila model of GEPD, which recapitulates the human GEPD-linked 
D434G missense mutation in form of the novel sloE366G allele (Du et al., 2005). 
Prior to this work, in vitro studies had defined the biophysical effects of the GEPD-
linked mutation, as described in Paragraph 1.4.1.2 (Yang et al., 2010). The in 
vivo and ex vivo data on sloE366G/+ animals presented in this thesis complement 
those results and incorporate them into an organismal framework. 
 First, this thesis provides supporting evidence for the hypothesis that the 
increased Ca2+ sensitivity exhibited by the murine (D369G) and human (D434G) 
mutations in vitro is conserved ex vivo in Drosophila harbouring the equivalent 
mutation (E366G) (Figure 3.11) (Du et al., 2005; Yang et al., 2010). 
Characterising the effects of this mutation at the organismal level revealed that 
sloE366G/+ larvae and adults exhibit severe locomotor abnormalities, most notably 
a decrease in travelling distance and altered action selection (Figure 3.4, Figure 
3.17, Figure 3.8, Figure 3.19). Importantly, in adults, these defects could be 
localised to cholinergic neurons (Figure 4.15). Further, transcriptomic analyses 
identified potential roles for altered metabolic-, redox-, and immune function in 
GEPD pathogenesis. Based on these data, preliminary evidence is provided that 
insulin signalling might be perturbed- (Figure 5.21), and foxo differentially 
regulated in GEPD (Figure 5.22). 
 Altogether, these data address the three questions set out in the project 
aim (Paragraph 1.6): (1) what are the organismal effects of the D434G-equivalent 
mutation in flies? (2) Where is the mutation required to exert its pathogenic 
effects? (3) What are the molecular mechanisms underlying GEPD? This thesis 
does not exhaustively (1) or definitively (2, 3) answer these questions, but it 
provides a wealth of data that lay the foundation for a better understanding of 
GEPD pathogenesis. Based on these data, three main strands of future 
investigation are of particular interest: (1) a more restricted pathogenic locus of 
GEPD might be identified; (2) experiments might be conducted to confirm and 




avenues might be explored that could lead to an increased understanding of 
GEPD pathogenesis.  
6.1 Future Directions 
6.1.1 Restricting the Pathogenic Locus of GEPD 
In order to validate the spatial dissection results presented in Chapter 4, 
Paragraph 4.5.1.1 suggested to perform an RNAi-based screen in a sloE366G/+ 
background, targeting either slo itself, or genes that Slo function depends on, 
such as dysc and genes encoding Cav channels (Griguoli et al., 2016; Jepson et 
al., 2012). A knock-down of these genes in cholinergic neurons would be 
predicted to rescue the sloE366G/+ locomotor defect, strengthening the hypothesis 
that cholinergic neurons contain the pathogenic locus of GEPD. Notably, 
cholinergic neurons are the main neuronal subtype in the Drosophila nervous 
system, as illustrated by the detection of ChAT immunoreactivity in almost the 
entire adult brain neuropil (Yasuyama and Salvaterra, 1999). 
Indeed, cholinergic neurons can be found in both the central and 
peripheral nervous system (Salvaterra and Kitamoto, 2001; Yasuyama and 
Salvaterra, 1999), and both populations might contribute to the sloE366G/+ 
locomotor defect – which may be thought of as a compound phenotype consisting 
of various pathological processes acting in parallel. Via selectively targeting the 
central and peripheral nervous system with the two spatial dissection strategies 
outlined in Chapter 4, their relative contributions to the sloE366G/+ locomotor defect 
could be determined – this approach might further be applied to test individual 
sensory modalities that are known to involve cholinergic signalling, such as 
audition (Ishikawa et al., 2017; Sanes and Hildebrand, 1976). Similarly, more 
restricted cholinergic subpopulations in the CNS could be investigated. 
Moreover, it is possible that, despite not affecting locomotion by 
themselves (Figure 4.12), peptidergic neurons modulate the sloE366G/+ locomotor 
phenotype – potentially via an involvement in the metabolic dysregulation 
observed in sloE366G/+ (Figure 5.15, Figure 5.16), which would be consistent with 




could be tested by simultaneously targeting peptidergic and cholinergic neurons 
with the spatial dissection strategies described in Chapter 4. 
 Instead of targeting neurons based on neurotransmitter identity, a 
complementary approach could target specific brain areas based on 
neuroanatomy. Since sloE366G/+ animals exhibit severe locomotor defects, this 
approach might commence by targeting locomotor centres in the CNS. Of 
particular interest would be the fly central complex, because this central brain 
structure has been suggested to be homologous to the vertebrate basal ganglia 
(Strausfeld and Hirth, 2013), whose involvement in movement disorders, 
including dyskinesia, is widely appreciated (Wichmann and Dostrovsky, 2011). 
The central complex consists of the fan-shaped body, the ellipsoid body, the 
protocerebral bridge, and the paired noduli, and its disruption has been linked to 
a variety of locomotor defects, including decreases in locomotor speed and -bout 
length (Strauss, 2002) – reminiscent of the sloE366G/+ adult locomotor defect 
(Figure 3.18, Figure 3.20). Hence, applying the RNAi- and Dysc-mediated spatial 
dissection strategies to sub-compartments of the central complex would elucidate 
whether aberrant activity within this network contributes to the sloE366G/+ 
locomotor defect. In Paragraph 4.5.2.2, I ascribed an important role in GEPD 
pathogenesis to striatal cholinergic interneurons, due to their involvement in 
modulating MSN activity (Kandel et al., 2013). Using the spatial dissection 
strategies to target the homologous neurons in the central complex would allow 
for this hypothesis to be tested in flies. Indeed, local interneurons in the fan-
shaped body have been described as homologous to striatal cholinergic 
interneurons (Strausfeld and Hirth, 2013). Hence, if appropriate Gal4-drivers can 
be identified, an ideal future experiment would target these interneurons in the 
fan-shaped body to assess their role in mediating the sloE366G/+ locomotor defect. 
6.1.2 Investigating Insulin Signalling in GEPD 
An RNA-seq-informed modifier screen suggested a potential role for insulin 
signalling in GEPD pathogenesis (Figure 5.21). However, further evidence is 
required to confirm these results (Paragraphs 5.5.1.2 and 5.5.2.2). In order to 
definitively test whether insulin signalling is involved in GEPD pathogenesis, two 




does experimental modulation of insulin signalling affect sloE366G/+ behaviour? 
Dilp secretion can be measured directly via a tagged dilp2 construct that allows 
for ELISA-based quantification of secreted Dilp2 from the Drosophila 
haemolymph at picomolar concentrations (Park et al., 2014). Using this 
experimental strategy, Dilp2 release could be compared between sloE366G/+ and 
sloloxP/+, revealing whether IPC-mediated insulin signalling is dysregulated in this 
fly model of GEPD. To modulate Dilp release in vivo, the activity of IPCs could 
be manipulated. Interestingly, it has recently been shown that IPC-targeted 
expression of Kir2.1, encoding a hyperpolarising inward-rectifying K+ channel 
(Baines et al., 2001), significantly reduces Dilp2 secretion (Park et al., 2014). 
Performing an analogous experiment with the UAS-TrpA1 construct, which 
encodes a depolarising temperature- and voltage-gated cation channel (Hamada 
et al., 2008; Pulver et al., 2009), would increase IPC activity and Dilp release in 
vivo. Dilp release can also be manipulated pharmacologically: direct sensing of 
extracellular leucine by IPCs has been shown to induce Dilp2- and Dilp5 release 
in Drosophila larvae (Manière et al., 2016), while the chemical inhibitor SecinH3 
decreases insulin signalling in Drosophila larvae and adults (Fuss et al., 2006; 
Hafner et al., 2006). Together, quantifying endogenous levels of Dilp secretion 
and manipulating Dilp secretion in vivo would provide strong evidence to 
demonstrate or refute an involvement of insulin signalling in GEPD. If insulin 
signalling can be confirmed to participate in GEPD pathogenesis, it would be of 
great interest to investigate it in more detail. 
Insulin signalling is pleitropic and targets virtually all mammalian cells, 
including myocytes, adipocytes, hepatocytes, and neurons (Haeusler et al., 
2018). Via neurons, it affects anorexigenic and locomotor behaviour, while 
stimulating glucose uptake in myocytes and adipocytes by increasing GLUT4 
expression on the plasma membrane (Haeusler et al., 2018). Furthermore, insulin 
signalling stimulates protein synthesis in muscle tissue, decreases lipolysis in 
adipose tissue, and increases glucose utilisation and triglyceride synthesis in the 
liver, where it also inhibits glucose production (Haeusler et al., 2018). Hence, if 
Foxo activation in sloE366G/+ occurs via dysregulated insulin signalling (Paragraph 
5.5.2.1), this genotype is predicted to cause wide-ranging metabolic 




Hence, it would be intriguing to investigate whether altering metabolism 
via a change in diet could modulate the sloE366G/+ locomotor defect. Subjecting 
sloE366G/+ flies to the ketogenic diet would be of particular interest, since this 
dietary intervention is an effective treatment for PED and GLUT1-DS (De Giorgis 
and Veggiotti, 2013), while also decreasing seizures in a Drosophila model of 
mitochondrial encephalomyelopathies (MEs), a seizure-associated group of 
metabolic disorders (Fogle et al., 2016) – illustrating its efficacy in disorders 
independent of SLC2A1 mutations. To specifically investigate a role for altered 
glucose metabolism in GEPD, the cellular glucose availability in sloE366G/+ could 
be reduced by performing a dominant modifier screen with hypomorphic Glut1 
alleles – if sloE366G/+ flies exhibit dysregulated glucose metabolism, they might be 
more sensitive to a reduction in Glut1 transcription. This screen could be 
accompanied by conditional over-expression and knock-down experiments 
targeting Glut1. Moreover, circulating glucose levels in the haemolymph could be 
quantified spectrophotometrically, as previously demonstrated in Drosophila 
larvae (Ugrankar et al., 2018). If these experiments were to yield positive results, 
large-scale metabolic shifts between sloE366G/+ and sloloxP/+ could be investigated 
using an unbiased metabolomics approach (Tennessen et al., 2014). Indeed, the 
availability of both metabolomic and transcriptomic datasets would allow for data 
analysis approaches aimed at linking pathogenic gene expression changes to 
metabolic dysregulation, further elucidating GEPD pathogenesis. 
6.1.3 Unexplored Mechanisms Linked to GEPD 
6.1.3.1 Dopamine Signalling in GEPD 
The spatial dissection data presented in Chapter 4 suggest a role for striatal 
cholinergic interneurons in GEPD pathogenesis (Paragraph 4.5.2.2). Since these 
neurons express BK channels (Bennett et al., 2000; Goldberg and Wilson, 2005), 
it is possible that the D434G mutation alters their intrinsic firing properties 
(Paragraph 4.5.2.2). Hence, Paragraph 6.1.1 suggests to specifically re-
introduce Slo or knock-down slo in homologous neurons in Drosophila. A 
complementary strategy could investigate a role for dopaminergic modulation of 




mouse model described in in Paragraph 4.5.2.2, the response of striatal 
cholinergic interneurons to the dopamine receptor D2 (D2R) agonist quinpirole 
was found to be altered: while not affecting the firing properties of these neurons 
in wild-type controls, quinpirole induced a persistent increase in firing rate in 
DYT1 mice (Martella et al., 2014). These data suggest that an altered response 
of striatal cholinergic interneurons to dopaminergic nigrostriatal projections might 
be involved in DYT1 pathogenesis. 
To test whether dopaminergic modulation of striatal cholinergic 
interneurons might also be involved in GEPD pathogenesis, RNAi-mediated 
knock-down of Drosophila dopamine receptors (Dop1R1, Dop1R2, Dop2R, and 
DopEcR) in cholinergic neurons – or subpopulations thereof – could be 
performed. If aberrant dopaminergic modulation of striatal cholinergic 
interneurons is involved in GEPD pathogenesis, knock-down of the relevant 
dopamine receptor in cholinergic neurons should modulate the sloE366G/+ 
locomotor defect. Of note, the mechanisms underlying dopaminergic modulation 
in the insect central complex have been suggested to be homologous to 
nigrostriatal dopaminergic modulation in the vertebrate basal ganglia (Strausfeld 
and Hirth, 2013), supporting this experimental approach. 
6.1.3.2 Oxidative Stress in GEPD 
While Foxo is inhibited by insulin signalling, it is activated by oxidative stress 
either via Jun N-terminal kinase (JNK) signalling or by direct oxidation of its own 
amino acid residues (Figure 5.20) (Eijkelenboom and Burgering, 2013). Hence, 
in addition to confirming and further exploring insulin signalling in GEPD 
pathogenesis (Paragraph 6.1.2), future experiments might also investigate an 
involvement of oxidative stress. A potential role for oxidative stress in GEPD 
pathogenesis is supported by the expression of mtBK channels on the IMM, as 
described in Paragraph 1.4.3.2 (Li and Gao, 2016). Mitochondria are the site of 
aerobic respiration, a process that generates ROS – including superoxide 
radicals (O2•-), hydrogen peroxide (H2O2), and hydroxyl radicals (•OH) – as 
metabolic by-products (Turrens, 2003). As discussed in Paragraph 1.4.3.2, ROS 
levels have been found to be increased in murine KCNMA1-/- cardiomyocytes in 




stress (Soltysinska et al., 2014). Hence, dysregulated mitochondrial Slo function 
in sloE366G/+ animals might lead to increased levels of ROS production, which 
would, in turn, activate Foxo so as to counteract oxidative stress (Figure 5.20). 
If oxidative stress is involved in GEPD pathogenesis, one would predict 
different ROS levels between sloE366G/+ and sloloxP/+. Hence, it would be of 
interest to quantify ROS levels in these genotypes, which can be done 
fluorometrically, as demonstrated previously in Drosophila (Chakrabarti et al., 
2014). In order to address whether oxidative stress might be causally linked to 
the sloE366G/+ locomotor defect, in vivo modulation of ROS levels would be 
required. Pharmacologically, oxidative stress can be increased in vivo via 
injection or feeding of the herbicide paraquat, which increases the production of 
O2•- (Cochemé and Murphy, 2008; Hill et al., 2018), or via feeding of H2O2, which 
induces •OH production and has been shown to alter Drosophila locomotor 
behaviour (Grover et al., 2009; Hill et al., 2018). In order to decrease ROS levels 
in vivo, Gal4-mediated over-expression of the antioxidant genes catalase, Sod1, 
and Sod2 could be performed (Hill et al., 2018): Superoxide dismutase (Sod) 
catalyses the disproportionation/dismutation of O2•- into O2 and H2O2, while 
catalase catalyses the reaction of H2O2 to H2O and O2 (Chelikani et al., 2004; 
Hayyan et al., 2016), both counteracting oxidative stress. If oxidative stress 
contributes to GEPD pathogenesis, increasing it would be predicted to     
enhance-, while decreasing it would be predicted to suppress the sloE366G/+ 
locomotor defect. 
6.2 Classifying GEPD 
As described in Paragraph 1.2.1.4, PxDs, with or without epilepsy, have been 
classified using a tripartite system comprising channelopathies, synaptopathies, 
and transportopathies (Erro et al., 2017). Since PRRT2 and PNKD are implicated 
in synaptic function, their associated forms of PxD – PKD and PNKD, respectively 
– have been classified as synaptopathies (Erro et al., 2017; Gardiner et al., 2015). 
Similarly, the transporter function of GLUT1 led to the classification of SLC2A1-
linked PED as a transportopathy (Erro et al., 2017). Since KCNMA1 encodes the 




suggesting that altered neuronal excitability causes PNKD and epilepsy (Erro et 
al., 2017; Shen et al., 2015). However, the possible involvement of perturbed 
metabolic-, redox-, and immune function in GEPD pathogenesis suggests 
additional nuance to this pathological framework (Figure 5.15, Figure 5.16) – a 
proposition strengthened by a suggested role for PNKD in regulating cellular 
redox state in addition to pre-synaptic neurotransmitter release (Shen et al., 
2011). Hence, although the GEPD-linked D434G mutation in KCNMA1 has been 
shown to lead to a gain of BK channel function in vitro (Yang et al., 2010) and ex 
vivo (Figure 3.11), changes in neuronal excitability might contribute to-, but not 
represent the whole picture of GEPD pathogenesis. Indeed, while cholinergic 
neurons might contain the pathogenic locus of GEPD (Figure 4.15), the 
expressivity of this disorder could be dependent on additional modulatory effects, 
such as insulin signalling and glucose metabolism (Figure 5.21). As such, the 
data presented in this thesis warrant a multi-systems approach to GEPD, and 
potentially other forms of PxD and PxD-epilepsy syndromes – which might, 
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Figure 9.1 Example of Aberrant Larval Tracking 
This larva, of genotype 72.1.1/+, is the only larva, out of a total of 164, AnimApp 
failed to track properly. Improper tracking is identified visually by acknowledging 
that it would be impossible for a larva to jump ~200 pixels, which converts to 








Figure 9.2 Sample Sheets Used for De-multiplexing of RNA-seq Data 
During the conversion from BCL- to FASTQ file format, RNA-seq data were de-
multiplexed based on index sequences (column 7 at the bottom of A and B). De-
multiplexing runs were performed separately for 6-bp indices (A) and 8-bp 
indices (B). These sample sheets are based on templates provided by Deborah 














Table 69 lists the 1036 significantly DEGs (FDR < 0.05), as identified by the DGE 
analysis described in Paragraph 5.4.6. (FB-ID = FlyBase-identifier; Mean = 
mean gene expression in normalised counts; log2FC = log2(fold-change); FDR 
= false discovery rate; Gene = gene name). Fold-changes are presented relative 
to sloloxP/+, with positive values indicating genes up-regulated in sloE366G/+, and 
negative values indicating genes down-regulated in sloE366G/+. This table is 
sorted by significance, with smaller FDRs at the top. 
 
Table 69 Differentially Expressed Gene List 
FB-ID Mean log2FC FDR Gene 
FBgn0030773 3549.73262 -1.7098074 6.52E-59 CG9676 
FBgn0039703 834.790327 -1.5213454 1.63E-50 CG7829 
FBgn0052523 265.798827 -3.0244496 1.89E-41 CG32523 
FBgn0033067 1016.04847 -1.4611967 1.71E-32 CG11211 
FBgn0031306 6579.55166 -0.3923524 1.27E-29 CG4577 
FBgn0039298 284.402164 -1.2342204 2.39E-27 to 
FBgn0039430 3367.24617 -0.3440621 1.58E-26 CG5455 
FBgn0028374 674.008251 -0.5250827 1.58E-26 Hug 
FBgn0259226 583.377642 -0.5195097 5.45E-26 CG42326 
FBgn0014019 6884.15053 -0.4345284 3.35E-22 Rh5 
FBgn0243514 761.943326 0.81082722 5.29E-21 eater 
FBgn0040502 8326.21149 -1.1155059 1.55E-20 CG8343 
FBgn0036022 8350.66925 -0.9420731 1.60E-20 CG8329 
FBgn0035207 5490.7641 0.25043493 3.37E-20 Herc4 
FBgn0035766 1883.40999 0.57480876 4.63E-20 eco 
FBgn0036015 7152.30965 -0.7160127 1.89E-19 CG3088 
FBgn0035550 20.4356082 -5.1152893 1.89E-19 CG11349 
FBgn0035189 716.522065 -0.8640943 1.71E-18 CG9119 
FBgn0039543 568.250595 -0.6206445 6.66E-18 CROT 
FBgn0001234 2357.95846 -0.328993 1.75E-17 lncRNA:Hsromega 
FBgn0040601 18.1465684 -2.9615533 2.33E-17 CG13643 
FBgn0023178 878.06907 -0.2951113 4.87E-17 Pdf 
FBgn0036620 1561.48682 -0.3683267 2.09E-16 CG4842 
FBgn0013813 463.851835 0.73758584 2.48E-16 Dhc98D 
FBgn0010041 55.0248686 1.92997995 4.56E-16 GstD5 
FBgn0039537 1404.9545 -0.3345209 6.33E-16 CG5590 
FBgn0003250 12542.8011 -0.2802346 1.44E-15 Rh4 
FBgn0039474 16.2178153 -4.4358386 1.44E-15 CG6283 
FBgn0035160 81.8891073 -1.0373095 1.53E-15 hng3 
FBgn0035382 235.372915 0.61271849 5.17E-15 Or63a 
FBgn0043783 763.621593 -0.8296132 1.94E-14 CG32444 
FBgn0003249 16964.971 -0.2431108 6.60E-14 Rh3 




FBgn0035438 1985.27679 -0.2448651 1.48E-13 PHGPx 
FBgn0029093 10779.1054 -0.1728207 1.74E-13 cathD 
FBgn0037298 2465.13497 -0.3267261 1.93E-13 Sccpdh1 
FBgn0013812 93.2133252 1.25762369 3.37E-13 Dhc93AB 
FBgn0035205 2184.93779 0.25730498 3.45E-13 Ctr9 
FBgn0035726 2581.64488 -0.3877591 3.59E-13 CG9953 
FBgn0032139 478.376304 0.35521273 1.62E-12 CG13116 
FBgn0032652 2436.96034 -0.2568111 1.74E-12 CG6870 
FBgn0267792 596.155285 0.48728041 4.09E-12 rgr 
FBgn0003074 9090.72192 -0.1862617 5.13E-12 Pgi 
FBgn0039770 670.383526 -0.2706541 6.45E-12 CG15537 
FBgn0045038 653.845997 -0.3415125 1.99E-11 Proc 
FBgn0016031 2305.36631 0.17310874 3.98E-11 lama 
FBgn0005614 72970.1863 -0.3673527 3.98E-11 trpl 
FBgn0032505 254.248704 8.24133101 1.07E-10 CG16826 
FBgn0283437 2692.44751 -0.913452 1.07E-10 PPO1 
FBgn0035206 738.100858 0.2840037 1.31E-10 CG9186 
FBgn0035578 197.822588 -0.4890503 1.54E-10 CG13707 
FBgn0036921 3931.07106 -0.1692141 2.20E-10 RhoGDI 
FBgn0032538 365.786725 -0.4349093 2.32E-10 Vajk2 
FBgn0036106 13555.4619 0.43317641 3.13E-10 CG6409 
FBgn0266918 5245.29319 -0.1379594 3.68E-10 CG32486 
FBgn0031902 419.342953 -0.3037581 6.24E-10 Wnt6 
FBgn0032322 825.472567 0.45281265 9.99E-10 CG16743 
FBgn0035676 788.7051 -0.2550177 9.99E-10 ssp6 
FBgn0052392 157.250893 -0.569043 1.06E-09 CG32392 
FBgn0027348 2406.28924 0.48479939 1.09E-09 bgm 
FBgn0051207 691.191968 -0.2875409 1.86E-09 CG31207 
FBgn0085334 13.8468092 -2.1833449 1.91E-09 CG34305 
FBgn0027655 2131.15284 -0.2424644 1.92E-09 htt 
FBgn0035523 834.070888 0.21437435 2.07E-09 Ctl1 
FBgn0038257 466.253556 -0.5583844 2.19E-09 smp-30 
FBgn0259209 1360.61134 0.30614825 2.26E-09 Mlp60A 
FBgn0011672 1093.51126 0.22296609 2.69E-09 Mvl 
FBgn0039609 511.367058 -0.3037757 2.85E-09 Nepl17 
FBgn0036381 2011.50251 0.22134122 8.26E-09 CG8745 
FBgn0014859 350.414292 -0.7234224 9.89E-09 Hr38 
FBgn0039226 402.793142 -0.3222772 1.18E-08 Ude 
FBgn0261859 4433.01555 0.22339925 1.25E-08 CG42788 
FBgn0029896 5012.27233 0.17757862 1.25E-08 CG3168 
FBgn0265182 4618.51687 -0.2472873 1.25E-08 CG44247 




FBgn0015245 6423.13089 -0.1166087 1.39E-08 Hsp60A 
FBgn0052282 599.157579 -0.5059436 1.40E-08 Drsl4 
FBgn0036750 117.228731 -0.8069401 1.40E-08 CG6034 
FBgn0011204 1273.26323 0.29988118 2.13E-08 cue 
FBgn0044452 2276.67319 0.17864869 2.13E-08 Atg2 
FBgn0041712 671.129032 -0.5913632 2.13E-08 yellow-d 
FBgn0032436 43.1825053 -1.0433179 2.13E-08 CG5418 
FBgn0010548 4467.93755 -0.1808586 2.82E-08 Aldh-III 
FBgn0000241 990.88908 -0.2730976 3.18E-08 bw 
FBgn0032726 696.030671 -0.5575626 4.24E-08 CG10621 
FBgn0023526 1265.15013 0.17576429 5.21E-08 CG2865 
FBgn0051075 1169.53478 -0.471006 5.77E-08 CG31075 
FBgn0034660 585.431514 -0.3641283 7.10E-08 Loxl2 
FBgn0038395 93.9465446 -0.7985562 7.52E-08 CG10407 
FBgn0000044 9644.6385 0.342689 7.73E-08 Act57B 
FBgn0023479 15231.4054 0.18935897 8.09E-08 teq 
FBgn0035791 121.480021 -0.7344486 9.97E-08 CG8539 
FBgn0054054 92.5938026 0.91372203 1.15E-07 CG34054 
FBgn0039886 112.402953 0.50293112 1.23E-07 CG2003 
FBgn0031775 352.253709 -0.6334201 1.35E-07 CG9150 
FBgn0039052 230.434457 -0.8878484 1.53E-07 CG6733 
FBgn0265103 41.383688 3.151232 1.87E-07 asRNA:CR44205 
FBgn0267729 40.3028043 -0.8364978 1.87E-07 lncRNA:CR46060 
FBgn0042201 6384.26918 -0.4048671 1.89E-07 Nplp3 
FBgn0035246 6506.62092 -0.1158102 1.96E-07 CG13928 
FBgn0040629 33.1722707 -2.7273906 2.36E-07 CAH5 
FBgn0040532 3215.80722 0.18029243 2.98E-07 CG8369 
FBgn0040309 5108.7154 -0.1591459 3.28E-07 Jafrac1 
FBgn0266719 671.812413 0.22772303 4.03E-07 stac 
FBgn0024943 6054.22287 -0.1725936 4.31E-07 PIP82 
FBgn0033367 2704.70191 -0.7863852 4.39E-07 PPO2 
FBgn0035985 1302.84855 0.20297448 4.49E-07 Cpr67B 
FBgn0032336 1103.88862 -0.2558298 4.78E-07 AstC 
FBgn0036992 3033.29752 0.56628873 4.94E-07 Hpd 
FBgn0028648 189.528937 -0.3952394 5.13E-07 mRpL50 
FBgn0051038 3440.75844 0.2111167 5.15E-07 CG31038 
FBgn0087013 9005.2081 0.11047353 5.42E-07 Karybeta3 
FBgn0016013 701.047012 0.2949784 5.64E-07 Faa 
FBgn0013305 5053.23714 -0.1509428 5.80E-07 Nmda1 
FBgn0014863 3235.98523 0.2881248 6.42E-07 Mlp84B 
FBgn0035168 37.3827291 -0.8565345 6.96E-07 cep290 




FBgn0030519 1551.41106 -0.1406713 7.87E-07 CG11151 
FBgn0283471 2909.60076 0.25852771 8.02E-07 wupA 
FBgn0038286 2418.30265 0.18279011 8.89E-07 CG6966 
FBgn0040305 681.43332 0.2093576 8.93E-07 MTF-1 
FBgn0035770 7053.18381 0.1733876 1.10E-06 pst 
FBgn0038877 4346.97912 -0.1430508 1.10E-06 CG3308 
FBgn0250839 1336.48395 -0.1692449 1.15E-06 CG2016 
FBgn0026077 853.100043 -0.2602173 1.39E-06 Gasp 
FBgn0036875 677.752753 0.31021059 1.44E-06 CG9449 
FBgn0027932 4997.6632 0.1687865 1.45E-06 Akap200 
FBgn0032685 726.892767 -0.255102 2.02E-06 CG10211 
FBgn0031426 34.1305157 -0.9162223 2.06E-06 CG18641 
FBgn0035398 104.487266 -0.5602471 2.19E-06 Cht7 
FBgn0035348 5425.46153 -0.3602005 2.35E-06 CG16758 
FBgn0031176 102.395416 8.27695356 2.51E-06 whe 
FBgn0035627 33.7362351 0.78259294 2.51E-06 Sse 
FBgn0030968 990.11815 -0.2990909 2.57E-06 CG7322 
FBgn0035969 91.013109 -0.7510056 2.63E-06 CG4476 
FBgn0053116 651.98678 -0.3041043 2.84E-06 CG33116 
FBgn0040211 698.969973 0.38385542 2.87E-06 hgo 
FBgn0020493 1145.362 0.18110681 2.99E-06 Dad 
FBgn0023477 3704.40951 -0.2618205 2.99E-06 Taldo 
FBgn0039051 55.7701352 -0.9434001 3.34E-06 CG17109 
FBgn0052687 2126.63434 0.17332096 3.85E-06 CG32687 
FBgn0040349 1140.92374 -0.3311703 3.85E-06 CG3699 
FBgn0032721 1146.26634 -0.1554405 4.09E-06 CG10602 
FBgn0035574 950.854843 -0.1689246 4.09E-06 RhoGEF64C 
FBgn0264077 100.066766 0.60176938 4.17E-06 Cnx14D 
FBgn0261560 2836.10222 0.2321486 4.21E-06 Thor 
FBgn0267011 13.1145031 -1.3510189 4.65E-06 lncRNA:CR45455 
FBgn0035346 794.886353 0.19469531 4.80E-06 CG1146 
FBgn0033697 64.3794115 0.5921017 4.86E-06 Cyp6t3 
FBgn0031850 3821.43008 -0.1460565 4.86E-06 Tsp 
FBgn0004047 766.734763 -0.2555778 5.04E-06 Yp3 
FBgn0032785 706.890539 -0.2771319 5.60E-06 CG10026 
FBgn0039299 7.13856057 -2.0033061 5.60E-06 CG11854 
FBgn0086677 4228.34923 -0.2304855 5.75E-06 jeb 
FBgn0261113 10841.2282 -0.3016296 5.75E-06 Xrp1 
FBgn0262838 144.784371 0.86774494 5.76E-06 CG43202 
FBgn0035331 288.918475 0.28685696 6.45E-06 MsR1 
FBgn0032945 132.08147 0.78855361 6.51E-06 CG8665 




FBgn0033603 154.685416 -0.4281812 6.85E-06 Cpr47Ef 
FBgn0035076 1307.8928 -0.3597823 7.37E-06 Ance-5 
FBgn0032382 3179.29499 0.23489647 7.55E-06 Mal-B2 
FBgn0028497 3118.14931 -0.1324382 7.55E-06 CG3530 
FBgn0033926 21032.3182 -0.7398553 7.55E-06 Arc1 
FBgn0038946 2227.7875 -0.1908688 8.39E-06 rdhB 
FBgn0039099 553.169621 0.26060965 8.40E-06 GILT2 
FBgn0032879 1462.40196 -0.5167511 9.15E-06 CarT 
FBgn0035186 345.173759 0.26082097 9.68E-06 CG13912 
FBgn0002719 13855.2255 0.17380849 9.77E-06 Men 
FBgn0003053 941.257544 -0.2138574 9.77E-06 peb 
FBgn0035113 153.767464 -0.3751704 9.77E-06 pyx 
FBgn0038129 692.875817 0.26489468 9.86E-06 TBC1D5 
FBgn0031245 1290.62071 -0.147197 1.32E-05 CG3625 
FBgn0000163 1745.87129 0.14323398 1.50E-05 baz 
FBgn0011722 2249.42614 0.18735441 1.59E-05 Tig 
FBgn0037835 1097.24594 -0.3214506 1.61E-05 CG14687 
FBgn0036589 156.915736 -0.4858328 1.61E-05 CG13067 
FBgn0033927 6644.26561 -0.7263265 1.61E-05 CR10102 
FBgn0003390 646.708092 0.30469506 1.64E-05 shf 
FBgn0037896 731.457181 -0.2294193 1.64E-05 ninaG 
FBgn0036428 5559.42249 0.27366242 1.69E-05 Gbs-70E 
FBgn0036364 470.711491 0.2612109 1.69E-05 CG14109 
FBgn0001257 1662.79035 -0.3697802 1.69E-05 ImpL2 
FBgn0261004 76.9471894 -0.5701596 1.73E-05 asl 
FBgn0035873 82.434637 -0.5453211 1.74E-05 CG13670 
FBgn0086708 2878.5322 -0.1431236 1.75E-05 stv 
FBgn0035158 449.243735 0.29366344 1.77E-05 CG13895 
FBgn0003248 4210.17343 0.14046437 1.98E-05 Rh2 
FBgn0023212 2132.55116 0.13783543 1.98E-05 EloB 
FBgn0001229 113.05832 -0.5041567 2.04E-05 Hsp67Bc 
FBgn0039102 4082.0025 0.26228355 2.05E-05 SPE 
FBgn0263973 487.137325 -0.21149 2.05E-05 jv 
FBgn0036745 480.872454 -0.2219792 2.05E-05 CG7484 
FBgn0030208 1075.0472 -0.140202 2.17E-05 PPP4R2r 
FBgn0029820 1257.31591 0.15131886 2.24E-05 CG16721 
FBgn0041224 6.71129698 -2.1072693 2.27E-05 Gr97a 
FBgn0264894 3644.86441 0.14953195 2.28E-05 CG44085 
FBgn0029720 884.899698 -0.1691173 2.28E-05 CG3009 
FBgn0019830 1294.36372 -0.1934531 2.28E-05 colt 
FBgn0025641 3386.81564 -0.1198783 2.31E-05 DAAM 




FBgn0053109 20.5447344 5.29440256 2.41E-05 CG33109 
FBgn0003676 857.58202 -0.1948688 2.41E-05 CCT1 
FBgn0037976 555.643084 -0.2163614 2.62E-05 Tk 
FBgn0040752 4954.77701 0.16870292 2.78E-05 Prosap 
FBgn0036318 2836.75853 -0.1128017 2.81E-05 Wbp2 
FBgn0030505 4825.25046 0.15481926 2.87E-05 NFAT 
FBgn0025454 7445.6001 0.25487006 2.91E-05 Cyp6g1 
FBgn0038862 4017.03836 -0.2522548 3.00E-05 Usp8 
FBgn0004167 7669.77223 0.20131787 3.05E-05 kst 
FBgn0001092 11591.4547 -0.0945227 3.05E-05 Gapdh2 
FBgn0015569 761.159908 -0.2140974 3.18E-05 alpha-Est10 
FBgn0031418 1373.314 -0.3368909 3.18E-05 CG3609 
FBgn0035383 658.645721 -0.1916683 3.45E-05 CPT2 
FBgn0037090 1013.55543 -0.382008 3.46E-05 Est-Q 
FBgn0032753 680.93839 -0.2839633 3.50E-05 CG17572 
FBgn0032840 1512.76293 -0.1350859 3.63E-05 sNPF 
FBgn0038172 2022.20828 0.17963158 3.90E-05 Adgf-D 
FBgn0034140 2318.02324 0.29861622 4.11E-05 Lst 
FBgn0261575 2872.33332 -0.4991951 4.35E-05 tobi 
FBgn0030309 1011.0939 0.18864566 4.48E-05 CG1572 
FBgn0036208 287.54309 -0.3235733 4.51E-05 CG10361 
FBgn0052311 7504.06203 0.19257829 4.55E-05 zormin 
FBgn0001992 42.9260085 -0.6307725 4.65E-05 Cyp303a1 
FBgn0040382 11844.0979 -0.1121324 4.93E-05 CG5273 
FBgn0033544 7925.88458 -0.1336325 4.93E-05 CG7220 
FBgn0033158 41.9602448 -0.6021362 4.98E-05 CG12164 
FBgn0264753 1421.50727 -0.2140286 5.18E-05 Rgk1 
FBgn0026418 3108.86249 -0.1225876 5.22E-05 Hsc70Cb 
FBgn0015218 3663.2914 -0.083991 5.60E-05 eIF4E1 
FBgn0264272 1029.10441 -0.1814485 5.61E-05 mwh 
FBgn0036046 963.251295 -0.1969827 5.70E-05 Ilp2 
FBgn0020307 416.819136 -0.242734 6.37E-05 dve 
FBgn0033970 664.673669 0.19267216 6.52E-05 CG10205 
FBgn0039656 884.739383 0.20471223 6.60E-05 CG11951 
FBgn0032836 3405.69531 0.22139773 7.58E-05 CG10680 
FBgn0034538 176.33772 0.39164285 7.67E-05 CG16799 
FBgn0034405 3528.16388 -0.1210624 8.08E-05 Jheh2 
FBgn0034328 868.389311 1.59723558 8.20E-05 IM23 
FBgn0036770 719.512711 0.19378904 8.20E-05 Prestin 
FBgn0050052 1495.88576 0.19440633 9.03E-05 Obp49a 
FBgn0032402 1442.52803 0.13204417 9.03E-05 CG14945 




FBgn0032803 242.893327 -0.3268132 9.03E-05 CG13082 
FBgn0025687 702.407518 0.39051519 9.06E-05 NA 
FBgn0265935 1541.57857 0.15184899 9.09E-05 coro 
FBgn0031692 2385.91732 0.20348162 9.10E-05 TpnC25D 
FBgn0004169 5134.73991 0.24105662 9.20E-05 up 
FBgn0052250 424.769082 -0.2182115 9.66E-05 PMP34 
FBgn0023023 2624.80055 -0.1521235 0.00010611 CRMP 
FBgn0038035 420.135454 -0.248873 0.00010611 NA 
FBgn0036417 187.936316 -0.4300682 0.00010654 CG7906 
FBgn0030377 20.704249 0.92909731 0.00010949 CG1924 
FBgn0037448 806.779994 -0.1648459 0.00012263 CG15186 
FBgn0011581 1642.24439 -0.1278907 0.00012348 Ms 
FBgn0243586 8.0759438 -1.6192818 0.00012433 Tb 
FBgn0040299 298.315739 0.26701866 0.00013776 Myo28B1 
FBgn0001112 350.10395 -0.3125493 0.00013776 Gld 
FBgn0004652 1817.02134 0.14550699 0.00013906 fru 
FBgn0035388 1289.12663 0.13503848 0.0001398 CG2162 
FBgn0037936 827.126894 -0.2585961 0.00014047 CG6908 
FBgn0263039 344.098897 0.24482361 0.00014864 NA 
FBgn0014163 6781.86938 0.11899322 0.00015247 fax 
FBgn0003068 3170.38151 -0.2096108 0.00015337 per 
FBgn0041188 6292.72353 -0.0838667 0.00015492 Atx2 
FBgn0039028 43.5851912 -0.6579179 0.00015492 CG13840 
FBgn0000308 6413.33587 -0.1115386 0.00015697 chic 
FBgn0051414 465.854184 0.25089258 0.00016017 Gba1b 
FBgn0038341 577.146946 0.27503271 0.00016667 NA 
FBgn0021765 2124.95264 -0.1782669 0.00017093 scu 
FBgn0039611 870.199608 -0.296841 0.00017718 Nepl18 
FBgn0030041 1945.26353 0.30255252 0.00018485 CG12116 
FBgn0051103 1015.09679 0.20949888 0.00018868 CG31103 
FBgn0014018 2484.31823 0.26945935 0.00018907 Rel 
FBgn0030981 14.3494618 1.1030354 0.00019009 CG14191 
FBgn0032156 4889.52477 0.0870307 0.00019238 CG13124 
FBgn0053993 115.351137 -0.3371101 0.00022601 CG33993 
FBgn0264489 9059.89476 0.14831764 0.00026574 CG43897 
FBgn0039485 347.641083 -0.2536169 0.00026755 CG17189 
FBgn0285991 5169.57125 -0.0894187 0.00026808 hpRNA:CR18854 
FBgn0250746 1058.23973 -0.1219602 0.00027775 Prosbeta7 
FBgn0036666 1447.47467 -0.1141273 0.0003015 TSG101 
FBgn0012344 1228.4059 -0.1398629 0.00030378 Dh44 
FBgn0032609 90.5297019 -0.4809437 0.00030393 CG13280 




FBgn0037387 4421.38595 0.22627908 0.00032412 CG1213 
FBgn0000064 24809.0154 -0.0876895 0.00034848 Ald1 
FBgn0039324 471.432213 -0.2372411 0.00034848 CG10553 
FBgn0050411 24.1523177 -0.8811168 0.00034848 CG30411 
FBgn0027610 2046.38706 0.09593824 0.00039074 Dic1 
FBgn0019661 45497.3921 0.16445363 0.00040215 lncRNA:roX1 
FBgn0039232 421.689921 0.21758504 0.00041445 sosie 
FBgn0035360 61.6222633 0.45321505 0.00041938 CG1246 
FBgn0285913 1542.62943 -0.1137773 0.00043306 red 
FBgn0053143 1331.19412 -0.1978654 0.00045422 CG33143 
FBgn0283680 1056.84936 -0.1733917 0.00048853 IP3K2 
FBgn0003499 416.479119 -0.2297273 0.0005037 sr 
FBgn0030151 1390.12222 0.11799993 0.00051721 CG1354 
FBgn0034866 4.08017187 2.19059728 0.00052105 Or59c 
FBgn0039234 754.794425 -0.1315817 0.000524 Nct 
FBgn0035471 929.571414 -0.1595855 0.00053308 Sc2 
FBgn0250871 1443.32078 0.15808833 0.00054095 pot 
FBgn0283461 1382.18002 1.89608984 0.00055265 Drs 
FBgn0034512 15082.0154 0.71695058 0.00055265 CG18067 
FBgn0034638 6530.10564 0.12254287 0.00055275 CG10433 
FBgn0085209 107.839978 -0.4121645 0.00056689 CG34180 
FBgn0034966 115.100569 -0.3339116 0.00059561 CG13563 
FBgn0025186 865.716323 -0.1243454 0.00061562 ari-2 
FBgn0034602 329.773345 0.22317134 0.00061629 Lapsyn 
FBgn0028544 93.6103859 -0.3607026 0.00065096 Vajk3 
FBgn0030763 209.354431 -0.2550298 0.00065192 CG9782 
FBgn0033268 11058.3474 -0.1721123 0.00066567 Obp44a 
FBgn0035711 56.913432 0.49630372 0.00066654 CG8519 
FBgn0040070 2474.16332 -0.0942122 0.00067879 Trx-2 
FBgn0027574 298.128673 -0.2010784 0.00067879 CG5815 
FBgn0002789 2009.39607 0.17292711 0.00068675 Mp20 
FBgn0036334 915.888801 -0.1342784 0.00068885 CG11267 
FBgn0036661 1034.17766 -0.1612524 0.00074563 CG9705 
FBgn0001189 624.11511 0.1386838 0.00076078 hfw 
FBgn0063923 569.496564 -0.1883808 0.00076078 Kaz1-ORFB 
FBgn0019929 1725.59296 0.15549547 0.0007717 Ser7 
FBgn0260747 3588.95951 -0.111516 0.00079235 Chchd2 
FBgn0033913 2108.73695 0.17880697 0.00080893 CG8468 
FBgn0004102 1215.63691 0.16835804 0.00083839 oc 
FBgn0039500 31.128534 -0.5872326 0.00084665 CG5984 
FBgn0003861 59537.9326 -0.1243734 0.000887 trp 




FBgn0036659 633.024783 0.41361779 0.0009229 CG9701 
FBgn0025833 919.094786 -0.16121 0.0009229 CG8910 
FBgn0004117 3445.32538 0.17241309 0.00095641 Tm2 
FBgn0029843 1336.14235 -0.1119735 0.00097185 Nep1 
FBgn0039628 1682.59214 -0.1493132 0.00097617 CG11841 
FBgn0040736 8199.84319 0.48951486 0.00098659 IM3 
FBgn0028583 221.959884 2.23693273 0.0009967 lcs 
FBgn0284243 8884.08667 -0.1559131 0.0009967 betaTub56D 
FBgn0085370 2615.3086 0.10122614 0.00099797 Pde11 
FBgn0013772 656.771232 -0.3293364 0.00099835 Cyp6a8 
FBgn0034329 3989.62291 0.77877719 0.00100629 IM1 
FBgn0035173 2118.58058 -0.1293202 0.00102427 CG13907 
FBgn0036125 66.1803888 0.47040198 0.00103741 Iyd 
FBgn0037126 591.75975 0.27821154 0.00103763 CG14567 
FBgn0063491 1816.66068 -0.1777856 0.00104022 GstE9 
FBgn0028988 1440.36666 0.27819003 0.00106934 Spn42Dd 
FBgn0017545 15222.9652 0.0947948 0.00106934 RpS3A 
FBgn0026438 8589.97093 -0.1185413 0.00106934 Eaat2 
FBgn0036769 838.915057 -0.1371836 0.00106934 Tsp74F 
FBgn0052407 662.32851 -0.1561505 0.00106934 CG32407 
FBgn0033079 396.382667 0.22171541 0.00107268 Fmo-2 
FBgn0011828 3253.37562 0.12565377 0.00107951 Pxn 
FBgn0029504 2128.3101 0.14135289 0.00108229 CHES-1-like 
FBgn0035255 95.0682623 -0.324779 0.00110926 RabX5 
FBgn0260756 174.650151 0.24993613 0.00113847 CG42554 
FBgn0030230 648.925404 -0.1449162 0.00116731 Rph 
FBgn0025352 2732.1185 -0.1544614 0.00119543 Thiolase 
FBgn0259979 1086.01011 -0.202121 0.00119637 CG17337 
FBgn0033235 785.996834 -0.134916 0.00120303 CG8728 
FBgn0037230 3094.18332 0.1973707 0.0012325 Nepl11 
FBgn0261547 3136.45088 0.18173412 0.00123377 Exn 
FBgn0037719 370.018669 -0.2232901 0.00124304 bocks 
FBgn0036790 772.404691 0.18465652 0.00132733 AstC-R1 
FBgn0035187 263.389264 -0.2385809 0.00133659 Trh 
FBgn0266455 11.8874963 0.00388321 0.00134755 CG45080 
FBgn0025583 8596.43262 0.5005696 0.00137907 IM2 
FBgn0010611 1206.3615 0.14542 0.00144112 Hmgs 
FBgn0026602 1242.07082 -0.1276671 0.00145913 Ady43A 
FBgn0035434 1466.31262 -0.3926543 0.0014642 Drsl5 
FBgn0016715 420.536131 -0.2197039 0.00151066 Reg-2 
FBgn0039642 70.4351656 -0.4019676 0.00154368 CG11882 




FBgn0035553 472.168251 0.26586972 0.00168034 CG13722 
FBgn0032694 952.398799 0.13739066 0.00170842 MESR3 
FBgn0035488 787.983228 -0.1384073 0.00177403 CG11593 
FBgn0031646 42.004923 -0.5354003 0.00177403 snsl 
FBgn0031703 1134.03771 0.16764645 0.00179065 CG12512 
FBgn0002778 870.218475 0.15647005 0.00179065 mnd 
FBgn0032048 712.376436 -0.1411391 0.00180948 Dh31 
FBgn0028400 5433.73281 -0.1111665 0.00182653 Syt4 
FBgn0010278 502.8043 -0.180857 0.00182653 Ssrp 
FBgn0034511 1349.96975 0.76756443 0.00183447 GNBP-like3 
FBgn0037879 24.2667227 -0.6974051 0.00185428 scpr-C 
FBgn0021979 5519.87877 -0.0930803 0.00187999 l(2)k09913 
FBgn0040099 1622.20117 0.21126297 0.00188863 lectin-28C 
FBgn0032451 780.627422 -0.1293584 0.00188863 spict 
FBgn0051380 25.5801638 0.75675113 0.00194062 CG31380 
FBgn0034139 251.795401 0.27063334 0.00194249 CG4927 
FBgn0037324 67.8106805 0.5289718 0.00197139 Orco 
FBgn0052191 683.291027 0.17215943 0.00197957 CG32191 
FBgn0026562 4751.16472 0.12345833 0.00198173 SPARC 
FBgn0264324 2255.822 0.12235842 0.00198173 spg 
FBgn0039114 5595.39455 0.18464313 0.00198975 Lsd-1 
FBgn0015801 1360.04947 0.12376123 0.00199607 Reg-5 
FBgn0000406 13501.0359 0.11755605 0.0020068 Cyt-b5-r 
FBgn0030246 842.516214 -0.1407368 0.0020068 CG1582 
FBgn0263986 240.649399 -0.2505435 0.0020068 cd 
FBgn0050371 7.60757797 2.74893711 0.00202239 CG30371 
FBgn0030310 249.583099 0.30945801 0.00203855 PGRP-SA 
FBgn0027594 2579.48773 0.0910552 0.00205881 drpr 
FBgn0025621 1058.49147 0.12563383 0.00207747 CG16989 
FBgn0036880 280.490821 -0.3195672 0.00207747 Cpr76Bc 
FBgn0267013 229.037687 -0.7042758 0.00208489 lncRNA:CR45457 
FBgn0030993 343.780009 0.2197588 0.00211121 Mec2 
FBgn0283427 56630.9016 0.20714136 0.00212972 FASN1 
FBgn0052365 131.473052 -0.2722848 0.00215177 CG32365 
FBgn0038211 1259.93135 0.14859324 0.00216198 CG9649 
FBgn0031689 6598.63138 -0.1957172 0.00216198 Cyp28d1 
FBgn0033696 49.338527 0.75506037 0.00216521 Cyp6g2 
FBgn0035982 562.870225 -0.2282009 0.00216521 CG4461 
FBgn0003475 5324.63863 -0.0633333 0.00222158 spir 
FBgn0003884 18236.7875 -0.1174695 0.00222158 alphaTub84B 
FBgn0002567 5963.98735 -0.1224123 0.00222865 Rab32 




FBgn0014141 2641.05186 0.11939393 0.00224903 cher 
FBgn0029117 147.489415 -0.252814 0.00224903 Surf1 
FBgn0265575 718.905719 0.14864127 0.00226881 yin 
FBgn0263762 6.46597086 0.00470497 0.00227841 CG43679 
FBgn0037007 3140.45026 0.11968483 0.00228222 CG5059 
FBgn0035557 11.0456908 -0.0530444 0.00236731 CG11353 
FBgn0029839 336.601185 -0.1979353 0.00239155 CG4660 
FBgn0019982 1107.45968 -0.1055584 0.00240918 Gs1l 
FBgn0035817 1006.68024 -0.268992 0.00240918 CG7409 
FBgn0036016 40.3050464 -0.477251 0.00243752 CG3306 
FBgn0044047 1060.97536 0.17897759 0.00243822 Ilp6 
FBgn0038595 11.1715621 0.94304035 0.00244709 CG7142 
FBgn0020503 6574.31316 0.08414576 0.00244709 CLIP-190 
FBgn0003285 306.503617 -0.1876836 0.00244709 rst 
FBgn0026189 2412.99257 0.0997172 0.00246141 prominin-like 
FBgn0050203 429.975227 -0.2714768 0.00246381 CG30203 
FBgn0267506 328.77139 0.32969095 0.00249115 pre-rRNA:CR45846 
FBgn0050026 438.921649 0.48989297 0.00252966 CG30026 
FBgn0283462 18441.7753 0.60962325 0.00256923 IMPPP 
FBgn0037537 3011.40718 -0.0811863 0.00256952 CG2767 
FBgn0033122 334.34498 -0.1692502 0.00256971 CG17002 
FBgn0053470 37015.6492 0.60372039 0.00258008 CG33470 
FBgn0036199 606.709413 -0.1552722 0.00258008 Bmcp 
FBgn0067905 3444.75954 0.44833135 0.00259241 IM14 
FBgn0000121 153485.987 -0.1341436 0.00261522 Arr2 
FBgn0035181 603.634964 -0.156959 0.00261522 CG9205 
FBgn0050431 454.603957 -0.218501 0.00266742 CG30431 
FBgn0003162 3864.04855 0.15413563 0.00272698 Pu 
FBgn0037788 1860.87585 0.12701389 0.00273633 CAH7 
FBgn0028833 2426.54567 -0.0916852 0.00276477 Dak1 
FBgn0086450 1065.66341 0.13705714 0.00278406 su(r) 
FBgn0037607 9236.89514 -0.1814599 0.00279749 CG8036 
FBgn0013718 3276.43734 0.14010085 0.00282901 nuf 
FBgn0002773 10999.2214 0.15541242 0.00288159 Mlc2 
FBgn0086370 1088.32146 -0.1021017 0.00291107 sra 
FBgn0001565 1688.1352 0.15042363 0.00294807 Hlc 
FBgn0037697 877.558375 0.16494888 0.00296546 GstZ2 
FBgn0038874 175.7926 -0.2520989 0.00302333 ETHR 
FBgn0015010 49.2125278 1.89826782 0.00302549 Ag5r 
FBgn0265577 17.9151708 2.39491097 0.00303783 lncRNA:CR44404 
FBgn0010385 142.782068 1.26333202 0.00307501 Def 




FBgn0025777 1890.42334 0.15469991 0.00309695 homer 
FBgn0004133 624.439056 -0.1385348 0.00309925 blow 
FBgn0086673 89.902552 -0.4353908 0.00310177 CG13272 
FBgn0266405 46.107931 1.95655636 0.00312747 lncRNA:CR45045 
FBgn0039722 879.812395 -0.2882323 0.00312747 Capa 
FBgn0028399 4666.65911 -0.076673 0.00315836 TMS1 
FBgn0000046 1737.6999 0.16942969 0.00319024 Act87E 
FBgn0003391 1744.07476 0.12201601 0.00322234 shg 
FBgn0267507 331.780221 0.32219598 0.00324997 pre-rRNA:CR45847 
FBgn0028426 263.015541 0.56955563 0.00328477 RNaseZ 
FBgn0029134 1219.64864 -0.1036548 0.00328477 Prosbeta5 
FBgn0031858 1614.78081 -0.1193926 0.00336663 CG17378 
FBgn0034501 10568.0812 0.11103279 0.00337022 CG13868 
FBgn0000547 2860.56469 0.09766377 0.00337022 ed 
FBgn0014020 5425.0324 0.08181695 0.00337022 Rho1 
FBgn0027572 2044.54781 -0.0969023 0.00337022 CG5009 
FBgn0035092 1571.564 -0.1230299 0.00337022 Nplp1 
FBgn0039518 23.4173338 0.63868546 0.00342607 CG13978 
FBgn0027525 4045.34341 0.09985956 0.00346707 LTV1 
FBgn0038098 201.078483 -0.2145621 0.00350486 CG7381 
FBgn0267508 226.446248 0.4610267 0.00352566 28SrRNA-Psi:CR45848 
FBgn0036935 2986.45121 -0.1485584 0.0035648 CG14186 
FBgn0012042 166.449159 1.71670218 0.00356535 AttA 
FBgn0035802 1725.19766 0.11038247 0.00358117 Pura 
FBgn0002780 1223.46376 0.13387802 0.00361455 mod 
FBgn0020930 1078.32837 -0.1062135 0.00361455 Dgkepsilon 
FBgn0032684 985.266199 -0.1628584 0.00361455 Ugt301D1 
FBgn0030357 162.899069 0.26427039 0.00364542 Sclp 
FBgn0015282 1241.60919 -0.1164788 0.00365217 Rpt2 
FBgn0263077 15042.3972 0.14887453 0.00366849 CG43340 
FBgn0031392 522.934049 -0.1480936 0.00371272 AIF 
FBgn0014388 1488.63159 -0.1319121 0.00375401 sty 
FBgn0030012 129.691219 0.29282127 0.0037682 CG18262 
FBgn0265512 3901.6894 0.09946392 0.00377936 mlt 
FBgn0036857 1039.39786 -0.1347675 0.00381405 Aldh7A1 
FBgn0283499 1855.44672 0.24303631 0.0038349 InR 
FBgn0036619 5785.00074 -0.221735 0.00389518 Cpr72Ec 
FBgn0260474 722.577111 0.30694085 0.00395745 CG30002 
FBgn0038038 1484.75491 -0.102339 0.00395745 Sccpdh2 
FBgn0024179 1335.98963 -0.0935645 0.00397692 wit 
FBgn0262614 7089.78628 0.13775911 0.00397905 pyd 




FBgn0051064 1503.39311 -0.1001745 0.00411203 CG31064 
FBgn0261563 468.76584 -0.2077059 0.00411203 wb 
FBgn0032798 1856.29864 -0.1245779 0.00413365 CG10132 
FBgn0032109 1221.59519 -0.7009939 0.00428923 CG17005 
FBgn0004889 2946.81533 -0.1155698 0.00434149 tws 
FBgn0261243 1579.34166 -0.0944495 0.00436401 Psa 
FBgn0035806 775.375966 0.43495423 0.00455525 PGRP-SD 
FBgn0001297 4092.56282 -0.0903216 0.00455525 kay 
FBgn0029002 107.161432 -0.2602918 0.00459461 miple2 
FBgn0038850 16.0943204 0.92195814 0.00460223 CG17279 
FBgn0032484 658.588056 0.15626152 0.0046185 kek4 
FBgn0028479 3674.89041 -0.134336 0.00470048 Mtpalpha 
FBgn0001296 1579.4284 -0.1045391 0.00476098 kar 
FBgn0000024 9467.78898 0.14919821 0.00476568 Ace 
FBgn0261985 2442.77848 -0.0919677 0.00485483 Ptpmeg 
FBgn0035756 1744.43768 0.20561256 0.00485864 unc-13-4A 
FBgn0040206 1247.55257 0.15307555 0.00485864 krz 
FBgn0020660 4532.9007 0.09199919 0.00485864 eIF4B 
FBgn0051522 3341.77041 -0.0913503 0.00485864 CG31522 
FBgn0011768 1539.35092 -0.1369486 0.00485864 Fdh 
FBgn0046114 1825.83471 0.13264218 0.00486146 Gclm 
FBgn0028484 1586.03776 0.09839749 0.00495382 Ack 
FBgn0036927 6708.29925 0.08366492 0.00498588 Gabat 
FBgn0026570 165.777598 0.2340841 0.00501019 CG5704 
FBgn0035477 939.965796 0.1021707 0.00501282 CG14982 
FBgn0035816 1044.8659 0.13597835 0.00509769 CG13685 
FBgn0038247 42.986074 -0.4106527 0.00511231 Cad88C 
FBgn0037539 451.397312 -0.1716676 0.00517674 CG10435 
FBgn0039523 33.808489 0.50426989 0.00523569 CG12885 
FBgn0261628 108.345528 0.33967776 0.00524509 CG42711 
FBgn0052695 250.975967 0.23652515 0.00524509 CG32695 
FBgn0038465 3318.30388 0.19542159 0.00524509 Irc 
FBgn0262531 24.3406358 -0.8235071 0.00524509 CG43085 
FBgn0085771 3118.7028 0.52001632 0.00530344 28SrRNA-Psi:CR40741 
FBgn0033483 725.516754 0.1098802 0.00530344 egr 
FBgn0037842 226.720951 -0.1861967 0.00532895 CG6567 
FBgn0260660 2060.23392 0.09184117 0.00536431 Mp 
FBgn0035334 664.321123 -0.1525093 0.00536431 CG8993 
FBgn0033358 489.476318 -0.1633364 0.00536431 spab 
FBgn0003886 14.7047475 -0.8897445 0.00536431 alphaTub85E 
FBgn0033875 2589.13049 0.14293656 0.00540296 CG6357 




FBgn0035159 50.2781033 -0.4386894 0.00562067 CG13896 
FBgn0013272 13793.8243 0.05950509 0.00565992 Gp150 
FBgn0026439 8227.71564 -0.074132 0.00565992 Eaat1 
FBgn0052820 113.010697 -0.4299081 0.00565992 CG32820 
FBgn0066365 5.92318149 -1.1818904 0.00565992 dyl 
FBgn0004513 1496.6641 -0.0920997 0.00567603 Mdr65 
FBgn0000008 545.382936 -0.1384046 0.00573437 a 
FBgn0267798 11.9122192 -0.8988276 0.00574822 lncRNA:CR46123 
FBgn0003462 5686.70201 -0.0943599 0.00575405 Sod1 
FBgn0035166 151.874927 -0.2189017 0.0057817 JMJD5 
FBgn0030508 1200.98632 0.11416662 0.00579135 CG15760 
FBgn0029891 3346.51375 0.06969497 0.0059988 Pink1 
FBgn0037063 1664.66771 -0.1099337 0.00600622 CG9391 
FBgn0033215 85.3380799 -0.4101569 0.00631512 Dgat2 
FBgn0267966 16.8931397 -0.7956163 0.00637537 asRNA:CR46246 
FBgn0030731 2209.86031 -0.096848 0.00638675 Mfe2 
FBgn0035709 8.96373368 1.07863859 0.00645518 eIF4E4 
FBgn0285955 2537.26108 0.09304622 0.00656064 cv-c 
FBgn0030103 56.8148886 -0.3565101 0.00656064 Obp8a 
FBgn0087005 6703.75953 -0.1784508 0.00658979 rtp 
FBgn0036597 218.382825 -0.227178 0.00659099 CG4962 
FBgn0040028 163.856323 -0.4150033 0.00659321 CG17450 
FBgn0031213 1315.33966 0.0969785 0.00667335 galectin 
FBgn0270926 1167.07122 -0.1514588 0.00667335 AsnS 
FBgn0267505 165.274253 0.30458088 0.00668051 pre-rRNA:CR45845 
FBgn0039040 1673.88333 0.15825875 0.00669372 CG13833 
FBgn0029769 617.661594 0.13487782 0.00670215 frma 
FBgn0040734 1253.26403 0.54205324 0.0067551 CG15065 
FBgn0036713 862.24274 -0.1276124 0.00676132 Mip 
FBgn0040609 144.99013 -0.640654 0.00685038 CG3348 
FBgn0023179 4683.96739 -0.0981798 0.00685396 amon 
FBgn0265052 522.10271 -0.1271075 0.0068981 St3 
FBgn0052698 902.121418 0.18727968 0.00696607 CARPB 
FBgn0031700 87.6969458 0.31351206 0.0071388 CG14022 
FBgn0036781 8.76665583 -0.0332606 0.00714367 CG13699 
FBgn0036975 1870.12447 -0.1201002 0.00714803 CG5618 
FBgn0031417 1048.46252 -0.2372167 0.00715053 CG3597 
FBgn0004359 483.814518 0.13781533 0.00733044 T48 
FBgn0041581 548.15466 1.36999067 0.00739381 AttB 
FBgn0038237 2877.98776 0.0990146 0.00739381 Pde6 
FBgn0259224 1374.92649 -0.1270241 0.00758976 CG42324 




FBgn0033153 436.047857 -0.2658287 0.0077856 Gadd45 
FBgn0036516 754.046623 -0.1143968 0.00790207 CG7656 
FBgn0031987 486.071017 -0.1334904 0.00792391 CG12375 
FBgn0033574 1188.33295 0.10759842 0.00794878 Spn47C 
FBgn0038143 15810.2649 -0.0698781 0.00794878 CG9813 
FBgn0035906 1155.61936 -0.1193213 0.0080029 GstO2 
FBgn0039807 373.120629 0.16935241 0.00804056 CG15546 
FBgn0051999 1362.72662 0.13672107 0.00810908 CG31999 
FBgn0034761 1198.59114 0.24017168 0.008265 CG4250 
FBgn0039254 491.214892 -0.1747625 0.00827122 Nmnat 
FBgn0033739 2412.70677 0.08691783 0.00848222 Dyb 
FBgn0035538 6612.47073 -0.1389827 0.00848222 DopEcR 
FBgn0038738 2026.08418 -0.1187322 0.00848992 CG4572 
FBgn0265598 1129.79302 0.09684473 0.00850939 Bx 
FBgn0263106 2272.24921 -0.0938094 0.00850939 DnaJ-1 
FBgn0031069 3579.22829 -0.1070453 0.00850939 Pmp70 
FBgn0030610 452.377164 -0.1273369 0.008558 CG9065 
FBgn0051326 3199.12907 0.16117309 0.00857252 CG31326 
FBgn0035151 48.5333586 0.35286508 0.00867821 CG17129 
FBgn0004401 4934.00743 -0.067149 0.00867821 Pep 
FBgn0031432 223.462231 -0.424338 0.00869808 Cyp309a1 
FBgn0033304 601.781516 0.1567815 0.00880661 Cyp6a13 
FBgn0010053 2170.18643 -0.130539 0.00882909 Jheh1 
FBgn0283531 228.630779 0.19177251 0.00895357 Duox 
FBgn0037796 1101.82847 0.11056032 0.00901282 CG12814 
FBgn0034259 426.085212 -0.1277889 0.00902731 P32 
FBgn0052553 67.1502949 0.37534964 0.00903026 lncRNA:CR32553 
FBgn0003721 4602.9292 0.1207903 0.00903485 Tm1 
FBgn0030090 773.964164 0.12097607 0.00912525 fend 
FBgn0263220 9016.07934 0.09285295 0.00912525 Hk 
FBgn0029870 5115.3436 0.05816287 0.00912525 Marf 
FBgn0029996 2955.15325 0.12535809 0.00920558 UbcE2H 
FBgn0035830 662.025995 -0.1145436 0.0092105 CG8209 
FBgn0034500 598.904376 -0.1647172 0.0092105 CG11200 
FBgn0004436 2784.31853 0.09666732 0.00927379 Ubc6 
FBgn0266756 5046.07134 0.12671521 0.00937273 btsz 
FBgn0035718 7.9249539 0.96429108 0.00946397 CG14820 
FBgn0028855 51.6517182 0.70545281 0.00946397 CG15282 
FBgn0039495 346.962791 0.22181858 0.00946397 CG5909 
FBgn0003149 3715.86662 0.1767919 0.00946397 Prm 
FBgn0035344 1014.21152 -0.1268087 0.00946397 Cyp4d20 




FBgn0086254 2537.51743 -0.1092729 0.00948274 CG6084 
FBgn0039970 2861.44501 0.11670369 0.00960996 CG17508 
FBgn0024957 2443.62233 0.15486089 0.00962983 Irp-1B 
FBgn0037721 474.102792 -0.1645808 0.0096691 CG9427 
FBgn0032882 540.803521 -0.121901 0.00972398 Ns4 
FBgn0003716 1263.98937 0.10272245 0.00973721 tkv 
FBgn0034717 814.378981 0.15873605 0.00978143 CG5819 
FBgn0010621 994.709396 -0.1494817 0.0097884 CCT5 
FBgn0051248 768.841926 0.11680955 0.00980137 CG31248 
FBgn0002891 369.015951 -0.190096 0.00980137 mus205 
FBgn0015576 3096.15371 -0.1347218 0.01007102 alpha-Est8 
FBgn0085819 2947.097 0.46502322 0.01007251 28SrRNA-Psi:CR41609 
FBgn0052056 1212.92755 -0.0831742 0.01017463 scramb1 
FBgn0026576 3662.09736 -0.1648846 0.0101854 Pisd 
FBgn0003189 831.059011 -0.1434096 0.01018578 r 
FBgn0037327 1336.82841 -0.1151016 0.01024913 PEK 
FBgn0033988 1541.1759 0.07852436 0.01031619 pcs 
FBgn0262579 13959.4982 0.06543939 0.01038457 Ect4 
FBgn0040064 2638.11894 -0.1236424 0.01042796 yip2 
FBgn0026315 243.777747 -0.1658457 0.01061296 Ugt35A1 
FBgn0036152 626.489802 0.11497207 0.01065319 CG6175 
FBgn0266019 7103.00636 0.08122257 0.01065319 rudhira 
FBgn0053296 291.821488 0.20392012 0.01078279 CG33296 
FBgn0267913 345.218712 0.18048601 0.01080824 lncRNA:CR46194 
FBgn0036351 8.0444923 -0.0314173 0.01080824 CG14107 
FBgn0011283 70.1493014 0.9471584 0.01107807 Obp28a 
FBgn0033936 106.452767 0.69777179 0.01107807 Achl 
FBgn0031801 883.610987 0.23975376 0.01107807 CG9498 
FBgn0030432 812.849828 0.09500201 0.01107807 CG4404 
FBgn0038397 70.4344932 0.92146676 0.01114174 CG10185 
FBgn0265413 986.668348 0.12037497 0.01116717 CG44325 
FBgn0031111 142.135965 -0.2482759 0.0112011 Obp19c 
FBgn0037819 472.605435 -0.1854202 0.01128096 CG14688 
FBgn0037636 21858.0696 0.11132786 0.01129943 NA 
FBgn0027835 7497.71452 0.10676767 0.01129943 Dp1 
FBgn0027086 1431.22888 0.20026552 0.01142898 IleRS 
FBgn0040582 1804.80368 0.5097036 0.0115076 CG5791 
FBgn0037433 945.455364 -0.0920854 0.0115405 CG17919 
FBgn0041713 475.466599 0.14040797 0.01156751 yellow-c 
FBgn0064225 20913.6063 0.07225433 0.01164745 RpL5 
FBgn0013307 449.005557 0.14553316 0.01168123 Odc1 




FBgn0013725 622.936756 -0.1173689 0.01183287 phyl 
FBgn0003943 45844.115 -0.0920263 0.01185499 Ubi-p63E 
FBgn0035888 927.987793 0.09619016 0.01185639 CG7120 
FBgn0037443 2241.1588 -0.0691441 0.011936 Dmtn 
FBgn0037889 9.05329791 -0.0360417 0.01197125 scpr-A 
FBgn0033649 584.873204 0.1573734 0.01222055 pyr 
FBgn0030160 7681.40104 0.0960189 0.01223104 CG9691 
FBgn0062928 12.7669314 -0.0463412 0.01235067 hpRNA:CR33940 
FBgn0051028 81.2539843 0.29290217 0.0123562 CG31028 
FBgn0032835 5056.84568 0.39640134 0.01238578 CG16772 
FBgn0050151 442.133868 0.16026194 0.01242143 CG30151 
FBgn0010620 1120.10448 0.10831455 0.01242143 CG10939 
FBgn0262782 8057.75658 -0.0910348 0.01249231 Mdh1 
FBgn0036627 221.253224 0.18757423 0.01268846 Gagr 
FBgn0035710 1822.71557 0.11620381 0.01271691 SP1173 
FBgn0027592 422.681652 -0.1308338 0.01277336 MED15 
FBgn0038830 212.263801 0.18554636 0.01292027 CG17272 
FBgn0011766 2277.57875 -0.0854958 0.01294759 E2f1 
FBgn0034480 48.5191225 -0.6129578 0.01297262 CG16898 
FBgn0266599 42551.8453 -0.0721274 0.01302186 Hsc70-4 
FBgn0039054 12781.696 -0.0843261 0.01305945 Cow 
FBgn0025615 511.657781 -0.1160915 0.01305945 Torsin 
FBgn0020653 3725.52388 -0.0895225 0.01308163 Trxr-1 
FBgn0039429 8.84690357 -0.0371356 0.0130992 CG14238 
FBgn0026593 1044.51115 -0.1309493 0.0130992 CG5707 
FBgn0004837 315.546506 -0.1420263 0.0130992 Su(H) 
FBgn0041210 2571.82243 0.0844941 0.0131987 HDAC4 
FBgn0029666 759.64829 0.12827378 0.0132514 CG10803 
FBgn0038017 114.07023 -0.312641 0.01340861 CG4115 
FBgn0053784 21.3696034 -0.5069528 0.01347495 CG33784 
FBgn0038074 1820.74165 0.48124211 0.01350141 Gnmt 
FBgn0267012 444.208341 -0.6224272 0.01351439 lncRNA:CR45456 
FBgn0026179 2902.46569 -0.0772816 0.01361436 siz 
FBgn0011763 1514.277 0.07512603 0.01365936 Dp 
FBgn0034628 597.305728 -0.1131483 0.01365936 Acox57D-p 
FBgn0033820 13170.5289 0.12391253 0.01369619 CG4716 
FBgn0033038 461.330798 -0.1174961 0.01381905 CG7791 
FBgn0030257 69.0715203 0.29459946 0.01382429 SmydA-4 
FBgn0031457 372.161366 -0.1307998 0.01382429 CG3077 
FBgn0034076 41.6213209 1.7676726 0.014087 Jhedup 
FBgn0034406 526.152253 -0.1597448 0.01419042 Jheh3 




FBgn0033250 11256.1542 0.10184643 0.01433234 CG14762 
FBgn0017418 2452.40994 0.08072307 0.01434947 ari-1 
FBgn0038809 4326.08101 0.06706107 0.01434947 CG16953 
FBgn0261394 949.266427 -0.1062995 0.01434947 Prosalpha3 
FBgn0038407 1940.71481 -0.1370976 0.01437953 CG6126 
FBgn0264695 32789.3387 0.14599798 0.01441977 Mhc 
FBgn0039316 76.2571062 0.30079481 0.01455411 CG11893 
FBgn0259150 3096.63127 0.11787593 0.0145595 OtopLc 
FBgn0036728 1851.81893 -0.1413971 0.01462279 UQCR-Q 
FBgn0014033 1041.48911 0.15449747 0.01462546 Sr-CI 
FBgn0034935 589.669639 -0.1680733 0.01468383 Orcokinin 
FBgn0053147 2734.8396 0.11558219 0.01490273 Hs3st-A 
FBgn0039348 1690.53798 -0.1610875 0.01491347 Npl4 
FBgn0002526 1879.19161 0.14101291 0.01499011 LanA 
FBgn0050423 1075.65518 -0.1015694 0.01499507 CG30423 
FBgn0029959 686.845249 0.10880518 0.01511408 Rab39 
FBgn0030850 1066.69084 0.08579535 0.01517242 stas 
FBgn0086680 1893.28574 -0.1083097 0.01517242 vvl 
FBgn0250843 686.085263 -0.1336833 0.01517242 Prosalpha6 
FBgn0000535 3078.20599 0.13603287 0.01532302 eag 
FBgn0034331 8903.33869 0.2387592 0.01536261 CG15067 
FBgn0052121 103.910355 0.25302964 0.01559579 CG32121 
FBgn0037487 55.3473707 0.3159657 0.01559839 thw 
FBgn0063667 19.9189241 -0.5433321 0.01568428 CG32335 
FBgn0041627 163.08788 -0.3750393 0.01571881 Ku80 
FBgn0039490 5.63344376 -1.0691794 0.01594196 CG5882 
FBgn0038681 2367.48578 0.09440278 0.0162507 Cyp12a4 
FBgn0051729 5345.78882 0.07291063 0.01640507 CG31729 
FBgn0085428 26.1032315 0.43211206 0.01641635 Nox 
FBgn0261929 472.547403 0.1278575 0.01641635 5-HT2B 
FBgn0016123 1184.39034 -0.1052008 0.01645591 Alp4 
FBgn0050033 221.976063 0.17310471 0.0164698 CG30033 
FBgn0027843 3194.63198 -0.0889063 0.0164698 CAH2 
FBgn0035811 374.02762 -0.1482836 0.0164698 Mcad 
FBgn0034136 421.590429 0.13805737 0.01659543 DAT 
FBgn0034474 2554.69781 0.13290806 0.01670683 Obp56g 
FBgn0062961 115.856118 0.26032444 0.01681238 lncRNA:CR33942 
FBgn0037683 290.407032 0.21614242 0.01681238 CG18473 
FBgn0000318 969.757274 -0.0932741 0.01685731 cl 
FBgn0029937 428.204598 -0.1244063 0.01685731 CG8300 
FBgn0035679 328.761292 -0.1781863 0.01685731 CG10467 




FBgn0031327 1480.36494 0.1267088 0.01721697 CG5397 
FBgn0010414 418.870844 -0.1154828 0.01728325 SerT 
FBgn0040001 58.1811929 0.28999361 0.01730255 FASN3 
FBgn0036028 286.127936 -0.1390414 0.01731718 CG16717 
FBgn0029174 1255.70297 -0.0809426 0.0174483 Fkbp59 
FBgn0038914 209.717107 0.50082825 0.01781839 fit 
FBgn0052819 53.8091366 -0.383941 0.01787418 CG32819 
FBgn0027532 1061.78695 0.10030138 0.01812946 CG7139 
FBgn0033465 1875.13668 -0.1058391 0.01813902 NA 
FBgn0267435 42359.2472 -0.0843093 0.0182382 chp 
FBgn0260941 3500.54421 0.11374686 0.01840823 app 
FBgn0031816 449.633876 -0.117275 0.01854383 Rchy1 
FBgn0037265 410.685798 -0.122694 0.01854383 spartin 
FBgn0031999 158.375388 0.35568515 0.01868662 CG8419 
FBgn0043535 786.277351 0.13323616 0.01868662 Obp57a 
FBgn0035371 1720.52197 -0.0795573 0.01868662 AhcyL1 
FBgn0004876 1935.21101 0.10656567 0.01869818 cdi 
FBgn0259714 940.631817 0.11644276 0.01871014 DIP-epsilon 
FBgn0033365 58.0978634 -0.2933763 0.01871014 CG8170 
FBgn0015766 34032.4485 -0.0710662 0.01871297 Msr-110 
FBgn0034994 7.27834679 0.86344488 0.01882574 Ir60a 
FBgn0261618 8211.15373 0.09546729 0.01887308 larp 
FBgn0036462 212.52003 -0.1677923 0.019035 mRpL39 
FBgn0025633 1092.09946 0.09849904 0.01907235 CG13366 
FBgn0265998 6905.57021 0.11680908 0.01907765 Doa 
FBgn0032233 759.905106 0.09464918 0.01923176 dpr19 
FBgn0053531 456.240853 0.12060816 0.01927447 Ddr 
FBgn0011274 2791.8201 0.11320456 0.01927447 Dif 
FBgn0085813 12827.1529 0.30367727 0.01928829 18SrRNA-Psi:CR41602 
FBgn0003091 4524.67353 0.08612474 0.01928829 Pkc53E 
FBgn0265253 10.518348 0.67633756 0.01930762 asRNA:CR44267 
FBgn0063449 70.1120007 0.26843115 0.0195059 Uhg2 
FBgn0011693 10169.5086 -0.1101916 0.0195076 Pdh 
FBgn0028841 21.2149748 0.76834053 0.01962376 jhamt 
FBgn0052082 3638.809 -0.0592509 0.01977484 IRSp53 
FBgn0011770 1520.97844 -0.1144749 0.01980936 Gip 
FBgn0039759 132.127358 0.63423546 0.02018282 CG9733 
FBgn0036773 587.001122 0.10814226 0.0202703 CG13698 
FBgn0010288 596.884616 -0.1043275 0.02033664 Uch 
FBgn0022359 153.001092 0.19084555 0.02054414 Sodh-2 
FBgn0028694 774.372828 -0.0970062 0.02089699 Rpn11 




FBgn0267511 14929.5843 0.38532046 0.02108947 28SrRNA-Psi:CR45851 
FBgn0050154 41.6888545 0.36449442 0.02108947 CG30154 
FBgn0052767 2984.91487 0.11844517 0.02108947 CG32767 
FBgn0028327 3140.73673 0.09566531 0.02108947 l(1)G0320 
FBgn0035402 654.312735 -0.1152136 0.02108947 Usp5 
FBgn0029723 733.19572 0.09728919 0.02118846 Proc-R 
FBgn0001250 2284.18809 0.07357082 0.02126623 if 
FBgn0083977 132.113377 -0.1920898 0.02127425 CG34141 
FBgn0034709 2911.36969 0.13060034 0.02129071 Swim 
FBgn0036382 93.9390566 0.27039843 0.02129909 CG13737 
FBgn0263144 1915.17604 0.06481714 0.02139894 bin3 
FBgn0266580 1048.53775 0.14850802 0.02181443 Gp210 
FBgn0004197 61.9332781 0.2708833 0.02184222 Ser 
FBgn0000723 1856.29975 0.12705004 0.02184222 FER 
FBgn0005278 5424.70721 0.0864766 0.02191708 Sam-S 
FBgn0266774 4.59403367 1.07217051 0.02201095 lncRNA:CR45239 
FBgn0028408 1696.06927 0.09169017 0.02201095 Drep2 
FBgn0028695 1961.29794 -0.0778203 0.02201095 Rpn1 
FBgn0038065 2085.59688 -0.0813252 0.02202971 Snx3 
FBgn0037533 4635.73453 0.10348013 0.02212214 CD98hc 
FBgn0042129 69.1953633 0.75450198 0.02224981 OS9 
FBgn0043799 53.2363901 -0.3106648 0.0223034 CG31381 
FBgn0029506 3154.59175 0.09003102 0.02240608 Tsp42Ee 
FBgn0261552 27617.4876 0.09745134 0.0224609 ps 
FBgn0262721 13.5077505 0.56616621 0.02260193 CG43165 
FBgn0032297 2660.92987 0.13061828 0.02260193 CG17124 
FBgn0035534 152.464565 -0.1723448 0.02260193 mRpS6 
FBgn0037016 500.06263 0.10984646 0.02276324 CG13252 
FBgn0260962 986.821491 -0.1001702 0.02284391 pic 
FBgn0030234 724.343396 -0.1253828 0.02299074 CG15211 
FBgn0030336 2640.87538 0.07291459 0.02317533 CG1578 
FBgn0036213 9238.60017 0.07139902 0.02322889 RpL10Ab 
FBgn0016075 7272.18258 0.10136591 0.02325921 vkg 
FBgn0029892 104.350207 0.2069006 0.02364983 CG3184 
FBgn0038683 826.740066 -0.1032509 0.02365408 CG11779 
FBgn0037845 260.574224 -0.1569706 0.02381429 CG14694 
FBgn0262532 55.8592515 0.34809208 0.02386796 CR43086 
FBgn0034398 6470.68127 0.06853836 0.02414679 CG15098 
FBgn0085195 2309.65489 -0.2730398 0.02414679 CG34166 
FBgn0032181 13.4430314 1.25322496 0.02417069 CG13133 
FBgn0001233 16376.7475 -0.1173075 0.02417604 Hsp83 




FBgn0039897 1692.46275 0.11223961 0.02470668 CG1674 
FBgn0263102 4733.21415 0.10776925 0.02470668 psq 
FBgn0014189 1209.44839 -0.0827557 0.02470668 Hel25E 
FBgn0028983 152.786326 -0.191911 0.02470668 Spn55B 
FBgn0040735 1824.02466 0.21561697 0.02482485 CG16836 
FBgn0040260 816.746289 -0.0954548 0.02489339 Ugt37D1 
FBgn0038142 17.2339041 -0.6284777 0.02519489 CheA87a 
FBgn0038115 654.304606 -0.1095249 0.02528364 CG7966 
FBgn0015791 2144.68507 -0.0869258 0.02562214 Rab14 
FBgn0031220 2044.38742 0.14342705 0.02574363 CG4822 
FBgn0041579 1480.76424 1.34646159 0.02585847 AttC 
FBgn0032216 697.035557 -0.0908389 0.02586265 Usp14 
FBgn0034802 7418.39247 -0.0825748 0.02590328 CNBP 
FBgn0033886 1209.56113 -0.0869892 0.02635971 Rpn13 
FBgn0032834 85.3042037 0.24359447 0.02640001 CG13965 
FBgn0032397 484.007732 -0.1146466 0.02640001 Tom70 
FBgn0039858 21214.3103 0.08812608 0.02641033 CycG 
FBgn0031998 425.951819 -0.1528597 0.0265706 SLC5A11 
FBgn0030159 693.922951 0.10554774 0.02663928 CG9689 
FBgn0010388 470.208547 1.33825163 0.02664657 Dro 
FBgn0014396 17948.0563 -0.088912 0.02690168 tim 
FBgn0000250 2858.13619 0.06988259 0.02709726 cact 
FBgn0033129 117.638945 0.19899499 0.02758809 Tsp42Eh 
FBgn0037249 4078.26058 0.06906382 0.02758809 eIF3a 
FBgn0040793 2384.16152 -0.0982343 0.02758809 CG7630 
FBgn0039155 472.651584 -0.1059008 0.02767219 Kal1 
FBgn0259745 1772.00697 0.10389001 0.02778574 wech 
FBgn0260753 1443.47667 -0.0732989 0.02778574 Pdfr 
FBgn0002592 25.1086346 -0.3875823 0.02778574 E(spl)m2-BFM 
FBgn0034253 155.660299 0.19478786 0.02794698 CG10936 
FBgn0085408 906.389302 0.0992902 0.02806291 Shrm 
FBgn0000116 28175.9065 -0.0887397 0.02828372 Argk 
FBgn0031497 735.851833 -0.1068991 0.02860221 SerRS 
FBgn0028699 1945.06333 0.08186319 0.02869567 Rh50 
FBgn0028360 682.486924 -0.1232835 0.02891566 Cdc7 
FBgn0037107 928.717812 0.10775965 0.02901871 CG7166 
FBgn0264000 1239.16766 0.08534449 0.02908068 GluRIB 
FBgn0039544 402.006635 -0.1217866 0.02916829 CG12877 
FBgn0067102 690.109625 -0.1163721 0.02917666 GlcT 
FBgn0039844 2539.18936 0.08967754 0.0295677 CG1607 
FBgn0087012 1784.82686 -0.0791035 0.02957122 5-HT2A 




FBgn0043791 471.272965 0.43329516 0.0295782 phu 
FBgn0265274 1825.62372 0.08000335 0.0295782 Inx3 
FBgn0001291 658.548799 -0.1162855 0.0295782 Jra 
FBgn0028542 347.879261 0.15839573 0.02972152 NimB4 
FBgn0029834 2233.94007 -0.09613 0.02972152 CG5937 
FBgn0000278 4.99251503 1.05785868 0.02999679 CecB 
FBgn0283472 2802.41319 0.06793799 0.03057621 S6k 
FBgn0038194 6302.44752 -0.1142487 0.03061498 Cyp6d5 
FBgn0023174 1088.30617 -0.0826959 0.03100196 Prosbeta2 
FBgn0025625 1947.52195 -0.0725713 0.03120766 Sik2 
FBgn0037672 67.5043279 -0.2579977 0.03128405 sage 
FBgn0011296 591.908398 0.14298827 0.03131774 l(2)efl 
FBgn0051935 588.433598 0.10261362 0.03156682 CG31935 
FBgn0032393 1431.06639 -0.079928 0.03188531 Nfs1 
FBgn0035781 14.6123091 0.53345982 0.03193751 CG8560 
FBgn0038742 699.128866 -0.1175121 0.03210228 Arc42 
FBgn0004880 8755.67373 0.09090714 0.03231872 scrt 
FBgn0035688 2954.15529 0.08656902 0.03231872 fmt 
FBgn0042179 15.8087996 0.47176706 0.03263639 Ugt305A1 
FBgn0034142 1774.42139 -0.0845083 0.03270595 CG8306 
FBgn0034069 205.68174 -0.1645478 0.03303703 CG8401 
FBgn0030893 204.077229 -0.1455016 0.03306348 RhoGAP16F 
FBgn0034246 1309.20477 0.07995961 0.03308049 Dcr-2 
FBgn0032482 3774.79949 -0.0723457 0.03308372 Pect 
FBgn0039993 1488.71561 0.09263602 0.03323207 CG17691 
FBgn0039089 961.32279 0.08864364 0.03327571 beat-IV 
FBgn0259878 327.750037 0.1260997 0.03355968 Fs 
FBgn0086358 1321.07941 -0.0865379 0.03355968 Tab2 
FBgn0034436 590.601228 -0.1023797 0.03355968 CG11961 
FBgn0037726 40.3813141 0.99557559 0.03358045 CG9492 
FBgn0003328 623.461897 0.10081244 0.03358045 NA 
FBgn0040653 20607.7554 0.24654971 0.03360745 IM4 
FBgn0000667 2744.60875 0.09284039 0.03377871 Actn 
FBgn0037712 221.832165 -0.1586092 0.03389422 CG16789 
FBgn0032821 1920.52652 -0.1104043 0.03400324 CdGAPr 
FBgn0039510 41.8358673 0.38665267 0.03446279 CG3339 
FBgn0032222 924.706081 -0.0859569 0.03490056 CG5037 
FBgn0031145 910.985567 -0.0849091 0.03498873 Ntf-2 
FBgn0038214 65.0232694 0.35731117 0.03507195 CG9616 
FBgn0029639 620.370805 0.22079174 0.03507195 CG14419 
FBgn0030976 3259.77832 -0.0638948 0.03507195 CG7378 




FBgn0250869 1413.67836 -0.0868312 0.03543407 CG42240 
FBgn0037163 1924.83947 -0.1010044 0.0354709 laza 
FBgn0037836 77.7495968 0.24172238 0.03549526 CG14692 
FBgn0001078 1485.03794 0.09679864 0.03549526 ftz-f1 
FBgn0037410 782.216883 -0.1934195 0.03590579 Osi2 
FBgn0036479 121.565744 0.18451969 0.03613903 CG13458 
FBgn0051777 236.087577 -0.1479683 0.03613903 CG31777 
FBgn0261553 2857.31934 0.08645198 0.03614072 CG42671 
FBgn0004687 1988.39454 -0.0846292 0.03672578 Mlc-c 
FBgn0037447 503.375135 0.12078435 0.03683072 Neurochondrin 
FBgn0034396 381.685067 -0.1270564 0.03710373 CG15097 
FBgn0038056 207.588429 -0.1496099 0.03729883 CG5961 
FBgn0040493 686.115657 -0.0929254 0.03736399 grsm 
FBgn0039205 151.901541 -0.160207 0.03740825 CG13623 
FBgn0035410 503.902261 0.10073832 0.03765369 CG14964 
FBgn0016672 3753.04965 -0.0669803 0.03765369 Ipp 
FBgn0034407 568.979961 1.21637008 0.03801415 DptB 
FBgn0087011 456.792575 0.15260015 0.03803323 CG41520 
FBgn0028494 60.356586 0.46691052 0.03810882 CG6424 
FBgn0030332 479.849355 -0.122002 0.0381841 CG9360 
FBgn0015039 3751.49009 -0.0908939 0.03837925 Cyp9b2 
FBgn0036882 1717.30229 -0.0945994 0.0386366 CG9279 
FBgn0085790 66.9540992 0.27949799 0.03889469 CR41507 
FBgn0033602 526.161989 0.11860247 0.03889469 Cpr47Ee 
FBgn0259175 1574.38445 0.09502417 0.03889469 ome 
FBgn0264989 1189.74577 0.15466091 0.03904484 CG44140 
FBgn0265487 5858.81205 0.13509356 0.03904484 mbl 
FBgn0035372 533.6342 0.10850061 0.03917895 CG12093 
FBgn0029824 616.851532 0.09558084 0.03917895 CG3726 
FBgn0037935 1230.13062 0.07546365 0.03917895 CG6834 
FBgn0035266 980.434632 0.13064944 0.03934208 Gk2 
FBgn0004859 873.25728 0.12292023 0.03945961 ci 
FBgn0035484 2263.95935 -0.1591677 0.03956241 CG11594 
FBgn0035831 48.2301667 -0.2467884 0.03956241 CG8038 
FBgn0035625 3133.61867 0.07949441 0.03968204 Blimp-1 
FBgn0031753 113.680244 -0.1982474 0.03974953 CG13999 
FBgn0000299 9035.94968 0.12098132 0.03991358 Col4a1 
FBgn0013771 1233.84051 0.07540667 0.03991358 Cyp6a9 
FBgn0027101 2205.84201 0.13337164 0.03995574 Dyrk3 
FBgn0040397 1005.78858 0.09786782 0.04012791 CG3655 
FBgn0051451 24793.2265 -0.107685 0.04022627 lncRNA:CR31451 




FBgn0267431 37.0855009 0.29387276 0.04058194 Myo81F 
FBgn0259111 3767.6794 0.0768486 0.04058194 Ndae1 
FBgn0023495 12.1944957 -0.0308474 0.04058194 Lip3 
FBgn0261999 1417.3329 -0.1267152 0.04059687 Ca-Ma2d 
FBgn0052602 136.943914 -0.2371816 0.04086913 Muc12Ea 
FBgn0034401 673.760009 0.12846649 0.04113495 MetRS 
FBgn0264990 1207.4876 0.15362374 0.04119801 CG44141 
FBgn0000370 5755.01402 0.09445849 0.04119801 crc 
FBgn0002121 1637.63631 0.11300565 0.0413323 l(2)gl 
FBgn0259711 90.1114187 -0.1919259 0.04161332 CG42365 
FBgn0032796 1600.65435 0.07277495 0.04177242 CG10188 
FBgn0034184 2358.70944 -0.0909982 0.04179038 CG9646 
FBgn0026268 725.95017 0.38249718 0.04189287 antdh 
FBgn0037363 2722.10666 0.0859213 0.04189287 Atg17 
FBgn0033836 500.923129 -0.113741 0.04189287 CG18278 
FBgn0050109 91.2116912 -0.2061461 0.04189287 CG30109 
FBgn0262881 56.6519523 0.64834608 0.04194363 CG43236 
FBgn0038299 495.797188 0.44349605 0.04224386 Spn88Eb 
FBgn0262533 57.2616808 0.33460753 0.04233755 CR43087 
FBgn0039685 888.447313 -0.3319913 0.04239294 Obp99b 
FBgn0027786 1277.46383 -0.0686267 0.04257791 Mtch 
FBgn0035370 941.457265 -0.0860492 0.04257791 Non2 
FBgn0034618 3460.61595 0.08755506 0.04259851 CG9485 
FBgn0036879 6.25779052 -0.0241771 0.04288245 Cpr76Bb 
FBgn0029710 86.7835342 0.19265395 0.0431289 CG3568 
FBgn0020414 2562.43633 0.07386403 0.04317375 Idgf3 
FBgn0039806 26.2603715 0.34802357 0.04331843 CG15545 
FBgn0085274 21.8687719 -0.3947129 0.04357046 CG34245 
FBgn0000715 232.388607 0.17097907 0.04359749 FMRFa 
FBgn0029944 209.465414 0.13600255 0.04389525 Dok 
FBgn0037755 510.150906 0.10106462 0.04389525 CG12945 
FBgn0039277 1314.47161 0.07767964 0.04389525 Nepl16 
FBgn0032889 2346.00697 -0.1162638 0.04390893 CG9331 
FBgn0051053 19.2482136 -0.4239496 0.04403068 CG31053 
FBgn0263911 1625.15884 -0.0912233 0.04446195 COX8 
FBgn0033093 544.960174 -0.1194266 0.04454543 CG3270 
FBgn0259233 559.139428 -0.1455996 0.0447053 CG42331 
FBgn0029898 1438.78125 0.13195484 0.04483505 CG14439 
FBgn0036534 3993.58719 0.10726336 0.04483505 DCP2 
FBgn0032129 3461.6124 0.09643087 0.04483505 jp 
FBgn0039332 2100.63512 0.0907303 0.04483505 alrm 




FBgn0004397 4417.75832 -0.0845725 0.04496902 Vinc 
FBgn0267253 1420.18448 -0.0751109 0.04510441 CG32700 
FBgn0261584 59.3941789 0.25490729 0.04530199 CG42694 
FBgn0036668 1239.5751 0.08316962 0.04581719 Zcchc7 
FBgn0039417 133.905247 0.17029349 0.0459216 CG6073 
FBgn0035111 941.622025 -0.0780258 0.0459216 Dis3l2 
FBgn0034266 6.08320845 0.61017166 0.0460156 CG4975 
FBgn0058470 1126.20826 0.23699443 0.04639193 CG40470 
FBgn0010314 92.4792886 -0.521823 0.04639193 Cks30A 
FBgn0034877 3395.53759 -0.0732639 0.04641756 levy 
FBgn0028953 2320.97663 0.05471366 0.0466987 CG14478 
FBgn0050410 608.355458 -0.1100617 0.04680255 Rpi 
FBgn0027836 748.170679 0.1001625 0.04697348 Dgp-1 
FBgn0263198 3225.45993 -0.0527889 0.04697348 Acn 
FBgn0029997 1542.19047 0.09480998 0.04722753 CG2258 
FBgn0085442 3565.38217 -0.0676837 0.04722753 NKAIN 
FBgn0031995 2434.82733 0.06449445 0.04738084 CG8475 
FBgn0028523 833.038573 0.09100745 0.04738452 CG5888 
FBgn0032026 943.512584 0.07663155 0.04740052 CG7627 
FBgn0033728 1722.10566 -0.1684897 0.04740052 Cpr49Ae 
FBgn0010551 1459.6636 -0.0776012 0.04807929 Phb2 
FBgn0063496 15.3632416 0.00730511 0.04812387 GstE4 
FBgn0025800 3576.63405 0.081165 0.04825416 Smox 
FBgn0264563 5.23641348 0.6674684 0.04827074 CG43935 
FBgn0041236 7.99043158 0.53526915 0.04861848 Gr59d 
FBgn0033170 1037.87519 0.11206661 0.04866174 sPLA2 
FBgn0028990 1432.1538 0.10196862 0.04884803 Spn27A 
FBgn0010213 1425.90246 -0.0913916 0.04884803 Sod2 
FBgn0034075 994.347844 0.09258136 0.04889612 Asph 
FBgn0082954 16.7546011 0.37642328 0.04895675 snoRNA:Psi28S-3571 
FBgn0032453 1341.95935 -0.0866824 0.04895675 CG6180 
FBgn0033692 350.542478 -0.1135579 0.04895675 wash 
FBgn0259229 82.4023501 0.2777851 0.04902508 CG42329 
FBgn0011361 1641.2997 -0.0904964 0.04915766 ND-ACP 
FBgn0037818 180.094536 -0.1594712 0.0494081 CG6465 
FBgn0029912 838.536002 -0.0759508 0.04955078 CG4557 
FBgn0046258 31.5345717 -0.2869443 0.04971545 CG12880 
 
 
 
 
 
